
<html lang="en"     class="pb-page"  data-request-id="9a494801-d53f-42bd-b163-fc15beef7d20"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/jm501562a;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2015.58.issue-3"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Nintedanib: From Discovery to the Clinic" /></meta><meta name="dc.Creator" content="Gerald J.  Roth" /></meta><meta name="dc.Creator" content="Rudolf  Binder" /></meta><meta name="dc.Creator" content="Florian  Colbatzky" /></meta><meta name="dc.Creator" content="Claudia  Dallinger" /></meta><meta name="dc.Creator" content="Rozsa  Schlenker-Herceg" /></meta><meta name="dc.Creator" content="Frank  Hilberg" /></meta><meta name="dc.Creator" content="Stefan-Lutz  Wollin" /></meta><meta name="dc.Creator" content="Rolf  Kaiser" /></meta><meta name="dc.Description" content="Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis. ..." /></meta><meta name="Description" content="Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis. ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 14, 2015" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm501562a" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2014 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm501562a" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm501562a" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm501562a" /></link>
        
    
    

<title>Nintedanib: From Discovery to the Clinic | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm501562a" /></meta><meta property="og:title" content="Nintedanib: From Discovery to the Clinic" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0006.jpeg" /></meta><meta property="og:description" content="Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis. Nintedanib targets proangiogenic and pro-fibrotic pathways mediated by the VEGFR family, the fibroblast growth factor receptor (FGFR) family, the platelet-derived growth factor receptor (PDGFR) family, as well as Src and Flt-3 kinases. The compound was identified during a lead optimization program for small-molecule inhibitors of angiogenesis and has since undergone extensive clinical investigation for the treatment of various solid tumors, and in patients with the debilitating lung disease idiopathic pulmonary fibrosis (IPF). Recent clinical evidence from phase III studies has shown that nintedanib has significant efficacy in the treatment of NSCLC, ovarian cancer, and IPF. This review article provides a comprehensive summary of the preclinical and clinical research and development of nintedanib from the initial drug discovery process to the latest available clinical trial data." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm501562a"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm501562a">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm501562a&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm501562a&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm501562a&amp;href=/doi/10.1021/jm501562a" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1053-1063</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm501092z" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.5b00057" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Nintedanib: From Discovery to the Clinic</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gerald+J.++Roth">Gerald J. Roth</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rudolf++Binder">Rudolf Binder</a></span><span class="author-xref-symbol author-aff-symbol"><sup>Â§</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Florian++Colbatzky">Florian Colbatzky</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¡</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claudia++Dallinger">Claudia Dallinger</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rozsa++Schlenker-Herceg">Rozsa Schlenker-Herceg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frank++Hilberg">Frank Hilberg</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â</sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan-Lutz++Wollin">Stefan-Lutz Wollin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â¥</sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rolf++Kaiser">Rolf Kaiser</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>â </sup>Department of Medicinal Chemistry; <sup>Â§</sup>Department of Drug Metabolism and Pharmacokinetics; <sup>â¡</sup>Department of Non-Clinical Drug Safety; <sup>â¥</sup>Department of Translational Medicine and Clinical Pharmacology; <sup>â¥</sup>Department of Respiratory Diseases Research; and <sup>#</sup>Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">â</span> <span class="aff-text">Clinical Development and Medical Affairs, Respiratory, Boehringer Ingelheim Inc., Ridgefield, Connecticut 06877, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">â</span> <span class="aff-text">Boehringer Ingelheim RCV GmbH & Co. KG, A-1121 Vienna, Austria</span></div><div class="corresp-info"><strong>*</strong>Phone: +49-7351-540. Fax: +49-7351-540. E-mail: <a href="/cdn-cgi/l/email-protection#03646671626f67716c776b43616c666b716a6d6466712e6a6d64666f6b666a6e2d606c6e"><span class="__cf_email__" data-cfemail="42252730232e26302d362a02202d272a302b2c2527306f2b2c25272e2a272b2f6c212d2f">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm501562a&amp;href=/doi/10.1021%2Fjm501562a" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1053â1063</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 4, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 October 2014</li><li><span class="item_label"><b>Published</b> online</span>14 January 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 February 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm501562a" title="DOI URL">https://doi.org/10.1021/jm501562a</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1053%26pageCount%3D11%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGerald%2BJ.%2BRoth%252C%2BRudolf%2BBinder%252C%2BFlorian%2BColbatzky%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D3%26contentID%3Djm501562a%26title%3DNintedanib%253A%2BFrom%2BDiscovery%2Bto%2Bthe%2BClinic%26numPages%3D11%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1063%26publicationDate%3DFebruary%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm501562a"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">14419</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">134</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm501562a" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Nintedanib: From Discovery to the Clinic&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gerald&quot;,&quot;last_name&quot;:&quot;J. Roth&quot;},{&quot;first_name&quot;:&quot;Rudolf&quot;,&quot;last_name&quot;:&quot;Binder&quot;},{&quot;first_name&quot;:&quot;Florian&quot;,&quot;last_name&quot;:&quot;Colbatzky&quot;},{&quot;first_name&quot;:&quot;Claudia&quot;,&quot;last_name&quot;:&quot;Dallinger&quot;},{&quot;first_name&quot;:&quot;Rozsa&quot;,&quot;last_name&quot;:&quot;Schlenker-Herceg&quot;},{&quot;first_name&quot;:&quot;Frank&quot;,&quot;last_name&quot;:&quot;Hilberg&quot;},{&quot;first_name&quot;:&quot;Stefan-Lutz&quot;,&quot;last_name&quot;:&quot;Wollin&quot;},{&quot;first_name&quot;:&quot;Rolf&quot;,&quot;last_name&quot;:&quot;Kaiser&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;1053-1063&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm501562a&quot;},&quot;abstract&quot;:&quot;Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis. Nintedanib targets proangiogenic and pro-fibrotic pathways mediated by the VEGFR family, the fibroblast growth factor receptor (FGFR) family, the platelet-derived growth factor receptor (PDGFR) family, as well as Src and Flt-3 kinases. The compound was identified during a lead optimization program for small-molecule inhibitors of angiogenesis and has since undergone extensive clinical investigation for the treatment of various solid tumors, and in patients with the debilitating lung disease idiopathic pulmonary fibrosis (IPF). Recent clinical evidence from phase III studies has shown that nintedanib has significant efficacy in the treatment of NSCLC, ovarian cancer, and IPF. This review article provides a comprehensive summary of the preclinical and clinical research and development of nintedanib from the initial dr&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501562a&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501562a" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501562a&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501562a" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm501562a&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501562a" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm501562a&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm501562a&amp;href=/doi/10.1021/jm501562a" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm501562a" /></input><a href="/doi/pdf/10.1021/jm501562a" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (385 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm501562a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm501562a%26sid%3Dliteratum%253Aachs%26pmid%3D25474320%26genre%3Darticle%26aulast%3DRoth%26date%3D2015%26atitle%3DNintedanib%253A%2BFrom%2BDiscovery%2Bto%2Bthe%2BClinic%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D3%26spage%3D1053%26epage%3D1063%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jmcmar.2015.58.issue-3/20150212/jmcmar.2015.58.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/medium/jm-2014-01562a_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501562a&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Nintedanib (BIBF1120) is a potent, oral, small-molecule tyrosine kinase inhibitor, also known as a triple angiokinase inhibitor, inhibiting three major signaling pathways involved in angiogenesis. Nintedanib targets proangiogenic and pro-fibrotic pathways mediated by the VEGFR family, the fibroblast growth factor receptor (FGFR) family, the platelet-derived growth factor receptor (PDGFR) family, as well as Src and Flt-3 kinases. The compound was identified during a lead optimization program for small-molecule inhibitors of angiogenesis and has since undergone extensive clinical investigation for the treatment of various solid tumors, and in patients with the debilitating lung disease idiopathic pulmonary fibrosis (IPF). Recent clinical evidence from phase III studies has shown that nintedanib has significant efficacy in the treatment of NSCLC, ovarian cancer, and IPF. This review article provides a comprehensive summary of the preclinical and clinical research and development of nintedanib from the initial drug discovery process to the latest available clinical trial data.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81112" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81112" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In 1998, a lead optimization program to develop angiogenesis inhibitors for the treatment of cancer was initiated at Boehringer Ingelheim. The key characteristics of the initial target profile were selective inhibition of vascular endothelial growth factor 2 (VEGFR-2) over other kinases, potent inhibition of endothelial cell proliferation, good oral bioavailability, and proven in vivo activity in tumor xenografts, and these characteristics guided the early optimization process. Nintedanib ethanesulfonate, a 6-methoxycarbonyl-substituted indolinone derivative (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), was identified during that program and has subsequently progressed to phase III clinical trial investigation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/medium/jm-2014-01562a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Molecular structure of nintedanib ethanesulfonate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501562a&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Structure and Synthesis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_24770" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_24770" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The convergent syntheses of nintedanib (<b>2</b>) and its ethanesulfonate salt (<b>1</b>) have been described previously<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1-3)</a> and comprise a sequence of five linear steps (including the formation of the final salt form) and a two-step sequence for the preparation of the aniline side chain (<b>9</b>). The reaction scheme shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a> depicts an optimized synthesis route that can be used for the preparation of >100 g batches of the compounds.</div><div class="NLM_p">After a classical malonic ester addition to arene <b>3</b>, the resulting nitro benzene (<b>4</b>) is hydrogenated under acidic conditions, furnishing the 6-methoxycarbonyl-substituted oxindole <b>5</b> via decarboxylative cyclization. Condensation of <b>5</b> with trimethyl orthobenzoate in acetic anhydride leads to compound <b>6</b>, one of the two key building blocks of the synthesis. The concomitant <i>N</i>-acetylation of the oxindole activates the scaffold for the condensation reaction.</div><div class="NLM_p last">The aniline side chain (<b>9</b>) can be prepared by a one-pot bromo-acetylation/amination of the <i>para</i>-nitro-phenylamine (<b>7</b>) using bromoacetyl bromide and <i>N</i>-methylpiperazine and a subsequent hydrogenation furnishing <b>9</b> as the second key building block. Condensation of both building blocks in an additionâelimination sequence and subsequent acetyl removal with piperidine furnishes <b>2</b> as free base (p<i>K</i><sub>a</sub> = 7.9), which subsequently is converted into its monoethanesulfonate salt (<b>1</b>). Compound <b>1</b> is highly crystalline (mp = 305 Â°C) and exhibits a log P of 3.0 and good aqueous solubility (>20 mg/mL in water).</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Medicinal Chemistry and StructureâActivity Relationships (SAR)</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85017" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85017" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hit finding for VEGFR-2 inhibition was initially based on a high-throughput screening strategy. In parallel, selectivity testing of derivatives from a related kinase project (CDK4) revealed compound <b>10</b> (see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) as a weakly potent but already cellular active VEGFR-2 inhibitor.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In addition, <b>10</b> was completely devoid of CDK4 activity and, when tested on a small kinase selectivity panel, it revealed a specificity pattern that was clearly superior to those of other hit structures.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/medium/jm-2014-01562a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Synthesis of nintedanib ethanesulfonate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501562a&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We reasoned that this promising selectivity profile could potentially be attributed to the substituent in the 6-position of the oxindole core. Our hypothesis that substituents in this position should occupy the specificity pocket of the ATP-binding region (see Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) would later be confirmed by an X-ray structure of nintedanib and the kinase domain of VEGFR-2.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Based on these findings, <b>10</b> was selected as the lead structure of the initial project.</div><div class="NLM_p">First synthesis campaigns were aimed at the generation of SAR and, in particular, improving the biochemical potency of <b>10</b>.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The overall SAR of the oxindole class are depicted in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. Replacing the central aryl moiety in the ribose pocket with smaller alkyl substituents turned out to be detrimental to the chemical stability of the molecules, probably due to the fact that only the phenyl moiety can adopt a strain-free conformation perpendicular to the rest of the molecule. This perpendicular conformation disrupts the overall flat compound shape and is probably one of the factors contributing to the good aqueous solubility of nintedanib. It was, therefore, decided to leave this position and the kinase hinge-binding motif unchanged. As expected, SAR in the 6-position of the oxindole core are steep, and substitution has a dramatic impact on the overall selectivity profile. Whereas the nonsubstituted oxindole <b>11</b> (see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) displayed low potency and less favorable selectivity over related kinases such as CDK4, InsR, and IGF1R (at 1 Î¼M), the substituent in the 6-position of the oxindole turned out to be a good handle to dial in or out kinase activity. By far the most potent variation discovered was the 6-nitro substitution (<b>12</b>, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) that we refrained from taking into the optimization process due to the mutagenic potential of the nitro group. Chloro-substituted compounds such as <b>13</b> were followed up for some time but were eventually terminated because of a less attractive selectivity profile. Although ester-substituted oxindoles such as <b>14</b> were identified as potent inhibitors, the obvious risk of metabolic degradation by esterases was a concern. Only when <b>14</b> and derivatives demonstrated acceptable oral exposure in rodents were they taken into the optimization process as new leads. Selectivity testing revealed that compounds such as <b>14</b> display excellent kinase-specificity profiles when tested against a screening set of 40 kinases.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Selectivity testing also identified inhibition of fibroblast growth factor receptors (FGFR) and platelet-derived growth factor receptors (PDGFR), which was considered to be beneficial to the overall antiangiogenic profile of the compound. 6-Carboxy oxindoles such as <b>15</b> show no or limited activity on the VEGFR-2, FGFR or PDGFR receptors.</div><div class="NLM_p">Optimization of aryl ring substitution at R<sup>2</sup> pointing toward the outer rim of the kinase pocket was straightforward. Shallow SAR allowed for fine-tuning of properties such as cellular activity and solubility. For most of the compounds, the biochemical potencies translated well into the inhibition of proliferation of human umbilical vein endothelial cells (HUVEC). Final optimization of R<sup>2</sup> furnished a set of highly potent, selective, and orally available compounds such as BIBF1000 (<b>16</b>). After evaluation in xenograft experiments (<a class="ref internalNav" href="#sec4" aria-label="Target Engagement">Target Engagement</a> section), chemistry manufacturing control characterization, general pharmacology, and tolerability testing (<a class="ref internalNav" href="#sec8" aria-label="Toxicology">Toxicology</a> section), lead optimization concluded in 2001 with the promotion of nintedanib (<b>2</b>) into preclinical development.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/medium/jm-2014-01562a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structureâactivity relationships of 6-substituted oxindoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501562a&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Activity of Key Compounds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/medium/jm-2014-01562a_0005.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">IC<sub>50</sub> (nM)</th><th class="rowsep1 colsep0" align="center">EC<sub>50</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">VEGFR-2<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">FGFR-1<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">PDGFR-Î±<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">HUVEC/VEGF<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>(piperidin-1-yl)</td><td class="colsep0 rowsep0" align="left">763Â Â±Â 198</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">342Â Â±Â 176</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>(piperidin-1-yl)</td><td class="colsep0 rowsep0" align="left">2112Â Â±Â 1215<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>(piperidin-1-yl)</td><td class="colsep0 rowsep0" align="left">7Â Â±Â 9</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">60Â Â±Â 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>(piperidin-1-yl)</td><td class="colsep0 rowsep0" align="left">129Â Â±Â 78<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">49Â Â±Â 54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">COOMe</td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>(piperidin-1-yl)</td><td class="colsep0 rowsep0" align="left">36Â Â±Â 36<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">103Â Â±Â 11<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">COOH</td><td class="colsep0 rowsep0" align="left">4-CH<sub>2</sub>(piperidin-1-yl)</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">COOMe</td><td class="colsep0 rowsep0" align="left">4-(NMe)-COCH<sub>2</sub>NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">61Â Â±Â 17</td><td class="colsep0 rowsep0" align="left">50Â Â±Â 4</td><td class="colsep0 rowsep0" align="left">20Â Â±Â 2</td><td class="colsep0 rowsep0" align="left">22Â Â±Â 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b><a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left"><b>COOMe</b></td><td class="colsep0 rowsep0" align="left"><b>4-(NMe)COCH<sub>2</sub>-(4-methylpiperazin-1-yl)</b></td><td class="colsep0 rowsep0" align="left"><b>21Â Â±Â 13</b></td><td class="colsep0 rowsep0" align="left"><b>69Â Â±Â 70</b></td><td class="colsep0 rowsep0" align="left"><b>59Â Â±Â 71</b></td><td class="colsep0 rowsep0" align="left"><b>10Â Â±Â 13</b></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Values are averages Â± standard deviation of at least three independent determinations.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Four independent determinations.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Selectivity values are averages Â± standard deviation of three independent determinations.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Not tested.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Nintedanib.</p></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Target Engagement</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81171" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81171" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The preclinical development of nintedanib utilized in vitro inhibition assays to demonstrate that nintedanib inhibits a distinctive, narrow range of kinases at pharmacologically relevant concentrations (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Targeted kinases included all three VEGFR subtypes, FGFR types 1, 2, and 3, and PDGFR-Î± and -Î². The ability of nintedanib to simultaneously target these three, distinct proangiogenic receptor classes may enhance its antitumor effects and overcome pathways of resistance to VEGF- and VEGFR-2-targeted agents. Nintedanib also inhibited Flt-3 and members of the Src-family (Src, Lyn, and Lck), which may have therapeutic potential for conditions such as hematologic diseases.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Summary of Nintedanibâs In Vitro Kinase Inhibition Profile<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR-1</td><td class="colsep0 rowsep0" align="left">34Â Â±Â 15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR-2</td><td class="colsep0 rowsep0" align="left">21Â Â±Â 13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR-2 (mouse)</td><td class="colsep0 rowsep0" align="left">13Â Â±Â 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">VEGFR-3</td><td class="colsep0 rowsep0" align="left">13Â Â±Â 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR-1</td><td class="colsep0 rowsep0" align="left">69Â Â±Â 70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR-2</td><td class="colsep0 rowsep0" align="left">37Â Â±Â 2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR-3</td><td class="colsep0 rowsep0" align="left">108Â Â±Â 41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR-4</td><td class="colsep0 rowsep0" align="left">610Â Â±Â 117</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-Î±</td><td class="colsep0 rowsep0" align="left">59Â Â±Â 71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFR-Î²</td><td class="colsep0 rowsep0" align="left">65Â Â±Â 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">InsR</td><td class="colsep0 rowsep0" align="left">>4000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IGF1R</td><td class="colsep0 rowsep0" align="left">>1000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">>50000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HER2</td><td class="colsep0 rowsep0" align="left">>50000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK4</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt-3</td><td class="colsep0 rowsep0" align="left">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lck</td><td class="colsep0 rowsep0" align="left">16Â Â±Â 16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Lyn</td><td class="colsep0 rowsep0" align="left">195Â Â±Â 12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">156Â Â±Â 40</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Assays performed with adenosine 5â²-triphosphate (ATP) concentrations at the respective Michaelis constant (<i>K</i><sub>m</sub>). Human kinases were tested except when stated otherwise. Data represent mean Â± standard error of at least three determinations; IC<sub>50</sub> values âgreater thanâ indicate that half-maximum inhibition was not achieved at the highest concentration tested.</p></div></div></div><div class="NLM_p">In vitro inhibition of VEGFR-2 was found to be sustained for at least 32 h in VEGFR-2-transfected NIH3T3 cells exposed to nintedanib for only 1 h, a remarkably sustained duration of target kinase inhibition.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Subsequent inhibition of VEGF-stimulated cell proliferation was demonstrated for endothelial cells derived from umbilical veins (HUVEC) and skin microvessels (HSMEC) (EC<sub>50</sub> < 10 nM).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> This inhibition was preceded by inhibition of MAPK and Akt phosphorylation. Nintedanib also inhibited FGF-stimulated HUVEC proliferation, and PDGF-stimulated pericytes and human umbilical artery vascular smooth muscle cells (HUASMC). However, no effect was observed on the proliferation of human epithelial cancer cell lines without detectable expression of VEGFR, FGFR, or PDGFR.</div><div class="NLM_p">Nintedanib demonstrated significant antitumor activity in xenograft models of a range of different tumor types, including NSCLC (Calu-6 cells), human renal cell carcinoma (RCC) (Caki-1), colorectal (HT-29), ovarian (SKOV-3), and prostate carcinoma (PAC-120).<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> In H460 cell NSCLC xenografts, nintedanib also demonstrated synergistic effects in combination with the cytotoxic drugs docetaxel or pemetrexed.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The combination of nintedanib with docetaxel resulted in tumor shrinkage to a volume that was only 27% of control, whereas monotherapy with nintedanib or docetaxel at the same dose had much less efficacy (tumor growth inhibition ratio: 75% and 66%, respectively).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Similar observations were made for the combination of nintedanib and pemetrexed in Calu-6 cell NSCLC xenografts.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p last">The antifibrotic potential of VEGFR, PDGFR, and FGFR inhibition with nintedanib has also been evaluated in a series of preclinical studies.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Nintedanib was shown to inhibit PDGFR-Î± and -Î² activation and proliferation of normal human lung fibroblasts in vitro and to inhibit PDGF-BB-, FGF-2-, and VEGF-induced proliferation of human lung fibroblasts from patients with IPF and control donors.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Nintedanib attenuated PDGF- or FGF-2-stimulated migration of lung fibroblasts from patients with IPF<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and inhibited transforming growth factor (TGF)-Î²-induced fibroblast to myofibroblast transformation of primary human lung fibroblasts from IPF patients. PDGFR activation and downstream signaling was inhibited by nintedanib in a dose-dependent manner in mouse lung tissue when administered orally in vivo. In two different mouse models of IPF, nintedanib exerted anti-inflammatory effects as shown by significant reductions in lymphocyte and neutrophil counts in the bronchoalveolar lavage fluid, reductions in inflammatory cytokines, and reduced inflammation and granuloma formation in histological analysis of lung tissue.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> IPF mouse models also revealed nintedanib-associated antifibrotic effects as shown by significant reductions in total lung collagen and by reduced fibrosis identified in histological analyses.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Nonclinical Drug Metabolism and Pharmacokinetics</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The PK profile of nintedanib was assessed in preclinical toxicity studies of CD1 mice, Wistar rats, and cynomolgus and rhesus monkeys. Significant exposure to nintedanib was observed in all of these investigated species with moderate variability (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Exposure increased proportionally with the nintedanib dose in the mouse and the monkey, but slightly more than proportionally in the rat. No accumulation and no consistent difference between sexes were observed. Oral bioavailability was approximately 12% in rats and 13% to 24% in monkeys (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Bioavailability was shown to be limited in rats by incomplete absorption followed by first-pass metabolism, mainly by ester cleavage. Suppression of gastric acid secretion had no effect on the absorption of nintedanib and administration of nintedanib hydrochloride or ethanesulfonate salts led to similar plasma concentrations and time profiles.</div><div class="NLM_p">Once absorbed, nintedanib was extensively distributed in tissues as indicated by high volumes of distribution at steady state in all investigated species (V(ss) > 8 L/kg; Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Detailed tissue distribution studies by means of whole body autoradiography or tissue dissection confirmed an extensive tissue distribution except in the CNS.</div><div class="NLM_p">Nintedanib showed concentration-independent plasma protein binding in the concentration range of 50 to 2000 ng/mL, with albumin being the major binding protein. The fraction of nintedanib bound was 97.8% in human plasma, 97.2% in mouse plasma, and 98.5% in rat plasma.</div><div class="NLM_p">Elimination of nintedanib was mainly governed by ester cleavage and subsequent metabolic pathways. Considered along with the metabolite patterns of plasma and excreta, the metabolism of nintedanib was shown to be subdivided into the following principal reactions: (1) ester cleavage of the methyl ester of the 6-substituted oxindole, (2) oxidative <i>N</i>-demethylation of the piperazine moiety, and (3) a combination of ester cleavage and oxidative <i>N</i>-demethylation.</div><div class="NLM_p">The main excretion pathway was as metabolites via bile. Renal excretion after oral administration was low, with 2.1% of dosed drug-related radioactivity in mice and 1.2% of the dose in rats excreted in urine.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Species Comparison of Plasma-Derived PK Parameters of the Parent Drug after Single Administration of Nintedanib<a class="ref internalNav" href="#t3-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Species</b></th><th class="colsep0 rowsep0" align="center">mouse</th><th class="colsep0 rowsep0" colspan="2" align="center">rat<a class="ref internalNav" href="#t3fn1" aria-label="b">b</a></th><th class="colsep0 rowsep0" colspan="2" align="center">cynomolgus<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a></th><th class="colsep0 rowsep0" colspan="2" align="center">rhesus<a class="ref internalNav" href="#t3fn2" aria-label="c">c</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Method of Administration</b></th><th class="colsep0 rowsep0" align="center">oral</th><th class="colsep0 rowsep0" align="center">oral</th><th class="colsep0 rowsep0" align="center">i.v.</th><th class="colsep0 rowsep0" align="center">oral</th><th class="colsep0 rowsep0" align="center">i.v.</th><th class="colsep0 rowsep0" align="center">oral</th><th class="colsep0 rowsep0" align="center">i.v.</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Nintedanib dose (mg/kg)</b></th><th class="colsep0 rowsep0" align="center">50</th><th class="colsep0 rowsep0" align="center">50</th><th class="colsep0 rowsep0" align="center">2</th><th class="colsep0 rowsep0" align="center">40</th><th class="colsep0 rowsep0" align="center">5</th><th class="colsep0 rowsep0" align="center">40</th><th class="colsep0 rowsep0" align="center">5</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> [ng/mL]</td><td class="colsep0 rowsep0" align="center">547</td><td class="colsep0 rowsep0" align="center">105</td><td class="colsep0 rowsep0" align="center">124</td><td class="colsep0 rowsep0" align="center">175</td><td class="colsep0 rowsep0" align="center">1300</td><td class="colsep0 rowsep0" align="center">311</td><td class="colsep0 rowsep0" align="center">1090</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub>Â [h]</td><td class="colsep0 rowsep0" align="center">5.15</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">3.95</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">5.95</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">7.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC [(ngÂ·h)/mL]</td><td class="colsep0 rowsep0" align="center">2720</td><td class="colsep0 rowsep0" align="center">375</td><td class="colsep0 rowsep0" align="center">181</td><td class="colsep0 rowsep0" align="center">2390</td><td class="colsep0 rowsep0" align="center">2260</td><td class="colsep0 rowsep0" align="center">4440</td><td class="colsep0 rowsep0" align="center">2830</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Clearance [mL/min/kg]</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">202</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">37.5</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">30.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRTÂ [h]</td><td class="colsep0 rowsep0" align="center">5.19</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">3.25</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">3.82</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">5.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V(ss) [L/kg]</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">41.2</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">8.64</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">10.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Bioavailability [%]</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">11.9</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">13.2</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">23.8</td><td class="colsep0 rowsep0" align="center">NA</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3-fn1"><div class="footnote" id="t3-fn1"><sup>a</sup><p class="last">AUC = area under the curve; <i>C</i><sub>max</sub> = maximal concentration; MRT = mean residence time; NA = not applicable; ND = not determined; <i>t</i><sub>1/2</sub> = half-life; V(ss) = volume of distribution at steady state.</p></div><div class="footnote" id="t3fn1"><sup>b</sup><p class="last">Several formulations and dosages were tested. Within the dose range of 30 to 300 mg/kg, AUC<sub>0â24h</sub> and <i>C</i><sub>max</sub> increased proportionally with dose.</p></div><div class="footnote" id="t3fn2"><sup>c</sup><p class="last">Single dose PK after i.v.-dosing was integrated in an oral dose range finding study. Additional dose groups were used. Only representative PK data are listed here. Linear dose dependency and no sex effect was observed. </p></div></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Disease and Mechanism of Action</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13725" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13725" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Oncology</h3><div class="NLM_p">The clinical success of bevacizumab has established the principle of antiangiogenesis as a valid treatment strategy in oncology. Bevacizumab in combination with chemotherapy significantly improves overall survival (OS) versus chemotherapy alone as first-line treatment for several malignancies, including NSCLC<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> and colorectal cancer (CRC).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Bevacizumab-based regimens are also an established second-line treatment option in patients with relapsed/refractory CRC. Antiangiogenic tyrosine kinase inhibitors have also been integrated into standard of care clinical practice for patients with other cancers, such as sunitinib, sorafenib, pazopanib or axitinib in RCC, and sorafenib in hepatocellular carcinoma (HCC) and differentiated thyroid carcinoma.</div><div class="NLM_p">Despite these successes, the limitations of current antiangiogenic agents are increasingly recognized, with insufficient efficacy and the development of resistance limiting the long-term success of VEGF-targeted therapies.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Toxicities, such as hypertension, bleeding, risk of gastrointestinal perforation, dermatological conditions and mucositis, may also limit treatment with VEGF or VEGFR inhibitors.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Activation of alternative, redundant proangiogenic pathways has been implicated in resistance to VEGF inhibition, including FGFs, PDGFs, placental growth factor (PlGF), and TNF-Î±. The mammalian FGF-pathway family comprises 23 growth factor proteins (FGF-1 to -23) and four receptors (FGFR-1 to -4).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Overexpression of various FGF ligands has been reported for a range of different tumor types.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> FGF-2, in particular, is a potent stimulator of angiogenesis<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> that is frequently overexpressed in tumors and correlated with poor outcomes in NSCLC.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Mutation or amplification of FGFR genes have been found in various human cancers.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Notably, FGFR activation in endothelial cell culture and animal models leads to angiogenesis.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Signaling via PDGF ligands (PDGF-A to PDGF-D) and the two forms of PDGF receptor (PDGFR-Î± and PDGFR-Î²), which is involved in physiological vessel maturation and the recruitment of pericytes, is also implicated in angiogenesis and cancer progression. Mutations involving upregulation of PDGF and/or PDGFR have been described in human cancers, and overexpression of PDGFR has been associated with poor prognosis.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p last">Thus, nintedanib as a potent inhibitor of three proangiogenic pathway receptor families (VEGFR, FGFR, and PDGFR) was considered promising as an antiangiogenic anticancer therapy.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Idiopathic Pulmonary Fibrosis</h3><div class="NLM_p">The potential for tyrosine kinase inhibition in the treatment of patients with IPF was also recognized during clinical development of nintedanib. IPF is a chronic and progressive, fibrotic lung disease associated with a short median survival post diagnosis of 2â3 years due to a lack of effective therapies.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> IPF is characterized by uncontrolled fibroblast/myofibroblast proliferation and differentiation, and excessive collagen deposition within the lung interstitium and alveolar space,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> leading to symptoms of cough and dyspnea, and ultimately to respiratory failure.</div><div class="NLM_p last">The pathogenic mechanisms that give rise to IPF are not fully understood, but a number of tyrosine kinase receptors inhibited by nintedanib have been implicated as mediators. FGFR-1 and FGFR-2 are expressed on a variety of cells in the lungs of patients with IPF.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Furthermore, FGF-2 stimulates proliferation of lung fibroblasts from patients with IPF<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and inhibition of FGF signaling reduces pulmonary fibrosis and improves survival in mouse models of IPF.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> PDGF stimulates proliferation, migration, and survival of myofibroblasts thought to be responsible for collagen deposition in IPF. VEGF expression also correlates with subepithelial fibrosis in patients with asthma,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and anti-VEGF therapy shows some functional benefit in mouse models of IPF.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Human ADME</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10848" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10848" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The clinical PK profile of nintedanib has been extensively investigated as monotherapy in healthy volunteers,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and in patients with cancer as monotherapy and in combination with other agents in a number of phase I<a onclick="showRef(event, 'ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34">(27-34)</a> and phase II clinical trials.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> These studies show that nintedanib is rapidly absorbed after oral administration, with a time to maximum plasma concentration of 1â3 h.<a onclick="showRef(event, 'ref26 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref28">(26, 28)</a> The mean terminal <i>t</i><sub>1/2</sub> of nintedanib is approximately 13â19 h.<a onclick="showRef(event, 'ref26 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref28">(26, 28)</a> Maximum plasma concentration (<i>C</i><sub>max</sub>) of nintedanib and overall drug exposure (area under the plasma concentrationâtime curve [AUC]) showed dose-proportional increases, with no decrease in exposure observed over a minimum 6-month treatment period.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Following multiple twice-daily administration of nintedanib, only slight accumulation of nintedanib exposure was observed, with a mean accumulation ratio of 1.33 based on <i>C</i><sub>max</sub> and 1.66 based on AUC<sub>0â12Â h</sub>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Interpatient variability of PK parameters for nintedanib was moderate to high.<a onclick="showRef(event, 'ref26 ref28 ref37'); return false;" href="javascript:void(0);" class="ref ref26 ref28 ref37">(26, 28, 37)</a> No PK interaction has been observed in phase I combination studies between nintedanib and the chemotherapeutic agents/regimens docetaxel,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> pemetrexed,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> carboplatin/paclitaxel,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and FOLFOX6.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">In a pharmacological study of healthy volunteers using [<sup>14</sup>C]-radiolabeled nintedanib, a high apparent volume of distribution during the terminal phase was observed, indicating a high tissue distribution of the drug, and a high apparent total body clearance.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Most [<sup>14</sup>C]-radioactivity (56.3%) was excreted within 24â48 h and mass balance was considered to be complete 96 h after administration, with a total of 92.4% of [<sup>14</sup>C]-radioactivity recovered in urine and feces. Cumulative recovery of excreted [<sup>14</sup>C]-radioactivity revealed that urinary excretion for nintedanib is minor (approximately 0.7% over 72 h) and that the major route of elimination is through metabolism, with metabolites excreted via the biliary system into the feces (93.4% over 120 h).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p last">Nintedanib metabolism in healthy humans occurs predominantly by cleavage of the methyl ester moiety to the carboxylate, which is then conjugated to glucuronic acid, yielding the 1-<i>O</i>-acylglucuronide. Thus, metabolism of nintedanib is predominantly CYP450 enzyme-independent, which may facilitate its combination with cytotoxic chemotherapies, such as docetaxel, that utilize CYP450 enzymes.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Toxicology</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85561" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85561" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The toxic potential of nintedanib has been fully explored in a toxicological program including single-dose toxicity studies in mice and rats, repeat-dose toxicity studies up to 26 weeks in rats, up to 13 weeks in cynomolgus monkeys and up to 52 weeks in rhesus monkeys. In vitro and in vivo genotoxicity assays have been performed, as well as reproductive and developmental toxicity studies in rats and rabbits, carcinogenicity studies in mice and rats, safety pharmacology studies in rats, and local tolerance studies in rats and rabbits.</div><div class="NLM_p">Single-dose safety studies in rats and mice concluded that the acute toxicity of nintedanib in these two species was low. In repeat-dose toxicology studies, all species except the rat showed dose-limiting adverse gastrointestinal reactions such as diarrhea and vomiting, but usually without prominent histopathological changes. In all animal species used for repeat-dose studies, only mild reversible elevations of liver transaminases were observed.</div><div class="NLM_p">In terms of histopathology, nintedanib induced pharmacologically mediated changes that may be considered so-called class effects of VEGFR inhibitors. These included epiphyseal growth plate thickening in the femur/tibia and sternum, dentopathy of the continuously growing incisors of rats, and mild cellular depletion of the bone marrow accompanied by minimal changes of red blood cell parameters. The presence of periodic acid-Schiff stain-positive hyaline intracytoplasmic granules in podocytes and glomerular endothelium was also observed, which did not exacerbate over time and did not compromise renal function.</div><div class="NLM_p">Because of the inhibition of tyrosine kinases such as Lck, Lyn and other members of the Src family of kinases by nintedanib, immunological investigations (phenotyping of lymphoid subpopulations in blood, spleen, and thymus, as well as determination of spleen natural killer cell activity) were performed in rats, cynomolgus monkeys, and rhesus monkeys, but no consistent adverse effects on the immune system were observed. No pertinent adverse effects of nintedanib on the cardiovascular and broncho-pulmonary system were observed in any of the repeat-dose toxicology studies. Furthermore, there was no evidence of a carcinogenic potential of nintedanib in 2-year carcinogenicity bioassays in mice or rats.</div><div class="NLM_p last">Reproductive toxicology studies in rats and rabbits showed no effects on male fertility, but as anticipated from its pharmacological activity, nintedanib was associated with increases in early fetal resorptions and teratogenic effects, most prominently variations and malformations of the major blood vessels and skeleton. A standard battery of in vitro and in vivo genotoxicity assays showed no mutagenic potential for nintedanib, and safety pharmacology studies indicated no adverse cardiovascular, respiratory, or neurological effects with nintedanib.</div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Clinical Data</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nintedanib is currently under investigation in several oncology indications, as well as for the treatment of IPF, and is in the most advanced stages of clinical development for the treatment of NSCLC. Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> summarizes the key results from phase III clinical studies with nintedanib.</div><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Oncology</h3><div class="NLM_p">The initial evidence of nintedanibâs tolerability and encouraging efficacy in patients with advanced NSCLC was noted in two phase I dose-finding studies of combination regimens with paclitaxel and carboplatin as first-line therapy<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> or with pemetrexed as second-line treatment.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Both studies determined the maximum tolerated nintedanib dose to be 200 mg b.i.d. Second- or third-line nintedanib monotherapy (150 or 250 mg b.i.d.) was evaluated in patients with advanced NSCLC and was subsequently assessed in a randomized, double-blind phase II study, which again indicated that nintedanib has a manageable safety profile and promising efficacy.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">Larger-scale evaluation of nintedanib in NSCLC was subsequently carried out in two multinational, randomized, double-blind, placebo-controlled phase III studies of a similar design. The LUME-Lung 1 study compared a regimen of nintedanib (200 mg b.i.d.) or placebo on days 2â21, plus docetaxel (75 mg/m<sup>2</sup> on day 1) as second-line therapy for patients with advanced NSCLC (NCT00805194).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> A total of 655 patients were randomized to nintedanib plus docetaxel and 659 to placebo plus docetaxel, and treated until unacceptable adverse events (AEs) or disease progression.</div><div class="NLM_p">The LUME-Lung 1 study met its primary end point: addition of nintedanib to docetaxel led to a significant reduction in the risk of progression-free survival (PFS) in the overall study population (median 3.4 months in the nintedanib arm vs 2.7 months in the placebo arm; hazard ratio [HR] = 0.79 [95% CI 0.68â0.92]; <i>p</i> = 0.002), regardless of patientsâ histology. The study also met the key secondary end point of OS, which was tested in a prespecified stepwise order: first in patients with adenocarcinoma histology who progressed <9 months after initiating first-line therapy, then in all patients with adenocarcinoma, and then in the overall study population. Treatment with nintedanib plus docetaxel significantly increased the duration of OS in patients with adenocarcinoma compared with placebo plus docetaxel (HR = 0.83 [95% CI, 0.70â0.99]; <i>p</i> = 0.036). Median OS improved in a clinically meaningful way from 10.3 months with placebo to 12.6 months in the nintedanib arm, surpassing 1 year of median OS. In fact, the nintedanib arm of the LUME-Lung 1 study is notable as no other study has achieved survival duration of >1 year for second-line therapy in unselected adenocarcinoma NSCLC over the preceding 10 years of clinical development. Consistent with these findings, patients with adenocarcinoma histology who had progressed <9 months after initiating first-line therapy showed a 3-month increase in median OS and a 25% risk reduction of death compared with placebo plus docetaxel (median 10.9 months in the nintedanib arm vs 7.9 months in the placebo arm; HR = 0.75, 95% CI 0.60â0.92; <i>p</i> = 0.007). In an exploratory analysis, patients most refractory to first-line treatment (defined as no better than progressive disease in response to first-line therapy), achieved a 38% reduction in the risk of death with nintedanib plus docetaxel (HR = 0.62, 95% CI 0.41â0.94) and a median OS improvement of 3.5 months (9.8 months in the nintedanib arm vs 6.3 months in the placebo arm). With respect to patients with squamous cell cancer, there was no OS benefit, but also no detrimental effect observed. In the overall study population, an increase in median OS of 1 month was observed (from 9.1 months in the placebo arm to 10.1 months in the nintedanib arm) that did not reach statistical significance (HR = 0.94, 95% CI 0.83â1.05; <i>p</i> = 0.272).</div><div class="NLM_p">Nintedanib plus docetaxel had a manageable safety profile. AEs graded by Common Terminology Criteria (CTCAE version 3.0) that were more common (â¥5% difference) in the nintedanib plus docetaxel group than the placebo plus docetaxel group were: diarrhea (all grades, 42.3% vs 21.8%; grade â¥3, 6.6% vs 2.6%), increases in alanine aminotransferase (ALT; all grades, 28.5% vs 8.4%; grade â¥3, 7.8% vs 0.9%), nausea (all grades, 24.2% vs 18.0%; grade â¥3, 0.8% vs 0.9%), increases in aspartate aminotransferase (AST; all grades, 22.5% vs 6.6%; grade â¥3, 3.4% vs 0.5%), decreased appetite (all grades, 22.2% vs 15.6%; grade â¥3, 1.4% vs 1.2%), vomiting (all grades, 16.9% vs 9.3%; grade â¥3, 0.8% vs 0.5%) and hyperbilirubinemia (all grades, 2.8% vs 1.8%; grade â¥3, 0.5% vs 0%). Most AEs were manageable with adequate treatment or dose reduction. At least one dose reduction of nintedanib or placebo was required by 18.6% and 6.3% of patients in the nintedanib plus docetaxel and placebo plus docetaxel groups, respectively. Gastrointestinal AEs and increases in liver enzymes accounted for most of the nintedanib dose reductions. Docetaxel dose reductions were needed for 15.6% and 11.9% of patients in the nintedanib plus docetaxel and placebo plus docetaxel groups, respectively, with hematological AEs being the main reason for docetaxel dose reduction. Of characteristic AEs associated with antiangiogenic agents, nintedanib plus docetaxel did not increase the frequency of thrombotic events and arterial thromboembolism or gastrointestinal perforation relative to placebo plus docetaxel, but there were small increases in the proportion of patients with bleeding (all grades, 14.1% vs 11.6%; grade â¥3, 2.3% vs 1.8%), hypertension (all grades, 3.5% vs 0.9%; grade â¥3, 0.6% vs 0.2%), and venous thromboembolism (all grades, 2.8% vs 1.5%; grade â¥3, 1.2% vs 1.1%).</div><div class="NLM_p">The LUME-Lung 2 study evaluated the efficacy and safety of second-line nintedanib (200 mg b.i.d. on days 2â21) plus standard pemetrexed (500 mg/m<sup>2</sup> on day 1) for patients with advanced NSCLC and nonsquamous histology (NCT00806819).<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> As in the LUME-Lung 1 study, the primary end point was PFS by independent central review. A preplanned futility analysis based on conditional power for investigator-assessed PFS was performed after 50% of events had been observed (â¼356 events), when 713 patients of a planned 1300 had been enrolled. This analysis indicated that the study was futile and that the primary end point was unlikely to be met. Consequently, enrollment of additional patients into the study was stopped, treatment randomization was unblinded, and follow-up of randomized patients was continued per protocol. There were no safety concerns impacting this decision.</div><div class="NLM_p">Despite being stopped prematurely, the study met its primary end point, and analysis of PFS by independent central review revealed a significant improvement with nintedanib plus pemetrexed versus placebo plus pemetrexed (4.4 months vs 3.6 months; HR = 0.83, 95% CI 0.70â0.99; <i>p</i> = 0.0435; Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> OS was not significantly different between the treatment groups (12.2 months vs 12.7 months; HR = 1.03, 95% CI 0.85â1.24; <i>p</i> = 0.7921). The most frequent CTCAEs were increases in liver enzymes and gastrointestinal events. The incidence of patients with grade 3/4 AEs was higher with nintedanib plus pemetrexed versus placebo plus pemetrexed (58.5% vs 42.3%) but incidences of serious AEs (30.0% vs 32.8%), grade 5 AEs (9.8% vs 12.0%) or AEs leading to permanent discontinuation (16.1% vs 17.9%) were comparable between the groups.</div><div class="NLM_p">In addition to NSCLC, nintedanib has also been evaluated in a number of other solid tumors, including ovarian cancer,<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42, 43)</a> CRC,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> RCC,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and HCC.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> A preliminary report from a randomized (2:1) phase III study of nintedanib 200 mg b.i.d. added to standard first-line chemotherapy (carboplatin and paclitaxel) in patients with advanced epithelial ovarian cancer showed a significantly longer PFS compared with placebo plus standard chemotherapy (median 17.3 vs 16.6 months; HR 0.84, 95% CI 0.72â0.98; <i>p</i> = 0.0239) (LUME-Ovar 1 also known as AGO-OVAR 12; NCT01015118).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> A posthoc analysis of nonhigh-risk patients defined as those with FIGO stage II or III disease and â¤1 cm of postsurgical residual tumor, revealed a more pronounced PFS benefit with nintedanib versus placebo (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Nintedanib showed a manageable tolerability profile in patients with ovarian cancer, with a higher rate of gastrointestinal events and elevations in liver enzymes than with placebo, in line with studies in other tumor types.</div><div class="NLM_p">Nintedanib 200 mg b.i.d. monotherapy demonstrated comparable efficacy versus standard of care sunitinib as first-line systemic therapy in a randomized (2:1) phase II study in patients with advanced RCC. A comparable risk of progression or death (median PFS 8.4 months in each treatment group; [HR = 1.12 [95% CI: 0.70, 1.80]) and risk of death (median OS 20.4 vs 21.2 months; HR 0.92 [95% CI: 0.54, 1.56]) (NCT01024920) was observed between the two groups.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Additionally, there was no statistical difference in PFS at 9 months (43% vs 45%), a primary end point of the study. The overall incidence of any grade AE was similar between the nintedanib and sunitinib groups (90.6% vs 93.8%) but grade â¥3 AEs were less common with nintedanib versus sunitinib (48.4% vs 59.4%). AEs occurring markedly more frequently in patients receiving nintedanib versus sunitinib were diarrhea (any grade: 62.5% vs 50.0%; grade â¥3: 3.1% vs 3.1%), increases in gamma-glutamyltransferase (GGT; any grade: 12.5% vs 3.1%; grade â¥3: 10.9% vs 3.1%), AST (any grade: 9.4% vs 0%; grade â¥3: 3.1% vs 0%) and ALT (any grade: 7.8% vs 0%; grade â¥3: 4.7% vs 0%), and hyperbilirubinemia (any grade: 1.6% vs 0%; grade â¥3: 0 vs 0%). However, the incidence of patients with AEs commonly associated with antiangiogenic agents was markedly lower with nintedanib versus sunitinib, including hypertension (3.1% vs 15.6%), hand-foot syndrome (0% vs 31.3%), stomatitis (0% vs 31.3%), and hematological AEs (6.3% vs 28.1%).</div><div class="NLM_p">Preliminary results of a randomized (2:1) phase II study of nintedanib 200 mg b.i.d. versus sorafenib 400 mg b.i.d. in Asian patients with advanced HCC showed similar efficacy between treatment arms (NCT00987935).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Median time to progression was comparable (2.7 vs 3.7 months; HR 1.36 [95% CI: 0.80, 2.30]), as was median OS (10.7 vs 9.5 months; HR 0.77 [95% CI: 0.42, 1.41]). CTCAE AEs of grade 3 (32% vs 56%), grade 4 (8% vs 16%) and AEs leading to dose reduction (18% vs 56%) were higher with sorafenib than with nintedanib.</div><div class="NLM_p last">Investigations of nintedanib in other solid tumors are also underway. Following promising phase I trials in patients with refractory CRC, the randomized (1:1) phase III LUME-Colon 1 study is recruiting patients to assess nintedanib plus best supportive care as last-line treatment for CRC (NCT02149108).<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> A randomized (1:1) phase II study to evaluate the efficacy and safety of nintedanib versus placebo in combination with pemetrexed/cisplatin combination chemotherapy is recruiting patients with malignant pleural mesothelioma (NCT01907100).</div></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Idiopathic Pulmonary Fibrosis</h3><div class="NLM_p">Nintedanib has also undergone phase III clinical evaluation in IPF based on evidence of nominal significant efficacy, and manageable and acceptable tolerability in a multinational, randomized, double-blind, placebo-controlled, phase II study that identified a nintedanib dose of 150 mg b.i.d. as the most favorable in this setting (TOMORROW; NCT00514683).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Phase III evaluation of nintedanib in IPF was conducted in two identically designed, multinational, randomized, double-blind, placebo-controlled studies.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> INPULSIS-1 (SNCT01335464) and INPULSIS-2 (NCT01335477) enrolled a total of 1066 patients, randomized (3:2) to receive nintedanib or placebo for 52 weeks. Nintedanib 150 mg b.i.d. was shown to consistently and significantly slow disease progression by reducing the annual rate of decline in forced vital capacity (FVC, primary end point) by approximately 50% versus placebo in both INPULSIS-1 (mean treatment difference +125.3 mL/yr [95% CI 77.7â172.8]; <i>p</i> < 0.001) and INPULSIS-2 (mean treatment difference +93.7 mL/yr [95% CI 44.8â142.7]; <i>p</i> < 0.001) (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). There were significant differences in favor of nintedanib for the key secondary end point of time to the first acute exacerbation and the change from baseline in the total St. Georgeâs Respiratory Questionnaire (SGRQ) score in INPULSIS-2 but not in INPULSIS-1 (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). In a pooled analysis of both INPULSIS  trials, there was a numerical risk reduction of having a first acute exacerbation by 36% in favor of nintedanib (HR = 0.64, 95% CI 0.39â1.05; <i>p</i> = 0.082). This finding was supported in a prespecified sensitivity analysis of time to first confirmed or suspected exacerbation as centrally assessed by a blinded adjudication committee (HR = 0.32, 95% CI 0.16â0.65; <i>p</i> = 0.001). A prespecified pooled analysis also revealed that patients treated with nintedanib had a numerical risk reduction in all-cause mortality by 30% compared with patients in the placebo group (HR = 0.70, 95% CI 0.43â1.12; <i>p</i> = 0.14).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Summary of Key Efficacy Results from Phase III Studies with Nintedanib</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center"><b>Nintedanib arm</b></th><th class="colsep0 rowsep0" align="center"><b>Placebo arm</b></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>NSCLC</b></th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>LUME-Lung 1</b></th><th class="colsep0 rowsep0" align="center">Nintedanib + docetaxel</th><th class="colsep0 rowsep0" align="center">Placebo + docetaxel</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left"><b>Primary end point: PFS by central independent review</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">All patients, <i>n</i></td><td class="colsep0 rowsep0" align="center">565</td><td class="colsep0 rowsep0" align="center">569</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.79 (0.68â0.92); <i>p</i>Â =Â 0.0019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Median PFS, months</td><td class="colsep0 rowsep0" align="center">3.4</td><td class="colsep0 rowsep0" align="center">2.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left"><b>Key secondary end point: OS analysis</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Patients with adenocarcinoma and <9 months since start of first-line therapy, <i>n</i></td><td class="colsep0 rowsep0" align="center">206</td><td class="colsep0 rowsep0" align="center">199</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.75 (0.60â0.92); <i>p</i>Â =Â 0.0073</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Median OS, months</td><td class="colsep0 rowsep0" align="center">10.9</td><td class="colsep0 rowsep0" align="center">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Patients with adenocarcinoma, <i>n</i></td><td class="colsep0 rowsep0" align="center">322</td><td class="colsep0 rowsep0" align="center">336</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.83 (0.70â0.99); <i>p</i>Â =Â 0.0359</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Median OS, months</td><td class="colsep0 rowsep0" align="center">12.6</td><td class="colsep0 rowsep0" align="center">10.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">All patients, <i>n</i></td><td class="colsep0 rowsep0" align="center">655</td><td class="colsep0 rowsep0" align="center">659</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.94 (0.83â1.05); <i>p</i>Â =Â 0.2720</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Median OS, months</td><td class="colsep0 rowsep0" align="center">10.1</td><td class="colsep0 rowsep0" align="center">9.1</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>LUME-Lung 2</b></th><th class="colsep0 rowsep0" align="center">Nintedanib + pemetrexed</th><th class="colsep0 rowsep0" align="center">Placebo + pemetrexed</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left"><b>Primary end point: PFS by central independent review</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">All patients, <i>n</i></td><td class="colsep0 rowsep0" align="center">353</td><td class="colsep0 rowsep0" align="center">360</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.83 (0.70â0.99); <i>p</i>Â =Â 0.0435</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Median PFS, months</td><td class="colsep0 rowsep0" align="center">4.4</td><td class="colsep0 rowsep0" align="center">3.6</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Ovarian cancer/LUME-Ovar 1</b></th><th class="colsep0 rowsep0" align="center">Nintedanib + carboplatin/paclitaxel</th><th class="colsep0 rowsep0" align="center">Placebo + carboplatin/paclitaxel</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="3" align="left"><b>Primary end point: PFS by investigator assessment</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">All patients, <i>n</i></td><td class="colsep0 rowsep0" align="center">911</td><td class="colsep0 rowsep0" align="center">455</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.84 (0.72â0.98); <i>p</i>Â =Â 0.0239</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Median PFS, months</td><td class="colsep0 rowsep0" align="center">17.3</td><td class="colsep0 rowsep0" align="center">16.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">âNon-high-riskâ patients<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a>,Â <i>n</i></td><td class="colsep0 rowsep0" align="center">556</td><td class="colsep0 rowsep0" align="center">283</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.75 (0.61â0.92); <i>p</i>Â =Â 0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Median PFS, months</td><td class="colsep0 rowsep0" align="center">27.1</td><td class="colsep0 rowsep0" align="center">20.8</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>IPF</b></th><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>INPULSIS-1</b></th><th class="colsep0 rowsep0" align="center">Nintedanib</th><th class="colsep0 rowsep0" align="center">Placebo</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">All patients, <i>n</i></td><td class="colsep0 rowsep0" align="center">309</td><td class="colsep0 rowsep0" align="center">204</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Primary end point: Annual rate of decline in FVC, mL/yr</td><td class="colsep0 rowsep0" align="center">â114.7</td><td class="colsep0 rowsep0" align="center">â239.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Difference (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">125.3 (77.7â172.8); <i>p</i>Â <Â 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Key secondary end point: Time to first acute IPF exacerbation by investigator assessment</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">1.15 (0.54â2.42); <i>p</i>Â =Â 0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Patients with â¥1 IPF exacerbation (%)</td><td class="colsep0 rowsep0" align="center">6.1</td><td class="colsep0 rowsep0" align="center">5.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Key secondary end point: Change from baseline in the total SGRQ score<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a>, mean</td><td class="colsep0 rowsep0" align="center">4.34</td><td class="colsep0 rowsep0" align="center">4.39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Difference (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">â0.05 (â2.50â2.40); <i>p</i>Â =Â 0.97</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>INPULSIS-2</b></th><th class="colsep0 rowsep0" align="center">Nintedanib</th><th class="colsep0 rowsep0" align="center">Placebo</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">All patients, <i>n</i></td><td class="colsep0 rowsep0" align="center">329</td><td class="colsep0 rowsep0" align="center">219</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Primary end point: Annual rate of decline in FVC, mL/yr</td><td class="colsep0 rowsep0" align="center">â113.6</td><td class="colsep0 rowsep0" align="center">â207.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Difference (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">93.7 (44.8â142.7); <i>p</i>Â <Â 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Key secondary end point: Time to first acute IPF exacerbation by investigator assessment</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.38 (0.19â0.77); <i>p</i>Â =Â 0.005</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Patients with â¥1 IPF exacerbation (%)</td><td class="colsep0 rowsep0" align="center">3.6</td><td class="colsep0 rowsep0" align="center">9.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Key secondary end point: Change from baseline in the total SGRQ score<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a>, mean</td><td class="colsep0 rowsep0" align="center">2.80</td><td class="colsep0 rowsep0" align="center">5.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Difference (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">â2.69 (â4.95 to â0.43); <i>p</i>Â =Â 0.02</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"><b>Pooled analysis of INPULSIS-1 and -2</b></th><th class="colsep0 rowsep0" align="center"><b>Nintedanib</b></th><th class="colsep0 rowsep0" align="center"><b>Placebo</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">All patients, <i>n</i></td><td class="colsep0 rowsep0" align="center">638</td><td class="colsep0 rowsep0" align="center">423</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Deaths from any cause (%)</b></td><td class="colsep0 rowsep0" align="center">5.5</td><td class="colsep0 rowsep0" align="center">7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.70 (0.43â1.12); <i>p</i>Â =Â 0.014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Deaths from respiratory cause (%)</b></td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HR (95% CI); <i>p</i> value</td><td class="colsep0 rowsep0" colspan="2" align="center">0.74 (0.41â1.34); <i>p</i>Â =Â 0.034</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Based on modified RECIST 1.1 in conjunction with cancer antigen (CA)-125 and malignant bowel obstruction assessment.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Exploratory posthoc analysis.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last"><i>n</i> = 289 for nintedanib and <i>n</i> = 200 for placebo.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last"><i>n</i> = 320 for nintedanib and <i>n</i> = 213 for placebo.</p></div></div></div><div class="NLM_p">Across both studies, gastrointestinal events were the most frequent AEs in the nintedanib groups of both trials. Diarrhea was the most commonly reported AE (61.5% in the pooled nintedanib group vs 18.6% in the pooled placebo group), was mostly of mild or moderate intensity, and was manageable with <5% of patients in the nintedanib groups prematurely discontinuing due to diarrhea. Elevated liver transaminases determined by laboratory investigation occurred in 32 (5.0%) patients receiving nintedanib and in 3 (0.7%) patients receiving placebo. Liver enzyme elevations were reported as AEs in 13.6% of patients receiving nintedanib and 2.6% of patients receiving placebo. Bilirubin increases were reported as AEs in 1.3% of the nintedanib group and 0.2% of the placebo group. Overall, AEs leading to treatment discontinuation occurred in 123 (19.3%) patients receiving nintedanib and in 55 (13.0%) patients receiving placebo.</div><div class="NLM_p last">Patients who completed the 52-week treatment period and the 4-week follow-up period in the INPULSIS trials were offered nintedanib treatment in an open-label extension trial (NCT01619085), which is currently ongoing.</div></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Biomarkers</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although angiogenic pathways clearly play a major role in the pathogenesis of cancers and fibrotic pathways are important in IPF, the extent of the clinical efficacy and safety of antiangiogenic or antifibrotic therapies can vary between patients. As a result, there is a need to identify effective biomarkers that can be used to predict the likelihood of antiangiogenic and antifibrotic treatment success to monitor patientsâ disease progression.</div><div id="sec10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Oncology</h3><div class="NLM_p">To date, no clinically applicable predictive biomarkers have been identified for antiangiogenic treatments in oncology.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Predictive biomarkers that have been investigated include physiological parameters, such as hypertension; circulating markers, such as VEGF, soluble VEGFR, or PlGF; genetic markers; and functional tumor imaging.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was performed to assess the antiangiogenic effects of nintedanib directly in a phase I study of 42 patients with a variety of solid tumors.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Outcome measures were the initial area under the gadolinium concentrationâtime curve for the first 60 s after the onset of contrast agent uptake (iAUC<sub>60</sub>) and the transfer constant (<i>K</i><sup>trans</sup>). In response to nintedanib therapy, 17 of 42 evaluable patients had significant reductions (>40%) in iAUC<sub>60</sub> and 23 patients had significant reductions (>40%) in <i>K</i><sup>trans</sup>. These results confirm that the changes to the tumor vasculature expected during effective antiangiogenic therapy can indeed be observed in nintedanib-treated patients.</div><div class="NLM_p last">Tumor characteristics, including tumor burden and the dynamics of disease progression, may also have predictive potential for nintedanib therapy. In the LUME-Lung 1 study of nintedanib as a second-line treatment for NSCLC, mean OS for patients with adenocarcinoma histology and early progression after first-line treatment (time since start of first-line therapy <9 months) was significantly greater with nintedanib plus docetaxel versus placebo plus docetaxel.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> A subsequent analysis of data from both the LUME-Lung 1 and 2 studies confirmed time since start of first-line therapy <9 months as a predictive clinical biomarker for nintedanib plus cytotoxic therapy in NSCLC.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> For patients with NSCLC and squamous cell histology in the LUME-Lung 1 trial, patients with a high tumor burden (sum of longest diameters of target lesion â¥7.5 cm) showed a trend toward improved OS with nintedanib plus docetaxel versus placebo plus docetaxel (median OS 7.7 vs 6.1 months; HR = 0.82; <i>p</i> = 0.0995), in keeping with the trend for higher benefit with nintedanib in the patients with the poorest prognosis.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Expression of genes relevant to cell proliferation has been shown to be markedly higher for patients with rapid versus more modest disease progression, suggesting that aggressive tumors have a large fraction of proliferating cells.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> A high rate of cell proliferation is likely to require high levels of vascularization to deliver the nutrients to sustain growth. This may explain the benefit of antiangiogenic therapy with nintedanib in patients with early progressive disease. Further investigations are required to validate these potential molecular and clinical biomarkers of nintedanib benefit.</div></div><div id="sec10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Idiopathic Pulmonary Fibrosis</h3><div class="NLM_p last">As is the case in oncology, no validated predictive biomarker currently exists to guide the treatment of nintedanib in patients with IPF. Indeed, there are no clinically accepted biomarkers to predict disease progression and treatment efficacy, with the exception of lung function measurements. Patientsâ FVC is considered to be an adequate and objective physiological measure of disease progression and of the pathological process underlying IPF.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Although there is evidence to suggest that genetic or circulating protein biomarkers do contain prognostic information for IPF,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> no data are available with respect to nintedanib treatment.</div></div></div><div id="sec11" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87285" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87285" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">More than 15 years have passed since the initial lead optimization program for novel angiogenesis inhibitors was first initiated. Much effort has been expended to characterize and assess those initial leads, and nintedanib represents the fruit of that effort. The clinical efficacy and tolerability data for nintedanib in patients with a range of different tumor types, as well as patients with IPF, is highly encouraging, and it is hoped that nintedanib will be available as a treatment option for at least some of these indications in the not too distant future.<a onclick="showRef(event, 'ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref55 ref56">(55, 56)</a> However, there is more work to be done to understand the biological mechanisms underlying nintedanibâs efficacy, including the clinical significance of VEGFR, PDGFR, and FGFR inhibition first identified in selectivity testing. Identifying molecular biomarkers that can predict a response to nintedanib remains an important goal to help maximize the clinical benefit of this agent.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm501562a" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76085" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76085" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gerald J. Roth</span> - <span class="hlFld-Affiliation affiliation">â Department of Medicinal Chemistry; Â§Department of Drug
Metabolism and Pharmacokinetics; â¡Department of Non-Clinical
Drug Safety; â¥Department of Translational Medicine and Clinical
Pharmacology; â¥Department of Respiratory Diseases Research; and #Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany</span>;Â 
    <span class="hlFld-Affiliation affiliation">Clinical
Development and Medical Affairs, Respiratory, Boehringer Ingelheim Inc., Ridgefield, Connecticut 06877, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Boehringer Ingelheim
RCV GmbH & Co. KG, A-1121 Vienna, Austria</span>;Â 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#7a1d1f081b161e08150e123a18151f120813141d1f085713141d1f16121f131754191517"><span class="__cf_email__" data-cfemail="5c3b392e3d30382e3328341c3e3339342e35323b392e7135323b393034393531723f3331">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rudolf Binder</span> - <span class="hlFld-Affiliation affiliation">â Department of Medicinal Chemistry; Â§Department of Drug
Metabolism and Pharmacokinetics; â¡Department of Non-Clinical
Drug Safety; â¥Department of Translational Medicine and Clinical
Pharmacology; â¥Department of Respiratory Diseases Research; and #Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany</span>;Â 
    <span class="hlFld-Affiliation affiliation">Clinical
Development and Medical Affairs, Respiratory, Boehringer Ingelheim Inc., Ridgefield, Connecticut 06877, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Boehringer Ingelheim
RCV GmbH & Co. KG, A-1121 Vienna, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florian Colbatzky</span> - <span class="hlFld-Affiliation affiliation">â Department of Medicinal Chemistry; Â§Department of Drug
Metabolism and Pharmacokinetics; â¡Department of Non-Clinical
Drug Safety; â¥Department of Translational Medicine and Clinical
Pharmacology; â¥Department of Respiratory Diseases Research; and #Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany</span>;Â 
    <span class="hlFld-Affiliation affiliation">Clinical
Development and Medical Affairs, Respiratory, Boehringer Ingelheim Inc., Ridgefield, Connecticut 06877, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Boehringer Ingelheim
RCV GmbH & Co. KG, A-1121 Vienna, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudia Dallinger</span> - <span class="hlFld-Affiliation affiliation">â Department of Medicinal Chemistry; Â§Department of Drug
Metabolism and Pharmacokinetics; â¡Department of Non-Clinical
Drug Safety; â¥Department of Translational Medicine and Clinical
Pharmacology; â¥Department of Respiratory Diseases Research; and #Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany</span>;Â 
    <span class="hlFld-Affiliation affiliation">Clinical
Development and Medical Affairs, Respiratory, Boehringer Ingelheim Inc., Ridgefield, Connecticut 06877, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Boehringer Ingelheim
RCV GmbH & Co. KG, A-1121 Vienna, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rozsa Schlenker-Herceg</span> - <span class="hlFld-Affiliation affiliation">Clinical
Development and Medical Affairs, Respiratory, Boehringer Ingelheim Inc., Ridgefield, Connecticut 06877, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frank Hilberg</span> - <span class="hlFld-Affiliation affiliation">Boehringer Ingelheim
RCV GmbH & Co. KG, A-1121 Vienna, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan-Lutz Wollin</span> - <span class="hlFld-Affiliation affiliation">â Department of Medicinal Chemistry; Â§Department of Drug
Metabolism and Pharmacokinetics; â¡Department of Non-Clinical
Drug Safety; â¥Department of Translational Medicine and Clinical
Pharmacology; â¥Department of Respiratory Diseases Research; and #Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany</span>;Â 
    <span class="hlFld-Affiliation affiliation">Clinical
Development and Medical Affairs, Respiratory, Boehringer Ingelheim Inc., Ridgefield, Connecticut 06877, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Boehringer Ingelheim
RCV GmbH & Co. KG, A-1121 Vienna, Austria</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rolf Kaiser</span> - <span class="hlFld-Affiliation affiliation">â Department of Medicinal Chemistry; Â§Department of Drug
Metabolism and Pharmacokinetics; â¡Department of Non-Clinical
Drug Safety; â¥Department of Translational Medicine and Clinical
Pharmacology; â¥Department of Respiratory Diseases Research; and #Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany</span>;Â 
    <span class="hlFld-Affiliation affiliation">Clinical
Development and Medical Affairs, Respiratory, Boehringer Ingelheim Inc., Ridgefield, Connecticut 06877, United States</span>;Â 
    <span class="hlFld-Affiliation affiliation">Boehringer Ingelheim
RCV GmbH & Co. KG, A-1121 Vienna, Austria</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>G. J. Roth is the main inventor of nintedanib, acted as the program leader (medicinal chemistry) during the research phase, wrote the Structure and Synthesis, as well as Medicinal Chemistry and SAR sections, and critically reviewed the manuscript. F. Hilberg is a coinventor of nintedanib, was the program leader (biology) during the research phase, contributed the Target Engagement section, and critically reviewed the manuscript. S.-L. Wollin conducted preclinical experiments, wrote the pharmacodynamics IPF section, and critically reviewed the manuscript. R. Binder wrote the nonclinical pharmacokinetics/metabolism of nintedanib section and critically reviewed the manuscript. F. Colbatzky acted as contact person (oncology) during the research phase, helping to select nintedanib as a developmental candidate based on toxicological data, and as a team member during the development phase including CTD submission, wrote the Toxicology section, and critically reviewed the manuscript. C. Dallinger wrote the human ADME paragraph and critically reviewed the manuscript. R. Schlenker-Herceg acted as clinical program leader of nintedanib clinical development, provided guidance on the IPF section, and critically reviewed the manuscript. R. Kaiser is the International Medical Project Leader for phase IâIII studies in oncology, assisted with author co-ordination, and critically reviewed the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Gerald J. Roth, Rudolf Binder, Florian Colbatzky, Claudia Dallinger, Stefan-Lutz Wollin and Rolf Kaiser are employees of Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. Rozsa Schlenker-Herceg is an employee of Boehringer Ingelheim Inc., Ridgefield, CT, USA. Frank Hilberg is an employee of Boehringer Ingelheim RCV GmbH & Co. KG, A-1121 Vienna, Austria. Medical writing assistance, supported financially by Boehringer Ingelheim, was provided by Huw Jones of inVentiv Medical Communications, London.<br /></br></div></li></ul></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i23" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i23"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i24" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i24"> Abbreviations Used</h2><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximal concentration</p></td></tr><tr><td class="NLM_term">CRC</td><td class="NLM_def"><p class="first last">colorectal cancer</p></td></tr><tr><td class="NLM_term">CTCAE</td><td class="NLM_def"><p class="first last">common terminology criteria for adverse events</p></td></tr><tr><td class="NLM_term">CTD</td><td class="NLM_def"><p class="first last">common technical document</p></td></tr><tr><td class="NLM_term">DCE-MRI</td><td class="NLM_def"><p class="first last">dynamic contrast-enhanced magnetic resonance imaging</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">FIGO</td><td class="NLM_def"><p class="first last">International Federation of Gynecology and Obstetrics</p></td></tr><tr><td class="NLM_term">Flt-3</td><td class="NLM_def"><p class="first last">Fms-like tyrosine kinase 3</p></td></tr><tr><td class="NLM_term">FVC</td><td class="NLM_def"><p class="first last">forced vital capacity</p></td></tr><tr><td class="NLM_term">GGT</td><td class="NLM_def"><p class="first last">gamma-glutamyltransferase</p></td></tr><tr><td class="NLM_term">HCC</td><td class="NLM_def"><p class="first last">hepatocellular carcinoma</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">hazard ratio</p></td></tr><tr><td class="NLM_term">HUASMC</td><td class="NLM_def"><p class="first last">human umbilical artery smooth muscle cells</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cells</p></td></tr><tr><td class="NLM_term">IGF1R</td><td class="NLM_def"><p class="first last">insulin-like growth factor 1 receptor</p></td></tr><tr><td class="NLM_term">InsR</td><td class="NLM_def"><p class="first last">insulin receptor</p></td></tr><tr><td class="NLM_term">IPF</td><td class="NLM_def"><p class="first last">idiopathic pulmonary fibrosis</p></td></tr><tr><td class="NLM_term"><i>K</i><sup>trans</sup></td><td class="NLM_def"><p class="first last">transfer constant</p></td></tr><tr><td class="NLM_term">Lck</td><td class="NLM_def"><p class="first last">lymphocyte-specific protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">Lyn</td><td class="NLM_def"><p class="first last">Lck/Yes novel tyrosine kinase</p></td></tr><tr><td class="NLM_term">MRT</td><td class="NLM_def"><p class="first last">mean residence time</p></td></tr><tr><td class="NLM_term">NA</td><td class="NLM_def"><p class="first last">not applicable</p></td></tr><tr><td class="NLM_term">ND</td><td class="NLM_def"><p class="first last">not determined</p></td></tr><tr><td class="NLM_term">NT</td><td class="NLM_def"><p class="first last">not tested</p></td></tr><tr><td class="NLM_term">OS</td><td class="NLM_def"><p class="first last">overall survival</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PFS</td><td class="NLM_def"><p class="first last">progression-free survival</p></td></tr><tr><td class="NLM_term">P1GF</td><td class="NLM_def"><p class="first last">placental growth factor</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">SGRQ</td><td class="NLM_def"><p class="first last">St. Georgeâs respiratory questionnaire</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">sarcoma</p></td></tr><tr><td class="NLM_term">V(ss)</td><td class="NLM_def"><p class="first last">volume of distribution at steady state</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14111" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14111" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 56 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handschuh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Lintz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4466</span><span class="NLM_x">â</span> <span class="NLM_lpage">4480</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Roth, G. J.; Sieger, P.; Linz, G.; Rall, W.; Hilberg, F.; Bock, T.</span><span> </span><span class="NLM_article-title">3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone monoethanesulphonate and the use thereof as a pharmaceutical composition</span>. WO2004/013099.<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+J.+Roth&author=P.+Sieger&author=G.+Linz&author=W.+Rall&author=F.+Hilberg&author=T.+Bock&title=3-Z-%5B1-%284-%28N-%28%284-Methyl-piperazin-1-yl%29-methylcarbonyl%29-N-methyl-amino%29-anilino%29-1-phenyl-methylene%5D-6-methoxycarbonyl-2-indolinone+monoethanesulphonate+and+the+use+thereof+as+a+pharmaceutical+composition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26atitle%3D3-Z-%255B1-%25284-%2528N-%2528%25284-Methyl-piperazin-1-yl%2529-methylcarbonyl%2529-N-methyl-amino%2529-anilino%2529-1-phenyl-methylene%255D-6-methoxycarbonyl-2-indolinone%2520monoethanesulphonate%2520and%2520the%2520use%2520thereof%2520as%2520a%2520pharmaceutical%2520composition%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Merten, J.; Linz, G.; Schnaubelt, J.; Schmid, R.; Rall, W.; Renner, S.; Reichel, C.; Schiffers, R.</span><span> </span><span class="NLM_article-title">Process for the manufacture of an indolinone derivative</span>. WO2009/071523.<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+Merten&author=G.+Linz&author=J.+Schnaubelt&author=R.+Schmid&author=W.+Rall&author=S.+Renner&author=C.+Reichel&author=R.+Schiffers&title=Process+for+the+manufacture+of+an+indolinone+derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMerten%26aufirst%3DJ.%26atitle%3DProcess%2520for%2520the%2520manufacture%2520of%2520an%2520indolinone%2520derivative%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krssak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kautschitsch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommergruber, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span> </span><span class="NLM_article-title">BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">4774</span><span class="NLM_x">â</span> <span class="NLM_lpage">4782</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4774-4782&author=F.+Hilbergauthor=G.+J.+Rothauthor=M.+Krssakauthor=S.+Kautschitschauthor=W.+Sommergruberauthor=U.+Tontsch-Gruntauthor=P.+Garin-Chesaauthor=G.+Baderauthor=A.+Zoephelauthor=J.+Quantauthor=A.+Heckelauthor=W.+J.+Rettig&title=BIBF+1120%3A+triple+angiokinase+inhibitor+with+sustained+receptor+blockade+and+good+antitumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DKrssak%26aufirst%3DM.%26aulast%3DKautschitsch%26aufirst%3DS.%26aulast%3DSommergruber%26aufirst%3DW.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBIBF%25201120%253A%2520triple%2520angiokinase%2520inhibitor%2520with%2520sustained%2520receptor%2520blockade%2520and%2520good%2520antitumor%2520efficacy%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4774%26epage%3D4782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="note"><p class="first last">As described in ref <a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">1</a>, no inhibition of the following kinases was detected when analyzed at 10 Î¼mol/L with 100 Î¼mol/L ATP: AMPK, CAMK1, CDK2, CHK1, CHK2, CK1, CK2, CSK, DYRK1A, ERK2, ERK8, GSK3Î², JNK1A1, MAPKAPK2, MAPK2ERK2, MKK2, Mnk1, Mnk2, MSK1, NEK2A, NEK6, p38a, PKA, PKBÎ±, PKBb, PDK1, PKCÎ±, PHK, PKD1, Plk1, PRAK, PRK2, ROCKII, SAPK2AP38, S6K1, SAPK2BP38Î²2, SAPK3P38Î³, SAPK4P38Î´, SGK, SRPK1.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandstetter, I.</span><span> </span><span class="NLM_article-title">Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">S380</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=S380&author=F.+Hilbergauthor=I.+Brandstetter&title=Efficacy+of+BIBF+1120%2C+a+potent+triple+angiokinase+inhibitor%2C+in+models+of+human+non-small+cell+lung+cancer+is+augmented+by+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DBrandstetter%26aufirst%3DI.%26atitle%3DEfficacy%2520of%2520BIBF%25201120%252C%2520a%2520potent%2520triple%2520angiokinase%2520inhibitor%252C%2520in%2520models%2520of%2520human%2520non-small%2520cell%2520lung%2520cancer%2520is%2520augmented%2520by%2520chemotherapy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D2%26spage%3DS380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Wollin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maillet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quesniaux, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holweg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryffel, B.</span><span> </span><span class="NLM_article-title">Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1124%2Fjpet.113.208223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24556663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVCmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=209-220&author=L.+Wollinauthor=I.+Mailletauthor=V.+Quesniauxauthor=A.+Holwegauthor=B.+Ryffel&title=Antifibrotic+and+anti-inflammatory+activity+of+the+tyrosine+kinase+inhibitor+nintedanib+in+experimental+models+of+lung+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis</span></div><div class="casAuthors">Wollin, Lutz; Maillet, Isabelle; Quesniaux, Valerie; Holweg, Alexander; Ryffel, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-220, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clin. development for the treatment of idiopathic pulmonary fibrosis.  To explore its mode of action, nintedanib was tested in human lung fibroblasts and mouse models of lung fibrosis.  Human lung fibroblasts expressing platelet-derived growth factor (PDGF) receptor-Î± and -Î² were stimulated with platelet-derived growth factor BB (homodimer) (PDGF-BB).  Receptor activation was assessed by autophosphorylation and cell proliferation by bromodeoxyuridine incorporation.  Transforming growth factor Î² (TGFÎ²)-induced fibroblast to myofibroblast transformation was detd. by Î±-smooth muscle actin (Î±SMA) mRNA anal.  Lung fibrosis was induced in mice by intratracheal bleomycin or silica particle administration.  Nintedanib was administered every day by gavage at 30, 60, or 100 mg/kg.  Preventive nintedanib treatment regimen started on the day that bleomycin was administered.  Therapeutic treatment regimen started at various times after the induction of lung fibrosis.  Bleomycin caused increased macrophages and lymphocytes in the bronchoalveolar lavage (BAL) and elevated interleukin-1Î² (IL-1Î²), tissue inhibitor of metalloproteinase-1 (TIMP-1), and collagen in lung tissue.  Histol. revealed chronic inflammation and fibrosis.  Silica-induced lung pathol. addnl. showed elevated BAL neutrophils, keratinocyte chemoattractant (KC) levels, and granuloma formation.  Nintedanib inhibited PDGF receptor activation, fibroblast proliferation, and fibroblast to myofibroblast transformation.  Nintedanib significantly reduced BAL lymphocytes and neutrophils but not macrophages.  Furthermore, interleukin-1Î², KC, TIMP-1, and lung collagen were significantly reduced.  Histol. anal. showed significantly diminished lung inflammation, granuloma formation, and fibrosis.  The therapeutic effect was dependent on treatment start and duration.  Nintedanib inhibited receptor tyrosine kinase activation and the proliferation and transformation of human lung fibroblasts and showed antifibrotic and anti-inflammatory activity in two animal models of pulmonary fibrosis.  These results suggest that nintedanib may impact the progressive course of fibrotic lung diseases such as idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj82hlH5A1brVg90H21EOLACvtfcHk0liQCf7W8AAKzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVCmtLk%253D&md5=b8cb75e9d2630509986d9fb4760b263e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208223%26sid%3Dliteratum%253Aachs%26aulast%3DWollin%26aufirst%3DL.%26aulast%3DMaillet%26aufirst%3DI.%26aulast%3DQuesniaux%26aufirst%3DV.%26aulast%3DHolweg%26aufirst%3DA.%26aulast%3DRyffel%26aufirst%3DB.%26atitle%3DAntifibrotic%2520and%2520anti-inflammatory%2520activity%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520nintedanib%2520in%2520experimental%2520models%2520of%2520lung%2520fibrosis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D209%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Hostettler, K. E.; Papakonstantinou, E.; Klagas, J.; Karakiulakis, G.; Zhong, J.; Tamm, M.; Lardinois, D.; Roth, M.</span><span> </span><span class="NLM_article-title">Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from patients with idiopathic pulmonary fibrosis and from non-fibrotic controls</span>.  <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">187</span>, Abstract A3374.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2013&author=K.+E.+Hostettler&author=E.+Papakonstantinou&author=J.+Klagas&author=G.+Karakiulakis&author=J.+Zhong&author=M.+Tamm&author=D.+Lardinois&author=M.+Roth&title=Anti-fibrotic+effects+of+nintedanib+%28BIBF+1120%29+in+primary+human+lung+fibroblasts+derived+from+patients+with+idiopathic+pulmonary+fibrosis+and+from+non-fibrotic+controls"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHostettler%26aufirst%3DK.%2BE.%26atitle%3DAnti-fibrotic%2520effects%2520of%2520nintedanib%2520%2528BIBF%25201120%2529%2520in%2520primary%2520human%2520lung%2520fibroblasts%2520derived%2520from%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520from%2520non-fibrotic%2520controls%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2013%26volume%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Wollin, L.; Ostermann, A.; Wex, E.; Herrmann, F. E.; Doods, H.</span><span> </span><span class="NLM_article-title">Nintedanib attenuates motility of lung fibroblasts from patients with idiopathic pulmonary fibrosis</span>.  <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span>, Abstract A2008.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2014&author=L.+Wollin&author=A.+Ostermann&author=E.+Wex&author=F.+E.+Herrmann&author=H.+Doods&title=Nintedanib+attenuates+motility+of+lung+fibroblasts+from+patients+with+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWollin%26aufirst%3DL.%26atitle%3DNintedanib%2520attenuates%2520motility%2520of%2520lung%2520fibroblasts%2520from%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2014%26volume%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilenbaum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span> </span><span class="NLM_article-title">Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2542</span><span class="NLM_x">â</span> <span class="NLM_lpage">2550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1056%2FNEJMoa061884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=17167137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlWqsbzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2542-2550&author=A.+Sandlerauthor=R.+Grayauthor=M.+C.+Perryauthor=J.+Brahmerauthor=J.+H.+Schillerauthor=A.+Dowlatiauthor=R.+Lilenbaumauthor=D.+H.+Johnson&title=Paclitaxel-carboplatin+alone+or+with+bevacizumab+for+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</span></div><div class="casAuthors">Sandler, Alan; Gray, Robert; Perry, Michael C.; Brahmer, Julie; Schiller, Joan H.; Dowlati, Afshin; Lilenbaum, Rogerio; Johnson, David H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2542-2550</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers.  Between July 2001 and Apr. 2004, the Eastern Cooperative Oncol. Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434).  Chemotherapy was administered every 3 wk for six cycles, and bevacizumab was administered every 3 wk until disease progression was evident or toxic effects were intolerable.  Patients with squamous-cell tumors, brain metastases, clin. significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded.  The primary end point was overall survival.  The median survival was 12.3 mo in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 mo in the chemotherapy-alone group (hazard ratio for death, 0.79; P = 0.003).  The median progression-free survival in the two groups was 6.2 and 4.5 mo, resp. (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001).  Rates of clin. significant bleeding were 4.4% and 0.7%, resp. (P<0.001).  There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage.  The addn. of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHrplr-EnyyrVg90H21EOLACvtfcHk0lgwS6WW1oFhmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlWqsbzI&md5=f94c013f3961561feb564b2bf7148df4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa061884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa061884%26sid%3Dliteratum%253Aachs%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DPerry%26aufirst%3DM.%2BC.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DLilenbaum%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26atitle%3DPaclitaxel-carboplatin%2520alone%2520or%2520with%2520bevacizumab%2520for%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2542%26epage%3D2550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fyfe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">â</span> <span class="NLM_lpage">2342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0lgwS6WW1oFhmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Pathways mediating VEGF-independent tumor angiogenesis</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">â</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1016%2Fj.cytogfr.2009.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=20005148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFKgsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=21-26&author=N.+Ferrara&title=Pathways+mediating+VEGF-independent+tumor+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pathways mediating VEGF-independent tumor angiogenesis</span></div><div class="casAuthors">Ferrara, Napoleone</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-26</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  FDA approval of several inhibitors of the VEGF pathway has enabled significant advances in the therapy of cancer and neovascular age-related macular degeneration.  However, similar to other therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in patients, leading to disease progression.  So far the lack of predictive biomarkers has precluded identification of patients most likely to respond to such treatments.  Recent suggest that both tumor and non-tumor (stromal) cell types are involved in the reduced responsiveness to the treatments.  The present review examines the role of tumor- as well as stromal cell-derived pathways involved in tumor growth and in refractoriness to anti-VEGF therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD3to7NBagB7Vg90H21EOLACvtfcHk0lgwS6WW1oFhmw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFKgsrg%253D&md5=6ab03b42ee7c2d465b36cb9f709082b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2009.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2009.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DPathways%2520mediating%2520VEGF-independent%2520tumor%2520angiogenesis%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2010%26volume%3D21%26spage%3D21%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauguen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burcoveanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pignon, J. P.</span><span> </span><span class="NLM_article-title">meta-analysis of bevacizumab in advanced NSCLC collaborative group. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">â</span> <span class="NLM_lpage">30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1093%2Fannonc%2Fmds590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=23180113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC3s7mt1Sitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=20-30&author=J.+C.+Soriaauthor=A.+Mauguenauthor=M.+Reckauthor=A.+B.+Sandlerauthor=N.+Saijoauthor=D.+H.+Johnsonauthor=D.+Burcoveanuauthor=M.+Fukuokaauthor=B.+Besseauthor=J.+P.+Pignon&title=meta-analysis+of+bevacizumab+in+advanced+NSCLC+collaborative+group.+Systematic+review+and+meta-analysis+of+randomised%2C+phase+II%2FIII+trials+adding+bevacizumab+to+platinum-based+chemotherapy+as+first-line+treatment+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria J-C; Mauguen A; Reck M; Sandler A B; Saijo N; Johnson D H; Burcoveanu D; Fukuoka M; Besse B; Pignon J-P</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Previous studies have demonstrated the efficacy and safety of bevacizumab in the treatment of non-small-cell lung cancer (NSCLC).  METHODS:  Summary data from randomised trials comparing first-line bevacizumab plus platinum-based chemotherapy with chemotherapy alone for inoperable locally advanced, recurrent or metastatic NSCLC were meta-analysed.  Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and pooled odds ratio (OR) for adverse events were calculated.  The chi-squared tests evaluated interactions between treatment effects, and prognostic factors and patient characteristics.  RESULTS:  Data of 2194 patients (1313 bevacizumab; 881 controls) from four phase II and III trials: AVF-0757g, JO19907,ECOG 4599 and AVAiL, were analysed.  Compared with chemotherapy alone, bevacizumab significantly prolonged OS(HR 0.90; 95% confidence interval [CI] 0.81, 0.99; P=0.03), and PFS (0.72; 95% CI 0.66, 0.79; P<0.001).  Bevacizumab showed a significantly greater effect on OS in patients with adenocarcinoma versus other histologies (P=0.03), and patients with body weight loss â¤5% versus >5% (P=0.04).  Bevacizumab significantly increased the risk of grade â¥3 proteinuria, hypertension,haemorrhagic events, neutropenia, and febrile neutropenia [corrected].  CONCLUSIONS:  Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO7bsWktUBMw5nADWVYHg1fW6udTcc2eYjZnVWZ2aDx7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7mt1Sitw%253D%253D&md5=116a2ee349433c6d1bfc2c963e15e454</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds590%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DMauguen%26aufirst%3DA.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DSandler%26aufirst%3DA.%2BB.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26aulast%3DBurcoveanu%26aufirst%3DD.%26aulast%3DFukuoka%26aufirst%3DM.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DPignon%26aufirst%3DJ.%2BP.%26atitle%3Dmeta-analysis%2520of%2520bevacizumab%2520in%2520advanced%2520NSCLC%2520collaborative%2520group.%2520Systematic%2520review%2520and%2520meta-analysis%2520of%2520randomised%252C%2520phase%2520II%252FIII%2520trials%2520adding%2520bevacizumab%2520to%2520platinum-based%2520chemotherapy%2520as%2520first-line%2520treatment%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26spage%3D20%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Korc, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesel, R. E.</span><span> </span><span class="NLM_article-title">The role of fibroblast growth factors in tumor growth</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.2174%2F156800909789057006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=19508171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehtb7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=639-651&author=M.+Korcauthor=R.+E.+Friesel&title=The+role+of+fibroblast+growth+factors+in+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The role of fibroblast growth factors in tumor growth</span></div><div class="casAuthors">Korc, M.; Friesel, R. E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-651</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Biol. processes that drive cell growth are exciting targets for cancer therapy.  The fibroblast growth factor (FGF) signaling network plays a ubiquitous role in normal cell growth, survival, differentiation, and angiogenesis, but has also been implicated in tumor development.  Elucidation of the roles and relationships within the diverse FGF family and of their links to tumor growth and progression will be crit. in designing new drug therapies to target FGF receptor (FGFR) pathways.  Recent studies have shown that FGF can act synergistically with vascular endothelial growth factor (VEGF) to amplify tumor angiogenesis, highlighting that targeting of both the FGF and VEGF pathways may be more efficient in suppressing tumor growth and angiogenesis than targeting either factor alone.  In addn., through inducing tumor cell survival, FGF has the potential to overcome chemotherapy resistance highlighting that chemotherapy may be more effective when used in combination with FGF inhibitor therapy.  Furthermore, FGFRs have variable activity in promoting angiogenesis, with the FGFR-1 subgroup being assocd. with tumor progression and the FGFR-2 subgroup being assocd. with either early tumor development or decreased tumor progression.  This review highlights the growing knowledge of FGFs in tumor cell growth and survival, including an overview of FGF intracellular signaling pathways, the role of FGFs in angiogenesis, patterns of FGF and FGFR expression in various tumor types, and the role of FGFs in tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLQVriotus1LVg90H21EOLACvtfcHk0lgK68F1lNqRrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehtb7P&md5=674ac00a00899ee4fd3e46f543a946a7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F156800909789057006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800909789057006%26sid%3Dliteratum%253Aachs%26aulast%3DKorc%26aufirst%3DM.%26aulast%3DFriesel%26aufirst%3DR.%2BE.%26atitle%3DThe%2520role%2520of%2520fibroblast%2520growth%2520factors%2520in%2520tumor%2520growth%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2009%26volume%3D9%26spage%3D639%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Lindner, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majack, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reidy, M. A.</span><span> </span><span class="NLM_article-title">Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2004</span><span class="NLM_x">â</span> <span class="NLM_lpage">2008</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1990&pages=2004-2008&author=V.+Lindnerauthor=R.+A.+Majackauthor=M.+A.+Reidy&title=Basic+fibroblast+growth+factor+stimulates+endothelial+regrowth+and+proliferation+in+denuded+arteries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DV.%26aulast%3DMajack%26aufirst%3DR.%2BA.%26aulast%3DReidy%26aufirst%3DM.%2BA.%26atitle%3DBasic%2520fibroblast%2520growth%2520factor%2520stimulates%2520endothelial%2520regrowth%2520and%2520proliferation%2520in%2520denuded%2520arteries%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1990%26volume%3D85%26spage%3D2004%26epage%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Berger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setinek, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindas-Mugge, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetterlein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckersberger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micksche, M.</span><span> </span><span class="NLM_article-title">Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">â</span> <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1002%2F%28SICI%291097-0215%2819991029%2983%3A3%3C415%3A%3AAID-IJC19%3E3.0.CO%3B2-Y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=10495436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADyaK1MXntVelt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1999&pages=415-423&author=W.+Bergerauthor=U.+Setinekauthor=T.+Mohrauthor=I.+Kindas-Muggeauthor=M.+Vetterleinauthor=G.+Dekanauthor=F.+Eckersbergerauthor=C.+Caldasauthor=M.+Micksche&title=Evidence+for+a+role+of+FGF-2+and+FGF+receptors+in+the+proliferation+of+non-small+cell+lung+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells</span></div><div class="casAuthors">Berger, Walter; Setinek, Ulrike; Mohr, Thomas; Kindas-Mugge, Ingela; Vetterlein, Monika; Dekan, Gerhard; Eckersberger, Franz; Caldas, Carlos; Micksche, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Basic fibroblast growth factor (FGF-2) has been implicated in the progression of human tumors via both autocrine and paracrine (angiogenic) activities.  We investigated the expression of FGF-2 and FGF receptors (FGFR-1 to -4) in NSCLC cell lines (N = 16), NSCLC surgical specimens (N = 21) and 2 control cell lines.  Our data show that almost all NSCLC cells produce elevated levels of FGF-2 and FGFR in vitro and in vivo.  FGF-2 expression did correlate with a short doubling time as well as with potent anchorage-independent growth of NSCLC cell lines.  In contrast with control cells, NSCLC cells did not secrete considerable amts. of FGF-2 into the extracellular space.  Expression levels of FGFR-1 and -2 in NSCLC cell lines correlated with FGF-2 prodn.  FGFR were located at the plasma membranes in some low FGF-2-producing NSCLC and control cell lines.  These cells were sensitive to the proliferative effect of recombinant FGF-2 (rFGF-2).  In NSCLC cell lines with an enhanced FGF-2 prodn., representing the majority studied, FGFR localization was predominantly intracellular.  These cells were insensitive to both the proliferative effect of rFGF-2 and growth inhibition by FGF-2-neutralizing antibodies.  In contrast, several agents antagonized FGF-2 intracellularly impaired growth of almost all NSCLC cell lines.  Our data suggest a role of FGF-2 and FGFR in the growth stimulation of NSCLC cells possibly via an intracrine mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHR37uS77B7Vg90H21EOLACvtfcHk0lgK68F1lNqRrw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVelt7s%253D&md5=45d065a4230842aaa6d034ee9cd497c5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819991029%2983%3A3%3C415%3A%3AAID-IJC19%3E3.0.CO%3B2-Y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819991029%252983%253A3%253C415%253A%253AAID-IJC19%253E3.0.CO%253B2-Y%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DSetinek%26aufirst%3DU.%26aulast%3DMohr%26aufirst%3DT.%26aulast%3DKindas-Mugge%26aufirst%3DI.%26aulast%3DVetterlein%26aufirst%3DM.%26aulast%3DDekan%26aufirst%3DG.%26aulast%3DEckersberger%26aufirst%3DF.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DMicksche%26aufirst%3DM.%26atitle%3DEvidence%2520for%2520a%2520role%2520of%2520FGF-2%2520and%2520FGF%2520receptors%2520in%2520the%2520proliferation%2520of%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1999%26volume%3D83%26spage%3D415%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ho, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, B. T.</span><span> </span><span class="NLM_article-title">Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">â</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=51-62&author=H.+K.+Hoauthor=A.+H.+Yeoauthor=T.+S.+Kangauthor=B.+T.+Chua&title=Current+strategies+for+inhibiting+FGFR+activities+in+clinical+applications%3A+opportunities%2C+challenges+and+toxicological+considerations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DYeo%26aufirst%3DA.%2BH.%26aulast%3DKang%26aufirst%3DT.%2BS.%26aulast%3DChua%26aufirst%3DB.%2BT.%26atitle%3DCurrent%2520strategies%2520for%2520inhibiting%2520FGFR%2520activities%2520in%2520clinical%2520applications%253A%2520opportunities%252C%2520challenges%2520and%2520toxicological%2520considerations%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D51%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Heldin, C. H.</span><span> </span><span class="NLM_article-title">Targeting the PDGF signaling pathway in tumor treatment</span> <span class="citation_source-journal">Cell Commun. Signal</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1186%2F1478-811X-11-97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24359404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFOrurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=97&author=C.+H.+Heldin&title=Targeting+the+PDGF+signaling+pathway+in+tumor+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PDGF signaling pathway in tumor treatment</span></div><div class="casAuthors">Heldin, Carl-Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Cell Communication and Signaling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97/1-97/18, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">CCSEC6</span>;
        ISSN:<span class="NLM_cas:issn">1478-811X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Platelet-derived growth factor (PDGF) isoforms and PDGF receptors have important functions in the regulation of growth and survival of certain cell types during embryonal development and e.g. tissue repair in the adult.  Overactivity of PDGF receptor signaling, by overexpression or mutational events, may drive tumor cell growth.  In addn., pericytes of the vasculature and fibroblasts and myofibroblasts of the stroma of solid tumors express PDGF receptors and PDGF stimulation of such cells promotes tumorigenesis.  Inhibition of PDGF receptor signaling has proven to useful for the treatment of patients with certain rare tumors.  Whether treatment with PDGF/PDGF receptor antagonists will be beneficial for more common malignancies is the subject for ongoing studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnS6tBwNOJdbVg90H21EOLACvtfcHk0li70nNapLi6lg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFOrurk%253D&md5=17774f39a3f8214700471a9def048aa6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2F1478-811X-11-97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1478-811X-11-97%26sid%3Dliteratum%253Aachs%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26atitle%3DTargeting%2520the%2520PDGF%2520signaling%2520pathway%2520in%2520tumor%2520treatment%26jtitle%3DCell%2520Commun.%2520Signal%26date%3D2013%26volume%3D11%26spage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colby, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordier, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancochea, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johkoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudden, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griss, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzko, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schunemann, H. J.</span><span> </span><span class="NLM_article-title">ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">â</span> <span class="NLM_lpage">824</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1164%2Frccm.2009-040GL" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21471066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjvFWqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=788-824&author=G.+Raghuauthor=H.+R.+Collardauthor=J.+J.+Eganauthor=F.+J.+Martinezauthor=J.+Behrauthor=K.+K.+Brownauthor=T.+V.+Colbyauthor=J.+F.+Cordierauthor=K.+R.+Flahertyauthor=J.+A.+Laskyauthor=D.+A.+Lynchauthor=J.+H.+Ryuauthor=J.+J.+Swigrisauthor=A.+U.+Wellsauthor=J.+Ancocheaauthor=D.+Bourosauthor=C.+Carvalhoauthor=U.+Costabelauthor=M.+Ebinaauthor=D.+M.+Hansellauthor=T.+Johkohauthor=D.+S.+Kimauthor=T.+E.+Kingauthor=Y.+Kondohauthor=J.+Myersauthor=N.+L.+Mullerauthor=A.+G.+Nicholsonauthor=L.+Richeldiauthor=M.+Selmanauthor=R.+F.+Duddenauthor=B.+S.+Grissauthor=S.+L.+Protzkoauthor=H.+J.+Schunemann&title=ATS%2FERS%2FJRS%2FALAT+Committee+on+Idiopathic+Pulmonary+Fibrosis.+An+official+ATS%2FERS%2FJRS%2FALAT+statement%3A+idiopathic+pulmonary+fibrosis%3A+evidence-based+guidelines+for+diagnosis+and+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</span></div><div class="casAuthors">Raghu Ganesh; Collard Harold R; Egan Jim J; Martinez Fernando J; Behr Juergen; Brown Kevin K; Colby Thomas V; Cordier Jean-Francois; Flaherty Kevin R; Lasky Joseph A; Lynch David A; Ryu Jay H; Swigris Jeffrey J; Wells Athol U; Ancochea Julio; Bouros Demosthenes; Carvalho Carlos; Costabel Ulrich; Ebina Masahito; Hansell David M; Johkoh Takeshi; Kim Dong Soon; King Talmadge E Jr; Kondoh Yasuhiro; Myers Jeffrey; Muller Nestor L; Nicholson Andrew G; Richeldi Luca; Selman Moises; Dudden Rosalind F; Griss Barbara S; Protzko Shandra L; Schunemann Holger J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-824</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association.  It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course.  For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format.  For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak).  Recommendations were based on majority vote.  It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd3NNagTHJTiXXDYhVZBdlfW6udTcc2eakMTDkQ9vB4rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjvFWqsQ%253D%253D&md5=f47abe4551c8684d3af81f66598e9b2c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1164%2Frccm.2009-040GL&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.2009-040GL%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DEgan%26aufirst%3DJ.%2BJ.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DColby%26aufirst%3DT.%2BV.%26aulast%3DCordier%26aufirst%3DJ.%2BF.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DLasky%26aufirst%3DJ.%2BA.%26aulast%3DLynch%26aufirst%3DD.%2BA.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DAncochea%26aufirst%3DJ.%26aulast%3DBouros%26aufirst%3DD.%26aulast%3DCarvalho%26aufirst%3DC.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DEbina%26aufirst%3DM.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DJohkoh%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DMyers%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DN.%2BL.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DDudden%26aufirst%3DR.%2BF.%26aulast%3DGriss%26aufirst%3DB.%2BS.%26aulast%3DProtzko%26aufirst%3DS.%2BL.%26aulast%3DSchunemann%26aufirst%3DH.%2BJ.%26atitle%3DATS%252FERS%252FJRS%252FALAT%2520Committee%2520on%2520Idiopathic%2520Pulmonary%2520Fibrosis.%2520An%2520official%2520ATS%252FERS%252FJRS%252FALAT%2520statement%253A%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520evidence-based%2520guidelines%2520for%2520diagnosis%2520and%2520management%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D788%26epage%3D824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Fernandez, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickelberg, O.</span><span> </span><span class="NLM_article-title">The impact of TGF-beta on lung fibrosis: from targeting to biomarkers</span> <span class="citation_source-journal">Proc. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">â</span> <span class="NLM_lpage">1116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1513%2Fpats.201203-023AW" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22802283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKju7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=111-1116&author=I.+E.+Fernandezauthor=O.+Eickelberg&title=The+impact+of+TGF-beta+on+lung+fibrosis%3A+from+targeting+to+biomarkers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of TGF-Î² on lung fibrosis. From targeting to biomarkers</span></div><div class="casAuthors">Fernandez, Isis E.; Eickelberg, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">111-116</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Transforming growth factor-Î² (TGF-Î²) is extensively involved in the development of fibrosis in different organs.  Overprodn. or potentiation of its profibrotic effects leads to an aberrant wound healing response during the initiation of fibrotic processes.  Idiopathic pulmonary fibrosis (IPF) is a chronic, devastating disease, in which TGF-Î²-induced disturbances of the homeostatic microenvironment are crit. to promote cell activation, migration, invasion, or hyperplastic changes.  In addn., excess extracellular matrix prodn. contributes in a major way to disease pathogenesis.  For this reason, this review will focus on discussing novel data and highlight growing interest in deepening the understanding of the profibrotic role of TGF-Î² and its direct or indirect targeting for disease modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-7pApbz3eBbVg90H21EOLACvtfcHk0lj0BF8wKLv8YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKju7%252FF&md5=44317d32bc6dcadf7219209cfa590908</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1513%2Fpats.201203-023AW&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.201203-023AW%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DI.%2BE.%26aulast%3DEickelberg%26aufirst%3DO.%26atitle%3DThe%2520impact%2520of%2520TGF-beta%2520on%2520lung%2520fibrosis%253A%2520from%2520targeting%2520to%2520biomarkers%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2012%26volume%3D9%26spage%3D111%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniloff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, L. S.</span><span> </span><span class="NLM_article-title">Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">â</span> <span class="NLM_lpage">773</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1164%2Frccm.2010014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=12204879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BD38vkslGgsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2002&pages=765-773&author=Y.+Inoueauthor=T.+E.+Kingauthor=E.+Barkerauthor=E.+Daniloffauthor=L.+S.+Newman&title=Basic+fibroblast+growth+factor+and+its+receptors+in+idiopathic+pulmonary+fibrosis+and+lymphangioleiomyomatosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis</span></div><div class="casAuthors">Inoue Yoshikazu; King Talmadge E Jr; Barker Elizabeth; Daniloff Elaine; Newman Lee S</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">765-73</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Basic fibroblast growth factor (bFGF) is a potent mitogenic factor for smooth muscle cells, myofibroblasts, and fibroblasts, proliferation of which is a hallmark of idiopathic pulmonary fibrosis (IPF) and lymphangioleiomyomatosis (LAM).  Mast cells produce bFGF and have been associated with pulmonary fibrosis.  We hypothesize that smooth muscle cell/myofibroblast-like cells will be spatially associated with bFGF-containing mast cells and that bFGF receptors will be expressed on the effector cells in IPF and LAM.  We performed quantitative immunohistochemistry for bFGF, mast cell tryptase, smooth muscle actin for smooth muscle cell/myofibroblast-like cells, and fibroblast growth factor receptors (Flg, Bek) and measured collagen and elastic fiber in lung sections from IPF (n = 14), LAM (n = 9), and control lung (n = 10).  IPF and LAM lung contained more smooth muscle cell/myofibroblast-like cells than did control lung. bFGF-containing mast cells were abundant both in IPF and LAM and were associated with collagen, elastic fibers, and smooth muscle cell/myofibroblast-like cells in IPF.  Flg was expressed on epithelial cells, endothelial cells, smooth muscle cell/myofibroblast-like cells, and macrophages in IPF.  In LAM, Flg was expressed on epithelial cells adjacent to smooth muscle cell/myofibroblast-like cell aggregates.  Bek was expressed dominantly on smooth muscle cell/myofibroblast-like cells in LAM and on smooth muscle cell/myofibroblast-like cells as well as neutrophils in IPF.  These data suggest that mast cell-derived bFGF might exert fibrogenic, proliferative effects on smooth muscle cell/myofibroblast-like cells through its receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIOJoTcbBscyCEBeYuoi7AfW6udTcc2eY8WooUCe9exLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vkslGgsQ%253D%253D&md5=76afcf75d65d9dd16c8eb47c54b146e3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1164%2Frccm.2010014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.2010014%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DBarker%26aufirst%3DE.%26aulast%3DDaniloff%26aufirst%3DE.%26aulast%3DNewman%26aufirst%3DL.%2BS.%26atitle%3DBasic%2520fibroblast%2520growth%2520factor%2520and%2520its%2520receptors%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520lymphangioleiomyomatosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2002%26volume%3D166%26spage%3D765%26epage%3D773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Hetzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trischler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faehling, M.</span><span> </span><span class="NLM_article-title">Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">â</span> <span class="NLM_lpage">237</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2005&pages=225-237&author=M.+Hetzelauthor=M.+Bachemauthor=D.+Andersauthor=G.+Trischlerauthor=M.+Faehling&title=Different+effects+of+growth+factors+on+proliferation+and+matrix+production+of+normal+and+fibrotic+human+lung+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHetzel%26aufirst%3DM.%26aulast%3DBachem%26aufirst%3DM.%26aulast%3DAnders%26aufirst%3DD.%26aulast%3DTrischler%26aufirst%3DG.%26aulast%3DFaehling%26aufirst%3DM.%26atitle%3DDifferent%2520effects%2520of%2520growth%2520factors%2520on%2520proliferation%2520and%2520matrix%2520production%2520of%2520normal%2520and%2520fibrotic%2520human%2520lung%2520fibroblasts%26jtitle%3DLung%26date%3D2005%26volume%3D183%26spage%3D225%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Yu, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span> </span><span class="NLM_article-title">Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice</span> <span class="citation_source-journal">Biol. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">â</span> <span class="NLM_lpage">736</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1248%2Fbpb.35.731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22687409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFOmtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=731-736&author=Z.+H.+Yuauthor=D.+D.+Wangauthor=Z.+Y.+Zhouauthor=S.+L.+Heauthor=A.+A.+Chenauthor=J.+Wang&title=Mutant+soluble+ectodomain+of+fibroblast+growth+factor+receptor-2+IIIc+attenuates+bleomycin-induced+pulmonary+fibrosis+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice</span></div><div class="casAuthors">Yu, Zhi-hong; Wang, Ding-ding; Zhou, Zhi-you; He, Shui-lian; Chen, An-an; Wang, Ju</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-736</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">We have developed a strong inhibitor (S252W mutant sol. ectodomain of fibroblast growth factor receptor-2 IIIc, msFGFR2) that binds FGFs strongly and blocks the activation of FGFRs.  In vitro, msFGFR2 could inhibit the promoting effect of transforming growth factor (TGF)-Î²1 on the proliferation of primary lung fibroblasts.  In vivo, msFGFR2 alleviated lung fibrosis through inhibiting the expression of Î±-smooth muscle actin (SMA) and collagen deposit.  In Western blotting of the right lung tissues and immunohistochem. assay, we found the level of p-FGFRs, p-mitogen activated protein kinase (MAPK) and p-Smad3 in the mice of bleomycin (BLM) group treated with msFGFR2 was down dramatically compared with the mice of BLM group, which suggested the activations of FGF and TGF-Î² signals were blocked meanwhile.  In summary, msFGFR2 attenuated BLM-induced fibrosis and is an attractive therapeutic candidate for human pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYRow5kugSxbVg90H21EOLACvtfcHk0lj0BF8wKLv8YA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFOmtbc%253D&md5=ffcd92974b96ea20ca8c40b94bd77cbc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1248%2Fbpb.35.731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.35.731%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DWang%26aufirst%3DD.%2BD.%26aulast%3DZhou%26aufirst%3DZ.%2BY.%26aulast%3DHe%26aufirst%3DS.%2BL.%26aulast%3DChen%26aufirst%3DA.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DMutant%2520soluble%2520ectodomain%2520of%2520fibroblast%2520growth%2520factor%2520receptor-2%2520IIIc%2520attenuates%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2012%26volume%3D35%26spage%3D731%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Chetta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foresi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâIppolito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saetta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, D.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1437</span><span class="NLM_x">â</span> <span class="NLM_lpage">1442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1111%2Fj.1365-2222.2005.02360.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=16297139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCjtrzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2005&pages=1437-1442&author=A.+Chettaauthor=A.+Zaniniauthor=A.+Foresiauthor=R.+D%E2%80%99Ippolitoauthor=A.+Tipaauthor=A.+Castagnaroauthor=S.+Baraldoauthor=M.+Neriauthor=M.+Saettaauthor=D.+Olivieri&title=Vascular+endothelial+growth+factor+up-regulation+and+bronchial+wall+remodelling+in+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma</span></div><div class="casAuthors">Chetta, A.; Zanini, A.; Foresi, A.; D'Ippolito, R.; Tipa, A.; Castagnaro, A.; Baraldo, S.; Neri, M.; Saetta, M.; Olivieri, D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Allergy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1437-1442</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">There is increasing in vitro evidence to support a role for vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, as a mediator of fibrosis assocd. with neovascularization.  We tested the hypothesis that VEGF is involved both in increased airway mucosal vascularity and in the subepithelial fibrosis of asthmatic patients.  Bronchial biopsies were performed in 24 asthmatic patients and eight healthy controls.  Immunostaining, using computerized image anal., was performed using monoclonal antibodies against VEGF+ cells, type IV collagen, to outline the basement membrane thickness, and tryptase and EG2, to identify mast cells and eosinophils, resp.  The counts of VEGF+ cells (P < 0.05), mast cells and EG2+ cells (both P < 0.01) were higher in asthmatics than in controls.  The no. of vessels, the vascular area in the lamina propria, and the basement membrane thickness were significantly higher in asthmatics than in healthy volunteers (P < 0.01).  Moreover, in asthmatic patients, the no. of VEGF+ cells was significantly related to the no. of vessels (P < 0.01), to mast cells (P < 0.01) and to basement membrane thickness (P < 0.01).  A colocalization study also revealed that mast cells were a relevant cellular source of VEGF.  High doses of inhaled fluticasone propionate significantly reduced VEGF+ cells (P < 0.05), vessel no. (P < 0.05), vascular area (P < 0.05) and basement membrane thickness (P < 0.05) in a subgroup of asthmatic patients.  This study shows that VEGF, in addn. to being involved in the vascular component of airway remodelling, may play a role in the thickening of the basement membrane in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNsqQT2mbugbVg90H21EOLACvtfcHk0lg8BqMudNdvVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCjtrzK&md5=2c3d69d9c393624d5f8e1cfe8202abcc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.2005.02360.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.2005.02360.x%26sid%3Dliteratum%253Aachs%26aulast%3DChetta%26aufirst%3DA.%26aulast%3DZanini%26aufirst%3DA.%26aulast%3DForesi%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Ippolito%26aufirst%3DR.%26aulast%3DTipa%26aufirst%3DA.%26aulast%3DCastagnaro%26aufirst%3DA.%26aulast%3DBaraldo%26aufirst%3DS.%26aulast%3DNeri%26aufirst%3DM.%26aulast%3DSaetta%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DD.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520up-regulation%2520and%2520bronchial%2520wall%2520remodelling%2520in%2520asthma%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2005%26volume%3D35%26spage%3D1437%26epage%3D1442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Hamada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiasa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egashira, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, Y.</span><span> </span><span class="NLM_article-title">Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">1224</span><span class="NLM_x">â</span> <span class="NLM_lpage">1231</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2005&pages=1224-1231&author=N.+Hamadaauthor=K.+Kuwanoauthor=M.+Yamadaauthor=N.+Hagimotoauthor=K.+Hiasaauthor=K.+Egashiraauthor=N.+Nakashimaauthor=T.+Maeyamaauthor=M.+Yoshimiauthor=Y.+Nakanishi&title=Anti-vascular+endothelial+growth+factor+gene+therapy+attenuates+lung+injury+and+fibrosis+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamada%26aufirst%3DN.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DHagimoto%26aufirst%3DN.%26aulast%3DHiasa%26aufirst%3DK.%26aulast%3DEgashira%26aufirst%3DK.%26aulast%3DNakashima%26aufirst%3DN.%26aulast%3DMaeyama%26aufirst%3DT.%26aulast%3DYoshimi%26aufirst%3DM.%26aulast%3DNakanishi%26aufirst%3DY.%26atitle%3DAnti-vascular%2520endothelial%2520growth%2520factor%2520gene%2520therapy%2520attenuates%2520lung%2520injury%2520and%2520fibrosis%2520in%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2005%26volume%3D175%26spage%3D1224%26epage%3D1231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathgen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¼dtke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marzin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebner, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">â</span> <span class="NLM_lpage">311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=297-311&author=P.+Stopferauthor=K.+Rathgenauthor=D.+Bischoffauthor=S.+L%C3%BCdtkeauthor=K.+Marzinauthor=R.+Kaiserauthor=K.+Wagnerauthor=T.+Ebner&title=Pharmacokinetics+and+metabolism+of+BIBF+1120+after+oral+dosing+to+healthy+male+volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DRathgen%26aufirst%3DK.%26aulast%3DBischoff%26aufirst%3DD.%26aulast%3DL%25C3%25BCdtke%26aufirst%3DS.%26aulast%3DMarzin%26aufirst%3DK.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DEbner%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520metabolism%2520of%2520BIBF%25201120%2520after%2520oral%2520dosing%2520to%2520healthy%2520male%2520volunteers%26jtitle%3DXenobiotica%26date%3D2011%26volume%3D41%26spage%3D297%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienast, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanic, M.</span><span> </span><span class="NLM_article-title">Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients</span> <span class="citation_source-journal">Eur. J. Cancer Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><div class="note"><p class="first last">(Abstract 73)</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1016%2FS1359-6349%2806%2970079-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=26&author=P.+Stopferauthor=W.+Rothauthor=K.+Mrossauthor=I.+R.+Judsonauthor=J.+Kienastauthor=R.+Kaiserauthor=M.+Stefanic&title=Pharmacokinetic+characterization+of+BIBF+1120%2C+an+orally+active+triple+angiokinase+inhibitor+%28VEGFR%2C+PDGFR%2C+FGFR%29+in+advanced+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1359-6349%2806%2970079-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6349%252806%252970079-9%26sid%3Dliteratum%253Aachs%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DW.%26aulast%3DMross%26aufirst%3DK.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DKienast%26aufirst%3DJ.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DStefanic%26aufirst%3DM.%26atitle%3DPharmacokinetic%2520characterization%2520of%2520BIBF%25201120%252C%2520an%2520orally%2520active%2520triple%2520angiokinase%2520inhibitor%2520%2528VEGFR%252C%2520PDGFR%252C%2520FGFR%2529%2520in%2520advanced%2520cancer%2520patients%26jtitle%3DEur.%2520J.%2520Cancer%2520Suppl.%26date%3D2006%26volume%3D4%26spage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmehling, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strecker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henning, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Rossi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span> </span><span class="NLM_article-title">Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">â</span> <span class="NLM_lpage">319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1158%2F1078-0432.CCR-09-0694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=20028771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Sn" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=311-319&author=K.+Mrossauthor=M.+Stefanicauthor=D.+Gmehlingauthor=A.+Frostauthor=F.+Baasauthor=C.+Ungerauthor=R.+Streckerauthor=J.+Henningauthor=B.+Gaschler-Markefskiauthor=P.+Stopferauthor=L.+de+Rossiauthor=R.+Kaiser&title=Phase+I+study+of+the+angiogenesis+inhibitor+BIBF+1120+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Mross, Klaus; Stefanic, Martin; Gmehling, Daniela; Frost, Annette; Baas, Franziska; Unger, Clemens; Strecker, Ralph; Henning, Juergen; Gaschler-Markefski, Birgit; Stopfer, Peter; de Rossi, Lothar; Kaiser, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">311-319</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: BIBF 1120 is an oral, potent angiokinase inhibitor targeting receptors of the vascular endothelial growth factors, platelet-derived growth factors, and fibroblast growth factors.  This phase I, accelerated titrn. study assessed the max. tolerated dose, safety, pharmacokinetics, and pharmacodynamic effects of BIBF 1120.  Patients and Methods: Sixty-one patients with advanced cancers received BIBF 1120 in successive cohorts.  Twenty-five received 50 to 450 mg once daily and 36 received 150 to 300 mg twice daily in 4-wk treatment courses interspersed by 1 wk of washout.  Dynamic contrast-enhanced magnetic resonance imaging assessed antiangiogenic effect in 42 patients.  Results: Most frequent BIBF 1120-related adverse events were mostly mild to moderate (Common Toxicity Criteria grade 1-2) nausea (68.9%), vomiting (45.9%), and diarrhea (44.3%).  The majority of dose-limiting adverse events of Common Toxicity Criteria grade 3 or 4 were reversible liver enzyme elevations.  The max. tolerated dose was 250 mg of BIBF 1120 for once and twice daily dosing.  BIBF 1120 was absorbed moderately fast (tmax = 1-3 h at steady state), with no deviation from dose linearity and no decrease of exposure over time.  The gMean terminal half-life was from 13 to 19 h.  One complete and two partial responses occurred in patients with renal cell cancer (n = 2) and colorectal cancer (n = 1).  Dynamic contrast-enhanced magnetic resonance imaging showed a significant redn. in tumor blood flow in 55% of evaluable patients.  Conclusions: BIBF 1120 dosed continuously displayed a favorable safety and pharmacokinetics profile, and first efficacy signals were obsd.  Twice daily dosing permitted increased drug exposure without addnl. toxicity.  Two hundred milligrams BIBF 1120 twice daily is the recommended dose for phase II monotherapy studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg1SqFYDdXp7Vg90H21EOLACvtfcHk0lic2riPPVOWFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Sn&md5=608e438665fa3f523b3fce6cd7de3842</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0694%26sid%3Dliteratum%253Aachs%26aulast%3DMross%26aufirst%3DK.%26aulast%3DStefanic%26aufirst%3DM.%26aulast%3DGmehling%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DBaas%26aufirst%3DF.%26aulast%3DUnger%26aufirst%3DC.%26aulast%3DStrecker%26aufirst%3DR.%26aulast%3DHenning%26aufirst%3DJ.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3Dde%2BRossi%26aufirst%3DL.%26aulast%3DKaiser%26aufirst%3DR.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520angiogenesis%2520inhibitor%2520BIBF%25201120%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D311%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinaga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarashina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2825</span><span class="NLM_x">â</span> <span class="NLM_lpage">2833</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1158%2F1535-7163.MCT-10-0379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=20688946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KhtrnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2825-2833&author=I.+Okamotoauthor=H.+Kanedaauthor=T.+Satohauthor=W.+Okamotoauthor=M.+Miyazakiauthor=R.+Morinagaauthor=S.+Uedaauthor=M.+Terashimaauthor=A.+Tsuyaauthor=A.+Sarashinaauthor=K.+Konishiauthor=T.+Araoauthor=K.+Nishioauthor=R.+Kaiserauthor=K.+Nakagawa&title=Phase+I+safety%2C+pharmacokinetic%2C+and+biomarker+study+of+BIBF+1120%2C+an+oral+triple+tyrosine+kinase+inhibitor+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Okamoto, Isamu; Kaneda, Hiroyasu; Satoh, Taroh; Okamoto, Wataru; Miyazaki, Masaki; Morinaga, Ryotaro; Ueda, Shinya; Terashima, Masaaki; Tsuya, Asuka; Sarashina, Akiko; Konishi, Koichi; Arao, Tokuzo; Nishio, Kazuto; Kaiser, Rolf; Nakagawa, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2825-2833</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BIBF 1120 is an oral multitargeted tyrosine kinase inhibitor that blocks the activity of vascular endothelial growth factor (VEGF) and other growth factor receptors.  We have done a phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamic biomarkers of BIBF 1120.  Patients with advanced refractory solid tumors were treated with BIBF 1120 at oral doses of 150 to 250 mg twice daily.  Drug safety and pharmacokinetics were evaluated, as were baseline and post-treatment levels of circulating CD117-pos. bone marrow-derived progenitor cells and plasma sol. VEGF receptor 2 as potential biomarkers for BIBF 1120.  Twenty-one patients were treated at BIBF 1120 doses of 150 (n = 3), 200 (n = 12), or 250 mg twice daily (n = 6).  Dose-limiting toxicities of reversible grade 3 or 4 elevations of liver enzymes occurred in 3 of 12 patients at 200 mg twice daily and 3 of 6 patients at 250 mg twice daily.  Stable disease was achieved in 16 (76.2%) patients, and median progression-free survival was 113 days (95% confidence interval, 77-119 d).  Pharmacokinetic anal. indicated that the max. plasma concn. and area under the curve for BIBF 1120 increased with the dose within the dose range tested.  Levels of CD117-pos. bone marrow-derived progenitors and sol. VEGF receptor 2 decreased significantly during treatment over all BIBF 1120 dose cohorts.  In conclusion, the max. tolerated dose of BIBF 1120 in the current study was detd. to be 200 mg twice daily, and our biomarker anal. indicated that this angiokinase inhibitor is biol. active.  Mol Cancer Ther; 9(10); 2825-33.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvoGtHJ_4nebVg90H21EOLACvtfcHk0lic2riPPVOWFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KhtrnJ&md5=dd4f6a5b88239fcb5ebdf1ee219dd4f4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0379%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DKaneda%26aufirst%3DH.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DW.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DMorinaga%26aufirst%3DR.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DTerashima%26aufirst%3DM.%26aulast%3DTsuya%26aufirst%3DA.%26aulast%3DSarashina%26aufirst%3DA.%26aulast%3DKonishi%26aufirst%3DK.%26aulast%3DArao%26aufirst%3DT.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DPhase%2520I%2520safety%252C%2520pharmacokinetic%252C%2520and%2520biomarker%2520study%2520of%2520BIBF%25201120%252C%2520an%2520oral%2520triple%2520tyrosine%2520kinase%2520inhibitor%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2825%26epage%3D2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Kropff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienast, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisping, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munzert, G.</span><span> </span><span class="NLM_article-title">An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4233</span><span class="NLM_x">â</span> <span class="NLM_lpage">4238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=19846979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVOltL7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=4233-4238&author=M.+Kropffauthor=J.+Kienastauthor=G.+Bispingauthor=W.+E.+Berdelauthor=B.+Gaschler-Markefskiauthor=P.+Stopferauthor=M.+Stefanicauthor=G.+Munzert&title=An+open-label+dose-escalation+study+of+BIBF+1120+in+patients+with+relapsed+or+refractory+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma</span></div><div class="casAuthors">Kropff, Martin; Kienast, Joachim; Bisping, Guido; Berdel, Wolfgang E.; Gaschler-Markefski, Birgit; Stopfer, Peter; Stefanic, Martin; Munzert, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4233-4238</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">To det. the max. tolerated dose (MTD) and dose-limiting toxicities (DLTs) of BIBF 1120, a triple angiokinase inhibitor administered once-daily in patients with advanced multiple myeloma.  This Phase I study included 17 patients.  Planned dose escalations of BIBF 1120 were 100, 200, 250, and 300 mg.  Safety and pharmacokinetic (PK) assessments were performed.  Two DLTs (200 and 250 mg) occurred due to increased gamma-glutamyltransferase levels (CTC grade 3).  The 250 mg dose was well tolerated; no dose escalation beyond 250 mg was made.  The most common adverse events included diarrhoea, nausea and vomiting.  No detectable deviation from dose linear PKs was obsd.  Regarding tumor control, two patients had stable disease for â¥4 mo.  BIBF 1120 was safe and well tolerated up to 250 mg/day.  The MTD was not reached.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS8DKB1OE8G7Vg90H21EOLACvtfcHk0lic2riPPVOWFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVOltL7P&md5=7fd157250c0ee2843bee45fbedb77947</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKropff%26aufirst%3DM.%26aulast%3DKienast%26aufirst%3DJ.%26aulast%3DBisping%26aufirst%3DG.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DStefanic%26aufirst%3DM.%26aulast%3DMunzert%26aufirst%3DG.%26atitle%3DAn%2520open-label%2520dose-escalation%2520study%2520of%2520BIBF%25201120%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DAnticancer%2520Res.%26date%3D2009%26volume%3D29%26spage%3D4233%26epage%3D4238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conkling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2094</span><span class="NLM_x">â</span> <span class="NLM_lpage">2102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1093%2Fannonc%2Fmdr596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22345119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC38vjsVOjtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=2094-2102&author=R.+C.+Doebeleauthor=P.+Conklingauthor=A.+M.+Traynorauthor=G.+A.+Ottersonauthor=Y.+Zhaoauthor=S.+Windauthor=P.+Stopferauthor=R.+Kaiserauthor=D.+R.+Camidge&title=A+phase+I%2C+open-label+dose-escalation+study+of+continuous+treatment+with+BIBF+1120+in+combination+with+paclitaxel+and+carboplatin+as+first-line+treatment+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Doebele R C; Conkling P; Traynor A M; Otterson G A; Zhao Y; Wind S; Stopfer P; Kaiser R; Camidge D R</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2094-102</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  BIBF 1120 is an oral potent inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet-derived growth factor receptor, the three key receptor families involved in angiogenesis.  This phase I, open-label dose-escalation study investigated BIBF 1120 combined with paclitaxel (Taxol) and carboplatin in first-line patients with advanced (IIIB/IV) non-small-cell lung cancer.  PATIENTS AND METHODS:  Patients received BIBF 1120 (starting dose 50 mg b.i.d.) on days 2-21 and paclitaxel (200 mg/m2) and carboplatin [area under curve (AUC)=6 mg/ml/min] on day 1 of each 21-day cycle.  Primary end points were safety and BIBF 1120 maximum tolerated dose (MTD) in this combination.  Pharmacokinetics (PK) profiles were evaluated.  RESULTS:  Twenty-six patients were treated (BIBF 1120 50-250 mg b.i.d.).  BIBF 1120 MTD was 200 mg b.i.d. in combination with paclitaxel and carboplatin.  Six dose-limiting toxicity events occurred during treatment cycle 1 (liver enzyme elevations, thrombocytopenia, abdominal pain, and rash).  Best responses included 7 confirmed partial responses (26.9%); 10 patients had stable disease.  BIBF 1120 200 mg b.i.d. had no clinically relevant influence on the PK of paclitaxel 200 mg/m2 and carboplatin AUC 6 mg/ml/min and vice versa.  CONCLUSIONS:  BIBF 1120 MTD was 200 mg b.i.d when given with paclitaxel and carboplatin; this combination demonstrated an acceptable safety profile.  No relevant changes in PK parameters of the backbone chemotherapeutic agents or BIBF 1120 were observed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSy39mgYhSpKmGmni0r9GoKfW6udTcc2eZY7Yz6UpggOLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vjsVOjtA%253D%253D&md5=90ab7e209cd8d3e3c8eda005571ad989</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr596%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DConkling%26aufirst%3DP.%26aulast%3DTraynor%26aufirst%3DA.%2BM.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWind%26aufirst%3DS.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DA%2520phase%2520I%252C%2520open-label%2520dose-escalation%2520study%2520of%2520continuous%2520treatment%2520with%2520BIBF%25201120%2520in%2520combination%2520with%2520paclitaxel%2520and%2520carboplatin%2520as%2520first-line%2520treatment%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D2094%26epage%3D2102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Ellis, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyorffy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, N.</span><span> </span><span class="NLM_article-title">Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2881</span><span class="NLM_x">â</span> <span class="NLM_lpage">2889</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1158%2F1078-0432.CCR-09-2944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=20460487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvF2hs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2881-2889&author=P.+M.+Ellisauthor=R.+Kaiserauthor=Y.+Zhaoauthor=P.+Stopferauthor=S.+Gyorffyauthor=N.+Hanna&title=Phase+I+open-label+study+of+continuous+treatment+with+BIBF+1120%2C+a+triple+angiokinase+inhibitor%2C+and+pemetrexed+in+pretreated+non-small+cell+lung+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Ellis, Peter M.; Kaiser, Rolf; Zhao, Yihua; Stopfer, Peter; Gyorffy, Steve; Hanna, Nasser</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2881-2889</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Introduction: BIBF 1120 (planned brand name Vargatef) is a novel, oral, triple angiokinase inhibitor targeting three receptor classes involved in blood vessel formation.  The objectives of this phase I, open-label dose-escalation study were to det. the safety, tolerability, and max. tolerated dose (MTD) of BIBF 1120 with pemetrexed in patients with recurrent advanced-stage non-small cell lung carcinoma.  Patients and Methods: Patients harboring a tumor of any non-small cell lung carcinoma histol., previously treated with one first-line platinum-based chemotherapy regimen, received a BIBF 1120 starting dose of 100 mg bid (days 2-21) with pemetrexed 500 mg/m2 (day 1) over a 21-day cycle.  Previous pemetrexed treatment was not permitted.  BIBF 1120 dose was escalated until the MTD was detd.  Results: Twenty-six patients were treated.  During treatment cycle (TC) 1, dose-limiting toxicities were experienced by one patient receiving 100 mg bid, one patient receiving 150 mg bid, one patient receiving 200 mg bid, and two patients receiving 250 mg bid BIBF 1120.  Two addnl. dose-limiting toxicities were obsd. in TC 1 in an expanded patient cohort receiving 200 mg bid.  Gastrointestinal disorders (84.6%), general disorders, and administration site conditions (76.9%) were the most frequent drug-related adverse events.  One patient had a complete response 44 days after initiating trial medication; 50% had stable disease as the best overall response.  No clin. relevant pharmacokinetic interactions between BIBF 1120 and pemetrexed were obsd.  Conclusion: The MTD of BIBF 1120 in combination with std.-dose pemetrexed was 200 mg bid.  Continuous daily treatment with BIBF 1120 in this combination was tolerable, with promising signs of efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9FbuDjhbXYbVg90H21EOLACvtfcHk0lgeL5I-371tIA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvF2hs74%253D&md5=32d5ee996c570bc3c3f63d55ef4dd128</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-2944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-2944%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DP.%2BM.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DGyorffy%26aufirst%3DS.%26aulast%3DHanna%26aufirst%3DN.%26atitle%3DPhase%2520I%2520open-label%2520study%2520of%2520continuous%2520treatment%2520with%2520BIBF%25201120%252C%2520a%2520triple%2520angiokinase%2520inhibitor%252C%2520and%2520pemetrexed%2520in%2520pretreated%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D2881%26epage%3D2889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Bousquet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Tourneau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwasser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Mont-Serrat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misset, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1640</span><span class="NLM_x">â</span> <span class="NLM_lpage">1645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1038%2Fbjc.2011.440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22027711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWqs7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=1640-1645&author=G.+Bousquetauthor=J.+Alexandreauthor=C.+Le+Tourneauauthor=F.+Goldwasserauthor=S.+Faivreauthor=H.+de+Mont-Serratauthor=R.+Kaiserauthor=J.+L.+Missetauthor=E.+Raymond&title=Phase+I+study+of+BIBF+1120+with+docetaxel+and+prednisone+in+metastatic+chemo-naive+hormone-refractory+prostate+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients</span></div><div class="casAuthors">Bousquet, G.; Alexandre, J.; Le Tourneau, C.; Goldwasser, F.; Faivre, S.; de Mont-Serrat, H.; Kaiser, R.; Misset, J. L.; Raymond, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1640-1645</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: BIBF 1120 is an oral, potent, tyrosine kinase inhibitor that simultaneously targets vascular endothelial growth factor receptors 1-3, platelet-derived growth factor receptors Î± and Î², and fibroblast growth factor receptors 1-3, as well as FLT3 and Src.  Currently, the mol. is in phase III development for second-line non-small cell lung cancer and first-line ovarian cancer patients.  Methods: This phase I dose-escalation study assessed the safety and max. tolerated dose of continuous daily treatment with BIBF 1120 plus std.-dose docetaxel (75 mg m-2, every 3 wk) and prednisone (5 mg BID) in patients with metastatic, chemo-naive, hormone-refractory prostate cancer (HRPC).  Secondary objectives were characterization of BIBF 1120 and docetaxel pharmacokinetics (PK), and preliminary antitumor activity.  Results: Patients received BIBF 1120 100 mg BID (n=3), 150 mg BID (n=3), 200 mg BID (n=3), and 250 mg BID (n=12).  The most frequent drug-related adverse events were diarrhoea (71.4%), asthenia (61.9%), nausea (28.6%), vomiting (28.6%), and alopecia (23.8%).  The max. tolerated dose was 250 mg BID of BIBF 1120.  Overall, reversible grade 3/4 liver enzyme elevations occurred in six of twelve patients at this dose level.  Among 19 assessable patients, 13 (68.4%) showed a â¥50% redn. in prostate serum antigen levels from baseline and among 6 evaluable patients with measurable lesions 1 patient experienced a partial response by Response Evaluation Criteria In Solid Tumors criteria.  Pharmacokinetic anal. showed no interactions between BIBF 1120 and docetaxel/prednisone.  Conclusion: Based on the overall safety profile, 200 mg BID was the recommended dose for the combination of BIBF 1120 with the std. dose of 75 mg m-2 of docetaxel and prednisone that might be further investigated in HRPC patients.  This combination was well tolerated, with preliminary signs of efficacy and no indication of PK interaction between BIBF 1120 and docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJ-f4p4NOvbVg90H21EOLACvtfcHk0ljhJXKO91AX9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWqs7bK&md5=3921483e65f108ff0e4b8a4ff90b5a29</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.440%26sid%3Dliteratum%253Aachs%26aulast%3DBousquet%26aufirst%3DG.%26aulast%3DAlexandre%26aufirst%3DJ.%26aulast%3DLe%2BTourneau%26aufirst%3DC.%26aulast%3DGoldwasser%26aufirst%3DF.%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3Dde%2BMont-Serrat%26aufirst%3DH.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DMisset%26aufirst%3DJ.%2BL.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DPhase%2520I%2520study%2520of%2520BIBF%25201120%2520with%2520docetaxel%2520and%2520prednisone%2520in%2520metastatic%2520chemo-naive%2520hormone-refractory%2520prostate%2520cancer%2520patients%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D105%26spage%3D1640%26epage%3D1645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">du Bois, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huober, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfisterer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wimberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loibl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span> </span><span class="NLM_article-title">A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">â</span> <span class="NLM_lpage">375</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1093%2Fannonc%2Fmdp506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=19889612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FlslKksw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=370-375&author=A.+du+Boisauthor=J.+Huoberauthor=P.+Stopferauthor=J.+Pfistererauthor=P.+Wimbergerauthor=S.+Loiblauthor=V.+L.+Reichardtauthor=P.+Harter&title=A+phase+I+open-label+dose-escalation+study+of+oral+BIBF+1120+combined+with+standard+paclitaxel+and+carboplatin+in+patients+with+advanced+gynecological+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies</span></div><div class="casAuthors">du Bois A; Huober J; Stopfer P; Pfisterer J; Wimberger P; Loibl S; Reichardt V L; Harter P</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">370-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The purpose of the phase I dose-escalation study was to evaluate the maximum tolerated dose (MTD) of BIBF 1120, an oral triple angiokinase inhibitor of vascular endothelial growth factor, platelet derived growth factor and fibroblast growth factor receptors, combined with paclitaxel and carboplatin.  PATIENTS AND METHODS:  Patients with advanced gynecological malignancies received BIBF 1120 twice-daily (b.i.d.) continuously at 100, 150, 200 or 250 mg, combined with paclitaxel (175 mg/m(2)) and carboplatin (area under the curve 5 min.mg/ml) every 3 weeks.  The MTD, safety, pharmacokinetics (PK) and clinical activity were evaluated.  RESULTS:  Twenty-two patients were treated.  Three experienced dose-limiting toxic effects in the first treatment cycle: 1 of 13 at 200 mg b.i.d.  BIBF 1120 [diarrhea, common terminology criteria for adverse events (CTCAE) grade 3]; two of two at 250 mg b.i.d.  BIBF 1120 (elevated alanine aminotransferase and aspartate aminotransferase, CTCAE grade 3/4).  The MTD was defined as 200 mg b.i.d.  Principal adverse events were gastrointestinal disorders.  No clinically relevant drug-drug interaction was observed after 20 days treatment with 200 mg b.i.d.  BIBF 1120 on the PK of paclitaxel or carboplatin and vice versa.  CONCLUSIONS:  The MTD of BIBF 1120 in a 20-day continuous dosing regimen with standard-dose paclitaxel and carboplatin was 200 mg b.i.d.  This combination had an acceptable safety profile and no clinically relevant drug-drug interactions.  Further evaluation of this combination is warranted in this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxtGT4liPC1Kx48Rj5GnGofW6udTcc2ebqtsJAvuLaiLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FlslKksw%253D%253D&md5=49b5af97c9d197c561b59f663b893dbf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdp506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdp506%26sid%3Dliteratum%253Aachs%26aulast%3Ddu%2BBois%26aufirst%3DA.%26aulast%3DHuober%26aufirst%3DJ.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DPfisterer%26aufirst%3DJ.%26aulast%3DWimberger%26aufirst%3DP.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DReichardt%26aufirst%3DV.%2BL.%26aulast%3DHarter%26aufirst%3DP.%26atitle%3DA%2520phase%2520I%2520open-label%2520dose-escalation%2520study%2520of%2520oral%2520BIBF%25201120%2520combined%2520with%2520standard%2520paclitaxel%2520and%2520carboplatin%2520in%2520patients%2520with%2520advanced%2520gynecological%2520malignancies%26jtitle%3DAnn.%2520Oncol.%26date%3D2010%26volume%3D21%26spage%3D370%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eschbach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatzemeier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span> </span><span class="NLM_article-title">A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1374</span><span class="NLM_x">â</span> <span class="NLM_lpage">1381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1093%2Fannonc%2Fmdq618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21212157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC3MrkvFyhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=1374-1381&author=M.+Reckauthor=R.+Kaiserauthor=C.+Eschbachauthor=M.+Stefanicauthor=J.+Loveauthor=U.+Gatzemeierauthor=P.+Stopferauthor=J.+von+Pawel&title=A+phase+II+double-blind+study+to+investigate+efficacy+and+safety+of+two+doses+of+the+triple+angiokinase+inhibitor+BIBF+1120+in+patients+with+relapsed+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer</span></div><div class="casAuthors">Reck M; Kaiser R; Eschbach C; Stefanic M; Love J; Gatzemeier U; Stopfer P; von Pawel J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1374-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To assess the efficacy, safety, tolerability and pharmacokinetics of BIBF 1120 in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).  METHODS:  Patients with locally advanced or metastatic relapsed NSCLC in whom first- or second-line platinum-based chemotherapy failed were randomly allocated to daily 250 mg BIBF 1120 b.i.d. or 150 mg BIBF 1120 b.i.d.  Primary end points were progression-free survival (PFS) and objective tumour response (RECIST).  Incidence and severity of adverse events (AEs) were reported.  RESULTS:  Seventy-three patients received BIBF 1120.  Median PFS was 6.9 weeks, with no significant difference between treatment arms.  Median overall survival (OS) was 21.9 weeks.  Eastern Cooperative Oncology Group (ECOG) 0-1 patients (n = 56) had a median PFS of 11.6 weeks and a median OS of 37.7 weeks.  Tumour stabilisation was achieved in 46% of patients (ECOG 0-1 patients: 59%), with one confirmed partial response (250 mg b.i.d.).  Most commonly reported drug-related AEs were nausea (57.5%), diarrhoea (47.9%), vomiting (42.5%), anorexia (28.8%), abdominal pain (13.7%) and reversible alanine transaminase (13.7%) and aspartate aminotransferase elevations (9.6%).  BIBF 1120 displayed dose-linear pharmacokinetic characteristics.  CONCLUSION:  Continuous treatment with BIBF 1120 was well tolerated, with no difference in efficacy between treatment arms.  PFS and objective response with single-agent treatment in advanced disease warrants further exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwkcPypD6aCAaK-_ZudimnfW6udTcc2ebqtsJAvuLaiLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrkvFyhtw%253D%253D&md5=4bb9f15176ce2e68bc2d5d83d8f6deb0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq618%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DEschbach%26aufirst%3DC.%26aulast%3DStefanic%26aufirst%3DM.%26aulast%3DLove%26aufirst%3DJ.%26aulast%3DGatzemeier%26aufirst%3DU.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26atitle%3DA%2520phase%2520II%2520double-blind%2520study%2520to%2520investigate%2520efficacy%2520and%2520safety%2520of%2520two%2520doses%2520of%2520the%2520triple%2520angiokinase%2520inhibitor%2520BIBF%25201120%2520in%2520patients%2520with%2520relapsed%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D1374%26epage%3D1381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Van Cutsem, E.; Prenen, H.; Guillen-Ponce, C.</span><span> </span><span class="NLM_article-title">A phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus FOLFOX6 in patients with metastatic colorectal cancer</span>.  <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span>, Abstract 14LBA.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&author=E.+Van+Cutsem&author=H.+Prenen&author=C.+Guillen-Ponce&title=A+phase+I%2FII%2C+open-label%2C+randomised+study+of+BIBF+1120+plus+mFOLFOX6+compared+to+bevacizumab+plus+FOLFOX6+in+patients+with+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26atitle%3DA%2520phase%2520I%252FII%252C%2520open-label%252C%2520randomised%2520study%2520of%2520BIBF%25201120%2520plus%2520mFOLFOX6%2520compared%2520to%2520bevacizumab%2520plus%2520FOLFOX6%2520in%2520patients%2520with%2520metastatic%2520colorectal%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shparyk, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khder, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studeny, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loembe, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span> </span><span class="NLM_article-title">Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1283</span><span class="NLM_x">â</span> <span class="NLM_lpage">1293</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1283-1293&author=T.+Eisenauthor=Y.+Shparykauthor=N.+Macleodauthor=R.+Jonesauthor=G.+Wallensteinauthor=G.+Templeauthor=Y.+Khderauthor=C.+Dallingerauthor=M.+Studenyauthor=A.+B.+Loembeauthor=I.+Bondarenko&title=Effect+of+small+angiokinase+inhibitor+nintedanib+%28BIBF+1120%29+on+QT+interval+in+patients+with+previously+untreated%2C+advanced+renal+cell+cancer+in+an+open-label%2C+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DShparyk%26aufirst%3DY.%26aulast%3DMacleod%26aufirst%3DN.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DTemple%26aufirst%3DG.%26aulast%3DKhder%26aufirst%3DY.%26aulast%3DDallinger%26aufirst%3DC.%26aulast%3DStudeny%26aufirst%3DM.%26aulast%3DLoembe%26aufirst%3DA.%2BB.%26aulast%3DBondarenko%26aufirst%3DI.%26atitle%3DEffect%2520of%2520small%2520angiokinase%2520inhibitor%2520nintedanib%2520%2528BIBF%25201120%2529%2520on%2520QT%2520interval%2520in%2520patients%2520with%2520previously%2520untreated%252C%2520advanced%2520renal%2520cell%2520cancer%2520in%2520an%2520open-label%252C%2520phase%2520II%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D1283%26epage%3D1293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Prenen, H.; DâHaens, G.; Capdevila, J.; Carrato, A.; Sobrero, A.; Ducreux, M.; FranÃ§ois, E.; Staines, H.; Amellal, N.; Van Cutsem, E.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBF 1120 combined with FOLFOX in metastatic colorectal cancer (mCRC) patients</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span>, Abstract e14054.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&author=H.+Prenen&author=G.+D%E2%80%99Haens&author=J.+Capdevila&author=A.+Carrato&author=A.+Sobrero&author=M.+Ducreux&author=E.+Fran%C3%A7ois&author=H.+Staines&author=N.+Amellal&author=E.+Van+Cutsem&title=A+phase+I+dose+escalation+study+of+BIBF+1120+combined+with+FOLFOX+in+metastatic+colorectal+cancer+%28mCRC%29+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPrenen%26aufirst%3DH.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBF%25201120%2520combined%2520with%2520FOLFOX%2520in%2520metastatic%2520colorectal%2520cancer%2520%2528mCRC%2529%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellemgaard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douillard, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottfried, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gann, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrueco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LUME-Lung 1 Study Group</span><span> </span><span class="NLM_article-title">Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">â</span> <span class="NLM_lpage">155</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1016%2FS1470-2045%2813%2970586-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24411639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Sjtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=143-155&author=M.+Reckauthor=R.+Kaiserauthor=A.+Mellemgaardauthor=J.+Y.+Douillardauthor=S.+Orlovauthor=M.+Krzakowskiauthor=J.+von+Pawelauthor=M.+Gottfriedauthor=I.+Bondarenkoauthor=M.+Liaoauthor=C.+N.+Gannauthor=J.+Barruecoauthor=B.+Gaschler-Markefskiauthor=S.+Novelloauthor=+LUME-Lung+1+Study+Group&title=Docetaxel+plus+nintedanib+versus+docetaxel+plus+placebo+in+patients+with+previously+treated+non-small-cell+lung+cancer+%28LUME-Lung+1%29%3A+a+phase+3%2C+double-blind%2C+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial</span></div><div class="casAuthors">Reck, Martin; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Sergey; Krzakowski, Maciej; von Pawel, Joachim; Gottfried, Maya; Bondarenko, Igor; Liao, Meilin; Gann, Claudia-Nanette; Barrueco, Jose; Gaschler-Markefski, Birgit; Novello, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-155</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).  Patients from 211 centers in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histol., and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m2 by i.v. infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 wk until unacceptable adverse events or disease progression.  Investigators and patients were masked to assignment.  The primary endpoint was progression-free survival (PFS) by independent central review, analyzed by intention to treat after 714 events in all patients.  The key secondary endpoint was overall survival, analyzed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in patients with adenocarcinoma who progressed within 9 mo after start of first-line therapy, then in all patients with adenocarcinoma, then in all patients.  This trial is registered with ClinicalTrials.gov, no. NCT00805194.  Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo.  The primary anal. was done after a median follow-up of 7Â·1 mo (IQR 3Â·8-11Â·0).  PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group (median 3Â·4 mo [95% CI 2Â·9-3Â·9] vs 2Â·7 mo [2Â·6-2Â·8]; hazard ratio [HR] 0Â·79 [95% CI 0Â·68-0Â·92], p=0Â·0019).  After a median follow-up of 31Â·7 mo (IQR 27Â·8-36Â·1), overall survival was significantly improved for patients with adenocarcinoma histol. who progressed within 9 mo after start of first-line treatment in the docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo group (199 patients; median 10Â·9 mo [95% CI 8Â·5-12Â·6] vs 7Â·9 mo [6Â·7-9Â·1]; HR 0Â·75 [95% CI 0Â·60-0Â·92], p=0Â·0073).  Similar results were noted for all patients with adenocarcinoma histol. (322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; median overall survival 12Â·6 mo [95% CI 10Â·6-15Â·1] vs 10Â·3 mo [95% CI 8Â·6-12Â·2]; HR 0Â·83 [95% CI 0Â·70-0Â·99], p=0Â·0359), but not in the total study population (median 10Â·1 mo [95% CI 8Â·8-11Â·2] vs 9Â·1 mo [8Â·4-10Â·4]; HR 0Â·94, 95% CI 0Â·83-1Â·05, p=0Â·2720).  Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea (43 [6Â·6%] of 652 vs 17 [2Â·6%] of 655), reversible increases in alanine aminotransferase (51 [7Â·8%] vs six [0Â·9%]), and reversible increases in aspartate aminotransferase (22 [3Â·4%] vs three [0Â·5%]).  35 Patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and pulmonary embolism (none vs three).  Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, esp. for patients with adenocarcinoma.Boehringer Ingelheim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-E4GE6PlVPrVg90H21EOLACvtfcHk0lh8W6VaAgFflA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Sjtg%253D%253D&md5=6a774d4be37ac998e7635ba155507424</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970586-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970586-2%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DMellemgaard%26aufirst%3DA.%26aulast%3DDouillard%26aufirst%3DJ.%2BY.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DKrzakowski%26aufirst%3DM.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGottfried%26aufirst%3DM.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DLiao%26aufirst%3DM.%26aulast%3DGann%26aufirst%3DC.%2BN.%26aulast%3DBarrueco%26aufirst%3DJ.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DLUME-Lung%2B1%2BStudy%2BGroup%26atitle%3DDocetaxel%2520plus%2520nintedanib%2520versus%2520docetaxel%2520plus%2520placebo%2520in%2520patients%2520with%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%2520%2528LUME-Lung%25201%2529%253A%2520a%2520phase%25203%252C%2520double-blind%252C%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D143%26epage%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Hanna, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aren, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiangco, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voccia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrueco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glomb, P.</span><span> </span><span class="NLM_article-title">Retrospective evaluation of the futility analysis in LUME Lung 2, a randomized, double-blind, placebo-controlled phase 3 trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first line chemotherapy</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">S802</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S802&author=N.+Hannaauthor=R.+Kaiserauthor=J.+H.+Kimauthor=R.+Sullivanauthor=O.+Arenauthor=M.+J.+Ahnauthor=B.+J.+Tiangcoauthor=I.+Vocciaauthor=J.+Barruecoauthor=P.+Glomb&title=Retrospective+evaluation+of+the+futility+analysis+in+LUME+Lung+2%2C+a+randomized%2C+double-blind%2C+placebo-controlled+phase+3+trial+of+nintedanib+%28BIBF+1120%29+in+combination+with+pemetrexed+in+NSCLC+patients+progressing+after+one+prior+first+line+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DSullivan%26aufirst%3DR.%26aulast%3DAren%26aufirst%3DO.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DTiangco%26aufirst%3DB.%2BJ.%26aulast%3DVoccia%26aufirst%3DI.%26aulast%3DBarrueco%26aufirst%3DJ.%26aulast%3DGlomb%26aufirst%3DP.%26atitle%3DRetrospective%2520evaluation%2520of%2520the%2520futility%2520analysis%2520in%2520LUME%2520Lung%25202%252C%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25203%2520trial%2520of%2520nintedanib%2520%2528BIBF%25201120%2529%2520in%2520combination%2520with%2520pemetrexed%2520in%2520NSCLC%2520patients%2520progressing%2520after%2520one%2520prior%2520first%2520line%2520chemotherapy%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D49%26spage%3DS802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Hanna, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aren, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiangco, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvirbule, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demirkazik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voccia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrueco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span> </span><span class="NLM_article-title">Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">8034</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1200%2FJCO.2013.48.8932" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=8034&author=N.+H.+Hannaauthor=R.+Kaiserauthor=R.+N.+Sullivanauthor=O.+R.+Arenauthor=M.+J.+Ahnauthor=B.+J.+Tiangcoauthor=Z.+Zvirbuleauthor=C.+H.+Barriosauthor=A.+Demirkazikauthor=B.+Gaschler-Markefskiauthor=I.+Vocciaauthor=J.+Barruecoauthor=J.+H.+Kim&title=Lume-lung+2%3A+A+multicenter%2C+randomized%2C+double-blind%2C+phase+III+study+of+nintedanib+plus+pemetrexed+versus+placebo+plus+pemetrexed+in+patients+with+advanced+nonsquamous+non-small+cell+lung+cancer+%28NSCLC%29+after+failure+of+first-line+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.48.8932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.48.8932%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%2BH.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DSullivan%26aufirst%3DR.%2BN.%26aulast%3DAren%26aufirst%3DO.%2BR.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DTiangco%26aufirst%3DB.%2BJ.%26aulast%3DZvirbule%26aufirst%3DZ.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DDemirkazik%26aufirst%3DA.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DVoccia%26aufirst%3DI.%26aulast%3DBarrueco%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26atitle%3DLume-lung%25202%253A%2520A%2520multicenter%252C%2520randomized%252C%2520double-blind%252C%2520phase%2520III%2520study%2520of%2520nintedanib%2520plus%2520pemetrexed%2520versus%2520placebo%2520plus%2520pemetrexed%2520in%2520patients%2520with%2520advanced%2520nonsquamous%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520after%2520failure%2520of%2520first-line%2520chemotherapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D8034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">du Bois, A.; Kristensen, G.; Ray-Coquard, I.; ReuÃ, A.; Pignata, S.; Colombo, N.; Denison, U.; Vergote, I.; del Campo, J. M.; Ottevanger, P.; Merger, M.; Harter, P.</span><span> </span><span class="NLM_article-title">AGO-Ovar 12: A randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy Â± nintedanib for advanced ovarian cancer</span>.  <span class="citation_source-journal">Int. J. Gynecol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span>, Abstract.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&author=A.+du+Bois&author=G.+Kristensen&author=I.+Ray-Coquard&author=A.+Reu%C3%9F&author=S.+Pignata&author=N.+Colombo&author=U.+Denison&author=I.+Vergote&author=J.+M.+del+Campo&author=P.+Ottevanger&author=M.+Merger&author=P.+Harter&title=AGO-Ovar+12%3A+A+randomized+placebo-controlled+GCIG%2FENGOT-intergroup+phase+III+trial+of+standard+frontline+chemotherapy+%C2%B1+nintedanib+for+advanced+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Ddu%2BBois%26aufirst%3DA.%26atitle%3DAGO-Ovar%252012%253A%2520A%2520randomized%2520placebo-controlled%2520GCIG%252FENGOT-intergroup%2520phase%2520III%2520trial%2520of%2520standard%2520frontline%2520chemotherapy%2520%25C2%25B1%2520nintedanib%2520for%2520advanced%2520ovarian%2520cancer%26jtitle%3DInt.%2520J.%2520Gynecol.%2520Cancer%26date%3D2013%26volume%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Ledermann, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackshaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabra, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeish, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span> </span><span class="NLM_article-title">Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3798</span><span class="NLM_x">â</span> <span class="NLM_lpage">3804</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1200%2FJCO.2010.33.5208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21859991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWrsb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3798-3804&author=J.+A.+Ledermannauthor=A.+Hackshawauthor=S.+Kayeauthor=G.+Jaysonauthor=H.+Gabraauthor=I.+McNeishauthor=H.+Earlauthor=T.+Perrenauthor=M.+Goreauthor=M.+Persicauthor=M.+Adamsauthor=L.+Jamesauthor=G.+Templeauthor=M.+Mergerauthor=G.+Rustin&title=Randomized+phase+II+placebo-controlled+trial+of+maintenance+therapy+using+the+oral+triple+angiokinase+inhibitor+BIBF+1120+after+chemotherapy+for+relapsed+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer</span></div><div class="casAuthors">Ledermann, Jonathan A.; Hackshaw, Allan; Kaye, Stan; Jayson, Gordon; Gabra, Hani; McNeish, Iain; Earl, Helena; Perren, Tim; Gore, Martin; Persic, Mojca; Adams, Malcolm; James, Lindsay; Temple, Graham; Merger, Michael; Rustin, Gordon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3798-3804</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer.  We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease.  Patients and Methods: We conducted a randomized, double-blind, controlled phase II trial in 83 patients who had just completed chemotherapy for relapsed ovarian cancer, with evidence of response, but at high risk of further early recurrence.  The patients were randomly assigned to receive maintenance therapy using BIBF 1120 250 mg or placebo, twice per day, continuously for 36 wk.  End points were progression-free survival (PFS), toxicity, and overall survival.  Results: Thirty-six-week PFS rates were 16.3% and 5.0% in the BIBF 1120 and placebo groups, resp. (hazard ratio, 0.65; 95% CI, 0.42 to 1.02; P = .06).  Four patients continued on BIBF 1120, including two patients for another year or more.  The proportion of patients with any grade 3 or 4 adverse events was similar between the groups (34.9% for BIBF 1120 v 27.5% for placebo; P = .49; mostly grade 3).  However, more patients on BIBF 1120 experienced diarrhea, nausea, or vomiting (mainly grade 1 or 2 and no grade 4).  There was a higher rate of grade 3 or 4 hepatotoxicity in patients on BIBF 1120 (51.2%) compared with patients on placebo (7.5%; P < .001), but this was rarely of clin. significance, and patients continued with the trial treatment.  A single-level dose redn. to 150 mg was made in 15 patients, all on active drug.  Conclusion: BIBF 1120 is well tolerated and assocd. with a potential improvement in PFS.  The obsd. treatment effect is sufficient to justify further study within a large phase III trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZqwdS23hObVg90H21EOLACvtfcHk0lg_TtSXBmu7Fg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWrsb%252FE&md5=98a6a8e9c2a8c4cbcfa2fbb4f9c21c01</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.5208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.5208%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%2BA.%26aulast%3DHackshaw%26aufirst%3DA.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DJayson%26aufirst%3DG.%26aulast%3DGabra%26aufirst%3DH.%26aulast%3DMcNeish%26aufirst%3DI.%26aulast%3DEarl%26aufirst%3DH.%26aulast%3DPerren%26aufirst%3DT.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DPersic%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DTemple%26aufirst%3DG.%26aulast%3DMerger%26aufirst%3DM.%26aulast%3DRustin%26aufirst%3DG.%26atitle%3DRandomized%2520phase%2520II%2520placebo-controlled%2520trial%2520of%2520maintenance%2520therapy%2520using%2520the%2520oral%2520triple%2520angiokinase%2520inhibitor%2520BIBF%25201120%2520after%2520chemotherapy%2520for%2520relapsed%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3798%26epage%3D3804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillen-Ponce, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Benedetto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouche, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staines, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OumâHamed, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studeny, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdevila, J.</span><span> </span><span class="NLM_article-title">A phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">â</span> <span class="NLM_lpage">9</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=8-9&author=E.+Van+Cutsemauthor=H.+Prenenauthor=C.+Guillen-Ponceauthor=J.+Bennounaauthor=M.+Di+Benedettoauthor=O.+Boucheauthor=H.+Stainesauthor=Z.+Oum%E2%80%99Hamedauthor=M.+Studenyauthor=J.+Capdevila&title=A+phase+I%2FII%2C+open-label%2C+randomised+study+of+BIBF+1120+plus+mFOLFOX6+compared+to+bevacizumab+plus+mFOLFOX6+in+patients+with+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DGuillen-Ponce%26aufirst%3DC.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DDi%2BBenedetto%26aufirst%3DM.%26aulast%3DBouche%26aufirst%3DO.%26aulast%3DStaines%26aufirst%3DH.%26aulast%3DOum%25E2%2580%2599Hamed%26aufirst%3DZ.%26aulast%3DStudeny%26aufirst%3DM.%26aulast%3DCapdevila%26aufirst%3DJ.%26atitle%3DA%2520phase%2520I%252FII%252C%2520open-label%252C%2520randomised%2520study%2520of%2520BIBF%25201120%2520plus%2520mFOLFOX6%2520compared%2520to%2520bevacizumab%2520plus%2520mFOLFOX6%2520in%2520patients%2520with%2520metastatic%2520colorectal%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47%26spage%3D8%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Eisen, T.; Shparyk, Y.; Jones, R.; Macleod, N. J.; Temple, G.; Finnigan, H.; Kaiser, R.; Studeny, M.; Loembe, A. B.; Bondarenko, I.</span><span> </span><span class="NLM_article-title">Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span>, Abstract 4506.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24019545" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&author=T.+Eisen&author=Y.+Shparyk&author=R.+Jones&author=N.+J.+Macleod&author=G.+Temple&author=H.+Finnigan&author=R.+Kaiser&author=M.+Studeny&author=A.+B.+Loembe&author=I.+Bondarenko&title=Phase+II+efficacy+and+safety+study+of+nintedanib+versus+sunitinib+in+previously+untreated+renal+cell+carcinoma+%28RCC%29+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DT.%26atitle%3DPhase%2520II%2520efficacy%2520and%2520safety%2520study%2520of%2520nintedanib%2520versus%2520sunitinib%2520in%2520previously%2520untreated%2520renal%2520cell%2520carcinoma%2520%2528RCC%2529%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Yen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studeny, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D. C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryoo, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. L.</span><span> </span><span class="NLM_article-title">Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): a randomised Phase II trial</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">S612</span><div class="note"><p class="first last">(Abstract 2580)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S612&author=C.+Yenauthor=T.+Y.+Kimauthor=Y.+H.+Fengauthor=Y.+Chaoauthor=D.+Y.+Linauthor=M.+Studenyauthor=J.+Hockeauthor=D.+C.+L.+Huangauthor=B.+Y.+Ryooauthor=A.+L.+Cheng&title=Efficacy+and+safety+of+nintedanib+vs+sorafenib+in+Asian+patients+with+advanced+hepatocellular+carcinoma+%28HCC%29%3A+a+randomised+Phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYen%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DFeng%26aufirst%3DY.%2BH.%26aulast%3DChao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DD.%2BY.%26aulast%3DStudeny%26aufirst%3DM.%26aulast%3DHocke%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BL.%26aulast%3DRyoo%26aufirst%3DB.%2BY.%26aulast%3DCheng%26aufirst%3DA.%2BL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520nintedanib%2520vs%2520sorafenib%2520in%2520Asian%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%2520%2528HCC%2529%253A%2520a%2520randomised%2520Phase%2520II%2520trial%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3DS612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juhel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluglich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span> </span><span class="NLM_article-title">Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">â</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1056%2FNEJMoa1103690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21992121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WqsbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1079-1087&author=L.+Richeldiauthor=U.+Costabelauthor=M.+Selmanauthor=D.+S.+Kimauthor=D.+M.+Hansellauthor=A.+G.+Nicholsonauthor=K.+K.+Brownauthor=K.+R.+Flahertyauthor=P.+W.+Nobleauthor=G.+Raghuauthor=M.+Brunauthor=A.+Guptaauthor=N.+Juhelauthor=M.+Kluglichauthor=R.+M.+du+Bois&title=Efficacy+of+a+tyrosine+kinase+inhibitor+in+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; Costabel, Ulrich; Selman, Moises; Kim, Dong Soon; Hansell, David M.; Nicholson, Andrew G.; Brown, Kevin K.; Flaherty, Kevin R.; Noble, Paul W.; Raghu, Ganesh; Brun, Michele; Gupta, Abhya; Juhel, Nolwenn; Kluglich, Matthias; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1079-1087</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate.  Because the signaling pathways activated by several tyrosine kinase receptors were shown to be involved in lung fibrosis, it was suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis.  In a 12-mo, phase 2 trial, we assessed the efficacy and safety of 4 different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity.  A total of 432 patients underwent randomization to receive one of 4 doses of B1BF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo.  In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 L per yr, as compared with 0.19 L per yr in the placebo group, a 68.4% redn. in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure).  This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007).  Gastrointestinal symptoms (which led to more discontinuations in the. group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group.  In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was assocd. with a trend toward a redn. in the decline in lung function, with fewer acute exacerbations and preserved quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4JXOIjFKCRbVg90H21EOLACvtfcHk0ljeoUS8ZIcpZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WqsbrN&md5=6c076ac8d837944b4638ee7c444bb775</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103690%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DJuhel%26aufirst%3DN.%26aulast%3DKluglich%26aufirst%3DM.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DEfficacy%2520of%2520a%2520tyrosine%2520kinase%2520inhibitor%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1079%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Maulf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenker-Herceg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">â</span> <span class="NLM_lpage">2082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1056%2FNEJMoa1402584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24836310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2071-2082&author=L.+Richeldiauthor=R.+M.+du+Boisauthor=G.+Raghuauthor=A.+Azumaauthor=K.+K.+Brownauthor=U.+Costabelauthor=V.+Cottinauthor=K.+R.+Flahertyauthor=D.+M.+Hansellauthor=Y.+Inoueauthor=D.+S.+Kimauthor=M.+Kolbauthor=A.+G.+Nicholsonauthor=P.+W.+Nobleauthor=M.+Selmanauthor=H.+Taniguchiauthor=M.+Brunauthor=F.+Le+Maulfauthor=M.+Girardauthor=S.+Stowasserauthor=R.+Schlenker-Hercegauthor=B.+Disseauthor=H.+R.+Collard&title=INPULSIS+Trial+Investigators.+Efficacy+and+safety+of+nintedanib+in+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; du Bois, Roland M.; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell, David M.; Inoue, Yoshikazu; Kim, Dong Soon; Kolb, Martin; Nicholson, Andrew G.; Noble, Paul W.; Selman, Moises; Taniguchi, Hiroyuki; Brun, Michele; Le Maulf, Florence; Girard, Mannaig; Stowasser, Susanne; Schlenker-Herceg, Rozsa; Disse, Bernd; Collard, Harold R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2071-2082, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases.  A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.  Methods: We conducted two replicate 52-wk, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St.  George's Respiratory Questionnaire, both assessed over a 52-wk period.  Results: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo.  The adjusted annual rate of change in FVC was -114.7 mL with nintedanib vs. -239.9 mL with placebo (difference, 125.3 mL; 95% confidence interval [CI], 77.7 to 172.8; P < 0.001) in INPULSIS-1 and -113.6 mL with nintedanib vs. -207.3 mL with placebo (difference, 93.7 mL; 95% CI, 44.8 to 142.7; P < 0.001) in INPULSIS-2.  In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P = 0.67); in INPULSIS-2, there was a significant benefit with nintedanib vs. placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).  The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, resp., in INPULSIS-1 and 63.2% and 18.3% in the two groups, resp., in INPULSIS-2.  Conclusions: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently assocd. with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGuOhVKeZaSrVg90H21EOLACvtfcHk0ljeoUS8ZIcpZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK&md5=be977cd3b402c7c401f4a3dfaa0f484f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402584%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DLe%2BMaulf%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DSchlenker-Herceg%26aufirst%3DR.%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DINPULSIS%2520Trial%2520Investigators.%2520Efficacy%2520and%2520safety%2520of%2520nintedanib%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2071%26epage%3D2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Jubb, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span> </span><span class="NLM_article-title">Biomarkers to predict the clinical efficacy of bevacizumab in cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1172</span><span class="NLM_x">â</span> <span class="NLM_lpage">1183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1016%2FS1470-2045%2810%2970232-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21126687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVyhsLbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1172-1183&author=A.+M.+Jubbauthor=A.+L.+Harris&title=Biomarkers+to+predict+the+clinical+efficacy+of+bevacizumab+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers to predict the clinical efficacy of bevacizumab in cancer</span></div><div class="casAuthors">Jubb, Adrian M.; Harris, Adrian L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1172-1183</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that has antiangiogenic activity and improves progression-free survival in many solid malignancies when combined with cytotoxic chemotherapy, but has little effect on overall survival.  Despite the effects of this drug in unselected patients, the Response Evaluation Criteria in Solid Tumors are suboptimum to predict benefit.  Addnl., tumors show inherent and emerging resistance to regimens that include bevacizumab.  The ability to target therapy towards well selected subgroups of patients would increase the likelihood of benefits and would improve cost-effectiveness and therapeutic outcomes.  In this review we discuss putative clin., radiol., and mol. markers of bevacizumab efficacy, derived from data obtained in clin. trials.  Current evidence indicates some predictive value for hypertension, vascular imaging, and polymorphisms affecting components of the vascular endothelial growth factor pathway in patients receiving bevacizumab.  Many questions relating to these and other surrogate biomarkers, however, remain unanswered and their clin. usefulness has yet to be proven.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0K3HztmENnbVg90H21EOLACvtfcHk0ljeoUS8ZIcpZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVyhsLbP&md5=9a58aada56298f4d7feaf5c49ba86ddf</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970232-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970232-1%26sid%3Dliteratum%253Aachs%26aulast%3DJubb%26aufirst%3DA.%2BM.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DBiomarkers%2520to%2520predict%2520the%2520clinical%2520efficacy%2520of%2520bevacizumab%2520in%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26spage%3D1172%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrueco, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glomb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span> </span><span class="NLM_article-title">Identification of a clinical biomarker for 2nd line combination with nintedanib in adenocarcinoma non-small cell lung cancer (NSCLC) patients in two phase III trials</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">S822</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S822&author=R.+Kaiserauthor=J.+R.+Barruecoauthor=M.+Reckauthor=N.+Hannaauthor=C.+Gannauthor=P.+Glombauthor=B.+Gaschler-Markefski&title=Identification+of+a+clinical+biomarker+for+2nd+line+combination+with+nintedanib+in+adenocarcinoma+non-small+cell+lung+cancer+%28NSCLC%29+patients+in+two+phase+III+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DBarrueco%26aufirst%3DJ.%2BR.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DN.%26aulast%3DGann%26aufirst%3DC.%26aulast%3DGlomb%26aufirst%3DP.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520a%2520clinical%2520biomarker%2520for%25202nd%2520line%2520combination%2520with%2520nintedanib%2520in%2520adenocarcinoma%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520patients%2520in%2520two%2520phase%2520III%2520trials%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3DS822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Reck, M.; Novello, S.; Mellemgaard, A.; Orlov, S.; Kaiser, R.; Barrueco, J.; Gaschler-Markefski, B.; Douillard, J. Y.</span><span> </span><span class="NLM_article-title">Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: A randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy</span>.  <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span>, Presented at WCLC 2013, Abstract O16.01.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24389434" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=M.+Reck&author=S.+Novello&author=A.+Mellemgaard&author=S.+Orlov&author=R.+Kaiser&author=J.+Barrueco&author=B.+Gaschler-Markefski&author=J.+Y.+Douillard&title=Impact+of+tumor+burden+on+the+overall+survival+analysis+of+the+LUME-Lung+1+study%3A+A+randomized%2C+double-blind+phase+3+trial+of+nintedanib+%28BIBF+1120%29+%2B+docetaxel+in+NSCLC+patients+progressing+after+first-line+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DM.%26atitle%3DImpact%2520of%2520tumor%2520burden%2520on%2520the%2520overall%2520survival%2520analysis%2520of%2520the%2520LUME-Lung%25201%2520study%253A%2520A%2520randomized%252C%2520double-blind%2520phase%25203%2520trial%2520of%2520nintedanib%2520%2528BIBF%25201120%2529%2520%252B%2520docetaxel%2520in%2520NSCLC%2520patients%2520progressing%2520after%2520first-line%2520chemotherapy%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Hilberg, F.; Haslinger, C.; Garin-Chesa, P.; Adolf, G. R.</span><span> </span><span class="NLM_article-title">Molecular correlates of clinical benefit from anti-angiogenic therapy of lung adenocarcinoma: a hypothesis</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span>Presented at ASCO 2014, Abstract e22080.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=F.+Hilberg&author=C.+Haslinger&author=P.+Garin-Chesa&author=G.+R.+Adolf&title=Molecular+correlates+of+clinical+benefit+from+anti-angiogenic+therapy+of+lung+adenocarcinoma%3A+a+hypothesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DMolecular%2520correlates%2520of%2520clinical%2520benefit%2520from%2520anti-angiogenic%2520therapy%2520of%2520lung%2520adenocarcinoma%253A%2520a%2520hypothesis%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Demedts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span> </span><span class="NLM_article-title">ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">794</span><span class="NLM_x">â</span> <span class="NLM_lpage">796</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1183%2F09031936.02.00492002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=12030715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVCqsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=794-796&author=M.+Demedtsauthor=U.+Costabel&title=ATS%2FERS+international+multidisciplinary+consensus+classification+of+the+idiopathic+interstitial+pneumonias"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias</span></div><div class="casAuthors">Demedts, M.; Costabel, U.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">794-796</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  The article discusses the publication of the "ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias".  Previously, several classifications had been proposed, of which the most influential were the landmark histol. classification of chronic interstitial pneumonias.  The importance of the present ATS/ERS consensus classification is based on several issues.  First, it provides an integrated clin., radiol., and pathol. definition and classification of the whole group of IIP.  Secondly, it proposes multidisciplinary consensus guidelines to establish uniform criteria for the diagnosis of the different IIP, aimed at pulmonologists as well as radiologists and pathologists.  Third, while previous classifications have largely been conceived by individual authoritative pathologists or clinicians or by small collaborative groups of experts, the present consensus classification has been worked out by an international multidisciplinary core panel of some 20 pulmonologists, pulmonary pathologists, and thoracic radiologists, and was then approved by an extended review panel of some 65 experts from over 20 countries.  Also discussed are major new innovations in the ATS/ERS document as well as points raised that still require some discussion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsi9ZMmw7g1LVg90H21EOLACvtfcHk0liNlGYS5aZMxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVCqsbw%253D&md5=5403e07ec7d6349c1c8d1cc91885ae39</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.00492002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.00492002%26sid%3Dliteratum%253Aachs%26aulast%3DDemedts%26aufirst%3DM.%26aulast%3DCostabel%26aufirst%3DU.%26atitle%3DATS%252FERS%2520international%2520multidisciplinary%2520consensus%2520classification%2520of%2520the%2520idiopathic%2520interstitial%2520pneumonias%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D19%26spage%3D794%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminski, N.</span><span> </span><span class="NLM_article-title">Biomarkers in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Curr. Opin. Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1097%2FMCP.0b013e328356d03c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22847105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCmsb7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=441-446&author=Y.+Zhangauthor=N.+Kaminski&title=Biomarkers+in+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Zhang, Yingze; Kaminski, Naftali</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-446</span>CODEN:
                <span class="NLM_cas:coden">COPMFY</span>;
        ISSN:<span class="NLM_cas:issn">1070-5287</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: This review examines the recent literature on mol. biomarkers of idiopathic pulmonary fibrosis (IPF).  Specific attention is dedicated to the recent studies that identified the genes assocd. with IPF and the peripheral blood biomarkers that predict outcome in IPF.  Recent findings: Multiple studies attempted to identify diagnostic and predictive biomarkers in IPF.  Until recently, these studies were limited in size and lacked replication, but still when taken together provided convincing evidence that changes in blood proteins (KL-6, SP-A, MMP-7, CCL-18, among others) or cells (fibrocytes and T-cell subpopulations) are indicative of the disease presence and outcome.  More recently, larger studies have identified gene polymorphisms assocd. with IPF, as well as protein markers and integrated clin. and mol. prediction rules that accurately predict outcome in patients with IPF.  Summary: The peripheral blood contains disease presence and outcome relevant information, and suggests distinct biol. defined outcome trajectories in patients with IPF.  Although recently identified biomarkers should still be validated in multiple clin. contexts, there is sufficient evidence to suggest that collection of peripheral blood biomarkers needs to be incorporated in the design of drug studies and that some of these markers be clin. evaluated in lung transplant prioritization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMcTz1Tn-157Vg90H21EOLACvtfcHk0liNlGYS5aZMxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCmsb7P&md5=921e8b6cd0ada474dc1021859e154f2e</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e328356d03c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e328356d03c%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKaminski%26aufirst%3DN.%26atitle%3DBiomarkers%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D441%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span> </span><span class="NLM_article-title">CHMP summary of positive opinion for Vargatef</span>. September 25,<span class="NLM_x"> </span><span class="NLM_year">2014</span>. <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002569/WC500173607.pdf" class="extLink">http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002569/WC500173607.pdf</a> (accessed November 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CHMP+summary+of+positive+opinion+for+Vargatef.+September+25%2C+2014.+http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FSummary_of_opinion_-_Initial_authorisation%2Fhuman%2F002569%2FWC500173607.pdf+%28accessed+November+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DCHMP%2520summary%2520of%2520positive%2520opinion%2520for%2520Vargatef%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span> </span><span class="NLM_article-title">FDA approves Ofev to treat idiopathic pulmonary fibrosis</span>. October 15, 2014. <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm</a> (accessed November<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+approves+Ofev+to+treat+idiopathic+pulmonary+fibrosis.+October+15%2C+2014.+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm418994.htm+%28accessed+November+2014%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520approves%2520Ofev%2520to%2520treat%2520idiopathic%2520pulmonary%2520fibrosis%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':[],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 134 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hartmut Beck, Tobias Thaler, Daniel Meibom, Mark Meininghaus, Hannah JÃ¶riÃen, Lisa Dietz, Carsten Terjung, Michaela Bairlein, Clemens-Jeremias von BÃ¼hler, Sonja Anlauf, Chantal FÃ¼rstner, Timo Stellfeld, Dirk Schneider, Kersten M. Gericke, Thomas Buyck, Kai Lovis, Uwe MÃ¼nster, Johanna Anlahr, Elisabeth Kersten, Guillaume Levilain, Virginia Marossek, <span class="NLM_string-name hlFld-ContribAuthor">Raimund Kast</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11639-11662. <a href="https://doi.org/10.1021/acs.jmedchem.0c00834" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00834</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00834%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252Band%252BSelective%252BHuman%252BProstaglandin%252BF%252B%252528FP%252529%252BReceptor%252BAntagonist%252B%252528BAY-6672%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BIdiopathic%252BPulmonary%252BFibrosis%252B%252528IPF%252529%26aulast%3DBeck%26aufirst%3DHartmut%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16052020%26date%3D08102020%26date%3D24092020%26volume%3D63%26issue%3D20%26spage%3D11639%26epage%3D11662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lin Chen, <span class="NLM_string-name hlFld-ContribAuthor">Jin He</span>. </span><span class="cited-content_cbyCitation_article-title">DABCO-Catalyzed Michael/Alkylation Cascade Reactions Involving Î±-Substituted Ammonium Ylides for the Construction of Spirocyclopropyl Oxindoles: Access to the Powerful Chemical Leads against HIV-1. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (8)
                                     , 5203-5219. <a href="https://doi.org/10.1021/acs.joc.9b03164" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03164</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03164%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDABCO-Catalyzed%252BMichael%25252FAlkylation%252BCascade%252BReactions%252BInvolving%252B%2525CE%2525B1-Substituted%252BAmmonium%252BYlides%252Bfor%252Bthe%252BConstruction%252Bof%252BSpirocyclopropyl%252BOxindoles%25253A%252BAccess%252Bto%252Bthe%252BPowerful%252BChemical%252BLeads%252Bagainst%252BHIV-1%26aulast%3DChen%26aufirst%3DLin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D03122019%26date%3D03042020%26date%3D23032020%26volume%3D85%26issue%3D8%26spage%3D5203%26epage%3D5219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Girish
Singh Bisht, <span class="NLM_string-name hlFld-ContribAuthor">Boopathy Gnanaprakasam</span>. </span><span class="cited-content_cbyCitation_article-title">Transition-Metal-Free Addition Reaction for the Synthesis of 3-(Aminobenzylidene/aminoalkylidene)indolin-2-ones and Its Synthetic Applications. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (21)
                                     , 13516-13527. <a href="https://doi.org/10.1021/acs.joc.9b01771" title="DOI URL">https://doi.org/10.1021/acs.joc.9b01771</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b01771&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b01771%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTransition-Metal-Free%252BAddition%252BReaction%252Bfor%252Bthe%252BSynthesis%252Bof%252B3-%252528Aminobenzylidene%25252Faminoalkylidene%252529indolin-2-ones%252Band%252BIts%252BSynthetic%252BApplications%26aulast%3DBisht%26aufirst%3DGirish%2BSingh%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D01072019%26date%3D10102019%26date%3D26092019%26volume%3D84%26issue%3D21%26spage%3D13516%26epage%3D13527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rita Meleddu, Vilma Petrikaite, Simona Distinto, Antonella Arridu, Rossella Angius, Lorenzo Serusi, Laura Å karnulytÄ, UgnÄ EndriulaitytÄ, MiglÄ PaÅ¡keviÄiuÌtÄ, Filippo Cottiglia, Marco Gaspari, Domenico Taverna, Serenella Deplano, Benedetta Fois, <span class="NLM_string-name hlFld-ContribAuthor">Elias Maccioni</span>. </span><span class="cited-content_cbyCitation_article-title">Investigating the Anticancer Activity of Isatin/Dihydropyrazole Hybrids. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (4)
                                     , 571-576. <a href="https://doi.org/10.1021/acsmedchemlett.8b00596" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00596%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DInvestigating%252Bthe%252BAnticancer%252BActivity%252Bof%252BIsatin%25252FDihydropyrazole%252BHybrids%26aulast%3DMeleddu%26aufirst%3DRita%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D29112018%26date%3D17122018%26date%3D21122018%26date%3D18122018%26volume%3D10%26issue%3D4%26spage%3D571%26epage%3D576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Kemant Pratap, <span class="NLM_string-name hlFld-ContribAuthor">Atul Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Intermolecular Dehydrogenative Carboamination of Alkenes with Amines and N-Substituted Isatin. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (23)
                                     , 7451-7454. <a href="https://doi.org/10.1021/acs.orglett.8b03196" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b03196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b03196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b03196%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPalladium-Catalyzed%252BIntermolecular%252BDehydrogenative%252BCarboamination%252Bof%252BAlkenes%252Bwith%252BAmines%252Band%252BN-Substituted%252BIsatin%26aulast%3DPratap%26aufirst%3DKemant%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D08102018%26date%3D12112018%26volume%3D20%26issue%3D23%26spage%3D7451%26epage%3D7454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian A.  Kuttruff</span>, <span class="hlFld-ContribAuthor ">Marco  Ferrara</span>, <span class="hlFld-ContribAuthor ">Tom  Bretschneider</span>, <span class="hlFld-ContribAuthor ">Stefan  Hoerer</span>, <span class="hlFld-ContribAuthor ">Sandra  Handschuh</span>, <span class="hlFld-ContribAuthor ">Bernd  Nosse</span>, <span class="hlFld-ContribAuthor ">Helmut  Romig</span>, <span class="hlFld-ContribAuthor ">Paul  Nicklin</span>, and <span class="hlFld-ContribAuthor ">Gerald J.  Roth</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (12)
                                     , 1252-1257. <a href="https://doi.org/10.1021/acsmedchemlett.7b00312" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00312</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00312%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BBI-2545%25253A%252BA%252BNovel%252BAutotaxin%252BInhibitor%252BThat%252BSignificantly%252BReduces%252BLPA%252BLevels%252Bin%252BVivo%26aulast%3DKuttruff%26aufirst%3DChristian%2BA.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D05082017%26date%3D08112017%26date%3D14112017%26date%3D14122017%26date%3D08112017%26volume%3D8%26issue%3D12%26spage%3D1252%26epage%3D1257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhenhua  Huang</span>, <span class="hlFld-ContribAuthor ">Heran  Li</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Fangzheng  Lu</span>, <span class="hlFld-ContribAuthor ">Mei  Hong</span>, <span class="hlFld-ContribAuthor ">Zhigang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaocui  Guo</span>, <span class="hlFld-ContribAuthor ">Yuanju  Zhu</span>, <span class="hlFld-ContribAuthor ">Sanming  Li</span>, and <span class="hlFld-ContribAuthor ">Hongzhuo  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>8 </em>
                                    (11)
                                     , 1142-1147. <a href="https://doi.org/10.1021/acsmedchemlett.7b00164" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.7b00164</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.7b00164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.7b00164%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BIndolinone-Based%252BMultikinase%252BInhibitors%252Bas%252BPotential%252BTherapeutics%252Bfor%252BIdiopathic%252BPulmonary%252BFibrosis%26aulast%3DHuang%26aufirst%3DZhenhua%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D06052017%26date%3D30092017%26date%3D10102017%26date%3D09112017%26date%3D30092017%26volume%3D8%26issue%3D11%26spage%3D1142%26epage%3D1147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei  Zhao</span>, <span class="hlFld-ContribAuthor ">Ji-Shi  Wei</span>, <span class="hlFld-ContribAuthor ">Peng  Zhang</span>, <span class="hlFld-ContribAuthor ">Jie  Chen</span>, <span class="hlFld-ContribAuthor ">Ji-Lie  Kong</span>, <span class="hlFld-ContribAuthor ">Lian-Hua  Sun</span>, <span class="hlFld-ContribAuthor ">Huan-Ming  Xiong</span>, and <span class="hlFld-ContribAuthor ">Helmuth  MÃ¶hwald</span>  . </span><span class="cited-content_cbyCitation_article-title">Self-Assembled ZnO Nanoparticle Capsules for Carrying and Delivering Isotretinoin to Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">ACS Applied Materials & Interfaces</span><span> <strong>2017,</strong> <em>9 </em>
                                    (22)
                                     , 18474-18481. <a href="https://doi.org/10.1021/acsami.7b02542" title="DOI URL">https://doi.org/10.1021/acsami.7b02542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsami.7b02542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsami.7b02542%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Applied%2520Materials%2520%2526%2520Interfaces%26atitle%3DSelf-Assembled%252BZnO%252BNanoparticle%252BCapsules%252Bfor%252BCarrying%252Band%252BDelivering%252BIsotretinoin%252Bto%252BCancer%252BCells%26aulast%3DZhao%26aufirst%3DWei%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D21022017%26date%3D17052017%26date%3D25052017%26date%3D07062017%26volume%3D9%26issue%3D22%26spage%3D18474%26epage%3D18481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoseb  Yu</span>, <span class="hlFld-ContribAuthor ">Kye Jung  Shin</span>, and <span class="hlFld-ContribAuthor ">Jae Hong  Seo</span>  . </span><span class="cited-content_cbyCitation_article-title">Stereoselective Synthesis of 3-(1,3-Diarylallylidene)oxindoles via a Palladium-Catalyzed Tandem Reaction. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (3)
                                     , 1864-1871. <a href="https://doi.org/10.1021/acs.joc.6b02909" title="DOI URL">https://doi.org/10.1021/acs.joc.6b02909</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b02909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b02909%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DStereoselective%252BSynthesis%252Bof%252B3-%2525281%25252C3-Diarylallylidene%252529oxindoles%252Bvia%252Ba%252BPalladium-Catalyzed%252BTandem%252BReaction%26aulast%3DYu%26aufirst%3DYoseb%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D05122016%26date%3D23012017%26date%3D03022017%26date%3D06012017%26volume%3D82%26issue%3D3%26spage%3D1864%26epage%3D1871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi-Min  Liu</span>, <span class="hlFld-ContribAuthor ">Kunal  Nepali</span>, and <span class="hlFld-ContribAuthor ">Jing-Ping  Liou</span>  . </span><span class="cited-content_cbyCitation_article-title">Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (2)
                                     , 527-553. <a href="https://doi.org/10.1021/acs.jmedchem.6b00935" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00935</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00935%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdiopathic%252BPulmonary%252BFibrosis%25253A%252BCurrent%252BStatus%25252C%252BRecent%252BProgress%25252C%252Band%252BEmerging%252BTargets%26aulast%3DLiu%26aufirst%3DYi-Min%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D22062016%26date%3D29112016%26date%3D26012017%26date%3D14112016%26volume%3D60%26issue%3D2%26spage%3D527%26epage%3D553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timothy P.  Heffron</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (22)
                                     , 10030-10066. <a href="https://doi.org/10.1021/acs.jmedchem.6b00618" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00618</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00618%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BBrain%252BCancer%26aulast%3DHeffron%26aufirst%3DTimothy%2BP.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D21042016%26date%3D03082016%26date%3D23112016%26date%3D14072016%26volume%3D59%26issue%3D22%26spage%3D10030%26epage%3D10066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Yong  Duan</span>, <span class="hlFld-ContribAuthor ">Xiu-Long  Yang</span>, <span class="hlFld-ContribAuthor ">Pan-Pan  Jia</span>, <span class="hlFld-ContribAuthor ">Man  Zhang</span>, and <span class="hlFld-ContribAuthor ">Bing  Han</span>  . </span><span class="cited-content_cbyCitation_article-title">Hydrazonyl Radical-Participated Tandem Reaction: A Strategy for the Synthesis of Pyrazoline-Functionalized Oxindoles. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2015,</strong> <em>17 </em>
                                    (24)
                                     , 6022-6025. <a href="https://doi.org/10.1021/acs.orglett.5b03003" title="DOI URL">https://doi.org/10.1021/acs.orglett.5b03003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.5b03003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.5b03003%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DHydrazonyl%252BRadical-Participated%252BTandem%252BReaction%25253A%252BA%252BStrategy%252Bfor%252Bthe%252BSynthesis%252Bof%252BPyrazoline-Functionalized%252BOxindoles%26aulast%3DDuan%26aufirst%3DXiao-Yong%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D16102015%26date%3D07122015%26date%3D18122015%26volume%3D17%26issue%3D24%26spage%3D6022%26epage%3D6025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V. C.  Karade</span>, <span class="hlFld-ContribAuthor ">A.  Sharma</span>, <span class="hlFld-ContribAuthor ">R. P.  Dhavale</span>, <span class="hlFld-ContribAuthor ">R. P.  Dhavale</span>, <span class="hlFld-ContribAuthor ">S. R.  Shingte</span>, <span class="hlFld-ContribAuthor ">P. S.  Patil</span>, <span class="hlFld-ContribAuthor ">J. H.  Kim</span>, <span class="hlFld-ContribAuthor ">D. R. T.  Zahn</span>, <span class="hlFld-ContribAuthor ">A. D.  Chougale</span>, <span class="hlFld-ContribAuthor ">G.  Salvan</span>, <span class="hlFld-ContribAuthor ">P. B.  Patil</span>. </span><span class="cited-content_cbyCitation_article-title">APTES monolayer coverage on self-assembled magnetic nanospheres for controlled release of anticancer drug Nintedanib. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-84770-0" title="DOI URL">https://doi.org/10.1038/s41598-021-84770-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-84770-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-84770-0%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DAPTES%252Bmonolayer%252Bcoverage%252Bon%252Bself-assembled%252Bmagnetic%252Bnanospheres%252Bfor%252Bcontrolled%252Brelease%252Bof%252Banticancer%252Bdrug%252BNintedanib%26aulast%3DKarade%26aufirst%3DV.%2BC.%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yue  Bai</span>, <span class="hlFld-ContribAuthor ">Yunhao  Zhang</span>, <span class="hlFld-ContribAuthor ">Peng  Chu</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Li</span>, <span class="hlFld-ContribAuthor ">Yan  Qi</span>, <span class="hlFld-ContribAuthor ">Xu  Han</span>, <span class="hlFld-ContribAuthor ">Baojing  Zhang</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Lixue  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>48 </em>, 128238. <a href="https://doi.org/10.1016/j.bmcl.2021.128238" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128238%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bselenogefitinib%252Bfor%252Breducing%252Bbleomycin-induced%252Bpulmonary%252Bfibrosis%26aulast%3DBai%26aufirst%3DYue%26date%3D2021%26volume%3D48%26spage%3D128238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joonbeom  Kwon</span>, <span class="hlFld-ContribAuthor ">EunâJu  Lee</span>, <span class="hlFld-ContribAuthor ">HyunâJung  Cho</span>, <span class="hlFld-ContribAuthor ">JiâAe  Jang</span>, <span class="hlFld-ContribAuthor ">MinâSu  Han</span>, <span class="hlFld-ContribAuthor ">Eunkyoung  Kwak</span>, <span class="hlFld-ContribAuthor ">Haesoo  Kim</span>, <span class="hlFld-ContribAuthor ">Jihyun  An</span>, <span class="hlFld-ContribAuthor ">Donghwi  Park</span>, <span class="hlFld-ContribAuthor ">Seungwoo  Han</span>, <span class="hlFld-ContribAuthor ">Nobutaka  Shimizu</span>, <span class="hlFld-ContribAuthor ">Takahisa  Suzuki</span>, <span class="hlFld-ContribAuthor ">EiâIchiro  Takaoka</span>, <span class="hlFld-ContribAuthor ">Naoki  Yoshimura</span>. </span><span class="cited-content_cbyCitation_article-title">Antifibrosis treatment by inhibition of VEGF, FGF, and PDGF receptors improves bladder wall remodeling and detrusor overactivity in association with modulation of Câfiber afferent activity in mice with spinal cord injury. </span><span class="cited-content_cbyCitation_journal-name">Neurourology and Urodynamics</span><span> <strong>2021,</strong> <em>40 </em>
                                    (6)
                                     , 1460-1469. <a href="https://doi.org/10.1002/nau.24704" title="DOI URL">https://doi.org/10.1002/nau.24704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/nau.24704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fnau.24704%26sid%3Dliteratum%253Aachs%26jtitle%3DNeurourology%2520and%2520Urodynamics%26atitle%3DAntifibrosis%252Btreatment%252Bby%252Binhibition%252Bof%252BVEGF%25252C%252BFGF%25252C%252Band%252BPDGF%252Breceptors%252Bimproves%252Bbladder%252Bwall%252Bremodeling%252Band%252Bdetrusor%252Boveractivity%252Bin%252Bassociation%252Bwith%252Bmodulation%252Bof%252BC%2525E2%252580%252590fiber%252Bafferent%252Bactivity%252Bin%252Bmice%252Bwith%252Bspinal%252Bcord%252Binjury%26aulast%3DKwon%26aufirst%3DJoonbeom%26date%3D2021%26date%3D2021%26volume%3D40%26issue%3D6%26spage%3D1460%26epage%3D1469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ingrida  TumosienÄ</span>, <span class="hlFld-ContribAuthor ">Ilona  JonuÅ¡kienÄ</span>, <span class="hlFld-ContribAuthor ">Kristina  KantminienÄ</span>, <span class="hlFld-ContribAuthor ">Vytautas  MickeviÄius</span>, <span class="hlFld-ContribAuthor ">Vilma  PetrikaitÄ</span>. </span><span class="cited-content_cbyCitation_article-title">Novel N-Substituted Amino Acid Hydrazone-Isatin Derivatives: Synthesis, Antioxidant Activity, and Anticancer Activity in 2D and 3D Models In Vitro. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (15)
                                     , 7799. <a href="https://doi.org/10.3390/ijms22157799" title="DOI URL">https://doi.org/10.3390/ijms22157799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22157799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22157799%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DNovel%252BN-Substituted%252BAmino%252BAcid%252BHydrazone-Isatin%252BDerivatives%25253A%252BSynthesis%25252C%252BAntioxidant%252BActivity%25252C%252Band%252BAnticancer%252BActivity%252Bin%252B2D%252Band%252B3D%252BModels%252BIn%252BVitro%26aulast%3DTumosien%25C4%2597%26aufirst%3DIngrida%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D15%26spage%3D7799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangyan  Du</span>, <span class="hlFld-ContribAuthor ">Jie  Jiang</span>, <span class="hlFld-ContribAuthor ">Qibiao  Wu</span>, <span class="hlFld-ContribAuthor ">Nathaniel J.  Henning</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Hong  Yue</span>, <span class="hlFld-ContribAuthor ">Jianwei  Che</span>, <span class="hlFld-ContribAuthor ">Wenchao  Lu</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nabeel  Bardeesy</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (29)
                                     , 16041-16047. <a href="https://doi.org/10.1002/ange.202101328" title="DOI URL">https://doi.org/10.1002/ange.202101328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202101328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202101328%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252BDegrader%252Bfor%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B1%25252F2%26aulast%3DDu%26aufirst%3DGuangyan%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D29%26spage%3D16041%26epage%3D16047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guangyan  Du</span>, <span class="hlFld-ContribAuthor ">Jie  Jiang</span>, <span class="hlFld-ContribAuthor ">Qibiao  Wu</span>, <span class="hlFld-ContribAuthor ">Nathaniel J.  Henning</span>, <span class="hlFld-ContribAuthor ">Katherine A.  Donovan</span>, <span class="hlFld-ContribAuthor ">Hong  Yue</span>, <span class="hlFld-ContribAuthor ">Jianwei  Che</span>, <span class="hlFld-ContribAuthor ">Wenchao  Lu</span>, <span class="hlFld-ContribAuthor ">Eric S.  Fischer</span>, <span class="hlFld-ContribAuthor ">Nabeel  Bardeesy</span>, <span class="hlFld-ContribAuthor ">Tinghu  Zhang</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent Degrader for Fibroblast Growth Factor Receptor 1/2. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (29)
                                     , 15905-15911. <a href="https://doi.org/10.1002/anie.202101328" title="DOI URL">https://doi.org/10.1002/anie.202101328</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202101328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202101328%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252BDegrader%252Bfor%252BFibroblast%252BGrowth%252BFactor%252BReceptor%252B1%25252F2%26aulast%3DDu%26aufirst%3DGuangyan%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D29%26spage%3D15905%26epage%3D15911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongyao  Liu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Wu</span>, <span class="hlFld-ContribAuthor ">Cailing  Gan</span>, <span class="hlFld-ContribAuthor ">Liqun  Wang</span>, <span class="hlFld-ContribAuthor ">Guan  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Yue</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Xingping  Su</span>, <span class="hlFld-ContribAuthor ">Qianyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Zui  Tan</span>, <span class="hlFld-ContribAuthor ">Yuqin  Yao</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>, <span class="hlFld-ContribAuthor ">Luoting  Yu</span>, <span class="hlFld-ContribAuthor ">Tinghong  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">A novel multikinase inhibitor SKLBâYTHâ60 ameliorates inflammation and fibrosis in bleomycinâinduced lung fibrosis mouse models. </span><span class="cited-content_cbyCitation_journal-name">Cell Proliferation</span><span> <strong>2021,</strong> <em>54 </em>
                                    (7)
                                     <a href="https://doi.org/10.1111/cpr.13081" title="DOI URL">https://doi.org/10.1111/cpr.13081</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cpr.13081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcpr.13081%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Proliferation%26atitle%3DA%252Bnovel%252Bmultikinase%252Binhibitor%252BSKLB%2525E2%252580%252590YTH%2525E2%252580%25259060%252Bameliorates%252Binflammation%252Band%252Bfibrosis%252Bin%252Bbleomycin%2525E2%252580%252590induced%252Blung%252Bfibrosis%252Bmouse%252Bmodels%26aulast%3DLiu%26aufirst%3DHongyao%26date%3D2021%26date%3D2021%26volume%3D54%26issue%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Noor A.  Hussein</span>, <span class="hlFld-ContribAuthor ">Saloni  Malla</span>, <span class="hlFld-ContribAuthor ">Mariah A.  Pasternak</span>, <span class="hlFld-ContribAuthor ">David  Terrero</span>, <span class="hlFld-ContribAuthor ">Noah G.  Brown</span>, <span class="hlFld-ContribAuthor ">Charles R.  Ashby</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>, <span class="hlFld-ContribAuthor ">Zhe-Sheng  Chen</span>, <span class="hlFld-ContribAuthor ">Amit K.  Tiwari</span>. </span><span class="cited-content_cbyCitation_article-title">The role of endolysosomal trafficking in anticancer drug resistance. </span><span class="cited-content_cbyCitation_journal-name">Drug Resistance Updates</span><span> <strong>2021,</strong> <em>57 </em>, 100769. <a href="https://doi.org/10.1016/j.drup.2021.100769" title="DOI URL">https://doi.org/10.1016/j.drup.2021.100769</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drup.2021.100769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drup.2021.100769%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Resistance%2520Updates%26atitle%3DThe%252Brole%252Bof%252Bendolysosomal%252Btrafficking%252Bin%252Banticancer%252Bdrug%252Bresistance%26aulast%3DHussein%26aufirst%3DNoor%2BA.%26date%3D2021%26volume%3D57%26spage%3D100769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Chao  Yu</span>, <span class="hlFld-ContribAuthor ">Huan  Qin</span>, <span class="hlFld-ContribAuthor ">Shenglei  Zhang</span>, <span class="hlFld-ContribAuthor ">Lu  Fang</span>, <span class="hlFld-ContribAuthor ">Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Binbin  Cui</span>, <span class="hlFld-ContribAuthor ">Susie  Hu</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>, <span class="hlFld-ContribAuthor ">Shougang  Zhuang</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib attenuates peritoneal fibrosis by inhibiting mesothelialâtoâmesenchymal transition, inflammation and angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular and Molecular Medicine</span><span> <strong>2021,</strong> <em>25 </em>
                                    (13)
                                     , 6103-6114. <a href="https://doi.org/10.1111/jcmm.16518" title="DOI URL">https://doi.org/10.1111/jcmm.16518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jcmm.16518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjcmm.16518%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520and%2520Molecular%2520Medicine%26atitle%3DNintedanib%252Battenuates%252Bperitoneal%252Bfibrosis%252Bby%252Binhibiting%252Bmesothelial%2525E2%252580%252590to%2525E2%252580%252590mesenchymal%252Btransition%25252C%252Binflammation%252Band%252Bangiogenesis%26aulast%3DLiu%26aufirst%3DFeng%26date%3D2021%26date%3D2021%26volume%3D25%26issue%3D13%26spage%3D6103%26epage%3D6114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdelfattah  Hassan</span>, <span class="hlFld-ContribAuthor ">Mohamed  Badr</span>, <span class="hlFld-ContribAuthor ">Heba A.  Hassan</span>, <span class="hlFld-ContribAuthor ">Dalia  Abdelhamid</span>, <span class="hlFld-ContribAuthor ">Gamal ElâDin A.  AbuoâRahma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 4-(piperazin-1-yl)quinolin-2(1H)-one bearing thiazoles with antiproliferative activity through VEGFR-2-TK inhibition. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>40 </em>, 116168. <a href="https://doi.org/10.1016/j.bmc.2021.116168" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116168%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DNovel%252B4-%252528piperazin-1-yl%252529quinolin-2%2525281H%252529-one%252Bbearing%252Bthiazoles%252Bwith%252Bantiproliferative%252Bactivity%252Bthrough%252BVEGFR-2-TK%252Binhibition%26aulast%3DHassan%26aufirst%3DAbdelfattah%26date%3D2021%26volume%3D40%26spage%3D116168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shiro  Kanegasaki</span>, <span class="hlFld-ContribAuthor ">Tomoko  Tsuchiya</span>. </span><span class="cited-content_cbyCitation_article-title">A possible way to prevent the progression of bone lesions in multiple myeloma via Srcâhomologyâregionâ2âdomainâcontainingâphosphataseâ1 activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Biochemistry</span><span> <strong>2021,</strong> <em>8 </em><a href="https://doi.org/10.1002/jcb.29949" title="DOI URL">https://doi.org/10.1002/jcb.29949</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcb.29949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcb.29949%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Biochemistry%26atitle%3DA%252Bpossible%252Bway%252Bto%252Bprevent%252Bthe%252Bprogression%252Bof%252Bbone%252Blesions%252Bin%252Bmultiple%252Bmyeloma%252Bvia%252BSrc%2525E2%252580%252590homology%2525E2%252580%252590region%2525E2%252580%2525902%2525E2%252580%252590domain%2525E2%252580%252590containing%2525E2%252580%252590phosphatase%2525E2%252580%2525901%252Bactivation%26aulast%3DKanegasaki%26aufirst%3DShiro%26date%3D2021%26date%3D2021%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yan  Fu</span>, <span class="hlFld-ContribAuthor ">Tao  Gong</span>, <span class="hlFld-ContribAuthor ">Jiaywei  Tsauo</span>, <span class="hlFld-ContribAuthor ">Mingchen  Sang</span>, <span class="hlFld-ContribAuthor ">He  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaowu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jingui  Li</span>, <span class="hlFld-ContribAuthor ">Xiao  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib, a multitarget tyrosine kinase inhibitor, suppresses postoperative peritoneal adhesion formation in a rat model. </span><span class="cited-content_cbyCitation_journal-name">Surgery</span><span> <strong>2021,</strong> <em>112 </em><a href="https://doi.org/10.1016/j.surg.2021.03.055" title="DOI URL">https://doi.org/10.1016/j.surg.2021.03.055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.surg.2021.03.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.surg.2021.03.055%26sid%3Dliteratum%253Aachs%26jtitle%3DSurgery%26atitle%3DNintedanib%25252C%252Ba%252Bmultitarget%252Btyrosine%252Bkinase%252Binhibitor%25252C%252Bsuppresses%252Bpostoperative%252Bperitoneal%252Badhesion%252Bformation%252Bin%252Ba%252Brat%252Bmodel%26aulast%3DFu%26aufirst%3DYan%26date%3D2021%26volume%3D112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Angiogenesis Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-66. <a href="https://doi.org/10.1002/0471266949.bmc271" title="DOI URL">https://doi.org/10.1002/0471266949.bmc271</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc271%26sid%3Dliteratum%253Aachs%26atitle%3DAngiogenesis%252BInhibitors%26aulast%3DShi%26aufirst%3DLei%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D66%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D61" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcelo A. S.  Toledo</span>, <span class="hlFld-ContribAuthor ">Malrun  Gatz</span>, <span class="hlFld-ContribAuthor ">Stephanie  Sontag</span>, <span class="hlFld-ContribAuthor ">Karoline V.  Gleixner</span>, <span class="hlFld-ContribAuthor ">Gregor  Eisenwort</span>, <span class="hlFld-ContribAuthor ">Kristina  Feldberg</span>, <span class="hlFld-ContribAuthor ">Ahmed E. I.  Hamouda</span>, <span class="hlFld-ContribAuthor ">Frederick  Kluge</span>, <span class="hlFld-ContribAuthor ">Riccardo  Guareschi</span>, <span class="hlFld-ContribAuthor ">Giulia  Rossetti</span>, <span class="hlFld-ContribAuthor ">Antonio S.  Sechi</span>, <span class="hlFld-ContribAuthor ">Olli M. J.  Dufva</span>, <span class="hlFld-ContribAuthor ">Satu M.  Mustjoki</span>, <span class="hlFld-ContribAuthor ">Angela  Maurer</span>, <span class="hlFld-ContribAuthor ">Herdit M.  SchÃ¼ler</span>, <span class="hlFld-ContribAuthor ">Roman  Goetzke</span>, <span class="hlFld-ContribAuthor ">Till  Braunschweig</span>, <span class="hlFld-ContribAuthor ">Anne  Kaiser</span>, <span class="hlFld-ContribAuthor ">Jens  Panse</span>, <span class="hlFld-ContribAuthor ">Mohamad  Jawhar</span>, <span class="hlFld-ContribAuthor ">Andreas  Reiter</span>, <span class="hlFld-ContribAuthor ">Frank  Hilberg</span>, <span class="hlFld-ContribAuthor ">Peter  Ettmayer</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Wagner</span>, <span class="hlFld-ContribAuthor ">Steffen  Koschmieder</span>, <span class="hlFld-ContribAuthor ">Tim H.  BrÃ¼mmendorf</span>, <span class="hlFld-ContribAuthor ">Peter  Valent</span>, <span class="hlFld-ContribAuthor ">Nicolas  Chatain</span>, <span class="hlFld-ContribAuthor ">Martin  Zenke</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2021,</strong> <em>137 </em>
                                    (15)
                                     , 2070-2084. <a href="https://doi.org/10.1182/blood.2019004509" title="DOI URL">https://doi.org/10.1182/blood.2019004509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood.2019004509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood.2019004509%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DNintedanib%252Btargets%252BKIT%252BD816V%252Bneoplastic%252Bcells%252Bderived%252Bfrom%252Binduced%252Bpluripotent%252Bstem%252Bcells%252Bof%252Bsystemic%252Bmastocytosis%26aulast%3DToledo%26aufirst%3DMarcelo%2BA.%2BS.%26date%3D2021%26volume%3D137%26issue%3D15%26spage%3D2070%26epage%3D2084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kamila  Kitowska</span>, <span class="hlFld-ContribAuthor ">Monika  Gorska-Arcisz</span>, <span class="hlFld-ContribAuthor ">Dima  Antoun</span>, <span class="hlFld-ContribAuthor ">Izabela  Zarczynska</span>, <span class="hlFld-ContribAuthor ">Dominika  Czaplinska</span>, <span class="hlFld-ContribAuthor ">Adrian  Szczepaniak</span>, <span class="hlFld-ContribAuthor ">Andrzej C.  Skladanowski</span>, <span class="hlFld-ContribAuthor ">Maciej  Wieczorek</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Stanczak</span>, <span class="hlFld-ContribAuthor ">Monika  Skupinska</span>, <span class="hlFld-ContribAuthor ">Rafal  Sadej</span>. </span><span class="cited-content_cbyCitation_article-title">MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fonc.2021.633410" title="DOI URL">https://doi.org/10.3389/fonc.2021.633410</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2021.633410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2021.633410%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DMET-Pyk2%252BAxis%252BMediates%252BAcquired%252BResistance%252Bto%252BFGFR%252BInhibition%252Bin%252BCancer%252BCells%26aulast%3DKitowska%26aufirst%3DKamila%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prajwal  Dhokne</span>, <span class="hlFld-ContribAuthor ">Akash P.  Sakla</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">Structural insights of oxindole based kinase inhibitors as anticancer agents: Recent advances. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113334. <a href="https://doi.org/10.1016/j.ejmech.2021.113334" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113334</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113334%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Binsights%252Bof%252Boxindole%252Bbased%252Bkinase%252Binhibitors%252Bas%252Banticancer%252Bagents%25253A%252BRecent%252Badvances%26aulast%3DDhokne%26aufirst%3DPrajwal%26date%3D2021%26volume%3D216%26spage%3D113334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiong  Chen</span>, <span class="hlFld-ContribAuthor ">Menglin  Li</span>, <span class="hlFld-ContribAuthor ">Manru  Li</span>, <span class="hlFld-ContribAuthor ">Dongmei  Wang</span>, <span class="hlFld-ContribAuthor ">Jinlan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Harnessing affinity-based protein profiling to reveal a novel target of nintedanib. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>57 </em>
                                    (25)
                                     , 3139-3142. <a href="https://doi.org/10.1039/D1CC00354B" title="DOI URL">https://doi.org/10.1039/D1CC00354B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CC00354B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CC00354B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DHarnessing%252Baffinity-based%252Bprotein%252Bprofiling%252Bto%252Breveal%252Ba%252Bnovel%252Btarget%252Bof%252Bnintedanib%26aulast%3DChen%26aufirst%3DXiong%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D25%26spage%3D3139%26epage%3D3142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yoshihiro  Gocho</span>, <span class="hlFld-ContribAuthor ">Jingjing  Liu</span>, <span class="hlFld-ContribAuthor ">Jianzhong  Hu</span>, <span class="hlFld-ContribAuthor ">Wentao  Yang</span>, <span class="hlFld-ContribAuthor ">Neekesh V.  Dharia</span>, <span class="hlFld-ContribAuthor ">Jingliao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hao  Shi</span>, <span class="hlFld-ContribAuthor ">Guoqing  Du</span>, <span class="hlFld-ContribAuthor ">August  John</span>, <span class="hlFld-ContribAuthor ">Ting-Nien  Lin</span>, <span class="hlFld-ContribAuthor ">Jeremy  Hunt</span>, <span class="hlFld-ContribAuthor ">Xin  Huang</span>, <span class="hlFld-ContribAuthor ">Bensheng  Ju</span>, <span class="hlFld-ContribAuthor ">Lauren  Rowland</span>, <span class="hlFld-ContribAuthor ">Lei  Shi</span>, <span class="hlFld-ContribAuthor ">Dylan  Maxwell</span>, <span class="hlFld-ContribAuthor ">Brandon  Smart</span>, <span class="hlFld-ContribAuthor ">Kristine R.  Crews</span>, <span class="hlFld-ContribAuthor ">Wenjian  Yang</span>, <span class="hlFld-ContribAuthor ">Kohei  Hagiwara</span>, <span class="hlFld-ContribAuthor ">Yingchi  Zhang</span>, <span class="hlFld-ContribAuthor ">Kathryn  Roberts</span>, <span class="hlFld-ContribAuthor ">Hong  Wang</span>, <span class="hlFld-ContribAuthor ">Elias  Jabbour</span>, <span class="hlFld-ContribAuthor ">Wendy  Stock</span>, <span class="hlFld-ContribAuthor ">Bartholomew  Eisfelder</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Paietta</span>, <span class="hlFld-ContribAuthor ">Scott  Newman</span>, <span class="hlFld-ContribAuthor ">Giovanni  Roti</span>, <span class="hlFld-ContribAuthor ">Mark  Litzow</span>, <span class="hlFld-ContribAuthor ">John  Easton</span>, <span class="hlFld-ContribAuthor ">Jinghui  Zhang</span>, <span class="hlFld-ContribAuthor ">Junmin  Peng</span>, <span class="hlFld-ContribAuthor ">Hongbo  Chi</span>, <span class="hlFld-ContribAuthor ">Stanley  Pounds</span>, <span class="hlFld-ContribAuthor ">Mary V.  Relling</span>, <span class="hlFld-ContribAuthor ">Hiroto  Inaba</span>, <span class="hlFld-ContribAuthor ">Xiaofan  Zhu</span>, <span class="hlFld-ContribAuthor ">Steven  Kornblau</span>, <span class="hlFld-ContribAuthor ">Ching-Hon  Pui</span>, <span class="hlFld-ContribAuthor ">Marina  Konopleva</span>, <span class="hlFld-ContribAuthor ">David  Teachey</span>, <span class="hlFld-ContribAuthor ">Charles G.  Mullighan</span>, <span class="hlFld-ContribAuthor ">Kimberly  Stegmaier</span>, <span class="hlFld-ContribAuthor ">William E.  Evans</span>, <span class="hlFld-ContribAuthor ">Jiyang  Yu</span>, <span class="hlFld-ContribAuthor ">Jun J.  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. </span><span class="cited-content_cbyCitation_journal-name">Nature Cancer</span><span> <strong>2021,</strong> <em>2 </em>
                                    (3)
                                     , 284-299. <a href="https://doi.org/10.1038/s43018-020-00167-4" title="DOI URL">https://doi.org/10.1038/s43018-020-00167-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s43018-020-00167-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs43018-020-00167-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Cancer%26atitle%3DNetwork-based%252Bsystems%252Bpharmacology%252Breveals%252Bheterogeneity%252Bin%252BLCK%252Band%252BBCL2%252Bsignaling%252Band%252Btherapeutic%252Bsensitivity%252Bof%252BT-cell%252Bacute%252Blymphoblastic%252Bleukemia%26aulast%3DGocho%26aufirst%3DYoshihiro%26date%3D2021%26date%3D2021%26volume%3D2%26issue%3D3%26spage%3D284%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">B.  Wu</span>, <span class="hlFld-ContribAuthor ">L.  Tang</span>, <span class="hlFld-ContribAuthor ">M.  Kapoor</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblasts and their responses to chronic injury in pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Arthritis and Rheumatism</span><span> <strong>2021,</strong> <em>51 </em>
                                    (1)
                                     , 310-317. <a href="https://doi.org/10.1016/j.semarthrit.2020.12.003" title="DOI URL">https://doi.org/10.1016/j.semarthrit.2020.12.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semarthrit.2020.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semarthrit.2020.12.003%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Arthritis%2520and%2520Rheumatism%26atitle%3DFibroblasts%252Band%252Btheir%252Bresponses%252Bto%252Bchronic%252Binjury%252Bin%252Bpulmonary%252Bfibrosis%26aulast%3DWu%26aufirst%3DB.%26date%3D2021%26volume%3D51%26issue%3D1%26spage%3D310%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clara  Dees</span>, <span class="hlFld-ContribAuthor ">Debomita  Chakraborty</span>, <span class="hlFld-ContribAuthor ">JÃ¶rg H. W.  Distler</span>. </span><span class="cited-content_cbyCitation_article-title">Cellular and molecular mechanisms in fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Experimental Dermatology</span><span> <strong>2021,</strong> <em>30 </em>
                                    (1)
                                     , 121-131. <a href="https://doi.org/10.1111/exd.14193" title="DOI URL">https://doi.org/10.1111/exd.14193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/exd.14193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fexd.14193%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520Dermatology%26atitle%3DCellular%252Band%252Bmolecular%252Bmechanisms%252Bin%252Bfibrosis%26aulast%3DDees%26aufirst%3DClara%26date%3D2021%26date%3D2020%26volume%3D30%26issue%3D1%26spage%3D121%26epage%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Grzegorz  GrzeÅk</span>, <span class="hlFld-ContribAuthor ">Anita  WoÅºniak-WiÅniewska</span>, <span class="hlFld-ContribAuthor ">Jan  BÅaÅ¼ejewski</span>, <span class="hlFld-ContribAuthor ">Bartosz  GÃ³rny</span>, <span class="hlFld-ContribAuthor ">Åukasz  WoÅowiec</span>, <span class="hlFld-ContribAuthor ">Daniel  Rogowicz</span>, <span class="hlFld-ContribAuthor ">Alicja  Nowaczyk</span>. </span><span class="cited-content_cbyCitation_article-title">The Interactions of Nintedanib and Oral AnticoagulantsâMolecular Mechanisms and Clinical Implications. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (1)
                                     , 282. <a href="https://doi.org/10.3390/ijms22010282" title="DOI URL">https://doi.org/10.3390/ijms22010282</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22010282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22010282%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DThe%252BInteractions%252Bof%252BNintedanib%252Band%252BOral%252BAnticoagulants%2525E2%252580%252594Molecular%252BMechanisms%252Band%252BClinical%252BImplications%26aulast%3DGrze%25C5%259Bk%26aufirst%3DGrzegorz%26date%3D2021%26date%3D2020%26volume%3D22%26issue%3D1%26spage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaki  Dobashi</span>, <span class="hlFld-ContribAuthor ">Hisashi  Tanaka</span>, <span class="hlFld-ContribAuthor ">Kageaki  Taima</span>, <span class="hlFld-ContribAuthor ">Masamichi  Itoga</span>, <span class="hlFld-ContribAuthor ">Yoshiko  Ishioka</span>, <span class="hlFld-ContribAuthor ">Toshihiro  Shiratori</span>, <span class="hlFld-ContribAuthor ">Fumihiko  Okumura</span>, <span class="hlFld-ContribAuthor ">Chiori  Tabe</span>, <span class="hlFld-ContribAuthor ">Yoshihito  Tanaka</span>, <span class="hlFld-ContribAuthor ">Takeshi  Morimoto</span>, <span class="hlFld-ContribAuthor ">Yukihiro  Hasegawa</span>, <span class="hlFld-ContribAuthor ">Hideo  Yasugahira</span>, <span class="hlFld-ContribAuthor ">Koichi  Okudera</span>, <span class="hlFld-ContribAuthor ">Shingo  Takanashi</span>, <span class="hlFld-ContribAuthor ">Sadatomo  Tasaka</span>. </span><span class="cited-content_cbyCitation_article-title">The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study. </span><span class="cited-content_cbyCitation_journal-name">SAGE Open Medicine</span><span> <strong>2021,</strong> <em>9 </em>, 205031212110233. <a href="https://doi.org/10.1177/20503121211023357" title="DOI URL">https://doi.org/10.1177/20503121211023357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/20503121211023357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F20503121211023357%26sid%3Dliteratum%253Aachs%26jtitle%3DSAGE%2520Open%2520Medicine%26atitle%3DThe%252Befficacy%252Bof%252Bnintedanib%252Bin%252B158%252Bpatients%252Bwith%252Bidiopathic%252Bpulmonary%252Bfibrosis%252Bin%252Breal-world%252Bsettings%25253A%252BA%252Bmulticenter%252Bretrospective%252Bstudy%26aulast%3DDobashi%26aufirst%3DMasaki%26date%3D2021%26date%3D2021%26volume%3D9%26spage%3D205031212110233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Khodr  Tello</span>, <span class="hlFld-ContribAuthor ">Werner  Seeger</span>, <span class="hlFld-ContribAuthor ">Robert  Naeije</span>, <span class="hlFld-ContribAuthor ">Rebecca  Vanderpool</span>, <span class="hlFld-ContribAuthor ">Hossein Ardeschir  Ghofrani</span>, <span class="hlFld-ContribAuthor ">Manuel  Richter</span>, <span class="hlFld-ContribAuthor ">Ryan J.  Tedford</span>, <span class="hlFld-ContribAuthor ">Harm J.  Bogaard</span>. </span><span class="cited-content_cbyCitation_article-title">Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2021,</strong> <em>178 </em>
                                    (1)
                                     , 90-107. <a href="https://doi.org/10.1111/bph.14866" title="DOI URL">https://doi.org/10.1111/bph.14866</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.14866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.14866%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DRight%252Bheart%252Bfailure%252Bin%252Bpulmonary%252Bhypertension%25253A%252BDiagnosis%252Band%252Bnew%252Bperspectives%252Bon%252Bvascular%252Band%252Bdirect%252Bright%252Bventricular%252Btreatment%26aulast%3DTello%26aufirst%3DKhodr%26date%3D2021%26date%3D2019%26volume%3D178%26issue%3D1%26spage%3D90%26epage%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yueyuan  Qiu</span>, <span class="hlFld-ContribAuthor ">Zhaowei  Wang</span>, <span class="hlFld-ContribAuthor ">Xutao  Zhang</span>, <span class="hlFld-ContribAuthor ">Ping  Huang</span>, <span class="hlFld-ContribAuthor ">Wangqian  Zhang</span>, <span class="hlFld-ContribAuthor ">Kuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Shuning  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  He</span>, <span class="hlFld-ContribAuthor ">Yanhai  Guo</span>, <span class="hlFld-ContribAuthor ">An  Xiang</span>, <span class="hlFld-ContribAuthor ">Cun  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiang  Hao</span>, <span class="hlFld-ContribAuthor ">Meng  Li</span>, <span class="hlFld-ContribAuthor ">Weina  Li</span>, <span class="hlFld-ContribAuthor ">Yingqi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">A longâacting isomer of
              AcâSDKP
              attenuates pulmonary fibrosis through
              SRPK1
              âmediated
              PI3K
              /
              AKT
              and Smad2 pathway inhibition. </span><span class="cited-content_cbyCitation_journal-name">IUBMB Life</span><span> <strong>2020,</strong> <em>72 </em>
                                    (12)
                                     , 2611-2626. <a href="https://doi.org/10.1002/iub.2389" title="DOI URL">https://doi.org/10.1002/iub.2389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/iub.2389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fiub.2389%26sid%3Dliteratum%253Aachs%26jtitle%3DIUBMB%2520Life%26atitle%3DA%252Blong%2525E2%252580%252590acting%252Bisomer%252Bof%252BAc%2525E2%252580%252590SDKP%252Battenuates%252Bpulmonary%252Bfibrosis%252Bthrough%252BSRPK1%252B%2525E2%252580%252590mediated%252BPI3K%252B%25252F%252BAKT%252Band%252BSmad2%252Bpathway%252Binhibition%26aulast%3DQiu%26aufirst%3DYueyuan%26date%3D2020%26date%3D2020%26volume%3D72%26issue%3D12%26spage%3D2611%26epage%3D2626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min-Jeong  Heo</span>, <span class="hlFld-ContribAuthor ">Chanmi  Lee</span>, <span class="hlFld-ContribAuthor ">Soo Young  Choi</span>, <span class="hlFld-ContribAuthor ">Yeong Min  Choi</span>, <span class="hlFld-ContribAuthor ">In-sook  An</span>, <span class="hlFld-ContribAuthor ">Seunghee  Bae</span>, <span class="hlFld-ContribAuthor ">Sungkwan  An</span>, <span class="hlFld-ContribAuthor ">Jin Hyuk  Jung</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib ameliorates animal model of dermatitis. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-61424-1" title="DOI URL">https://doi.org/10.1038/s41598-020-61424-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-61424-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-61424-1%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DNintedanib%252Bameliorates%252Banimal%252Bmodel%252Bof%252Bdermatitis%26aulast%3DHeo%26aufirst%3DMin-Jeong%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Valenzuela</span>, <span class="hlFld-ContribAuthor ">Sebastiano Emanuele  Torrisi</span>, <span class="hlFld-ContribAuthor ">Nicolas  Kahn</span>, <span class="hlFld-ContribAuthor ">Manuel  Quaresma</span>, <span class="hlFld-ContribAuthor ">Susanne  Stowasser</span>, <span class="hlFld-ContribAuthor ">Michael  Kreuter</span>. </span><span class="cited-content_cbyCitation_article-title">Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. </span><span class="cited-content_cbyCitation_journal-name">Respiratory Research</span><span> <strong>2020,</strong> <em>21 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12931-019-1269-6" title="DOI URL">https://doi.org/10.1186/s12931-019-1269-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12931-019-1269-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12931-019-1269-6%26sid%3Dliteratum%253Aachs%26jtitle%3DRespiratory%2520Research%26atitle%3DOngoing%252Bchallenges%252Bin%252Bpulmonary%252Bfibrosis%252Band%252Binsights%252Bfrom%252Bthe%252Bnintedanib%252Bclinical%252Bprogramme%26aulast%3DValenzuela%26aufirst%3DClaudia%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeronimo Rafael  RodrÃ­guez-Cid</span>, <span class="hlFld-ContribAuthor ">Saul  Campos-Gomez</span>, <span class="hlFld-ContribAuthor ">Vanessa  GarcÃ­a-Montes</span>, <span class="hlFld-ContribAuthor ">Manuel  Magallanes-Maciel</span>, <span class="hlFld-ContribAuthor ">Rodrigo Rafael  Flores-MariÃ±elarena</span>, <span class="hlFld-ContribAuthor ">Valeria Michelle  FernÃ¡ndez-Garibay</span>, <span class="hlFld-ContribAuthor ">IvÃ¡n Romarico  GonzÃ¡lez-Espinoza</span>, <span class="hlFld-ContribAuthor ">Juan Paulo  Ceja-GarcÃ­a</span>, <span class="hlFld-ContribAuthor ">Juan Carlos  CÃ¡zarez-Price</span>, <span class="hlFld-ContribAuthor ">Luis  MartÃ­nez-Barrera</span>, <span class="hlFld-ContribAuthor ">Leopoldo  Barriguete-Parra</span>, <span class="hlFld-ContribAuthor ">Carlos Jose  Zuloaga-Fernandez</span>, <span class="hlFld-ContribAuthor ">Roberto  Kuri-Exsome</span>, <span class="hlFld-ContribAuthor ">David  SuÃ¡rez-GarcÃ­a</span>, <span class="hlFld-ContribAuthor ">Jorge Ignacio  Gonzalez-Villanueva</span>, <span class="hlFld-ContribAuthor ">NoÃ©  Flores-Anaya</span>, <span class="hlFld-ContribAuthor ">Jose Antonio  Acevedo-Delgado</span>, <span class="hlFld-ContribAuthor ">Alma Magdalena  Astorga-Ramos</span>, <span class="hlFld-ContribAuthor ">Raquel  Gerson-Cwilich</span>, <span class="hlFld-ContribAuthor ">Alberto  Villalobos-Prieto</span>, <span class="hlFld-ContribAuthor ">Claudia  RodrÃ­guez-Silva</span>, <span class="hlFld-ContribAuthor ">Maria Fernanda  Noriega-Iriondo</span>, <span class="hlFld-ContribAuthor ">Leticia  VÃ¡zquez-CortÃ©s</span>, <span class="hlFld-ContribAuthor ">Eusebio  Perales-RodrÃ­guez</span>, <span class="hlFld-ContribAuthor ">Alicia  Acosta-Espinoza</span>, <span class="hlFld-ContribAuthor ">Yareni  Perez-Lozano</span>, <span class="hlFld-ContribAuthor ">Daniel  Capdeville-GarcÃ­a</span>, <span class="hlFld-ContribAuthor ">Jorge Arturo  Alatorre-Alexander</span>. </span><span class="cited-content_cbyCitation_article-title">Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">JCO Global Oncology</span><span> <strong>2020,</strong> <em> </em>
                                    (6)
                                     , 462-470. <a href="https://doi.org/10.1200/JGO.19.00330" title="DOI URL">https://doi.org/10.1200/JGO.19.00330</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1200/JGO.19.00330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1200%2FJGO.19.00330%26sid%3Dliteratum%253Aachs%26jtitle%3DJCO%2520Global%2520Oncology%26atitle%3DReal-World%252BEvidence%25253A%252BMulticenter%252BEfficacy%252Band%252BToxicity%252BAnalysis%252Bof%252BNintedanib%252BWith%252BDocetaxel%252Bas%252BSecond-Line%252BTreatment%252Bin%252BMexican%252BPatients%252BWith%252BAdvanced%252BLung%252BAdenocarcinoma%26aulast%3DRodr%25C3%25ADguez-Cid%26aufirst%3DJeronimo%2BRafael%26date%3D2020%26issue%3D6%26spage%3D462%26epage%3D470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paroma  Sarkar</span>, <span class="hlFld-ContribAuthor ">Cristina  Avram</span>, <span class="hlFld-ContribAuthor ">Nazia  Chaudhuri</span>. </span><span class="cited-content_cbyCitation_article-title">The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Respiratory Medicine</span><span> <strong>2020,</strong> <em>14 </em>
                                    (10)
                                     , 1001-1008. <a href="https://doi.org/10.1080/17476348.2020.1784730" title="DOI URL">https://doi.org/10.1080/17476348.2020.1784730</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17476348.2020.1784730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17476348.2020.1784730%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Respiratory%2520Medicine%26atitle%3DThe%252Bextended%252Butility%252Bof%252Bantifibrotic%252Btherapy%252Bin%252Bprogressive%252Bfibrosing%252Binterstitial%252Blung%252Bdisease%26aulast%3DSarkar%26aufirst%3DParoma%26date%3D2020%26date%3D2020%26volume%3D14%26issue%3D10%26spage%3D1001%26epage%3D1008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo-ya  Zhou</span>, <span class="hlFld-ContribAuthor ">Wen-bo  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-li  Wu</span>, <span class="hlFld-ContribAuthor ">Wen-jie  Zhang</span>, <span class="hlFld-ContribAuthor ">Guang-dong  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhen  Gao</span>, <span class="hlFld-ContribAuthor ">Wei  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib inhibits keloid fibroblast functions by blocking the phosphorylation of multiple kinases and enhancing receptor internalization. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2020,</strong> <em>41 </em>
                                    (9)
                                     , 1234-1245. <a href="https://doi.org/10.1038/s41401-020-0381-y" title="DOI URL">https://doi.org/10.1038/s41401-020-0381-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-020-0381-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-020-0381-y%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DNintedanib%252Binhibits%252Bkeloid%252Bfibroblast%252Bfunctions%252Bby%252Bblocking%252Bthe%252Bphosphorylation%252Bof%252Bmultiple%252Bkinases%252Band%252Benhancing%252Breceptor%252Binternalization%26aulast%3DZhou%26aufirst%3DBo-ya%26date%3D2020%26date%3D2020%26volume%3D41%26issue%3D9%26spage%3D1234%26epage%3D1245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuqin  Yao</span>, <span class="hlFld-ContribAuthor ">Zhuowei  Liu</span>, <span class="hlFld-ContribAuthor ">Manyu  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhengxia  Chen</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Yang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuxi  Wang</span>, <span class="hlFld-ContribAuthor ">Chengjian  Zhao</span>, <span class="hlFld-ContribAuthor ">Chaofeng  Long</span>, <span class="hlFld-ContribAuthor ">Xiaoxin  Chen</span>, <span class="hlFld-ContribAuthor ">Jinliang  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2020,</strong> <em>10 </em>
                                    (8)
                                     , 1453-1475. <a href="https://doi.org/10.1016/j.apsb.2020.04.002" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.04.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.04.002%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252B4-%2525283-chloro-4-%2525283-cyclopropylthioureido%252529-2-fluorophenoxy%252529-7-methoxyquinoline-6-carboxamide%252B%252528WXFL-152%252529%25253A%252Ba%252Bnovel%252Btriple%252Bangiokinase%252Binhibitor%252Bfor%252Bcancer%252Btherapy%26aulast%3DYao%26aufirst%3DYuqin%26date%3D2020%26volume%3D10%26issue%3D8%26spage%3D1453%26epage%3D1475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunjing  Zhu</span>, <span class="hlFld-ContribAuthor ">Xue  Liang</span>, <span class="hlFld-ContribAuthor ">Cong  Lu</span>, <span class="hlFld-ContribAuthor ">Yihan  Kong</span>, <span class="hlFld-ContribAuthor ">Xing  Tang</span>, <span class="hlFld-ContribAuthor ">Yu  Zhang</span>, <span class="hlFld-ContribAuthor ">Tian  Yin</span>, <span class="hlFld-ContribAuthor ">Jingxin  Gou</span>, <span class="hlFld-ContribAuthor ">Yanjiao  Wang</span>, <span class="hlFld-ContribAuthor ">Haibing  He</span>. </span><span class="cited-content_cbyCitation_article-title">Nanostructured lipid carriers as oral delivery systems for improving oral bioavailability of nintedanib by promoting intestinal absorption. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Pharmaceutics</span><span> <strong>2020,</strong> <em>586 </em>, 119569. <a href="https://doi.org/10.1016/j.ijpharm.2020.119569" title="DOI URL">https://doi.org/10.1016/j.ijpharm.2020.119569</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijpharm.2020.119569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijpharm.2020.119569%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Pharmaceutics%26atitle%3DNanostructured%252Blipid%252Bcarriers%252Bas%252Boral%252Bdelivery%252Bsystems%252Bfor%252Bimproving%252Boral%252Bbioavailability%252Bof%252Bnintedanib%252Bby%252Bpromoting%252Bintestinal%252Babsorption%26aulast%3DZhu%26aufirst%3DYunjing%26date%3D2020%26volume%3D586%26spage%3D119569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark W.  Surber</span>, <span class="hlFld-ContribAuthor ">Steve  Beck</span>, <span class="hlFld-ContribAuthor ">Stephen  Pham</span>, <span class="hlFld-ContribAuthor ">Angela T.  Marsden</span>, <span class="hlFld-ContribAuthor ">Senthil K.  Gandi</span>, <span class="hlFld-ContribAuthor ">James  Baily</span>, <span class="hlFld-ContribAuthor ">Mary C.  McElroy</span>. </span><span class="cited-content_cbyCitation_article-title">Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Pulmonary Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>63 </em>, 101938. <a href="https://doi.org/10.1016/j.pupt.2020.101938" title="DOI URL">https://doi.org/10.1016/j.pupt.2020.101938</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pupt.2020.101938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pupt.2020.101938%26sid%3Dliteratum%253Aachs%26jtitle%3DPulmonary%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DInhaled%252Bnintedanib%252Bis%252Bwell-tolerated%252Band%252Bdelivers%252Bkey%252Bpharmacokinetic%252Bparameters%252Brequired%252Bto%252Btreat%252Bbleomycin-induced%252Bpulmonary%252Bfibrosis%26aulast%3DSurber%26aufirst%3DMark%2BW.%26date%3D2020%26volume%3D63%26spage%3D101938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gali  Epstein-Shochet</span>, <span class="hlFld-ContribAuthor ">Stephen  Pham</span>, <span class="hlFld-ContribAuthor ">Steven  Beck</span>, <span class="hlFld-ContribAuthor ">Safaa  Naiel</span>, <span class="hlFld-ContribAuthor ">Olivia  Mekhael</span>, <span class="hlFld-ContribAuthor ">Spencer  Revill</span>, <span class="hlFld-ContribAuthor ">Aaron  Hayat</span>, <span class="hlFld-ContribAuthor ">Megan  Vierhout</span>, <span class="hlFld-ContribAuthor ">Becky  Bardestein-Wald</span>, <span class="hlFld-ContribAuthor ">David  Shitrit</span>, <span class="hlFld-ContribAuthor ">Kjetil  Ask</span>, <span class="hlFld-ContribAuthor ">A. Bruce  Montgomery</span>, <span class="hlFld-ContribAuthor ">Martin R.  Kolb</span>, <span class="hlFld-ContribAuthor ">Mark W.  Surber</span>. </span><span class="cited-content_cbyCitation_article-title">Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship. </span><span class="cited-content_cbyCitation_journal-name">Pulmonary Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>63 </em>, 101933. <a href="https://doi.org/10.1016/j.pupt.2020.101933" title="DOI URL">https://doi.org/10.1016/j.pupt.2020.101933</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pupt.2020.101933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pupt.2020.101933%26sid%3Dliteratum%253Aachs%26jtitle%3DPulmonary%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DInhalation%25253A%252BA%252Bmeans%252Bto%252Bexplore%252Band%252Boptimize%252Bnintedanib%252527s%252Bpharmacokinetic%25252Fpharmacodynamic%252Brelationship%26aulast%3DEpstein-Shochet%26aufirst%3DGali%26date%3D2020%26volume%3D63%26spage%3D101933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Linlin  Xue</span>, <span class="hlFld-ContribAuthor ">Dexin  Deng</span>, <span class="hlFld-ContribAuthor ">Shoujun  Zheng</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Yong  Chen</span>, <span class="hlFld-ContribAuthor ">Tao  Yang</span>, <span class="hlFld-ContribAuthor ">Kongjun  Liu</span>, <span class="hlFld-ContribAuthor ">Haoyu  Ye</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-Î²/smad dependent and independent pathway. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>197 </em>, 112259. <a href="https://doi.org/10.1016/j.ejmech.2020.112259" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112259</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112259%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bdiscovery%252Bof%252B2%2525281H%252529-quinolone%252Bderivatives%252Bfor%252Bthe%252Btreatment%252Bof%252Bpulmonary%252Bfibrosis%252Bthrough%252Binhibition%252Bof%252BTGF-%2525CE%2525B2%25252Fsmad%252Bdependent%252Band%252Bindependent%252Bpathway%26aulast%3DXue%26aufirst%3DLinlin%26date%3D2020%26volume%3D197%26spage%3D112259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rafael  Morales-Barrera</span>, <span class="hlFld-ContribAuthor ">Cristina  SuÃ¡rez</span>, <span class="hlFld-ContribAuthor ">Macarena  GonzÃ¡lez</span>, <span class="hlFld-ContribAuthor ">Claudia  Valverde</span>, <span class="hlFld-ContribAuthor ">Ester  Serra</span>, <span class="hlFld-ContribAuthor ">JoaquÃ­n  Mateo</span>, <span class="hlFld-ContribAuthor ">Carles  Raventos</span>, <span class="hlFld-ContribAuthor ">Xavier  Maldonado</span>, <span class="hlFld-ContribAuthor ">Juan  Morote</span>, <span class="hlFld-ContribAuthor ">Joan  Carles</span>. </span><span class="cited-content_cbyCitation_article-title">The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2020,</strong> <em>86 </em>, 102000. <a href="https://doi.org/10.1016/j.ctrv.2020.102000" title="DOI URL">https://doi.org/10.1016/j.ctrv.2020.102000</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2020.102000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2020.102000%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DThe%252Bfuture%252Bof%252Bbladder%252Bcancer%252Btherapy%25253A%252BOptimizing%252Bthe%252Binhibition%252Bof%252Bthe%252Bfibroblast%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DMorales-Barrera%26aufirst%3DRafael%26date%3D2020%26volume%3D86%26spage%3D102000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elke  Boxhammer</span>, <span class="hlFld-ContribAuthor ">Karla  Lehle</span>, <span class="hlFld-ContribAuthor ">Christof  Schmid</span>, <span class="hlFld-ContribAuthor ">Marietta  von Suesskind-Schwendi</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-oxidative effect of the tyrosine kinase inhibitor nintedanib: a potential therapy for chronic lung allograft dysfunction?. </span><span class="cited-content_cbyCitation_journal-name">Experimental Lung Research</span><span> <strong>2020,</strong> <em>46 </em>
                                    (5)
                                     , 128-145. <a href="https://doi.org/10.1080/01902148.2020.1738594" title="DOI URL">https://doi.org/10.1080/01902148.2020.1738594</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/01902148.2020.1738594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F01902148.2020.1738594%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520Lung%2520Research%26atitle%3DAnti-oxidative%252Beffect%252Bof%252Bthe%252Btyrosine%252Bkinase%252Binhibitor%252Bnintedanib%25253A%252Ba%252Bpotential%252Btherapy%252Bfor%252Bchronic%252Blung%252Ballograft%252Bdysfunction%25253F%26aulast%3DBoxhammer%26aufirst%3DElke%26date%3D2020%26date%3D2020%26volume%3D46%26issue%3D5%26spage%3D128%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hairui  Wu</span>, <span class="hlFld-ContribAuthor ">Xi  Gu</span>, <span class="hlFld-ContribAuthor ">Jinling  Li</span>, <span class="hlFld-ContribAuthor ">Mingxing  Wang</span>, <span class="hlFld-ContribAuthor ">Yanchun  Li</span>, <span class="hlFld-ContribAuthor ">Lei  Yuan</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Enlong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of potential platelet-derived growth factor receptor Î± inhibitors by computational screening and binding simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Graphics and Modelling</span><span> <strong>2020,</strong> <em>96 </em>, 107527. <a href="https://doi.org/10.1016/j.jmgm.2019.107527" title="DOI URL">https://doi.org/10.1016/j.jmgm.2019.107527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jmgm.2019.107527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jmgm.2019.107527%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Graphics%2520and%2520Modelling%26atitle%3DIdentification%252Bof%252Bpotential%252Bplatelet-derived%252Bgrowth%252Bfactor%252Breceptor%252B%2525CE%2525B1%252Binhibitors%252Bby%252Bcomputational%252Bscreening%252Band%252Bbinding%252Bsimulations%26aulast%3DWu%26aufirst%3DHairui%26date%3D2020%26volume%3D96%26spage%3D107527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michal  Stark</span>, <span class="hlFld-ContribAuthor ">TomÃ¡s F. D.  Silva</span>, <span class="hlFld-ContribAuthor ">Guy  Levin</span>, <span class="hlFld-ContribAuthor ">Miguel  Machuqueiro</span>, <span class="hlFld-ContribAuthor ">Yehuda G.  Assaraf</span>. </span><span class="cited-content_cbyCitation_article-title">The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2020,</strong> <em>9 </em>
                                    (5)
                                     , 1082. <a href="https://doi.org/10.3390/cells9051082" title="DOI URL">https://doi.org/10.3390/cells9051082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells9051082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells9051082%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DThe%252BLysosomotropic%252BActivity%252Bof%252BHydrophobic%252BWeak%252BBase%252BDrugs%252Bis%252BMediated%252Bvia%252BTheir%252BIntercalation%252Binto%252Bthe%252BLysosomal%252BMembrane%26aulast%3DStark%26aufirst%3DMichal%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D5%26spage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaohe  Li</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Liu</span>, <span class="hlFld-ContribAuthor ">Ruxia  Deng</span>, <span class="hlFld-ContribAuthor ">Shaoyan  Gao</span>, <span class="hlFld-ContribAuthor ">Haiyan  Yu</span>, <span class="hlFld-ContribAuthor ">Kai  Huang</span>, <span class="hlFld-ContribAuthor ">Qiuyan  Jiang</span>, <span class="hlFld-ContribAuthor ">Rui  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaoping  Li</span>, <span class="hlFld-ContribAuthor ">Liang  Zhang</span>, <span class="hlFld-ContribAuthor ">Honggang  Zhou</span>, <span class="hlFld-ContribAuthor ">Cheng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib Inhibits Wnt3a-Induced Myofibroblast Activation by Suppressing the Src/Î²-Catenin Pathway. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.00310" title="DOI URL">https://doi.org/10.3389/fphar.2020.00310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.00310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.00310%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DNintedanib%252BInhibits%252BWnt3a-Induced%252BMyofibroblast%252BActivation%252Bby%252BSuppressing%252Bthe%252BSrc%25252F%2525CE%2525B2-Catenin%252BPathway%26aulast%3DLi%26aufirst%3DXiaohe%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew J.  Haak</span>, <span class="hlFld-ContribAuthor ">Merrick T.  Ducharme</span>, <span class="hlFld-ContribAuthor ">Ana M.  Diaz Espinosa</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Tschumperlin</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting GPCR Signaling for Idiopathic Pulmonary Fibrosis Therapies. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2020,</strong> <em>41 </em>
                                    (3)
                                     , 172-182. <a href="https://doi.org/10.1016/j.tips.2019.12.008" title="DOI URL">https://doi.org/10.1016/j.tips.2019.12.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2019.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2019.12.008%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DTargeting%252BGPCR%252BSignaling%252Bfor%252BIdiopathic%252BPulmonary%252BFibrosis%252BTherapies%26aulast%3DHaak%26aufirst%3DAndrew%2BJ.%26date%3D2020%26volume%3D41%26issue%3D3%26spage%3D172%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna K.  Nowak</span>, <span class="hlFld-ContribAuthor ">Solenn  Brosseau</span>, <span class="hlFld-ContribAuthor ">Alistair  Cook</span>, <span class="hlFld-ContribAuthor ">GÃ©rard  Zalcman</span>. </span><span class="cited-content_cbyCitation_article-title">Antiangiogeneic Strategies in Mesothelioma. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.00126" title="DOI URL">https://doi.org/10.3389/fonc.2020.00126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.00126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.00126%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DAntiangiogeneic%252BStrategies%252Bin%252BMesothelioma%26aulast%3DNowak%26aufirst%3DAnna%2BK.%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Jiang</span>, <span class="hlFld-ContribAuthor ">Yuhong  Zhou</span>, <span class="hlFld-ContribAuthor ">Minglin  Zhu</span>, <span class="hlFld-ContribAuthor ">Junlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng  Cao</span>, <span class="hlFld-ContribAuthor ">Hongrui  Lei</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>, <span class="hlFld-ContribAuthor ">Guangyue  Su</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>187 </em>, 111904. <a href="https://doi.org/10.1016/j.ejmech.2019.111904" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111904</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111904&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111904%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Band%252Bevaluation%252Bof%252Bnovel%252Btetrahydropyrido%25255B4%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252BATX%252Binhibitors%252Bfor%252Bcardiac%252Band%252Bhepatic%252Bfibrosis%26aulast%3DJiang%26aufirst%3DNan%26date%3D2020%26volume%3D187%26spage%3D111904" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zi-Meng  Zhou</span>, <span class="hlFld-ContribAuthor ">Yi-Kun  Wang</span>, <span class="hlFld-ContribAuthor ">Dong-Mei  Yan</span>, <span class="hlFld-ContribAuthor ">Jian-He  Fang</span>, <span class="hlFld-ContribAuthor ">Xue-Rong  Xiao</span>, <span class="hlFld-ContribAuthor ">Ting  Zhang</span>, <span class="hlFld-ContribAuthor ">Yan  Cheng</span>, <span class="hlFld-ContribAuthor ">Kang-Ping  Xu</span>, <span class="hlFld-ContribAuthor ">Fei  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Metabolic proï¬ling of tyrosine kinase inhibitor nintedanib using metabolomics. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2020,</strong> <em>180 </em>, 113045. <a href="https://doi.org/10.1016/j.jpba.2019.113045" title="DOI URL">https://doi.org/10.1016/j.jpba.2019.113045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2019.113045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2019.113045%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DMetabolic%252Bpro%2525EF%2525AC%252581ling%252Bof%252Btyrosine%252Bkinase%252Binhibitor%252Bnintedanib%252Busing%252Bmetabolomics%26aulast%3DZhou%26aufirst%3DZi-Meng%26date%3D2020%26volume%3D180%26spage%3D113045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaowen  Liu</span>, <span class="hlFld-ContribAuthor ">Xu  Zheng</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Qiang  Meng</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2020,</strong> <em>15 </em>
                                    (2)
                                     , 182-187. <a href="https://doi.org/10.1002/cmdc.201900606" title="DOI URL">https://doi.org/10.1002/cmdc.201900606</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900606%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNovel%252BPyrimidines%252Bas%252BMultitarget%252BProtein%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BIdiopathic%252BPulmonary%252BFibrosis%252B%252528IPF%252529%26aulast%3DSun%26aufirst%3DBo%26date%3D2020%26date%3D2019%26volume%3D15%26issue%3D2%26spage%3D182%26epage%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanming  Zhu</span>, <span class="hlFld-ContribAuthor ">Xu  Zheng</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Huijun  Sun</span>, <span class="hlFld-ContribAuthor ">Tengyue  Ma</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Lixue  Chen</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (2)
                                     , 115254. <a href="https://doi.org/10.1016/j.bmc.2019.115254" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.115254</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.115254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.115254%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bactivity%252Bof%252Bthieno%25255B3%25252C2-d%25255Dpyrimidines%252Bas%252Bpotent%252BJAK3%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bidiopathic%252Bpulmonary%252Bfibrosis%26aulast%3DZhu%26aufirst%3DYanming%26date%3D2020%26volume%3D28%26issue%3D2%26spage%3D115254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benedetta  Pasquini</span>, <span class="hlFld-ContribAuthor ">Serena  Orlandini</span>, <span class="hlFld-ContribAuthor ">Sandra  Furlanetto</span>, <span class="hlFld-ContribAuthor ">Roberto  Gotti</span>, <span class="hlFld-ContribAuthor ">Massimo  Del Bubba</span>, <span class="hlFld-ContribAuthor ">Francesca  Boscaro</span>, <span class="hlFld-ContribAuthor ">Bruno  Bertaccini</span>, <span class="hlFld-ContribAuthor ">Michal  DouÅ¡a</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Pieraccini</span>. </span><span class="cited-content_cbyCitation_article-title">Quality by Design as a risk-based strategy in pharmaceutical analysis: Development of a liquid chromatography-tandem mass spectrometry method for the determination of nintedanib and its impurities. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography A</span><span> <strong>2020,</strong> <em>1611 </em>, 460615. <a href="https://doi.org/10.1016/j.chroma.2019.460615" title="DOI URL">https://doi.org/10.1016/j.chroma.2019.460615</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chroma.2019.460615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chroma.2019.460615%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520A%26atitle%3DQuality%252Bby%252BDesign%252Bas%252Ba%252Brisk-based%252Bstrategy%252Bin%252Bpharmaceutical%252Banalysis%25253A%252BDevelopment%252Bof%252Ba%252Bliquid%252Bchromatography-tandem%252Bmass%252Bspectrometry%252Bmethod%252Bfor%252Bthe%252Bdetermination%252Bof%252Bnintedanib%252Band%252Bits%252Bimpurities%26aulast%3DPasquini%26aufirst%3DBenedetta%26date%3D2020%26volume%3D1611%26spage%3D460615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dexin  Deng</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Tingxuan  Lan</span>, <span class="hlFld-ContribAuthor ">Jiali  Zhu</span>, <span class="hlFld-ContribAuthor ">Minghai  Tang</span>, <span class="hlFld-ContribAuthor ">Linlin  Xue</span>, <span class="hlFld-ContribAuthor ">Zhuang  Yang</span>, <span class="hlFld-ContribAuthor ">Shoujun  Zheng</span>, <span class="hlFld-ContribAuthor ">Haoyu  Ye</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>185 </em>, 111790. <a href="https://doi.org/10.1016/j.ejmech.2019.111790" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111790</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111790%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bdiscovery%252Bof%252Bnew%252Bcompounds%252Bbearing%252Bcoumarin%252Bscaffold%252Bfor%252Bthe%252Btreatment%252Bof%252Bpulmonary%252Bfibrosis%26aulast%3DDeng%26aufirst%3DDexin%26date%3D2020%26volume%3D185%26spage%3D111790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emilia  Bigaeva</span>, <span class="hlFld-ContribAuthor ">Elisabeth G. D.  Stribos</span>, <span class="hlFld-ContribAuthor ">Henricus A. M.  Mutsaers</span>, <span class="hlFld-ContribAuthor ">Bram  Piersma</span>, <span class="hlFld-ContribAuthor ">Anna M.  Leliveld</span>, <span class="hlFld-ContribAuthor ">Igle J.  de Jong</span>, <span class="hlFld-ContribAuthor ">Ruud A.  Bank</span>, <span class="hlFld-ContribAuthor ">Marc A.  Seelen</span>, <span class="hlFld-ContribAuthor ">Harry  van Goor</span>, <span class="hlFld-ContribAuthor ">Lutz  Wollin</span>, <span class="hlFld-ContribAuthor ">Peter  Olinga</span>, <span class="hlFld-ContribAuthor ">Miriam  Boersema</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of tyrosine kinase receptor signaling attenuates fibrogenesis in an ex vivo model of human renal fibrosis. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Physiology-Renal Physiology</span><span> <strong>2020,</strong> <em>318 </em>
                                    (1)
                                     , F117-F134. <a href="https://doi.org/10.1152/ajprenal.00108.2019" title="DOI URL">https://doi.org/10.1152/ajprenal.00108.2019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1152/ajprenal.00108.2019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1152%2Fajprenal.00108.2019%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Physiology-Renal%2520Physiology%26atitle%3DInhibition%252Bof%252Btyrosine%252Bkinase%252Breceptor%252Bsignaling%252Battenuates%252Bfibrogenesis%252Bin%252Ban%252Bex%252Bvivo%252Bmodel%252Bof%252Bhuman%252Brenal%252Bfibrosis%26aulast%3DBigaeva%26aufirst%3DEmilia%26date%3D2020%26volume%3D318%26issue%3D1%26spage%3DF117%26epage%3DF134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuseppe  Marseglia</span>, <span class="hlFld-ContribAuthor ">Alessio  Lodola</span>, <span class="hlFld-ContribAuthor ">Marco  Mor</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>. </span><span class="cited-content_cbyCitation_article-title">Fibroblast growth factor receptor inhibitors: patent review (2015â2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2019,</strong> <em>29 </em>
                                    (12)
                                     , 965-977. <a href="https://doi.org/10.1080/13543776.2019.1688300" title="DOI URL">https://doi.org/10.1080/13543776.2019.1688300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2019.1688300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2019.1688300%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DFibroblast%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%25253A%252Bpatent%252Breview%252B%2525282015%2525E2%252580%2525932019%252529%26aulast%3DMarseglia%26aufirst%3DGiuseppe%26date%3D2019%26date%3D2019%26volume%3D29%26issue%3D12%26spage%3D965%26epage%3D977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amornpun  Wongkarnjana</span>, <span class="hlFld-ContribAuthor ">Toyoshi  Yanagihara</span>, <span class="hlFld-ContribAuthor ">Martin RJ.  Kolb</span>. </span><span class="cited-content_cbyCitation_article-title">Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Respiratory Medicine</span><span> <strong>2019,</strong> <em>13 </em>
                                    (12)
                                     , 1139-1146. <a href="https://doi.org/10.1080/17476348.2019.1673733" title="DOI URL">https://doi.org/10.1080/17476348.2019.1673733</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17476348.2019.1673733&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17476348.2019.1673733%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Respiratory%2520Medicine%26atitle%3DTreatment%252Bof%252Bidiopathic%252Bpulmonary%252Bfibrosis%252Bwith%252BNintedanib%25253A%252Ban%252Bupdate%26aulast%3DWongkarnjana%26aufirst%3DAmornpun%26date%3D2019%26date%3D2019%26volume%3D13%26issue%3D12%26spage%3D1139%26epage%3D1146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">JÃ¶rg H. W.  Distler</span>, <span class="hlFld-ContribAuthor ">Andrea-Hermina  GyÃ¶rfi</span>, <span class="hlFld-ContribAuthor ">Meera  Ramanujam</span>, <span class="hlFld-ContribAuthor ">Michael L.  Whitfield</span>, <span class="hlFld-ContribAuthor ">Melanie  KÃ¶nigshoff</span>, <span class="hlFld-ContribAuthor ">Robert  Lafyatis</span>. </span><span class="cited-content_cbyCitation_article-title">Shared and distinct mechanisms of fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Rheumatology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (12)
                                     , 705-730. <a href="https://doi.org/10.1038/s41584-019-0322-7" title="DOI URL">https://doi.org/10.1038/s41584-019-0322-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41584-019-0322-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41584-019-0322-7%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Rheumatology%26atitle%3DShared%252Band%252Bdistinct%252Bmechanisms%252Bof%252Bfibrosis%26aulast%3DDistler%26aufirst%3DJ%25C3%25B6rg%2BH.%2BW.%26date%3D2019%26date%3D2019%26volume%3D15%26issue%3D12%26spage%3D705%26epage%3D730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Zhang</span>, <span class="hlFld-ContribAuthor ">Xi  Zong</span>, <span class="hlFld-ContribAuthor ">Min  Ji</span>. </span><span class="cited-content_cbyCitation_article-title">An iodine-promoted one-pot and metal-free access to indolin-2-ones. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Research</span><span> <strong>2019,</strong> <em>43 </em>
                                    (11-12)
                                     , 542-547. <a href="https://doi.org/10.1177/1747519819875862" title="DOI URL">https://doi.org/10.1177/1747519819875862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1747519819875862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1747519819875862%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Research%26atitle%3DAn%252Biodine-promoted%252Bone-pot%252Band%252Bmetal-free%252Baccess%252Bto%252Bindolin-2-ones%26aulast%3DZhang%26aufirst%3DYong%26date%3D2019%26date%3D2019%26volume%3D43%26issue%3D11-12%26spage%3D542%26epage%3D547" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Meng  Lv</span>, <span class="hlFld-ContribAuthor ">Yan  Liu</span>, <span class="hlFld-ContribAuthor ">Shuli  Ma</span>, <span class="hlFld-ContribAuthor ">Zutao  Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (19)
                                     , 2595-2620. <a href="https://doi.org/10.4155/fmc-2019-0111" title="DOI URL">https://doi.org/10.4155/fmc-2019-0111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0111%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Badvances%252Bin%252Bidiopathic%252Bpulmonary%252Bfibrosis%25253A%252Bthe%252Bpathogenesis%25252C%252Btherapeutic%252Bstrategies%252Band%252Bcandidate%252Bmolecules%26aulast%3DLv%26aufirst%3DMeng%26date%3D2019%26volume%3D11%26issue%3D19%26spage%3D2595%26epage%3D2620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sven  Wind</span>, <span class="hlFld-ContribAuthor ">Ulrike  Schmid</span>, <span class="hlFld-ContribAuthor ">Matthias  Freiwald</span>, <span class="hlFld-ContribAuthor ">Kristell  Marzin</span>, <span class="hlFld-ContribAuthor ">Ralf  Lotz</span>, <span class="hlFld-ContribAuthor ">Thomas  Ebner</span>, <span class="hlFld-ContribAuthor ">Peter  Stopfer</span>, <span class="hlFld-ContribAuthor ">Claudia  Dallinger</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacokinetics</span><span> <strong>2019,</strong> <em>58 </em>
                                    (9)
                                     , 1131-1147. <a href="https://doi.org/10.1007/s40262-019-00766-0" title="DOI URL">https://doi.org/10.1007/s40262-019-00766-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40262-019-00766-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40262-019-00766-0%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacokinetics%26atitle%3DClinical%252BPharmacokinetics%252Band%252BPharmacodynamics%252Bof%252BNintedanib%26aulast%3DWind%26aufirst%3DSven%26date%3D2019%26date%3D2019%26volume%3D58%26issue%3D9%26spage%3D1131%26epage%3D1147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hidemasa  Hikawa</span>, <span class="hlFld-ContribAuthor ">Yuuki  Matsuura</span>, <span class="hlFld-ContribAuthor ">Shoko  Kikkawa</span>, <span class="hlFld-ContribAuthor ">Isao  Azumaya</span>. </span><span class="cited-content_cbyCitation_article-title">Platinum(
              ii
              )-catalyzed dehydrative C3-benzylation of electron-deficient indoles with benzyl alcohols. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (17)
                                     , 3150-3157. <a href="https://doi.org/10.1039/C9QO00831D" title="DOI URL">https://doi.org/10.1039/C9QO00831D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO00831D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO00831D%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DPlatinum%252528%252Bii%252B%252529-catalyzed%252Bdehydrative%252BC3-benzylation%252Bof%252Belectron-deficient%252Bindoles%252Bwith%252Bbenzyl%252Balcohols%26aulast%3DHikawa%26aufirst%3DHidemasa%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D17%26spage%3D3150%26epage%3D3157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rebecca  Peyser</span>, <span class="hlFld-ContribAuthor ">Scott  MacDonnell</span>, <span class="hlFld-ContribAuthor ">Yinglin  Gao</span>, <span class="hlFld-ContribAuthor ">Luis  Cheng</span>, <span class="hlFld-ContribAuthor ">Yong  Kim</span>, <span class="hlFld-ContribAuthor ">Theodore  Kaplan</span>, <span class="hlFld-ContribAuthor ">Qin  Ruan</span>, <span class="hlFld-ContribAuthor ">Yi  Wei</span>, <span class="hlFld-ContribAuthor ">Min  Ni</span>, <span class="hlFld-ContribAuthor ">Christina  Adler</span>, <span class="hlFld-ContribAuthor ">Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Kishor  Devalaraja-Narashimha</span>, <span class="hlFld-ContribAuthor ">Justin  Grindley</span>, <span class="hlFld-ContribAuthor ">Gabor  Halasz</span>, <span class="hlFld-ContribAuthor ">Lori  Morton</span>. </span><span class="cited-content_cbyCitation_article-title">Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Respiratory Cell and Molecular Biology</span><span> <strong>2019,</strong> <em>61 </em>
                                    (1)
                                     , 74-85. <a href="https://doi.org/10.1165/rcmb.2018-0313OC" title="DOI URL">https://doi.org/10.1165/rcmb.2018-0313OC</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1165/rcmb.2018-0313OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1165%2Frcmb.2018-0313OC%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Respiratory%2520Cell%2520and%2520Molecular%2520Biology%26atitle%3DDefining%252Bthe%252BActivated%252BFibroblast%252BPopulation%252Bin%252BLung%252BFibrosis%252BUsing%252BSingle-Cell%252BSequencing%26aulast%3DPeyser%26aufirst%3DRebecca%26date%3D2019%26volume%3D61%26issue%3D1%26spage%3D74%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Liu</span>, <span class="hlFld-ContribAuthor ">George  Bayliss</span>, <span class="hlFld-ContribAuthor ">Shougang  Zhuang</span>. </span><span class="cited-content_cbyCitation_article-title">Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases. </span><span class="cited-content_cbyCitation_journal-name">Clinical Science</span><span> <strong>2019,</strong> <em>133 </em>
                                    (12)
                                     , 1309-1320. <a href="https://doi.org/10.1042/CS20190249" title="DOI URL">https://doi.org/10.1042/CS20190249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/CS20190249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FCS20190249%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Science%26atitle%3DApplication%252Bof%252Bnintedanib%252Band%252Bother%252Bpotential%252Banti-fibrotic%252Bagents%252Bin%252Bfibrotic%252Bdiseases%26aulast%3DLiu%26aufirst%3DFeng%26date%3D2019%26date%3D2019%26volume%3D133%26issue%3D12%26spage%3D1309%26epage%3D1320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pramod C.  Nair</span>, <span class="hlFld-ContribAuthor ">Ross A.  McKinnon</span>, <span class="hlFld-ContribAuthor ">John O.  Miners</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Prediction of the Site(s) of Metabolism and Binding Modes of Protein Kinase Inhibitors Metabolized by CYP3A4. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2019,</strong> <em>47 </em>
                                    (6)
                                     , 616-631. <a href="https://doi.org/10.1124/dmd.118.085167" title="DOI URL">https://doi.org/10.1124/dmd.118.085167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.118.085167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.118.085167%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DComputational%252BPrediction%252Bof%252Bthe%252BSite%252528s%252529%252Bof%252BMetabolism%252Band%252BBinding%252BModes%252Bof%252BProtein%252BKinase%252BInhibitors%252BMetabolized%252Bby%252BCYP3A4%26aulast%3DNair%26aufirst%3DPramod%2BC.%26date%3D2019%26date%3D2019%26volume%3D47%26issue%3D6%26spage%3D616%26epage%3D631" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abisola  Tepede</span>, <span class="hlFld-ContribAuthor ">Dinesh  Yogaratnam</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib for Idiopathic Pulmonary Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacy Practice</span><span> <strong>2019,</strong> <em>32 </em>
                                    (2)
                                     , 199-206. <a href="https://doi.org/10.1177/0897190017735242" title="DOI URL">https://doi.org/10.1177/0897190017735242</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/0897190017735242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F0897190017735242%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacy%2520Practice%26atitle%3DNintedanib%252Bfor%252BIdiopathic%252BPulmonary%252BFibrosis%26aulast%3DTepede%26aufirst%3DAbisola%26date%3D2019%26date%3D2017%26volume%3D32%26issue%3D2%26spage%3D199%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabine  FÃ¶rster</span>, <span class="hlFld-ContribAuthor ">Uriel  Koziol</span>, <span class="hlFld-ContribAuthor ">Tina  SchÃ¤fer</span>, <span class="hlFld-ContribAuthor ">Raphael  Duvoisin</span>, <span class="hlFld-ContribAuthor ">Katia  Cailliau</span>, <span class="hlFld-ContribAuthor ">Mathieu  Vanderstraete</span>, <span class="hlFld-ContribAuthor ">Colette  Dissous</span>, <span class="hlFld-ContribAuthor ">Klaus  Brehm</span>, . </span><span class="cited-content_cbyCitation_article-title">The role of fibroblast growth factor signalling in Echinococcus multilocularis development and host-parasite interaction. </span><span class="cited-content_cbyCitation_journal-name">PLOS Neglected Tropical Diseases</span><span> <strong>2019,</strong> <em>13 </em>
                                    (3)
                                     , e0006959. <a href="https://doi.org/10.1371/journal.pntd.0006959" title="DOI URL">https://doi.org/10.1371/journal.pntd.0006959</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pntd.0006959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pntd.0006959%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Neglected%2520Tropical%2520Diseases%26atitle%3DThe%252Brole%252Bof%252Bfibroblast%252Bgrowth%252Bfactor%252Bsignalling%252Bin%252BEchinococcus%252Bmultilocularis%252Bdevelopment%252Band%252Bhost-parasite%252Binteraction%26aulast%3DF%25C3%25B6rster%26aufirst%3DSabine%26date%3D2019%26date%3D2019%26volume%3D13%26issue%3D3%26spage%3De0006959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bao T.  Le</span>, <span class="hlFld-ContribAuthor ">Prithi  Raguraman</span>, <span class="hlFld-ContribAuthor ">Tamer R.  Kosbar</span>, <span class="hlFld-ContribAuthor ">Susan  Fletcher</span>, <span class="hlFld-ContribAuthor ">Steve D.  Wilton</span>, <span class="hlFld-ContribAuthor ">Rakesh N.  Veedu</span>. </span><span class="cited-content_cbyCitation_article-title">Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Molecular Therapy - Nucleic Acids</span><span> <strong>2019,</strong> <em>14 </em>, 142-157. <a href="https://doi.org/10.1016/j.omtn.2018.11.007" title="DOI URL">https://doi.org/10.1016/j.omtn.2018.11.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.omtn.2018.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.omtn.2018.11.007%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Therapy%2520-%2520Nucleic%2520Acids%26atitle%3DAntisense%252BOligonucleotides%252BTargeting%252BAngiogenic%252BFactors%252Bas%252BPotential%252BCancer%252BTherapeutics%26aulast%3DLe%26aufirst%3DBao%2BT.%26date%3D2019%26volume%3D14%26spage%3D142%26epage%3D157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bhuvaneshwar  Vaidya</span>, <span class="hlFld-ContribAuthor ">Snehal K.  Shukla</span>, <span class="hlFld-ContribAuthor ">Srikanth  Kolluru</span>, <span class="hlFld-ContribAuthor ">Melanie  Huen</span>, <span class="hlFld-ContribAuthor ">Nihal  Mulla</span>, <span class="hlFld-ContribAuthor ">Neelesh  Mehra</span>, <span class="hlFld-ContribAuthor ">Dipti  Kanabar</span>, <span class="hlFld-ContribAuthor ">Srinath  Palakurthi</span>, <span class="hlFld-ContribAuthor ">Seyoum  Ayehunie</span>, <span class="hlFld-ContribAuthor ">Aaron  Muth</span>, <span class="hlFld-ContribAuthor ">Vivek  Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib-cyclodextrin complex to improve bio-activity and intestinal permeability. </span><span class="cited-content_cbyCitation_journal-name">Carbohydrate Polymers</span><span> <strong>2019,</strong> <em>204 </em>, 68-77. <a href="https://doi.org/10.1016/j.carbpol.2018.09.080" title="DOI URL">https://doi.org/10.1016/j.carbpol.2018.09.080</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.carbpol.2018.09.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.carbpol.2018.09.080%26sid%3Dliteratum%253Aachs%26jtitle%3DCarbohydrate%2520Polymers%26atitle%3DNintedanib-cyclodextrin%252Bcomplex%252Bto%252Bimprove%252Bbio-activity%252Band%252Bintestinal%252Bpermeability%26aulast%3DVaidya%26aufirst%3DBhuvaneshwar%26date%3D2019%26volume%3D204%26spage%3D68%26epage%3D77" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luca  Richeldi</span>, <span class="hlFld-ContribAuthor ">Francesco  Varone</span>, <span class="hlFld-ContribAuthor ">Miguel  Bergna</span>, <span class="hlFld-ContribAuthor ">Joao  de Andrade</span>, <span class="hlFld-ContribAuthor ">Jeremy  Falk</span>, <span class="hlFld-ContribAuthor ">Robert  Hallowell</span>, <span class="hlFld-ContribAuthor ">StÃ©phane  Jouneau</span>, <span class="hlFld-ContribAuthor ">Yasuhiro  Kondoh</span>, <span class="hlFld-ContribAuthor ">Lee  Morrow</span>, <span class="hlFld-ContribAuthor ">Winfried  Randerath</span>, <span class="hlFld-ContribAuthor ">Mary  Strek</span>, <span class="hlFld-ContribAuthor ">Gabriela  Tabaj</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. </span><span class="cited-content_cbyCitation_journal-name">European Respiratory Review</span><span> <strong>2018,</strong> <em>27 </em>
                                    (150)
                                     , 180074. <a href="https://doi.org/10.1183/16000617.0074-2018" title="DOI URL">https://doi.org/10.1183/16000617.0074-2018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1183/16000617.0074-2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1183%2F16000617.0074-2018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Respiratory%2520Review%26atitle%3DPharmacological%252Bmanagement%252Bof%252Bprogressive-fibrosing%252Binterstitial%252Blung%252Bdiseases%25253A%252Ba%252Breview%252Bof%252Bthe%252Bcurrent%252Bevidence%26aulast%3DRicheldi%26aufirst%3DLuca%26date%3D2018%26date%3D2018%26volume%3D27%26issue%3D150%26spage%3D180074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giuliana  Pasciuto</span>, <span class="hlFld-ContribAuthor ">Riccardo  Inchingolo</span>, <span class="hlFld-ContribAuthor ">Carola  Condoluci</span>, <span class="hlFld-ContribAuthor ">Daniele  Magnini</span>, <span class="hlFld-ContribAuthor ">Bruno  Iovene</span>, <span class="hlFld-ContribAuthor ">Luca  Richeldi</span>. </span><span class="cited-content_cbyCitation_article-title">Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Current Pulmonology Reports</span><span> <strong>2018,</strong> <em>7 </em>
                                    (4)
                                     , 107-117. <a href="https://doi.org/10.1007/s13665-018-0209-0" title="DOI URL">https://doi.org/10.1007/s13665-018-0209-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s13665-018-0209-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs13665-018-0209-0%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Pulmonology%2520Reports%26atitle%3DApproved%252Band%252BExperimental%252BTherapies%252Bfor%252BIdiopathic%252BPulmonary%252BFibrosis%26aulast%3DPasciuto%26aufirst%3DGiuliana%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D4%26spage%3D107%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernhard  Englinger</span>, <span class="hlFld-ContribAuthor ">Sebastian  Kallus</span>, <span class="hlFld-ContribAuthor ">Julia  Senkiv</span>, <span class="hlFld-ContribAuthor ">Anna  Laemmerer</span>, <span class="hlFld-ContribAuthor ">Patrick  Moser</span>, <span class="hlFld-ContribAuthor ">Lisa  Gabler</span>, <span class="hlFld-ContribAuthor ">Diana  Groza</span>, <span class="hlFld-ContribAuthor ">Christian  Kowol</span>, <span class="hlFld-ContribAuthor ">Petra  Heffeter</span>, <span class="hlFld-ContribAuthor ">Michael  Grusch</span>, <span class="hlFld-ContribAuthor ">Walter  Berger</span>. </span><span class="cited-content_cbyCitation_article-title">Lysosomal Sequestration Impairs the Activity of the Preclinical FGFR Inhibitor PD173074. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2018,</strong> <em>7 </em>
                                    (12)
                                     , 259. <a href="https://doi.org/10.3390/cells7120259" title="DOI URL">https://doi.org/10.3390/cells7120259</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells7120259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells7120259%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DLysosomal%252BSequestration%252BImpairs%252Bthe%252BActivity%252Bof%252Bthe%252BPreclinical%252BFGFR%252BInhibitor%252BPD173074%26aulast%3DEnglinger%26aufirst%3DBernhard%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D12%26spage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soheila  Zeinali</span>, <span class="hlFld-ContribAuthor ">Colette A.  Bichsel</span>, <span class="hlFld-ContribAuthor ">Nina  Hobi</span>, <span class="hlFld-ContribAuthor ">Manuela  Funke</span>, <span class="hlFld-ContribAuthor ">Thomas M.  Marti</span>, <span class="hlFld-ContribAuthor ">Ralph A.  Schmid</span>, <span class="hlFld-ContribAuthor ">Olivier T.  Guenat</span>, <span class="hlFld-ContribAuthor ">Thomas  Geiser</span>. </span><span class="cited-content_cbyCitation_article-title">Human microvasculature-on-aÂ chip: anti-neovasculogenic effect of nintedanib in vitro. </span><span class="cited-content_cbyCitation_journal-name">Angiogenesis</span><span> <strong>2018,</strong> <em>21 </em>
                                    (4)
                                     , 861-871. <a href="https://doi.org/10.1007/s10456-018-9631-8" title="DOI URL">https://doi.org/10.1007/s10456-018-9631-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10456-018-9631-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10456-018-9631-8%26sid%3Dliteratum%253Aachs%26jtitle%3DAngiogenesis%26atitle%3DHuman%252Bmicrovasculature-on-a%2525C2%2525A0chip%25253A%252Banti-neovasculogenic%252Beffect%252Bof%252Bnintedanib%252Bin%252Bvitro%26aulast%3DZeinali%26aufirst%3DSoheila%26date%3D2018%26date%3D2018%26volume%3D21%26issue%3D4%26spage%3D861%26epage%3D871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sebastian  Kallus</span>, <span class="hlFld-ContribAuthor ">Bernhard  Englinger</span>, <span class="hlFld-ContribAuthor ">Julia  Senkiv</span>, <span class="hlFld-ContribAuthor ">Anna  Laemmerer</span>, <span class="hlFld-ContribAuthor ">Petra  Heffeter</span>, <span class="hlFld-ContribAuthor ">Walter  Berger</span>, <span class="hlFld-ContribAuthor ">Christian R.  Kowol</span>, <span class="hlFld-ContribAuthor ">Bernhard K.  Keppler</span>. </span><span class="cited-content_cbyCitation_article-title">Nanoformulations of anticancer FGFR inhibitors with improved therapeutic index. </span><span class="cited-content_cbyCitation_journal-name">Nanomedicine: Nanotechnology, Biology and Medicine</span><span> <strong>2018,</strong> <em>14 </em>
                                    (8)
                                     , 2632-2643. <a href="https://doi.org/10.1016/j.nano.2018.08.001" title="DOI URL">https://doi.org/10.1016/j.nano.2018.08.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.nano.2018.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.nano.2018.08.001%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomedicine%253A%2520Nanotechnology%252C%2520Biology%2520and%2520Medicine%26atitle%3DNanoformulations%252Bof%252Banticancer%252BFGFR%252Binhibitors%252Bwith%252Bimproved%252Btherapeutic%252Bindex%26aulast%3DKallus%26aufirst%3DSebastian%26date%3D2018%26volume%3D14%26issue%3D8%26spage%3D2632%26epage%3D2643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Parag P.  Patwardhan</span>, <span class="hlFld-ContribAuthor ">Elgilda  Musi</span>, <span class="hlFld-ContribAuthor ">Gary K.  Schwartz</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2018,</strong> <em>17 </em>
                                    (11)
                                     , 2329-2340. <a href="https://doi.org/10.1158/1535-7163.MCT-18-0319" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-18-0319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-18-0319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-18-0319%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DPreclinical%252BEvaluation%252Bof%252BNintedanib%25252C%252Ba%252BTriple%252BAngiokinase%252BInhibitor%25252C%252Bin%252BSoft-tissue%252BSarcoma%25253A%252BPotential%252BTherapeutic%252BImplication%252Bfor%252BSynovial%252BSarcoma%26aulast%3DPatwardhan%26aufirst%3DParag%2BP.%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D11%26spage%3D2329%26epage%3D2340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Girish Singh  Bisht</span>, <span class="hlFld-ContribAuthor ">Akanksha M.  Pandey</span>, <span class="hlFld-ContribAuthor ">Moreshwar B.  Chaudhari</span>, <span class="hlFld-ContribAuthor ">Sandip G.  Agalave</span>, <span class="hlFld-ContribAuthor ">Abhishek  Kanyal</span>, <span class="hlFld-ContribAuthor ">Krishanpal  Karmodiya</span>, <span class="hlFld-ContribAuthor ">Boopathy  Gnanaprakasam</span>. </span><span class="cited-content_cbyCitation_article-title">Ru-Catalyzed dehydrogenative synthesis of antimalarial arylidene oxindoles. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (39)
                                     , 7223-7229. <a href="https://doi.org/10.1039/C8OB01852A" title="DOI URL">https://doi.org/10.1039/C8OB01852A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8OB01852A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8OB01852A%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRu-Catalyzed%252Bdehydrogenative%252Bsynthesis%252Bof%252Bantimalarial%252Barylidene%252Boxindoles%26aulast%3DBisht%26aufirst%3DGirish%2BSingh%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D39%26spage%3D7223%26epage%3D7229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manuel J.  Richter</span>, <span class="hlFld-ContribAuthor ">Jan  Ewert</span>, <span class="hlFld-ContribAuthor ">Friedrich  Grimminger</span>, <span class="hlFld-ContribAuthor ">Hossein Ardeschir  Ghofrani</span>, <span class="hlFld-ContribAuthor ">Baktybek  Kojonazarov</span>, <span class="hlFld-ContribAuthor ">Aleksandar  Petrovic</span>, <span class="hlFld-ContribAuthor ">Werner  Seeger</span>, <span class="hlFld-ContribAuthor ">Ralph T.  Schermuly</span>, <span class="hlFld-ContribAuthor ">Khodr  Tello</span>, <span class="hlFld-ContribAuthor ">Henning  Gall</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib in Severe Pulmonary Arterial Hypertension. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Respiratory and Critical Care Medicine</span><span> <strong>2018,</strong> <em>198 </em>
                                    (6)
                                     , 808-810. <a href="https://doi.org/10.1164/rccm.201801-0195LE" title="DOI URL">https://doi.org/10.1164/rccm.201801-0195LE</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1164/rccm.201801-0195LE&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1164%2Frccm.201801-0195LE%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Respiratory%2520and%2520Critical%2520Care%2520Medicine%26atitle%3DNintedanib%252Bin%252BSevere%252BPulmonary%252BArterial%252BHypertension%26aulast%3DRichter%26aufirst%3DManuel%2BJ.%26date%3D2018%26volume%3D198%26issue%3D6%26spage%3D808%26epage%3D810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan  Liu</span>, <span class="hlFld-ContribAuthor ">Tao  Shen</span>, <span class="hlFld-ContribAuthor ">Blaine H M  Mooers</span>, <span class="hlFld-ContribAuthor ">Frank  Hilberg</span>, <span class="hlFld-ContribAuthor ">Jie  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Drug resistance profiles of mutations in the RET kinase domain. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2018,</strong> <em>175 </em>
                                    (17)
                                     , 3504-3515. <a href="https://doi.org/10.1111/bph.14395" title="DOI URL">https://doi.org/10.1111/bph.14395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.14395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.14395%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DDrug%252Bresistance%252Bprofiles%252Bof%252Bmutations%252Bin%252Bthe%252BRET%252Bkinase%252Bdomain%26aulast%3DLiu%26aufirst%3DXuan%26date%3D2018%26date%3D2018%26volume%3D175%26issue%3D17%26spage%3D3504%26epage%3D3515" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Fan  Zhao</span>, <span class="hlFld-ContribAuthor ">Wenbo  Yin</span>, <span class="hlFld-ContribAuthor ">Mingyue  Zhu</span>, <span class="hlFld-ContribAuthor ">Chenzhou  Hao</span>, <span class="hlFld-ContribAuthor ">Yu  Pang</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Haitao  Li</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, structure-activity relationships study and X-ray crystallography of 3-substituted-indolin-2-one-5-carboxamide derivatives as PAK4 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>155 </em>, 197-209. <a href="https://doi.org/10.1016/j.ejmech.2018.05.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.05.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.05.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.05.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bstructure-activity%252Brelationships%252Bstudy%252Band%252BX-ray%252Bcrystallography%252Bof%252B3-substituted-indolin-2-one-5-carboxamide%252Bderivatives%252Bas%252BPAK4%252Binhibitors%26aulast%3DGuo%26aufirst%3DJing%26date%3D2018%26volume%3D155%26spage%3D197%26epage%3D209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Forster</span>, <span class="hlFld-ContribAuthor ">Allan  Hackshaw</span>, <span class="hlFld-ContribAuthor ">Tommaso  De Pas</span>, <span class="hlFld-ContribAuthor ">Manuel  Cobo</span>, <span class="hlFld-ContribAuthor ">Pilar  Garrido</span>, <span class="hlFld-ContribAuthor ">Yvonne  Summers</span>, <span class="hlFld-ContribAuthor ">Anne-Marie C.  Dingemans</span>, <span class="hlFld-ContribAuthor ">Michael  Flynn</span>, <span class="hlFld-ContribAuthor ">David  Schnell</span>, <span class="hlFld-ContribAuthor ">Ute  von Wangenheim</span>, <span class="hlFld-ContribAuthor ">Arsene-Bienvenu  LoembÃ©</span>, <span class="hlFld-ContribAuthor ">Rolf  Kaiser</span>, <span class="hlFld-ContribAuthor ">Siow Ming  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). </span><span class="cited-content_cbyCitation_journal-name">Lung Cancer</span><span> <strong>2018,</strong> <em>120 </em>, 27-33. <a href="https://doi.org/10.1016/j.lungcan.2018.03.007" title="DOI URL">https://doi.org/10.1016/j.lungcan.2018.03.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lungcan.2018.03.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lungcan.2018.03.007%26sid%3Dliteratum%253Aachs%26jtitle%3DLung%2520Cancer%26atitle%3DA%252Bphase%252BI%252Bstudy%252Bof%252Bnintedanib%252Bcombined%252Bwith%252Bcisplatin%25252Fgemcitabine%252Bas%252Bfirst-line%252Btherapy%252Bfor%252Badvanced%252Bsquamous%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528LUME-Lung%252B3%252529%26aulast%3DForster%26aufirst%3DMartin%26date%3D2018%26volume%3D120%26spage%3D27%26epage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Geoffrey  Schwertz</span>, <span class="hlFld-ContribAuthor ">Matthias C.  Witschel</span>, <span class="hlFld-ContribAuthor ">Matthias  Rottmann</span>, <span class="hlFld-ContribAuthor ">Ubolsree  Leartsakulpanich</span>, <span class="hlFld-ContribAuthor ">Penchit  Chitnumsub</span>, <span class="hlFld-ContribAuthor ">Aritsara  Jaruwat</span>, <span class="hlFld-ContribAuthor ">Watcharee  Amornwatcharapong</span>, <span class="hlFld-ContribAuthor ">Wanwipa  Ittarat</span>, <span class="hlFld-ContribAuthor ">Anja  SchÃ¤fer</span>, <span class="hlFld-ContribAuthor ">Raphael A.  Aponte</span>, <span class="hlFld-ContribAuthor ">Nils  Trapp</span>, <span class="hlFld-ContribAuthor ">Pimchai  Chaiyen</span>, <span class="hlFld-ContribAuthor ">FranÃ§ois  Diederich</span>. </span><span class="cited-content_cbyCitation_article-title">Potent Inhibitors of
              Plasmodial
              Serine Hydroxymethyltransferase (SHMT) Featuring a Spirocyclic Scaffold. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (9)
                                     , 931-943. <a href="https://doi.org/10.1002/cmdc.201800053" title="DOI URL">https://doi.org/10.1002/cmdc.201800053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800053%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DPotent%252BInhibitors%252Bof%252BPlasmodial%252BSerine%252BHydroxymethyltransferase%252B%252528SHMT%252529%252BFeaturing%252Ba%252BSpirocyclic%252BScaffold%26aulast%3DSchwertz%26aufirst%3DGeoffrey%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D9%26spage%3D931%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tongfei  Jing</span>, <span class="hlFld-ContribAuthor ">Xiuqi  Miao</span>, <span class="hlFld-ContribAuthor ">Feng  Jiang</span>, <span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Junlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Hongrui  Lei</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (8)
                                     , 1784-1796. <a href="https://doi.org/10.1016/j.bmc.2018.02.023" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.02.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.02.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.02.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252Boptimization%252Bof%252Btetrahydropyrido%25255B4%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnovel%252BATX%252Band%252BEGFR%252Bdual%252Binhibitors%26aulast%3DJing%26aufirst%3DTongfei%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1784%26epage%3D1796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ulrike  Schmid</span>, <span class="hlFld-ContribAuthor ">Christiane  Doege</span>, <span class="hlFld-ContribAuthor ">Claudia  Dallinger</span>, <span class="hlFld-ContribAuthor ">Matthias  Freiwald</span>. </span><span class="cited-content_cbyCitation_article-title">Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Pulmonary Pharmacology & Therapeutics</span><span> <strong>2018,</strong> <em>48 </em>, 136-143. <a href="https://doi.org/10.1016/j.pupt.2017.11.004" title="DOI URL">https://doi.org/10.1016/j.pupt.2017.11.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pupt.2017.11.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pupt.2017.11.004%26sid%3Dliteratum%253Aachs%26jtitle%3DPulmonary%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DPopulation%252Bpharmacokinetics%252Bof%252Bnintedanib%252Bin%252Bpatients%252Bwith%252Bidiopathic%252Bpulmonary%252Bfibrosis%26aulast%3DSchmid%26aufirst%3DUlrike%26date%3D2018%26volume%3D48%26spage%3D136%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesco  Varone</span>, <span class="hlFld-ContribAuthor ">Giacomo  Sgalla</span>, <span class="hlFld-ContribAuthor ">Bruno  Iovene</span>, <span class="hlFld-ContribAuthor ">Teresa  Bruni</span>, <span class="hlFld-ContribAuthor ">Luca  Richeldi</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib for the treatment of idiopathic pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2018,</strong> <em>19 </em>
                                    (2)
                                     , 167-175. <a href="https://doi.org/10.1080/14656566.2018.1425681" title="DOI URL">https://doi.org/10.1080/14656566.2018.1425681</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2018.1425681&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2018.1425681%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DNintedanib%252Bfor%252Bthe%252Btreatment%252Bof%252Bidiopathic%252Bpulmonary%252Bfibrosis%26aulast%3DVarone%26aufirst%3DFrancesco%26date%3D2018%26date%3D2018%26volume%3D19%26issue%3D2%26spage%3D167%26epage%3D175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ulrike  Schmid</span>, <span class="hlFld-ContribAuthor ">Karl-Heinz  Liesenfeld</span>, <span class="hlFld-ContribAuthor ">Angele  Fleury</span>, <span class="hlFld-ContribAuthor ">Claudia  Dallinger</span>, <span class="hlFld-ContribAuthor ">Matthias  Freiwald</span>. </span><span class="cited-content_cbyCitation_article-title">Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2018,</strong> <em>81 </em>
                                    (1)
                                     , 89-101. <a href="https://doi.org/10.1007/s00280-017-3452-0" title="DOI URL">https://doi.org/10.1007/s00280-017-3452-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-017-3452-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-017-3452-0%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DPopulation%252Bpharmacokinetics%252Bof%252Bnintedanib%25252C%252Ban%252Binhibitor%252Bof%252Btyrosine%252Bkinases%25252C%252Bin%252Bpatients%252Bwith%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bor%252Bidiopathic%252Bpulmonary%252Bfibrosis%26aulast%3DSchmid%26aufirst%3DUlrike%26date%3D2018%26date%3D2017%26volume%3D81%26issue%3D1%26spage%3D89%26epage%3D101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentina  Serafin</span>, <span class="hlFld-ContribAuthor ">Giorgia  Capuzzo</span>, <span class="hlFld-ContribAuthor ">Gloria  Milani</span>, <span class="hlFld-ContribAuthor ">Sonia Anna  Minuzzo</span>, <span class="hlFld-ContribAuthor ">Marica  Pinazza</span>, <span class="hlFld-ContribAuthor ">Roberta  Bortolozzi</span>, <span class="hlFld-ContribAuthor ">Silvia  Bresolin</span>, <span class="hlFld-ContribAuthor ">Elena  PorcÃ¹</span>, <span class="hlFld-ContribAuthor ">Chiara  Frasson</span>, <span class="hlFld-ContribAuthor ">Stefano  Indraccolo</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Basso</span>, <span class="hlFld-ContribAuthor ">Benedetta  Accordi</span>. </span><span class="cited-content_cbyCitation_article-title">Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2017,</strong> <em>130 </em>
                                    (25)
                                     , 2750-2761. <a href="https://doi.org/10.1182/blood-2017-05-784603" title="DOI URL">https://doi.org/10.1182/blood-2017-05-784603</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2017-05-784603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2017-05-784603%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DGlucocorticoid%252Bresistance%252Bis%252Breverted%252Bby%252BLCK%252Binhibition%252Bin%252Bpediatric%252BT-cell%252Bacute%252Blymphoblastic%252Bleukemia%26aulast%3DSerafin%26aufirst%3DValentina%26date%3D2017%26volume%3D130%26issue%3D25%26spage%3D2750%26epage%3D2761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed Karam  Farag</span>, <span class="hlFld-ContribAuthor ">Ahmed  Elkamhawy</span>, <span class="hlFld-ContribAuthor ">Ashwini M.  Londhe</span>, <span class="hlFld-ContribAuthor ">Kyung-Tae  Lee</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Roh</span>. </span><span class="cited-content_cbyCitation_article-title">Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>141 </em>, 657-675. <a href="https://doi.org/10.1016/j.ejmech.2017.10.003" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252BLCK%25252FFMS%252Binhibitors%252Bbased%252Bon%252Bphenoxypyrimidine%252Bscaffold%252Bas%252Bpotential%252Btreatment%252Bfor%252Binflammatory%252Bdisorders%26aulast%3DFarag%26aufirst%3DAhmed%2BKaram%26date%3D2017%26volume%3D141%26spage%3D657%26epage%3D675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bernhard  Englinger</span>, <span class="hlFld-ContribAuthor ">Sebastian  Kallus</span>, <span class="hlFld-ContribAuthor ">Julia  Senkiv</span>, <span class="hlFld-ContribAuthor ">Daniela  Heilos</span>, <span class="hlFld-ContribAuthor ">Lisa  Gabler</span>, <span class="hlFld-ContribAuthor ">Sushilla  van Schoonhoven</span>, <span class="hlFld-ContribAuthor ">Alessio  Terenzi</span>, <span class="hlFld-ContribAuthor ">Patrick  Moser</span>, <span class="hlFld-ContribAuthor ">Christine  Pirker</span>, <span class="hlFld-ContribAuthor ">Gerald  Timelthaler</span>, <span class="hlFld-ContribAuthor ">Walter  JÃ¤ger</span>, <span class="hlFld-ContribAuthor ">Christian R.  Kowol</span>, <span class="hlFld-ContribAuthor ">Petra  Heffeter</span>, <span class="hlFld-ContribAuthor ">Michael  Grusch</span>, <span class="hlFld-ContribAuthor ">Walter  Berger</span>. </span><span class="cited-content_cbyCitation_article-title">Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Experimental & Clinical Cancer Research</span><span> <strong>2017,</strong> <em>36 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13046-017-0592-3" title="DOI URL">https://doi.org/10.1186/s13046-017-0592-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13046-017-0592-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13046-017-0592-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Experimental%2520%2526%2520Clinical%2520Cancer%2520Research%26atitle%3DIntrinsic%252Bfluorescence%252Bof%252Bthe%252Bclinically%252Bapproved%252Bmultikinase%252Binhibitor%252Bnintedanib%252Breveals%252Blysosomal%252Bsequestration%252Bas%252Bresistance%252Bmechanism%252Bin%252BFGFR-driven%252Blung%252Bcancer%26aulast%3DEnglinger%26aufirst%3DBernhard%26date%3D2017%26date%3D2017%26volume%3D36%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria Carmen  Riesco-Martinez</span>, <span class="hlFld-ContribAuthor ">Ana  Sanchez-Torre</span>, <span class="hlFld-ContribAuthor ">Rocio  Garcia-Carbonero</span>. </span><span class="cited-content_cbyCitation_article-title">Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2017,</strong> <em>26 </em>
                                    (11)
                                     , 1295-1305. <a href="https://doi.org/10.1080/13543784.2017.1385762" title="DOI URL">https://doi.org/10.1080/13543784.2017.1385762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2017.1385762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2017.1385762%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DSafety%252Band%252Befficacy%252Bof%252Bnintedanib%252Bfor%252Bthe%252Btreatment%252Bof%252Bmetastatic%252Bcolorectal%252Bcancer%26aulast%3DRiesco-Martinez%26aufirst%3DMaria%2BCarmen%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D11%26spage%3D1295%26epage%3D1305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saira  Khalique</span>, <span class="hlFld-ContribAuthor ">Susana  Banerjee</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib in ovarian cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2017,</strong> <em>26 </em>
                                    (9)
                                     , 1073-1081. <a href="https://doi.org/10.1080/13543784.2017.1353599" title="DOI URL">https://doi.org/10.1080/13543784.2017.1353599</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2017.1353599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2017.1353599%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DNintedanib%252Bin%252Bovarian%252Bcancer%26aulast%3DKhalique%26aufirst%3DSaira%26date%3D2017%26date%3D2017%26volume%3D26%26issue%3D9%26spage%3D1073%26epage%3D1081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giorgio V.  Scagliotti</span>, <span class="hlFld-ContribAuthor ">Rabab  Gaafar</span>, <span class="hlFld-ContribAuthor ">Anna K.  Nowak</span>, <span class="hlFld-ContribAuthor ">Martin  Reck</span>, <span class="hlFld-ContribAuthor ">Anne S.  Tsao</span>, <span class="hlFld-ContribAuthor ">Jan  van Meerbeeck</span>, <span class="hlFld-ContribAuthor ">Nicholas J.  Vogelzang</span>, <span class="hlFld-ContribAuthor ">Takashi  Nakano</span>, <span class="hlFld-ContribAuthor ">Ute  von Wangenheim</span>, <span class="hlFld-ContribAuthor ">Derek  Velema</span>, <span class="hlFld-ContribAuthor ">Nassim  Morsli</span>, <span class="hlFld-ContribAuthor ">Sanjay  Popat</span>. </span><span class="cited-content_cbyCitation_article-title">LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. </span><span class="cited-content_cbyCitation_journal-name">Clinical Lung Cancer</span><span> <strong>2017,</strong> <em>18 </em>
                                    (5)
                                     , 589-593. <a href="https://doi.org/10.1016/j.cllc.2017.03.010" title="DOI URL">https://doi.org/10.1016/j.cllc.2017.03.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cllc.2017.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cllc.2017.03.010%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Lung%2520Cancer%26atitle%3DLUME-Meso%25253A%252BDesign%252Band%252BRationale%252Bof%252Bthe%252BPhase%252BIII%252BPart%252Bof%252Ba%252BPlacebo-Controlled%252BStudy%252Bof%252BNintedanib%252Band%252BPemetrexed%25252FCisplatin%252BFollowed%252Bby%252BMaintenance%252BNintedanib%252Bin%252BPatients%252BWith%252BUnresectable%252BMalignant%252BPleural%252BMesothelioma%26aulast%3DScagliotti%26aufirst%3DGiorgio%2BV.%26date%3D2017%26volume%3D18%26issue%3D5%26spage%3D589%26epage%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feng  Liu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Hualin  Qi</span>, <span class="hlFld-ContribAuthor ">Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Wang</span>, <span class="hlFld-ContribAuthor ">Wei  Jiang</span>, <span class="hlFld-ContribAuthor ">Liuqing  Xu</span>, <span class="hlFld-ContribAuthor ">Na  Liu</span>, <span class="hlFld-ContribAuthor ">Shougang  Zhuang</span>. </span><span class="cited-content_cbyCitation_article-title">Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease. </span><span class="cited-content_cbyCitation_journal-name">Clinical Science</span><span> <strong>2017,</strong> <em>131 </em>
                                    (16)
                                     , 2125-2143. <a href="https://doi.org/10.1042/CS20170134" title="DOI URL">https://doi.org/10.1042/CS20170134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1042/CS20170134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1042%2FCS20170134%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Science%26atitle%3DNintedanib%25252C%252Ba%252Btriple%252Btyrosine%252Bkinase%252Binhibitor%25252C%252Battenuates%252Brenal%252Bfibrosis%252Bin%252Bchronic%252Bkidney%252Bdisease%26aulast%3DLiu%26aufirst%3DFeng%26date%3D2017%26date%3D2017%26volume%3D131%26issue%3D16%26spage%3D2125%26epage%3D2143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maximilian  Ackermann</span>, <span class="hlFld-ContribAuthor ">Yong Ook  Kim</span>, <span class="hlFld-ContribAuthor ">Willi L.  Wagner</span>, <span class="hlFld-ContribAuthor ">Detlef  Schuppan</span>, <span class="hlFld-ContribAuthor ">Cristian D.  Valenzuela</span>, <span class="hlFld-ContribAuthor ">Steven J.  Mentzer</span>, <span class="hlFld-ContribAuthor ">Sebastian  Kreuz</span>, <span class="hlFld-ContribAuthor ">Detlef  Stiller</span>, <span class="hlFld-ContribAuthor ">Lutz  Wollin</span>, <span class="hlFld-ContribAuthor ">Moritz A.  Konerding</span>. </span><span class="cited-content_cbyCitation_article-title">Effects of nintedanib on the microvascular architecture in a lung fibrosis model. </span><span class="cited-content_cbyCitation_journal-name">Angiogenesis</span><span> <strong>2017,</strong> <em>20 </em>
                                    (3)
                                     , 359-372. <a href="https://doi.org/10.1007/s10456-017-9543-z" title="DOI URL">https://doi.org/10.1007/s10456-017-9543-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10456-017-9543-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10456-017-9543-z%26sid%3Dliteratum%253Aachs%26jtitle%3DAngiogenesis%26atitle%3DEffects%252Bof%252Bnintedanib%252Bon%252Bthe%252Bmicrovascular%252Barchitecture%252Bin%252Ba%252Blung%252Bfibrosis%252Bmodel%26aulast%3DAckermann%26aufirst%3DMaximilian%26date%3D2017%26date%3D2017%26volume%3D20%26issue%3D3%26spage%3D359%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John G.  Moffat</span>, <span class="hlFld-ContribAuthor ">Fabien  Vincent</span>, <span class="hlFld-ContribAuthor ">Jonathan A.  Lee</span>, <span class="hlFld-ContribAuthor ">JÃ¶rg  Eder</span>, <span class="hlFld-ContribAuthor ">Marco  Prunotto</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities and challenges in phenotypic drug discovery: an industry perspective. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2017,</strong> <em>16 </em>
                                    (8)
                                     , 531-543. <a href="https://doi.org/10.1038/nrd.2017.111" title="DOI URL">https://doi.org/10.1038/nrd.2017.111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2017.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2017.111%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DOpportunities%252Band%252Bchallenges%252Bin%252Bphenotypic%252Bdrug%252Bdiscovery%25253A%252Ban%252Bindustry%252Bperspective%26aulast%3DMoffat%26aufirst%3DJohn%2BG.%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D8%26spage%3D531%26epage%3D543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Mingyue  Zhu</span>, <span class="hlFld-ContribAuthor ">Tianxiao  Wu</span>, <span class="hlFld-ContribAuthor ">Chenzhou  Hao</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Zizheng  Yan</span>, <span class="hlFld-ContribAuthor ">Wanxu  Huang</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Dongmei  Zhao</span>, <span class="hlFld-ContribAuthor ">Maosheng  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (13)
                                     , 3500-3511. <a href="https://doi.org/10.1016/j.bmc.2017.04.047" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.04.047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.04.047%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bindolin-2-one%252Bderivatives%252Bas%252Bpotent%252BPAK4%252Binhibitors%25253A%252BStructure-activity%252Brelationship%252Banalysis%25252C%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bdocking%252Bstudy%26aulast%3DGuo%26aufirst%3DJing%26date%3D2017%26volume%3D25%26issue%3D13%26spage%3D3500%26epage%3D3511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm501562a&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm501562a%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-3&amp;citedByCount=134&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="âtrueâ" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/medium/jm-2014-01562a_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501562a&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/medium/jm-2014-01562a_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Molecular structure of nintedanib ethanesulfonate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501562a&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/medium/jm-2014-01562a_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Synthesis of nintedanib ethanesulfonate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501562a&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/medium/jm-2014-01562a_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structureâactivity relationships of 6-substituted oxindoles.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-3/jm501562a/20150206/images/large/jm-2014-01562a_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm501562a&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i25">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 56 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colbatzky, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Handschuh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lehmann-Lintz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lotz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hilberg, F.</span><span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4466</span><span class="NLM_x">â</span> <span class="NLM_lpage">4480</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm900431g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=4466-4480&author=G.+J.+Rothauthor=A.+Heckelauthor=F.+Colbatzkyauthor=S.+Handschuhauthor=J.+Kleyauthor=T.+Lehmann-Lintzauthor=R.+Lotzauthor=U.+Tontsch-Gruntauthor=R.+Walterauthor=F.+Hilberg&title=Design%2C+synthesis%2C+and+evaluation+of+indolinones+as+triple+angiokinase+inhibitors+and+the+discovery+of+a+highly+specific+6-methoxycarbonyl-substituted+indolinone+%28BIBF+1120%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm900431g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900431g%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DColbatzky%26aufirst%3DF.%26aulast%3DHandschuh%26aufirst%3DS.%26aulast%3DKley%26aufirst%3DJ.%26aulast%3DLehmann-Lintz%26aufirst%3DT.%26aulast%3DLotz%26aufirst%3DR.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DWalter%26aufirst%3DR.%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520indolinones%2520as%2520triple%2520angiokinase%2520inhibitors%2520and%2520the%2520discovery%2520of%2520a%2520highly%2520specific%25206-methoxycarbonyl-substituted%2520indolinone%2520%2528BIBF%25201120%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D4466%26epage%3D4480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Roth, G. J.; Sieger, P.; Linz, G.; Rall, W.; Hilberg, F.; Bock, T.</span><span> </span><span class="NLM_article-title">3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone monoethanesulphonate and the use thereof as a pharmaceutical composition</span>. WO2004/013099.<span class="NLM_x"> </span><span class="NLM_year">2004</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2004&author=G.+J.+Roth&author=P.+Sieger&author=G.+Linz&author=W.+Rall&author=F.+Hilberg&author=T.+Bock&title=3-Z-%5B1-%284-%28N-%28%284-Methyl-piperazin-1-yl%29-methylcarbonyl%29-N-methyl-amino%29-anilino%29-1-phenyl-methylene%5D-6-methoxycarbonyl-2-indolinone+monoethanesulphonate+and+the+use+thereof+as+a+pharmaceutical+composition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26atitle%3D3-Z-%255B1-%25284-%2528N-%2528%25284-Methyl-piperazin-1-yl%2529-methylcarbonyl%2529-N-methyl-amino%2529-anilino%2529-1-phenyl-methylene%255D-6-methoxycarbonyl-2-indolinone%2520monoethanesulphonate%2520and%2520the%2520use%2520thereof%2520as%2520a%2520pharmaceutical%2520composition%26date%3D2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Merten, J.; Linz, G.; Schnaubelt, J.; Schmid, R.; Rall, W.; Renner, S.; Reichel, C.; Schiffers, R.</span><span> </span><span class="NLM_article-title">Process for the manufacture of an indolinone derivative</span>. WO2009/071523.<span class="NLM_x"> </span><span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&author=J.+Merten&author=G.+Linz&author=J.+Schnaubelt&author=R.+Schmid&author=W.+Rall&author=S.+Renner&author=C.+Reichel&author=R.+Schiffers&title=Process+for+the+manufacture+of+an+indolinone+derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMerten%26aufirst%3DJ.%26atitle%3DProcess%2520for%2520the%2520manufacture%2520of%2520an%2520indolinone%2520derivative%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krssak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kautschitsch, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sommergruber, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tontsch-Grunt, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garin-Chesa, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quant, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rettig, W. J.</span><span> </span><span class="NLM_article-title">BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">4774</span><span class="NLM_x">â</span> <span class="NLM_lpage">4782</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=4774-4782&author=F.+Hilbergauthor=G.+J.+Rothauthor=M.+Krssakauthor=S.+Kautschitschauthor=W.+Sommergruberauthor=U.+Tontsch-Gruntauthor=P.+Garin-Chesaauthor=G.+Baderauthor=A.+Zoephelauthor=J.+Quantauthor=A.+Heckelauthor=W.+J.+Rettig&title=BIBF+1120%3A+triple+angiokinase+inhibitor+with+sustained+receptor+blockade+and+good+antitumor+efficacy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DRoth%26aufirst%3DG.%2BJ.%26aulast%3DKrssak%26aufirst%3DM.%26aulast%3DKautschitsch%26aufirst%3DS.%26aulast%3DSommergruber%26aufirst%3DW.%26aulast%3DTontsch-Grunt%26aufirst%3DU.%26aulast%3DGarin-Chesa%26aufirst%3DP.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DQuant%26aufirst%3DJ.%26aulast%3DHeckel%26aufirst%3DA.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26atitle%3DBIBF%25201120%253A%2520triple%2520angiokinase%2520inhibitor%2520with%2520sustained%2520receptor%2520blockade%2520and%2520good%2520antitumor%2520efficacy%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D4774%26epage%3D4782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="note"><p class="first last">As described in ref <a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">1</a>, no inhibition of the following kinases was detected when analyzed at 10 Î¼mol/L with 100 Î¼mol/L ATP: AMPK, CAMK1, CDK2, CHK1, CHK2, CK1, CK2, CSK, DYRK1A, ERK2, ERK8, GSK3Î², JNK1A1, MAPKAPK2, MAPK2ERK2, MKK2, Mnk1, Mnk2, MSK1, NEK2A, NEK6, p38a, PKA, PKBÎ±, PKBb, PDK1, PKCÎ±, PHK, PKD1, Plk1, PRAK, PRK2, ROCKII, SAPK2AP38, S6K1, SAPK2BP38Î²2, SAPK3P38Î³, SAPK4P38Î´, SGK, SRPK1.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Hilberg, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandstetter, I.</span><span> </span><span class="NLM_article-title">Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmented by chemotherapy</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">S380</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=S380&author=F.+Hilbergauthor=I.+Brandstetter&title=Efficacy+of+BIBF+1120%2C+a+potent+triple+angiokinase+inhibitor%2C+in+models+of+human+non-small+cell+lung+cancer+is+augmented+by+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26aulast%3DBrandstetter%26aufirst%3DI.%26atitle%3DEfficacy%2520of%2520BIBF%25201120%252C%2520a%2520potent%2520triple%2520angiokinase%2520inhibitor%252C%2520in%2520models%2520of%2520human%2520non-small%2520cell%2520lung%2520cancer%2520is%2520augmented%2520by%2520chemotherapy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D2%26spage%3DS380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Wollin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maillet, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quesniaux, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holweg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryffel, B.</span><span> </span><span class="NLM_article-title">Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">â</span> <span class="NLM_lpage">220</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1124%2Fjpet.113.208223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24556663" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovVCmtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2014&pages=209-220&author=L.+Wollinauthor=I.+Mailletauthor=V.+Quesniauxauthor=A.+Holwegauthor=B.+Ryffel&title=Antifibrotic+and+anti-inflammatory+activity+of+the+tyrosine+kinase+inhibitor+nintedanib+in+experimental+models+of+lung+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis</span></div><div class="casAuthors">Wollin, Lutz; Maillet, Isabelle; Quesniaux, Valerie; Holweg, Alexander; Ryffel, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-220, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clin. development for the treatment of idiopathic pulmonary fibrosis.  To explore its mode of action, nintedanib was tested in human lung fibroblasts and mouse models of lung fibrosis.  Human lung fibroblasts expressing platelet-derived growth factor (PDGF) receptor-Î± and -Î² were stimulated with platelet-derived growth factor BB (homodimer) (PDGF-BB).  Receptor activation was assessed by autophosphorylation and cell proliferation by bromodeoxyuridine incorporation.  Transforming growth factor Î² (TGFÎ²)-induced fibroblast to myofibroblast transformation was detd. by Î±-smooth muscle actin (Î±SMA) mRNA anal.  Lung fibrosis was induced in mice by intratracheal bleomycin or silica particle administration.  Nintedanib was administered every day by gavage at 30, 60, or 100 mg/kg.  Preventive nintedanib treatment regimen started on the day that bleomycin was administered.  Therapeutic treatment regimen started at various times after the induction of lung fibrosis.  Bleomycin caused increased macrophages and lymphocytes in the bronchoalveolar lavage (BAL) and elevated interleukin-1Î² (IL-1Î²), tissue inhibitor of metalloproteinase-1 (TIMP-1), and collagen in lung tissue.  Histol. revealed chronic inflammation and fibrosis.  Silica-induced lung pathol. addnl. showed elevated BAL neutrophils, keratinocyte chemoattractant (KC) levels, and granuloma formation.  Nintedanib inhibited PDGF receptor activation, fibroblast proliferation, and fibroblast to myofibroblast transformation.  Nintedanib significantly reduced BAL lymphocytes and neutrophils but not macrophages.  Furthermore, interleukin-1Î², KC, TIMP-1, and lung collagen were significantly reduced.  Histol. anal. showed significantly diminished lung inflammation, granuloma formation, and fibrosis.  The therapeutic effect was dependent on treatment start and duration.  Nintedanib inhibited receptor tyrosine kinase activation and the proliferation and transformation of human lung fibroblasts and showed antifibrotic and anti-inflammatory activity in two animal models of pulmonary fibrosis.  These results suggest that nintedanib may impact the progressive course of fibrotic lung diseases such as idiopathic pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj82hlH5A1brVg90H21EOLACvtfcHk0lhrsF5MQownFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovVCmtLk%253D&md5=b8cb75e9d2630509986d9fb4760b263e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.208223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.208223%26sid%3Dliteratum%253Aachs%26aulast%3DWollin%26aufirst%3DL.%26aulast%3DMaillet%26aufirst%3DI.%26aulast%3DQuesniaux%26aufirst%3DV.%26aulast%3DHolweg%26aufirst%3DA.%26aulast%3DRyffel%26aufirst%3DB.%26atitle%3DAntifibrotic%2520and%2520anti-inflammatory%2520activity%2520of%2520the%2520tyrosine%2520kinase%2520inhibitor%2520nintedanib%2520in%2520experimental%2520models%2520of%2520lung%2520fibrosis%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2014%26volume%3D349%26spage%3D209%26epage%3D220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Hostettler, K. E.; Papakonstantinou, E.; Klagas, J.; Karakiulakis, G.; Zhong, J.; Tamm, M.; Lardinois, D.; Roth, M.</span><span> </span><span class="NLM_article-title">Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from patients with idiopathic pulmonary fibrosis and from non-fibrotic controls</span>.  <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">187</span>, Abstract A3374.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2013&author=K.+E.+Hostettler&author=E.+Papakonstantinou&author=J.+Klagas&author=G.+Karakiulakis&author=J.+Zhong&author=M.+Tamm&author=D.+Lardinois&author=M.+Roth&title=Anti-fibrotic+effects+of+nintedanib+%28BIBF+1120%29+in+primary+human+lung+fibroblasts+derived+from+patients+with+idiopathic+pulmonary+fibrosis+and+from+non-fibrotic+controls"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHostettler%26aufirst%3DK.%2BE.%26atitle%3DAnti-fibrotic%2520effects%2520of%2520nintedanib%2520%2528BIBF%25201120%2529%2520in%2520primary%2520human%2520lung%2520fibroblasts%2520derived%2520from%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520from%2520non-fibrotic%2520controls%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2013%26volume%3D187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Wollin, L.; Ostermann, A.; Wex, E.; Herrmann, F. E.; Doods, H.</span><span> </span><span class="NLM_article-title">Nintedanib attenuates motility of lung fibroblasts from patients with idiopathic pulmonary fibrosis</span>.  <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">189</span>, Abstract A2008.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=189&publication_year=2014&author=L.+Wollin&author=A.+Ostermann&author=E.+Wex&author=F.+E.+Herrmann&author=H.+Doods&title=Nintedanib+attenuates+motility+of+lung+fibroblasts+from+patients+with+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWollin%26aufirst%3DL.%26atitle%3DNintedanib%2520attenuates%2520motility%2520of%2520lung%2520fibroblasts%2520from%2520patients%2520with%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2014%26volume%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Sandler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahmer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowlati, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lilenbaum, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span> </span><span class="NLM_article-title">Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">355</span><span class="NLM_x">, </span> <span class="NLM_fpage">2542</span><span class="NLM_x">â</span> <span class="NLM_lpage">2550</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1056%2FNEJMoa061884" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=17167137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlWqsbzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=355&publication_year=2006&pages=2542-2550&author=A.+Sandlerauthor=R.+Grayauthor=M.+C.+Perryauthor=J.+Brahmerauthor=J.+H.+Schillerauthor=A.+Dowlatiauthor=R.+Lilenbaumauthor=D.+H.+Johnson&title=Paclitaxel-carboplatin+alone+or+with+bevacizumab+for+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer</span></div><div class="casAuthors">Sandler, Alan; Gray, Robert; Perry, Michael C.; Brahmer, Julie; Schiller, Joan H.; Dowlati, Afshin; Lilenbaum, Rogerio; Johnson, David H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">355</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2542-2550</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers.  Between July 2001 and Apr. 2004, the Eastern Cooperative Oncol. Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non-small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434).  Chemotherapy was administered every 3 wk for six cycles, and bevacizumab was administered every 3 wk until disease progression was evident or toxic effects were intolerable.  Patients with squamous-cell tumors, brain metastases, clin. significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded.  The primary end point was overall survival.  The median survival was 12.3 mo in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 mo in the chemotherapy-alone group (hazard ratio for death, 0.79; P = 0.003).  The median progression-free survival in the two groups was 6.2 and 4.5 mo, resp. (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001).  Rates of clin. significant bleeding were 4.4% and 0.7%, resp. (P<0.001).  There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage.  The addn. of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHrplr-EnyyrVg90H21EOLACvtfcHk0ljU1B5RDHzC7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlWqsbzI&md5=f94c013f3961561feb564b2bf7148df4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa061884&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa061884%26sid%3Dliteratum%253Aachs%26aulast%3DSandler%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DR.%26aulast%3DPerry%26aufirst%3DM.%2BC.%26aulast%3DBrahmer%26aufirst%3DJ.%26aulast%3DSchiller%26aufirst%3DJ.%2BH.%26aulast%3DDowlati%26aufirst%3DA.%26aulast%3DLilenbaum%26aufirst%3DR.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26atitle%3DPaclitaxel-carboplatin%2520alone%2520or%2520with%2520bevacizumab%2520for%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D355%26spage%3D2542%26epage%3D2550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Hurwitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehrenbacher, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cartwright, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hainsworth, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffing, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmgren, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fyfe, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ross, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span> </span><span class="NLM_article-title">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">350</span><span class="NLM_x">, </span> <span class="NLM_fpage">2335</span><span class="NLM_x">â</span> <span class="NLM_lpage">2342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1056%2FNEJMoa032691" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=15175435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=350&publication_year=2004&pages=2335-2342&author=H.+Hurwitzauthor=L.+Fehrenbacherauthor=W.+Novotnyauthor=T.+Cartwrightauthor=J.+Hainsworthauthor=W.+Heimauthor=J.+Berlinauthor=A.+Baronauthor=S.+Griffingauthor=E.+Holmgrenauthor=N.+Ferraraauthor=G.+Fyfeauthor=B.+Rogersauthor=R.+Rossauthor=F.+Kabbinavar&title=Bevacizumab+plus+irinotecan%2C+fluorouracil%2C+and+leucovorin+for+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer</span></div><div class="casAuthors">Hurwitz, Herbert; Fehrenbacher, Louis; Novotny, William; Cartwright, Thomas; Hainsworth, John; Heim, William; Berlin, Jordan; Baron, Ari; Griffing, Susan; Holmgren, Eric; Ferrara, Napoleone; Fyfe, Gwen; Rogers, Beth; Ross, Robert; Kabbinavar, Fairooz</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">350</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2335-2342</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclin. and clin. activity against metastatic colorectal cancer, particularly in combination with chemotherapy.  Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kg of body wt. every two weeks) and 411 to receive IFL plus placebo.  The primary end point was overall survival.  Secondary end points were progression-free survival, the response rate, the duration of the response, safety, and the quality of life.  The median duration of survival was 20.3 mo in the group given IFL plus bevacizumab, as compared with 15.6 mo in the group given IFL plus placebo, corresponding to a hazard ratio for death of 0.66 (P<0.001).  The median duration of progression-free survival was 10.6 mo in the group given IFL plus bevacizumab, as compared with 6.2 mo in the group given IFL plus placebo (hazard ratio for disease progression, 0.54; P<0.001); the corresponding rates of response were 44.8 % and 34.8 % (P = 0.004).  The median duration of the response was 10.4 mo in the group given IFL plus bevacizumab, as compared with 7.1 mo in the group given IFL plus placebo (hazard ratio for progression, 0.62; P = 0.001).  Grade 3 hypertension was more common during treatment with IFL plus bevacizumab than with IFL plus placebo (11.0 % vs. 2.3 %) but was easily managed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5r6uP5oxZU7Vg90H21EOLACvtfcHk0ljU1B5RDHzC7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXks1Gjt74%253D&md5=6a1289cdbf1501f121eb0482e5a1f536</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa032691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa032691%26sid%3Dliteratum%253Aachs%26aulast%3DHurwitz%26aufirst%3DH.%26aulast%3DFehrenbacher%26aufirst%3DL.%26aulast%3DNovotny%26aufirst%3DW.%26aulast%3DCartwright%26aufirst%3DT.%26aulast%3DHainsworth%26aufirst%3DJ.%26aulast%3DHeim%26aufirst%3DW.%26aulast%3DBerlin%26aufirst%3DJ.%26aulast%3DBaron%26aufirst%3DA.%26aulast%3DGriffing%26aufirst%3DS.%26aulast%3DHolmgren%26aufirst%3DE.%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DFyfe%26aufirst%3DG.%26aulast%3DRogers%26aufirst%3DB.%26aulast%3DRoss%26aufirst%3DR.%26aulast%3DKabbinavar%26aufirst%3DF.%26atitle%3DBevacizumab%2520plus%2520irinotecan%252C%2520fluorouracil%252C%2520and%2520leucovorin%2520for%2520metastatic%2520colorectal%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2004%26volume%3D350%26spage%3D2335%26epage%3D2342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Ferrara, N.</span><span> </span><span class="NLM_article-title">Pathways mediating VEGF-independent tumor angiogenesis</span> <span class="citation_source-journal">Cytokine Growth Factor Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">â</span> <span class="NLM_lpage">26</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1016%2Fj.cytogfr.2009.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=20005148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivFKgsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=21-26&author=N.+Ferrara&title=Pathways+mediating+VEGF-independent+tumor+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Pathways mediating VEGF-independent tumor angiogenesis</span></div><div class="casAuthors">Ferrara, Napoleone</div><div class="citationInfo"><span class="NLM_cas:title">Cytokine & Growth Factor Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-26</span>CODEN:
                <span class="NLM_cas:coden">CGFRFB</span>;
        ISSN:<span class="NLM_cas:issn">1359-6101</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  FDA approval of several inhibitors of the VEGF pathway has enabled significant advances in the therapy of cancer and neovascular age-related macular degeneration.  However, similar to other therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in patients, leading to disease progression.  So far the lack of predictive biomarkers has precluded identification of patients most likely to respond to such treatments.  Recent suggest that both tumor and non-tumor (stromal) cell types are involved in the reduced responsiveness to the treatments.  The present review examines the role of tumor- as well as stromal cell-derived pathways involved in tumor growth and in refractoriness to anti-VEGF therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD3to7NBagB7Vg90H21EOLACvtfcHk0ljU1B5RDHzC7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivFKgsrg%253D&md5=6ab03b42ee7c2d465b36cb9f709082b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.cytogfr.2009.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cytogfr.2009.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26atitle%3DPathways%2520mediating%2520VEGF-independent%2520tumor%2520angiogenesis%26jtitle%3DCytokine%2520Growth%2520Factor%2520Rev.%26date%3D2010%26volume%3D21%26spage%3D21%26epage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Soria, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mauguen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burcoveanu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pignon, J. P.</span><span> </span><span class="NLM_article-title">meta-analysis of bevacizumab in advanced NSCLC collaborative group. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">20</span><span class="NLM_x">â</span> <span class="NLM_lpage">30</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1093%2Fannonc%2Fmds590" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=23180113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC3s7mt1Sitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=20-30&author=J.+C.+Soriaauthor=A.+Mauguenauthor=M.+Reckauthor=A.+B.+Sandlerauthor=N.+Saijoauthor=D.+H.+Johnsonauthor=D.+Burcoveanuauthor=M.+Fukuokaauthor=B.+Besseauthor=J.+P.+Pignon&title=meta-analysis+of+bevacizumab+in+advanced+NSCLC+collaborative+group.+Systematic+review+and+meta-analysis+of+randomised%2C+phase+II%2FIII+trials+adding+bevacizumab+to+platinum-based+chemotherapy+as+first-line+treatment+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Soria J-C; Mauguen A; Reck M; Sandler A B; Saijo N; Johnson D H; Burcoveanu D; Fukuoka M; Besse B; Pignon J-P</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">20-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Previous studies have demonstrated the efficacy and safety of bevacizumab in the treatment of non-small-cell lung cancer (NSCLC).  METHODS:  Summary data from randomised trials comparing first-line bevacizumab plus platinum-based chemotherapy with chemotherapy alone for inoperable locally advanced, recurrent or metastatic NSCLC were meta-analysed.  Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and pooled odds ratio (OR) for adverse events were calculated.  The chi-squared tests evaluated interactions between treatment effects, and prognostic factors and patient characteristics.  RESULTS:  Data of 2194 patients (1313 bevacizumab; 881 controls) from four phase II and III trials: AVF-0757g, JO19907,ECOG 4599 and AVAiL, were analysed.  Compared with chemotherapy alone, bevacizumab significantly prolonged OS(HR 0.90; 95% confidence interval [CI] 0.81, 0.99; P=0.03), and PFS (0.72; 95% CI 0.66, 0.79; P<0.001).  Bevacizumab showed a significantly greater effect on OS in patients with adenocarcinoma versus other histologies (P=0.03), and patients with body weight loss â¤5% versus >5% (P=0.04).  Bevacizumab significantly increased the risk of grade â¥3 proteinuria, hypertension,haemorrhagic events, neutropenia, and febrile neutropenia [corrected].  CONCLUSIONS:  Bevacizumab significantly prolonged OS and PFS when added to first-line platinum-based chemotherapy in patients with advanced NSCLC; no unexpected toxicity was evident.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSO7bsWktUBMw5nADWVYHg1fW6udTcc2eZdgG16oMsSB7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7mt1Sitw%253D%253D&md5=116a2ee349433c6d1bfc2c963e15e454</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds590%26sid%3Dliteratum%253Aachs%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DMauguen%26aufirst%3DA.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DSandler%26aufirst%3DA.%2BB.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DD.%2BH.%26aulast%3DBurcoveanu%26aufirst%3DD.%26aulast%3DFukuoka%26aufirst%3DM.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DPignon%26aufirst%3DJ.%2BP.%26atitle%3Dmeta-analysis%2520of%2520bevacizumab%2520in%2520advanced%2520NSCLC%2520collaborative%2520group.%2520Systematic%2520review%2520and%2520meta-analysis%2520of%2520randomised%252C%2520phase%2520II%252FIII%2520trials%2520adding%2520bevacizumab%2520to%2520platinum-based%2520chemotherapy%2520as%2520first-line%2520treatment%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26spage%3D20%26epage%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Korc, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friesel, R. E.</span><span> </span><span class="NLM_article-title">The role of fibroblast growth factors in tumor growth</span> <span class="citation_source-journal">Curr. Cancer Drug Targets</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">â</span> <span class="NLM_lpage">651</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.2174%2F156800909789057006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=19508171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFehtb7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=639-651&author=M.+Korcauthor=R.+E.+Friesel&title=The+role+of+fibroblast+growth+factors+in+tumor+growth"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">The role of fibroblast growth factors in tumor growth</span></div><div class="casAuthors">Korc, M.; Friesel, R. E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Cancer Drug Targets</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-651</span>CODEN:
                <span class="NLM_cas:coden">CCDTB9</span>;
        ISSN:<span class="NLM_cas:issn">1568-0096</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Biol. processes that drive cell growth are exciting targets for cancer therapy.  The fibroblast growth factor (FGF) signaling network plays a ubiquitous role in normal cell growth, survival, differentiation, and angiogenesis, but has also been implicated in tumor development.  Elucidation of the roles and relationships within the diverse FGF family and of their links to tumor growth and progression will be crit. in designing new drug therapies to target FGF receptor (FGFR) pathways.  Recent studies have shown that FGF can act synergistically with vascular endothelial growth factor (VEGF) to amplify tumor angiogenesis, highlighting that targeting of both the FGF and VEGF pathways may be more efficient in suppressing tumor growth and angiogenesis than targeting either factor alone.  In addn., through inducing tumor cell survival, FGF has the potential to overcome chemotherapy resistance highlighting that chemotherapy may be more effective when used in combination with FGF inhibitor therapy.  Furthermore, FGFRs have variable activity in promoting angiogenesis, with the FGFR-1 subgroup being assocd. with tumor progression and the FGFR-2 subgroup being assocd. with either early tumor development or decreased tumor progression.  This review highlights the growing knowledge of FGFs in tumor cell growth and survival, including an overview of FGF intracellular signaling pathways, the role of FGFs in angiogenesis, patterns of FGF and FGFR expression in various tumor types, and the role of FGFs in tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLQVriotus1LVg90H21EOLACvtfcHk0lj4JnBRQ3x_kg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFehtb7P&md5=674ac00a00899ee4fd3e46f543a946a7</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2174%2F156800909789057006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156800909789057006%26sid%3Dliteratum%253Aachs%26aulast%3DKorc%26aufirst%3DM.%26aulast%3DFriesel%26aufirst%3DR.%2BE.%26atitle%3DThe%2520role%2520of%2520fibroblast%2520growth%2520factors%2520in%2520tumor%2520growth%26jtitle%3DCurr.%2520Cancer%2520Drug%2520Targets%26date%3D2009%26volume%3D9%26spage%3D639%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Lindner, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majack, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reidy, M. A.</span><span> </span><span class="NLM_article-title">Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">85</span><span class="NLM_x">, </span> <span class="NLM_fpage">2004</span><span class="NLM_x">â</span> <span class="NLM_lpage">2008</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=1990&pages=2004-2008&author=V.+Lindnerauthor=R.+A.+Majackauthor=M.+A.+Reidy&title=Basic+fibroblast+growth+factor+stimulates+endothelial+regrowth+and+proliferation+in+denuded+arteries"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DV.%26aulast%3DMajack%26aufirst%3DR.%2BA.%26aulast%3DReidy%26aufirst%3DM.%2BA.%26atitle%3DBasic%2520fibroblast%2520growth%2520factor%2520stimulates%2520endothelial%2520regrowth%2520and%2520proliferation%2520in%2520denuded%2520arteries%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D1990%26volume%3D85%26spage%3D2004%26epage%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Berger, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setinek, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohr, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kindas-Mugge, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vetterlein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckersberger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldas, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micksche, M.</span><span> </span><span class="NLM_article-title">Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">415</span><span class="NLM_x">â</span> <span class="NLM_lpage">423</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1002%2F%28SICI%291097-0215%2819991029%2983%3A3%3C415%3A%3AAID-IJC19%3E3.0.CO%3B2-Y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=10495436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADyaK1MXntVelt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1999&pages=415-423&author=W.+Bergerauthor=U.+Setinekauthor=T.+Mohrauthor=I.+Kindas-Muggeauthor=M.+Vetterleinauthor=G.+Dekanauthor=F.+Eckersbergerauthor=C.+Caldasauthor=M.+Micksche&title=Evidence+for+a+role+of+FGF-2+and+FGF+receptors+in+the+proliferation+of+non-small+cell+lung+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells</span></div><div class="casAuthors">Berger, Walter; Setinek, Ulrike; Mohr, Thomas; Kindas-Mugge, Ingela; Vetterlein, Monika; Dekan, Gerhard; Eckersberger, Franz; Caldas, Carlos; Micksche, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">415-423</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Basic fibroblast growth factor (FGF-2) has been implicated in the progression of human tumors via both autocrine and paracrine (angiogenic) activities.  We investigated the expression of FGF-2 and FGF receptors (FGFR-1 to -4) in NSCLC cell lines (N = 16), NSCLC surgical specimens (N = 21) and 2 control cell lines.  Our data show that almost all NSCLC cells produce elevated levels of FGF-2 and FGFR in vitro and in vivo.  FGF-2 expression did correlate with a short doubling time as well as with potent anchorage-independent growth of NSCLC cell lines.  In contrast with control cells, NSCLC cells did not secrete considerable amts. of FGF-2 into the extracellular space.  Expression levels of FGFR-1 and -2 in NSCLC cell lines correlated with FGF-2 prodn.  FGFR were located at the plasma membranes in some low FGF-2-producing NSCLC and control cell lines.  These cells were sensitive to the proliferative effect of recombinant FGF-2 (rFGF-2).  In NSCLC cell lines with an enhanced FGF-2 prodn., representing the majority studied, FGFR localization was predominantly intracellular.  These cells were insensitive to both the proliferative effect of rFGF-2 and growth inhibition by FGF-2-neutralizing antibodies.  In contrast, several agents antagonized FGF-2 intracellularly impaired growth of almost all NSCLC cell lines.  Our data suggest a role of FGF-2 and FGFR in the growth stimulation of NSCLC cells possibly via an intracrine mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFHR37uS77B7Vg90H21EOLACvtfcHk0li00NEm2xyE_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntVelt7s%253D&md5=45d065a4230842aaa6d034ee9cd497c5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291097-0215%2819991029%2983%3A3%3C415%3A%3AAID-IJC19%3E3.0.CO%3B2-Y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291097-0215%252819991029%252983%253A3%253C415%253A%253AAID-IJC19%253E3.0.CO%253B2-Y%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DSetinek%26aufirst%3DU.%26aulast%3DMohr%26aufirst%3DT.%26aulast%3DKindas-Mugge%26aufirst%3DI.%26aulast%3DVetterlein%26aufirst%3DM.%26aulast%3DDekan%26aufirst%3DG.%26aulast%3DEckersberger%26aufirst%3DF.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DMicksche%26aufirst%3DM.%26atitle%3DEvidence%2520for%2520a%2520role%2520of%2520FGF-2%2520and%2520FGF%2520receptors%2520in%2520the%2520proliferation%2520of%2520non-small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D1999%26volume%3D83%26spage%3D415%26epage%3D423" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ho, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeo, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, B. T.</span><span> </span><span class="NLM_article-title">Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">51</span><span class="NLM_x">â</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=51-62&author=H.+K.+Hoauthor=A.+H.+Yeoauthor=T.+S.+Kangauthor=B.+T.+Chua&title=Current+strategies+for+inhibiting+FGFR+activities+in+clinical+applications%3A+opportunities%2C+challenges+and+toxicological+considerations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DH.%2BK.%26aulast%3DYeo%26aufirst%3DA.%2BH.%26aulast%3DKang%26aufirst%3DT.%2BS.%26aulast%3DChua%26aufirst%3DB.%2BT.%26atitle%3DCurrent%2520strategies%2520for%2520inhibiting%2520FGFR%2520activities%2520in%2520clinical%2520applications%253A%2520opportunities%252C%2520challenges%2520and%2520toxicological%2520considerations%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D51%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Heldin, C. H.</span><span> </span><span class="NLM_article-title">Targeting the PDGF signaling pathway in tumor treatment</span> <span class="citation_source-journal">Cell Commun. Signal</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">97</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1186%2F1478-811X-11-97" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24359404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFOrurk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=97&author=C.+H.+Heldin&title=Targeting+the+PDGF+signaling+pathway+in+tumor+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the PDGF signaling pathway in tumor treatment</span></div><div class="casAuthors">Heldin, Carl-Henrik</div><div class="citationInfo"><span class="NLM_cas:title">Cell Communication and Signaling</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">97/1-97/18, 18 pp.</span>CODEN:
                <span class="NLM_cas:coden">CCSEC6</span>;
        ISSN:<span class="NLM_cas:issn">1478-811X</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Platelet-derived growth factor (PDGF) isoforms and PDGF receptors have important functions in the regulation of growth and survival of certain cell types during embryonal development and e.g. tissue repair in the adult.  Overactivity of PDGF receptor signaling, by overexpression or mutational events, may drive tumor cell growth.  In addn., pericytes of the vasculature and fibroblasts and myofibroblasts of the stroma of solid tumors express PDGF receptors and PDGF stimulation of such cells promotes tumorigenesis.  Inhibition of PDGF receptor signaling has proven to useful for the treatment of patients with certain rare tumors.  Whether treatment with PDGF/PDGF receptor antagonists will be beneficial for more common malignancies is the subject for ongoing studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnS6tBwNOJdbVg90H21EOLACvtfcHk0li00NEm2xyE_g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFOrurk%253D&md5=17774f39a3f8214700471a9def048aa6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1186%2F1478-811X-11-97&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1478-811X-11-97%26sid%3Dliteratum%253Aachs%26aulast%3DHeldin%26aufirst%3DC.%2BH.%26atitle%3DTargeting%2520the%2520PDGF%2520signaling%2520pathway%2520in%2520tumor%2520treatment%26jtitle%3DCell%2520Commun.%2520Signal%26date%3D2013%26volume%3D11%26spage%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colby, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordier, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasky, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swigris, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancochea, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouros, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carvalho, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebina, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johkoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Myers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dudden, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griss, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protzko, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schunemann, H. J.</span><span> </span><span class="NLM_article-title">ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">â</span> <span class="NLM_lpage">824</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1164%2Frccm.2009-040GL" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21471066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC3MrjvFWqsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2011&pages=788-824&author=G.+Raghuauthor=H.+R.+Collardauthor=J.+J.+Eganauthor=F.+J.+Martinezauthor=J.+Behrauthor=K.+K.+Brownauthor=T.+V.+Colbyauthor=J.+F.+Cordierauthor=K.+R.+Flahertyauthor=J.+A.+Laskyauthor=D.+A.+Lynchauthor=J.+H.+Ryuauthor=J.+J.+Swigrisauthor=A.+U.+Wellsauthor=J.+Ancocheaauthor=D.+Bourosauthor=C.+Carvalhoauthor=U.+Costabelauthor=M.+Ebinaauthor=D.+M.+Hansellauthor=T.+Johkohauthor=D.+S.+Kimauthor=T.+E.+Kingauthor=Y.+Kondohauthor=J.+Myersauthor=N.+L.+Mullerauthor=A.+G.+Nicholsonauthor=L.+Richeldiauthor=M.+Selmanauthor=R.+F.+Duddenauthor=B.+S.+Grissauthor=S.+L.+Protzkoauthor=H.+J.+Schunemann&title=ATS%2FERS%2FJRS%2FALAT+Committee+on+Idiopathic+Pulmonary+Fibrosis.+An+official+ATS%2FERS%2FJRS%2FALAT+statement%3A+idiopathic+pulmonary+fibrosis%3A+evidence-based+guidelines+for+diagnosis+and+management"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management</span></div><div class="casAuthors">Raghu Ganesh; Collard Harold R; Egan Jim J; Martinez Fernando J; Behr Juergen; Brown Kevin K; Colby Thomas V; Cordier Jean-Francois; Flaherty Kevin R; Lasky Joseph A; Lynch David A; Ryu Jay H; Swigris Jeffrey J; Wells Athol U; Ancochea Julio; Bouros Demosthenes; Carvalho Carlos; Costabel Ulrich; Ebina Masahito; Hansell David M; Johkoh Takeshi; Kim Dong Soon; King Talmadge E Jr; Kondoh Yasuhiro; Myers Jeffrey; Muller Nestor L; Nicholson Andrew G; Richeldi Luca; Selman Moises; Dudden Rosalind F; Griss Barbara S; Protzko Shandra L; Schunemann Holger J</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">788-824</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association.  It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course.  For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format.  For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak).  Recommendations were based on majority vote.  It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSd3NNagTHJTiXXDYhVZBdlfW6udTcc2eYT9jiw3C5xIbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrjvFWqsQ%253D%253D&md5=f47abe4551c8684d3af81f66598e9b2c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1164%2Frccm.2009-040GL&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.2009-040GL%26sid%3Dliteratum%253Aachs%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26aulast%3DEgan%26aufirst%3DJ.%2BJ.%26aulast%3DMartinez%26aufirst%3DF.%2BJ.%26aulast%3DBehr%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DColby%26aufirst%3DT.%2BV.%26aulast%3DCordier%26aufirst%3DJ.%2BF.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DLasky%26aufirst%3DJ.%2BA.%26aulast%3DLynch%26aufirst%3DD.%2BA.%26aulast%3DRyu%26aufirst%3DJ.%2BH.%26aulast%3DSwigris%26aufirst%3DJ.%2BJ.%26aulast%3DWells%26aufirst%3DA.%2BU.%26aulast%3DAncochea%26aufirst%3DJ.%26aulast%3DBouros%26aufirst%3DD.%26aulast%3DCarvalho%26aufirst%3DC.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DEbina%26aufirst%3DM.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DJohkoh%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DMyers%26aufirst%3DJ.%26aulast%3DMuller%26aufirst%3DN.%2BL.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DDudden%26aufirst%3DR.%2BF.%26aulast%3DGriss%26aufirst%3DB.%2BS.%26aulast%3DProtzko%26aufirst%3DS.%2BL.%26aulast%3DSchunemann%26aufirst%3DH.%2BJ.%26atitle%3DATS%252FERS%252FJRS%252FALAT%2520Committee%2520on%2520Idiopathic%2520Pulmonary%2520Fibrosis.%2520An%2520official%2520ATS%252FERS%252FJRS%252FALAT%2520statement%253A%2520idiopathic%2520pulmonary%2520fibrosis%253A%2520evidence-based%2520guidelines%2520for%2520diagnosis%2520and%2520management%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2011%26volume%3D183%26spage%3D788%26epage%3D824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Fernandez, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickelberg, O.</span><span> </span><span class="NLM_article-title">The impact of TGF-beta on lung fibrosis: from targeting to biomarkers</span> <span class="citation_source-journal">Proc. Am. Thorac. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">â</span> <span class="NLM_lpage">1116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1513%2Fpats.201203-023AW" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22802283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVKju7%252FF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=111-1116&author=I.+E.+Fernandezauthor=O.+Eickelberg&title=The+impact+of+TGF-beta+on+lung+fibrosis%3A+from+targeting+to+biomarkers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of TGF-Î² on lung fibrosis. From targeting to biomarkers</span></div><div class="casAuthors">Fernandez, Isis E.; Eickelberg, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the American Thoracic Society</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">111-116</span>CODEN:
                <span class="NLM_cas:coden">PATSBB</span>;
        ISSN:<span class="NLM_cas:issn">1546-3222</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">A review.  Transforming growth factor-Î² (TGF-Î²) is extensively involved in the development of fibrosis in different organs.  Overprodn. or potentiation of its profibrotic effects leads to an aberrant wound healing response during the initiation of fibrotic processes.  Idiopathic pulmonary fibrosis (IPF) is a chronic, devastating disease, in which TGF-Î²-induced disturbances of the homeostatic microenvironment are crit. to promote cell activation, migration, invasion, or hyperplastic changes.  In addn., excess extracellular matrix prodn. contributes in a major way to disease pathogenesis.  For this reason, this review will focus on discussing novel data and highlight growing interest in deepening the understanding of the profibrotic role of TGF-Î² and its direct or indirect targeting for disease modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-7pApbz3eBbVg90H21EOLACvtfcHk0lgxJglaWuWVGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVKju7%252FF&md5=44317d32bc6dcadf7219209cfa590908</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1513%2Fpats.201203-023AW&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1513%252Fpats.201203-023AW%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DI.%2BE.%26aulast%3DEickelberg%26aufirst%3DO.%26atitle%3DThe%2520impact%2520of%2520TGF-beta%2520on%2520lung%2520fibrosis%253A%2520from%2520targeting%2520to%2520biomarkers%26jtitle%3DProc.%2520Am.%2520Thorac.%2520Soc.%26date%3D2012%26volume%3D9%26spage%3D111%26epage%3D1116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, T. E.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daniloff, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, L. S.</span><span> </span><span class="NLM_article-title">Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis</span> <span class="citation_source-journal">Am. J. Respir. Crit. Care Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">166</span><span class="NLM_x">, </span> <span class="NLM_fpage">765</span><span class="NLM_x">â</span> <span class="NLM_lpage">773</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1164%2Frccm.2010014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=12204879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BD38vkslGgsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2002&pages=765-773&author=Y.+Inoueauthor=T.+E.+Kingauthor=E.+Barkerauthor=E.+Daniloffauthor=L.+S.+Newman&title=Basic+fibroblast+growth+factor+and+its+receptors+in+idiopathic+pulmonary+fibrosis+and+lymphangioleiomyomatosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis</span></div><div class="casAuthors">Inoue Yoshikazu; King Talmadge E Jr; Barker Elizabeth; Daniloff Elaine; Newman Lee S</div><div class="citationInfo"><span class="NLM_cas:title">American journal of respiratory and critical care medicine</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">765-73</span>
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    </div><div class="casAbstract">Basic fibroblast growth factor (bFGF) is a potent mitogenic factor for smooth muscle cells, myofibroblasts, and fibroblasts, proliferation of which is a hallmark of idiopathic pulmonary fibrosis (IPF) and lymphangioleiomyomatosis (LAM).  Mast cells produce bFGF and have been associated with pulmonary fibrosis.  We hypothesize that smooth muscle cell/myofibroblast-like cells will be spatially associated with bFGF-containing mast cells and that bFGF receptors will be expressed on the effector cells in IPF and LAM.  We performed quantitative immunohistochemistry for bFGF, mast cell tryptase, smooth muscle actin for smooth muscle cell/myofibroblast-like cells, and fibroblast growth factor receptors (Flg, Bek) and measured collagen and elastic fiber in lung sections from IPF (n = 14), LAM (n = 9), and control lung (n = 10).  IPF and LAM lung contained more smooth muscle cell/myofibroblast-like cells than did control lung. bFGF-containing mast cells were abundant both in IPF and LAM and were associated with collagen, elastic fibers, and smooth muscle cell/myofibroblast-like cells in IPF.  Flg was expressed on epithelial cells, endothelial cells, smooth muscle cell/myofibroblast-like cells, and macrophages in IPF.  In LAM, Flg was expressed on epithelial cells adjacent to smooth muscle cell/myofibroblast-like cell aggregates.  Bek was expressed dominantly on smooth muscle cell/myofibroblast-like cells in LAM and on smooth muscle cell/myofibroblast-like cells as well as neutrophils in IPF.  These data suggest that mast cell-derived bFGF might exert fibrogenic, proliferative effects on smooth muscle cell/myofibroblast-like cells through its receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIOJoTcbBscyCEBeYuoi7AfW6udTcc2eYT9jiw3C5xIbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vkslGgsQ%253D%253D&md5=76afcf75d65d9dd16c8eb47c54b146e3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1164%2Frccm.2010014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.2010014%26sid%3Dliteratum%253Aachs%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DKing%26aufirst%3DT.%2BE.%26aulast%3DBarker%26aufirst%3DE.%26aulast%3DDaniloff%26aufirst%3DE.%26aulast%3DNewman%26aufirst%3DL.%2BS.%26atitle%3DBasic%2520fibroblast%2520growth%2520factor%2520and%2520its%2520receptors%2520in%2520idiopathic%2520pulmonary%2520fibrosis%2520and%2520lymphangioleiomyomatosis%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2002%26volume%3D166%26spage%3D765%26epage%3D773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Hetzel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bachem, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trischler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faehling, M.</span><span> </span><span class="NLM_article-title">Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts</span> <span class="citation_source-journal">Lung</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">183</span><span class="NLM_x">, </span> <span class="NLM_fpage">225</span><span class="NLM_x">â</span> <span class="NLM_lpage">237</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2005&pages=225-237&author=M.+Hetzelauthor=M.+Bachemauthor=D.+Andersauthor=G.+Trischlerauthor=M.+Faehling&title=Different+effects+of+growth+factors+on+proliferation+and+matrix+production+of+normal+and+fibrotic+human+lung+fibroblasts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHetzel%26aufirst%3DM.%26aulast%3DBachem%26aufirst%3DM.%26aulast%3DAnders%26aufirst%3DD.%26aulast%3DTrischler%26aufirst%3DG.%26aulast%3DFaehling%26aufirst%3DM.%26atitle%3DDifferent%2520effects%2520of%2520growth%2520factors%2520on%2520proliferation%2520and%2520matrix%2520production%2520of%2520normal%2520and%2520fibrotic%2520human%2520lung%2520fibroblasts%26jtitle%3DLung%26date%3D2005%26volume%3D183%26spage%3D225%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Yu, Z. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Z. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span> </span><span class="NLM_article-title">Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice</span> <span class="citation_source-journal">Biol. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">â</span> <span class="NLM_lpage">736</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1248%2Fbpb.35.731" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22687409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFOmtbc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=731-736&author=Z.+H.+Yuauthor=D.+D.+Wangauthor=Z.+Y.+Zhouauthor=S.+L.+Heauthor=A.+A.+Chenauthor=J.+Wang&title=Mutant+soluble+ectodomain+of+fibroblast+growth+factor+receptor-2+IIIc+attenuates+bleomycin-induced+pulmonary+fibrosis+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Mutant soluble ectodomain of fibroblast growth factor receptor-2 IIIc attenuates bleomycin-induced pulmonary fibrosis in mice</span></div><div class="casAuthors">Yu, Zhi-hong; Wang, Ding-ding; Zhou, Zhi-you; He, Shui-lian; Chen, An-an; Wang, Ju</div><div class="citationInfo"><span class="NLM_cas:title">Biological & Pharmaceutical Bulletin</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">731-736</span>CODEN:
                <span class="NLM_cas:coden">BPBLEO</span>;
        ISSN:<span class="NLM_cas:issn">0918-6158</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Japan</span>)
        </div><div class="casAbstract">We have developed a strong inhibitor (S252W mutant sol. ectodomain of fibroblast growth factor receptor-2 IIIc, msFGFR2) that binds FGFs strongly and blocks the activation of FGFRs.  In vitro, msFGFR2 could inhibit the promoting effect of transforming growth factor (TGF)-Î²1 on the proliferation of primary lung fibroblasts.  In vivo, msFGFR2 alleviated lung fibrosis through inhibiting the expression of Î±-smooth muscle actin (SMA) and collagen deposit.  In Western blotting of the right lung tissues and immunohistochem. assay, we found the level of p-FGFRs, p-mitogen activated protein kinase (MAPK) and p-Smad3 in the mice of bleomycin (BLM) group treated with msFGFR2 was down dramatically compared with the mice of BLM group, which suggested the activations of FGF and TGF-Î² signals were blocked meanwhile.  In summary, msFGFR2 attenuated BLM-induced fibrosis and is an attractive therapeutic candidate for human pulmonary fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYRow5kugSxbVg90H21EOLACvtfcHk0lhlggAB0inhTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFOmtbc%253D&md5=ffcd92974b96ea20ca8c40b94bd77cbc</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1248%2Fbpb.35.731&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fbpb.35.731%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DZ.%2BH.%26aulast%3DWang%26aufirst%3DD.%2BD.%26aulast%3DZhou%26aufirst%3DZ.%2BY.%26aulast%3DHe%26aufirst%3DS.%2BL.%26aulast%3DChen%26aufirst%3DA.%2BA.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DMutant%2520soluble%2520ectodomain%2520of%2520fibroblast%2520growth%2520factor%2520receptor-2%2520IIIc%2520attenuates%2520bleomycin-induced%2520pulmonary%2520fibrosis%2520in%2520mice%26jtitle%3DBiol.%2520Pharm.%2520Bull.%26date%3D2012%26volume%3D35%26spage%3D731%26epage%3D736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Chetta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zanini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foresi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâIppolito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tipa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castagnaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baraldo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saetta, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivieri, D.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">1437</span><span class="NLM_x">â</span> <span class="NLM_lpage">1442</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1111%2Fj.1365-2222.2005.02360.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=16297139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCjtrzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2005&pages=1437-1442&author=A.+Chettaauthor=A.+Zaniniauthor=A.+Foresiauthor=R.+D%E2%80%99Ippolitoauthor=A.+Tipaauthor=A.+Castagnaroauthor=S.+Baraldoauthor=M.+Neriauthor=M.+Saettaauthor=D.+Olivieri&title=Vascular+endothelial+growth+factor+up-regulation+and+bronchial+wall+remodelling+in+asthma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma</span></div><div class="casAuthors">Chetta, A.; Zanini, A.; Foresi, A.; D'Ippolito, R.; Tipa, A.; Castagnaro, A.; Baraldo, S.; Neri, M.; Saetta, M.; Olivieri, D.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Allergy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1437-1442</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">There is increasing in vitro evidence to support a role for vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, as a mediator of fibrosis assocd. with neovascularization.  We tested the hypothesis that VEGF is involved both in increased airway mucosal vascularity and in the subepithelial fibrosis of asthmatic patients.  Bronchial biopsies were performed in 24 asthmatic patients and eight healthy controls.  Immunostaining, using computerized image anal., was performed using monoclonal antibodies against VEGF+ cells, type IV collagen, to outline the basement membrane thickness, and tryptase and EG2, to identify mast cells and eosinophils, resp.  The counts of VEGF+ cells (P < 0.05), mast cells and EG2+ cells (both P < 0.01) were higher in asthmatics than in controls.  The no. of vessels, the vascular area in the lamina propria, and the basement membrane thickness were significantly higher in asthmatics than in healthy volunteers (P < 0.01).  Moreover, in asthmatic patients, the no. of VEGF+ cells was significantly related to the no. of vessels (P < 0.01), to mast cells (P < 0.01) and to basement membrane thickness (P < 0.01).  A colocalization study also revealed that mast cells were a relevant cellular source of VEGF.  High doses of inhaled fluticasone propionate significantly reduced VEGF+ cells (P < 0.05), vessel no. (P < 0.05), vascular area (P < 0.05) and basement membrane thickness (P < 0.05) in a subgroup of asthmatic patients.  This study shows that VEGF, in addn. to being involved in the vascular component of airway remodelling, may play a role in the thickening of the basement membrane in asthma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNsqQT2mbugbVg90H21EOLACvtfcHk0lhlggAB0inhTg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCjtrzK&md5=2c3d69d9c393624d5f8e1cfe8202abcc</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.2005.02360.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.2005.02360.x%26sid%3Dliteratum%253Aachs%26aulast%3DChetta%26aufirst%3DA.%26aulast%3DZanini%26aufirst%3DA.%26aulast%3DForesi%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Ippolito%26aufirst%3DR.%26aulast%3DTipa%26aufirst%3DA.%26aulast%3DCastagnaro%26aufirst%3DA.%26aulast%3DBaraldo%26aufirst%3DS.%26aulast%3DNeri%26aufirst%3DM.%26aulast%3DSaetta%26aufirst%3DM.%26aulast%3DOlivieri%26aufirst%3DD.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520up-regulation%2520and%2520bronchial%2520wall%2520remodelling%2520in%2520asthma%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D2005%26volume%3D35%26spage%3D1437%26epage%3D1442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Hamada, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagimoto, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiasa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egashira, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakanishi, Y.</span><span> </span><span class="NLM_article-title">Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice</span> <span class="citation_source-journal">J. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">175</span><span class="NLM_x">, </span> <span class="NLM_fpage">1224</span><span class="NLM_x">â</span> <span class="NLM_lpage">1231</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2005&pages=1224-1231&author=N.+Hamadaauthor=K.+Kuwanoauthor=M.+Yamadaauthor=N.+Hagimotoauthor=K.+Hiasaauthor=K.+Egashiraauthor=N.+Nakashimaauthor=T.+Maeyamaauthor=M.+Yoshimiauthor=Y.+Nakanishi&title=Anti-vascular+endothelial+growth+factor+gene+therapy+attenuates+lung+injury+and+fibrosis+in+mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamada%26aufirst%3DN.%26aulast%3DKuwano%26aufirst%3DK.%26aulast%3DYamada%26aufirst%3DM.%26aulast%3DHagimoto%26aufirst%3DN.%26aulast%3DHiasa%26aufirst%3DK.%26aulast%3DEgashira%26aufirst%3DK.%26aulast%3DNakashima%26aufirst%3DN.%26aulast%3DMaeyama%26aufirst%3DT.%26aulast%3DYoshimi%26aufirst%3DM.%26aulast%3DNakanishi%26aufirst%3DY.%26atitle%3DAnti-vascular%2520endothelial%2520growth%2520factor%2520gene%2520therapy%2520attenuates%2520lung%2520injury%2520and%2520fibrosis%2520in%2520mice%26jtitle%3DJ.%2520Immunol.%26date%3D2005%26volume%3D175%26spage%3D1224%26epage%3D1231" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rathgen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bischoff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¼dtke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marzin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebner, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">â</span> <span class="NLM_lpage">311</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2011&pages=297-311&author=P.+Stopferauthor=K.+Rathgenauthor=D.+Bischoffauthor=S.+L%C3%BCdtkeauthor=K.+Marzinauthor=R.+Kaiserauthor=K.+Wagnerauthor=T.+Ebner&title=Pharmacokinetics+and+metabolism+of+BIBF+1120+after+oral+dosing+to+healthy+male+volunteers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DRathgen%26aufirst%3DK.%26aulast%3DBischoff%26aufirst%3DD.%26aulast%3DL%25C3%25BCdtke%26aufirst%3DS.%26aulast%3DMarzin%26aufirst%3DK.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DWagner%26aufirst%3DK.%26aulast%3DEbner%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520metabolism%2520of%2520BIBF%25201120%2520after%2520oral%2520dosing%2520to%2520healthy%2520male%2520volunteers%26jtitle%3DXenobiotica%26date%3D2011%26volume%3D41%26spage%3D297%26epage%3D311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judson, I. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienast, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanic, M.</span><span> </span><span class="NLM_article-title">Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients</span> <span class="citation_source-journal">Eur. J. Cancer Suppl.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><div class="note"><p class="first last">(Abstract 73)</p></div></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1016%2FS1359-6349%2806%2970079-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=26&author=P.+Stopferauthor=W.+Rothauthor=K.+Mrossauthor=I.+R.+Judsonauthor=J.+Kienastauthor=R.+Kaiserauthor=M.+Stefanic&title=Pharmacokinetic+characterization+of+BIBF+1120%2C+an+orally+active+triple+angiokinase+inhibitor+%28VEGFR%2C+PDGFR%2C+FGFR%29+in+advanced+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2FS1359-6349%2806%2970079-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6349%252806%252970079-9%26sid%3Dliteratum%253Aachs%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DRoth%26aufirst%3DW.%26aulast%3DMross%26aufirst%3DK.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26aulast%3DKienast%26aufirst%3DJ.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DStefanic%26aufirst%3DM.%26atitle%3DPharmacokinetic%2520characterization%2520of%2520BIBF%25201120%252C%2520an%2520orally%2520active%2520triple%2520angiokinase%2520inhibitor%2520%2528VEGFR%252C%2520PDGFR%252C%2520FGFR%2529%2520in%2520advanced%2520cancer%2520patients%26jtitle%3DEur.%2520J.%2520Cancer%2520Suppl.%26date%3D2006%26volume%3D4%26spage%3D26" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Mross, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmehling, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baas, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strecker, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henning, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Rossi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span> </span><span class="NLM_article-title">Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">â</span> <span class="NLM_lpage">319</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1158%2F1078-0432.CCR-09-0694" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=20028771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Sn" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=311-319&author=K.+Mrossauthor=M.+Stefanicauthor=D.+Gmehlingauthor=A.+Frostauthor=F.+Baasauthor=C.+Ungerauthor=R.+Streckerauthor=J.+Henningauthor=B.+Gaschler-Markefskiauthor=P.+Stopferauthor=L.+de+Rossiauthor=R.+Kaiser&title=Phase+I+study+of+the+angiogenesis+inhibitor+BIBF+1120+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Mross, Klaus; Stefanic, Martin; Gmehling, Daniela; Frost, Annette; Baas, Franziska; Unger, Clemens; Strecker, Ralph; Henning, Juergen; Gaschler-Markefski, Birgit; Stopfer, Peter; de Rossi, Lothar; Kaiser, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">311-319</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: BIBF 1120 is an oral, potent angiokinase inhibitor targeting receptors of the vascular endothelial growth factors, platelet-derived growth factors, and fibroblast growth factors.  This phase I, accelerated titrn. study assessed the max. tolerated dose, safety, pharmacokinetics, and pharmacodynamic effects of BIBF 1120.  Patients and Methods: Sixty-one patients with advanced cancers received BIBF 1120 in successive cohorts.  Twenty-five received 50 to 450 mg once daily and 36 received 150 to 300 mg twice daily in 4-wk treatment courses interspersed by 1 wk of washout.  Dynamic contrast-enhanced magnetic resonance imaging assessed antiangiogenic effect in 42 patients.  Results: Most frequent BIBF 1120-related adverse events were mostly mild to moderate (Common Toxicity Criteria grade 1-2) nausea (68.9%), vomiting (45.9%), and diarrhea (44.3%).  The majority of dose-limiting adverse events of Common Toxicity Criteria grade 3 or 4 were reversible liver enzyme elevations.  The max. tolerated dose was 250 mg of BIBF 1120 for once and twice daily dosing.  BIBF 1120 was absorbed moderately fast (tmax = 1-3 h at steady state), with no deviation from dose linearity and no decrease of exposure over time.  The gMean terminal half-life was from 13 to 19 h.  One complete and two partial responses occurred in patients with renal cell cancer (n = 2) and colorectal cancer (n = 1).  Dynamic contrast-enhanced magnetic resonance imaging showed a significant redn. in tumor blood flow in 55% of evaluable patients.  Conclusions: BIBF 1120 dosed continuously displayed a favorable safety and pharmacokinetics profile, and first efficacy signals were obsd.  Twice daily dosing permitted increased drug exposure without addnl. toxicity.  Two hundred milligrams BIBF 1120 twice daily is the recommended dose for phase II monotherapy studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg1SqFYDdXp7Vg90H21EOLACvtfcHk0lijnDquubelGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Sn&md5=608e438665fa3f523b3fce6cd7de3842</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-0694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-0694%26sid%3Dliteratum%253Aachs%26aulast%3DMross%26aufirst%3DK.%26aulast%3DStefanic%26aufirst%3DM.%26aulast%3DGmehling%26aufirst%3DD.%26aulast%3DFrost%26aufirst%3DA.%26aulast%3DBaas%26aufirst%3DF.%26aulast%3DUnger%26aufirst%3DC.%26aulast%3DStrecker%26aufirst%3DR.%26aulast%3DHenning%26aufirst%3DJ.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3Dde%2BRossi%26aufirst%3DL.%26aulast%3DKaiser%26aufirst%3DR.%26atitle%3DPhase%2520I%2520study%2520of%2520the%2520angiogenesis%2520inhibitor%2520BIBF%25201120%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D311%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morinaga, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terashima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sarashina, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konishi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2825</span><span class="NLM_x">â</span> <span class="NLM_lpage">2833</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1158%2F1535-7163.MCT-10-0379" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=20688946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KhtrnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2825-2833&author=I.+Okamotoauthor=H.+Kanedaauthor=T.+Satohauthor=W.+Okamotoauthor=M.+Miyazakiauthor=R.+Morinagaauthor=S.+Uedaauthor=M.+Terashimaauthor=A.+Tsuyaauthor=A.+Sarashinaauthor=K.+Konishiauthor=T.+Araoauthor=K.+Nishioauthor=R.+Kaiserauthor=K.+Nakagawa&title=Phase+I+safety%2C+pharmacokinetic%2C+and+biomarker+study+of+BIBF+1120%2C+an+oral+triple+tyrosine+kinase+inhibitor+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Safety, Pharmacokinetic, and Biomarker Study of BIBF 1120, an Oral Triple Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors</span></div><div class="casAuthors">Okamoto, Isamu; Kaneda, Hiroyasu; Satoh, Taroh; Okamoto, Wataru; Miyazaki, Masaki; Morinaga, Ryotaro; Ueda, Shinya; Terashima, Masaaki; Tsuya, Asuka; Sarashina, Akiko; Konishi, Koichi; Arao, Tokuzo; Nishio, Kazuto; Kaiser, Rolf; Nakagawa, Kazuhiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2825-2833</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BIBF 1120 is an oral multitargeted tyrosine kinase inhibitor that blocks the activity of vascular endothelial growth factor (VEGF) and other growth factor receptors.  We have done a phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamic biomarkers of BIBF 1120.  Patients with advanced refractory solid tumors were treated with BIBF 1120 at oral doses of 150 to 250 mg twice daily.  Drug safety and pharmacokinetics were evaluated, as were baseline and post-treatment levels of circulating CD117-pos. bone marrow-derived progenitor cells and plasma sol. VEGF receptor 2 as potential biomarkers for BIBF 1120.  Twenty-one patients were treated at BIBF 1120 doses of 150 (n = 3), 200 (n = 12), or 250 mg twice daily (n = 6).  Dose-limiting toxicities of reversible grade 3 or 4 elevations of liver enzymes occurred in 3 of 12 patients at 200 mg twice daily and 3 of 6 patients at 250 mg twice daily.  Stable disease was achieved in 16 (76.2%) patients, and median progression-free survival was 113 days (95% confidence interval, 77-119 d).  Pharmacokinetic anal. indicated that the max. plasma concn. and area under the curve for BIBF 1120 increased with the dose within the dose range tested.  Levels of CD117-pos. bone marrow-derived progenitors and sol. VEGF receptor 2 decreased significantly during treatment over all BIBF 1120 dose cohorts.  In conclusion, the max. tolerated dose of BIBF 1120 in the current study was detd. to be 200 mg twice daily, and our biomarker anal. indicated that this angiokinase inhibitor is biol. active.  Mol Cancer Ther; 9(10); 2825-33.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvoGtHJ_4nebVg90H21EOLACvtfcHk0lgKaspflbVuoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KhtrnJ&md5=dd4f6a5b88239fcb5ebdf1ee219dd4f4</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0379&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0379%26sid%3Dliteratum%253Aachs%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DKaneda%26aufirst%3DH.%26aulast%3DSatoh%26aufirst%3DT.%26aulast%3DOkamoto%26aufirst%3DW.%26aulast%3DMiyazaki%26aufirst%3DM.%26aulast%3DMorinaga%26aufirst%3DR.%26aulast%3DUeda%26aufirst%3DS.%26aulast%3DTerashima%26aufirst%3DM.%26aulast%3DTsuya%26aufirst%3DA.%26aulast%3DSarashina%26aufirst%3DA.%26aulast%3DKonishi%26aufirst%3DK.%26aulast%3DArao%26aufirst%3DT.%26aulast%3DNishio%26aufirst%3DK.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DPhase%2520I%2520safety%252C%2520pharmacokinetic%252C%2520and%2520biomarker%2520study%2520of%2520BIBF%25201120%252C%2520an%2520oral%2520triple%2520tyrosine%2520kinase%2520inhibitor%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2825%26epage%3D2833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Kropff, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kienast, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bisping, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berdel, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munzert, G.</span><span> </span><span class="NLM_article-title">An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma</span> <span class="citation_source-journal">Anticancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4233</span><span class="NLM_x">â</span> <span class="NLM_lpage">4238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=19846979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVOltL7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2009&pages=4233-4238&author=M.+Kropffauthor=J.+Kienastauthor=G.+Bispingauthor=W.+E.+Berdelauthor=B.+Gaschler-Markefskiauthor=P.+Stopferauthor=M.+Stefanicauthor=G.+Munzert&title=An+open-label+dose-escalation+study+of+BIBF+1120+in+patients+with+relapsed+or+refractory+multiple+myeloma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma</span></div><div class="casAuthors">Kropff, Martin; Kienast, Joachim; Bisping, Guido; Berdel, Wolfgang E.; Gaschler-Markefski, Birgit; Stopfer, Peter; Stefanic, Martin; Munzert, Gerd</div><div class="citationInfo"><span class="NLM_cas:title">Anticancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">4233-4238</span>CODEN:
                <span class="NLM_cas:coden">ANTRD4</span>;
        ISSN:<span class="NLM_cas:issn">0250-7005</span>.
    
            (<span class="NLM_cas:orgname">International Institute of Anticancer Research</span>)
        </div><div class="casAbstract">To det. the max. tolerated dose (MTD) and dose-limiting toxicities (DLTs) of BIBF 1120, a triple angiokinase inhibitor administered once-daily in patients with advanced multiple myeloma.  This Phase I study included 17 patients.  Planned dose escalations of BIBF 1120 were 100, 200, 250, and 300 mg.  Safety and pharmacokinetic (PK) assessments were performed.  Two DLTs (200 and 250 mg) occurred due to increased gamma-glutamyltransferase levels (CTC grade 3).  The 250 mg dose was well tolerated; no dose escalation beyond 250 mg was made.  The most common adverse events included diarrhoea, nausea and vomiting.  No detectable deviation from dose linear PKs was obsd.  Regarding tumor control, two patients had stable disease for â¥4 mo.  BIBF 1120 was safe and well tolerated up to 250 mg/day.  The MTD was not reached.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS8DKB1OE8G7Vg90H21EOLACvtfcHk0lgKaspflbVuoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVOltL7P&md5=7fd157250c0ee2843bee45fbedb77947</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKropff%26aufirst%3DM.%26aulast%3DKienast%26aufirst%3DJ.%26aulast%3DBisping%26aufirst%3DG.%26aulast%3DBerdel%26aufirst%3DW.%2BE.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DStefanic%26aufirst%3DM.%26aulast%3DMunzert%26aufirst%3DG.%26atitle%3DAn%2520open-label%2520dose-escalation%2520study%2520of%2520BIBF%25201120%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520multiple%2520myeloma%26jtitle%3DAnticancer%2520Res.%26date%3D2009%26volume%3D29%26spage%3D4233%26epage%3D4238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Doebele, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conkling, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traynor, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otterson, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wind, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">2094</span><span class="NLM_x">â</span> <span class="NLM_lpage">2102</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1093%2Fannonc%2Fmdr596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22345119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC38vjsVOjtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2012&pages=2094-2102&author=R.+C.+Doebeleauthor=P.+Conklingauthor=A.+M.+Traynorauthor=G.+A.+Ottersonauthor=Y.+Zhaoauthor=S.+Windauthor=P.+Stopferauthor=R.+Kaiserauthor=D.+R.+Camidge&title=A+phase+I%2C+open-label+dose-escalation+study+of+continuous+treatment+with+BIBF+1120+in+combination+with+paclitaxel+and+carboplatin+as+first-line+treatment+in+patients+with+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Doebele R C; Conkling P; Traynor A M; Otterson G A; Zhao Y; Wind S; Stopfer P; Kaiser R; Camidge D R</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2094-102</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  BIBF 1120 is an oral potent inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet-derived growth factor receptor, the three key receptor families involved in angiogenesis.  This phase I, open-label dose-escalation study investigated BIBF 1120 combined with paclitaxel (Taxol) and carboplatin in first-line patients with advanced (IIIB/IV) non-small-cell lung cancer.  PATIENTS AND METHODS:  Patients received BIBF 1120 (starting dose 50 mg b.i.d.) on days 2-21 and paclitaxel (200 mg/m2) and carboplatin [area under curve (AUC)=6 mg/ml/min] on day 1 of each 21-day cycle.  Primary end points were safety and BIBF 1120 maximum tolerated dose (MTD) in this combination.  Pharmacokinetics (PK) profiles were evaluated.  RESULTS:  Twenty-six patients were treated (BIBF 1120 50-250 mg b.i.d.).  BIBF 1120 MTD was 200 mg b.i.d. in combination with paclitaxel and carboplatin.  Six dose-limiting toxicity events occurred during treatment cycle 1 (liver enzyme elevations, thrombocytopenia, abdominal pain, and rash).  Best responses included 7 confirmed partial responses (26.9%); 10 patients had stable disease.  BIBF 1120 200 mg b.i.d. had no clinically relevant influence on the PK of paclitaxel 200 mg/m2 and carboplatin AUC 6 mg/ml/min and vice versa.  CONCLUSIONS:  BIBF 1120 MTD was 200 mg b.i.d when given with paclitaxel and carboplatin; this combination demonstrated an acceptable safety profile.  No relevant changes in PK parameters of the backbone chemotherapeutic agents or BIBF 1120 were observed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSy39mgYhSpKmGmni0r9GoKfW6udTcc2ea_bmFo0dpnGLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vjsVOjtA%253D%253D&md5=90ab7e209cd8d3e3c8eda005571ad989</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdr596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdr596%26sid%3Dliteratum%253Aachs%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DConkling%26aufirst%3DP.%26aulast%3DTraynor%26aufirst%3DA.%2BM.%26aulast%3DOtterson%26aufirst%3DG.%2BA.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DWind%26aufirst%3DS.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DA%2520phase%2520I%252C%2520open-label%2520dose-escalation%2520study%2520of%2520continuous%2520treatment%2520with%2520BIBF%25201120%2520in%2520combination%2520with%2520paclitaxel%2520and%2520carboplatin%2520as%2520first-line%2520treatment%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2012%26volume%3D23%26spage%3D2094%26epage%3D2102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Ellis, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyorffy, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, N.</span><span> </span><span class="NLM_article-title">Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2881</span><span class="NLM_x">â</span> <span class="NLM_lpage">2889</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1158%2F1078-0432.CCR-09-2944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=20460487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlvF2hs74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2881-2889&author=P.+M.+Ellisauthor=R.+Kaiserauthor=Y.+Zhaoauthor=P.+Stopferauthor=S.+Gyorffyauthor=N.+Hanna&title=Phase+I+open-label+study+of+continuous+treatment+with+BIBF+1120%2C+a+triple+angiokinase+inhibitor%2C+and+pemetrexed+in+pretreated+non-small+cell+lung+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Ellis, Peter M.; Kaiser, Rolf; Zhao, Yihua; Stopfer, Peter; Gyorffy, Steve; Hanna, Nasser</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2881-2889</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Introduction: BIBF 1120 (planned brand name Vargatef) is a novel, oral, triple angiokinase inhibitor targeting three receptor classes involved in blood vessel formation.  The objectives of this phase I, open-label dose-escalation study were to det. the safety, tolerability, and max. tolerated dose (MTD) of BIBF 1120 with pemetrexed in patients with recurrent advanced-stage non-small cell lung carcinoma.  Patients and Methods: Patients harboring a tumor of any non-small cell lung carcinoma histol., previously treated with one first-line platinum-based chemotherapy regimen, received a BIBF 1120 starting dose of 100 mg bid (days 2-21) with pemetrexed 500 mg/m2 (day 1) over a 21-day cycle.  Previous pemetrexed treatment was not permitted.  BIBF 1120 dose was escalated until the MTD was detd.  Results: Twenty-six patients were treated.  During treatment cycle (TC) 1, dose-limiting toxicities were experienced by one patient receiving 100 mg bid, one patient receiving 150 mg bid, one patient receiving 200 mg bid, and two patients receiving 250 mg bid BIBF 1120.  Two addnl. dose-limiting toxicities were obsd. in TC 1 in an expanded patient cohort receiving 200 mg bid.  Gastrointestinal disorders (84.6%), general disorders, and administration site conditions (76.9%) were the most frequent drug-related adverse events.  One patient had a complete response 44 days after initiating trial medication; 50% had stable disease as the best overall response.  No clin. relevant pharmacokinetic interactions between BIBF 1120 and pemetrexed were obsd.  Conclusion: The MTD of BIBF 1120 in combination with std.-dose pemetrexed was 200 mg bid.  Continuous daily treatment with BIBF 1120 in this combination was tolerable, with promising signs of efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9FbuDjhbXYbVg90H21EOLACvtfcHk0ljQFyAnmmVANg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlvF2hs74%253D&md5=32d5ee996c570bc3c3f63d55ef4dd128</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-2944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-2944%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DP.%2BM.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DGyorffy%26aufirst%3DS.%26aulast%3DHanna%26aufirst%3DN.%26atitle%3DPhase%2520I%2520open-label%2520study%2520of%2520continuous%2520treatment%2520with%2520BIBF%25201120%252C%2520a%2520triple%2520angiokinase%2520inhibitor%252C%2520and%2520pemetrexed%2520in%2520pretreated%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D2881%26epage%3D2889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Bousquet, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alexandre, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Tourneau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldwasser, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Mont-Serrat, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Misset, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">1640</span><span class="NLM_x">â</span> <span class="NLM_lpage">1645</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1038%2Fbjc.2011.440" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22027711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFWqs7bK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2011&pages=1640-1645&author=G.+Bousquetauthor=J.+Alexandreauthor=C.+Le+Tourneauauthor=F.+Goldwasserauthor=S.+Faivreauthor=H.+de+Mont-Serratauthor=R.+Kaiserauthor=J.+L.+Missetauthor=E.+Raymond&title=Phase+I+study+of+BIBF+1120+with+docetaxel+and+prednisone+in+metastatic+chemo-naive+hormone-refractory+prostate+cancer+patients"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients</span></div><div class="casAuthors">Bousquet, G.; Alexandre, J.; Le Tourneau, C.; Goldwasser, F.; Faivre, S.; de Mont-Serrat, H.; Kaiser, R.; Misset, J. L.; Raymond, E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1640-1645</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: BIBF 1120 is an oral, potent, tyrosine kinase inhibitor that simultaneously targets vascular endothelial growth factor receptors 1-3, platelet-derived growth factor receptors Î± and Î², and fibroblast growth factor receptors 1-3, as well as FLT3 and Src.  Currently, the mol. is in phase III development for second-line non-small cell lung cancer and first-line ovarian cancer patients.  Methods: This phase I dose-escalation study assessed the safety and max. tolerated dose of continuous daily treatment with BIBF 1120 plus std.-dose docetaxel (75 mg m-2, every 3 wk) and prednisone (5 mg BID) in patients with metastatic, chemo-naive, hormone-refractory prostate cancer (HRPC).  Secondary objectives were characterization of BIBF 1120 and docetaxel pharmacokinetics (PK), and preliminary antitumor activity.  Results: Patients received BIBF 1120 100 mg BID (n=3), 150 mg BID (n=3), 200 mg BID (n=3), and 250 mg BID (n=12).  The most frequent drug-related adverse events were diarrhoea (71.4%), asthenia (61.9%), nausea (28.6%), vomiting (28.6%), and alopecia (23.8%).  The max. tolerated dose was 250 mg BID of BIBF 1120.  Overall, reversible grade 3/4 liver enzyme elevations occurred in six of twelve patients at this dose level.  Among 19 assessable patients, 13 (68.4%) showed a â¥50% redn. in prostate serum antigen levels from baseline and among 6 evaluable patients with measurable lesions 1 patient experienced a partial response by Response Evaluation Criteria In Solid Tumors criteria.  Pharmacokinetic anal. showed no interactions between BIBF 1120 and docetaxel/prednisone.  Conclusion: Based on the overall safety profile, 200 mg BID was the recommended dose for the combination of BIBF 1120 with the std. dose of 75 mg m-2 of docetaxel and prednisone that might be further investigated in HRPC patients.  This combination was well tolerated, with preliminary signs of efficacy and no indication of PK interaction between BIBF 1120 and docetaxel.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRJ-f4p4NOvbVg90H21EOLACvtfcHk0ljQFyAnmmVANg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFWqs7bK&md5=3921483e65f108ff0e4b8a4ff90b5a29</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.440&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.440%26sid%3Dliteratum%253Aachs%26aulast%3DBousquet%26aufirst%3DG.%26aulast%3DAlexandre%26aufirst%3DJ.%26aulast%3DLe%2BTourneau%26aufirst%3DC.%26aulast%3DGoldwasser%26aufirst%3DF.%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3Dde%2BMont-Serrat%26aufirst%3DH.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DMisset%26aufirst%3DJ.%2BL.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DPhase%2520I%2520study%2520of%2520BIBF%25201120%2520with%2520docetaxel%2520and%2520prednisone%2520in%2520metastatic%2520chemo-naive%2520hormone-refractory%2520prostate%2520cancer%2520patients%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D105%26spage%3D1640%26epage%3D1645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">du Bois, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huober, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfisterer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wimberger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loibl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reichardt, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harter, P.</span><span> </span><span class="NLM_article-title">A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">370</span><span class="NLM_x">â</span> <span class="NLM_lpage">375</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1093%2Fannonc%2Fmdp506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=19889612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC3c%252FlslKksw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=370-375&author=A.+du+Boisauthor=J.+Huoberauthor=P.+Stopferauthor=J.+Pfistererauthor=P.+Wimbergerauthor=S.+Loiblauthor=V.+L.+Reichardtauthor=P.+Harter&title=A+phase+I+open-label+dose-escalation+study+of+oral+BIBF+1120+combined+with+standard+paclitaxel+and+carboplatin+in+patients+with+advanced+gynecological+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies</span></div><div class="casAuthors">du Bois A; Huober J; Stopfer P; Pfisterer J; Wimberger P; Loibl S; Reichardt V L; Harter P</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">370-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The purpose of the phase I dose-escalation study was to evaluate the maximum tolerated dose (MTD) of BIBF 1120, an oral triple angiokinase inhibitor of vascular endothelial growth factor, platelet derived growth factor and fibroblast growth factor receptors, combined with paclitaxel and carboplatin.  PATIENTS AND METHODS:  Patients with advanced gynecological malignancies received BIBF 1120 twice-daily (b.i.d.) continuously at 100, 150, 200 or 250 mg, combined with paclitaxel (175 mg/m(2)) and carboplatin (area under the curve 5 min.mg/ml) every 3 weeks.  The MTD, safety, pharmacokinetics (PK) and clinical activity were evaluated.  RESULTS:  Twenty-two patients were treated.  Three experienced dose-limiting toxic effects in the first treatment cycle: 1 of 13 at 200 mg b.i.d.  BIBF 1120 [diarrhea, common terminology criteria for adverse events (CTCAE) grade 3]; two of two at 250 mg b.i.d.  BIBF 1120 (elevated alanine aminotransferase and aspartate aminotransferase, CTCAE grade 3/4).  The MTD was defined as 200 mg b.i.d.  Principal adverse events were gastrointestinal disorders.  No clinically relevant drug-drug interaction was observed after 20 days treatment with 200 mg b.i.d.  BIBF 1120 on the PK of paclitaxel or carboplatin and vice versa.  CONCLUSIONS:  The MTD of BIBF 1120 in a 20-day continuous dosing regimen with standard-dose paclitaxel and carboplatin was 200 mg b.i.d.  This combination had an acceptable safety profile and no clinically relevant drug-drug interactions.  Further evaluation of this combination is warranted in this indication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSxtGT4liPC1Kx48Rj5GnGofW6udTcc2ebAswziJIfKn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c%252FlslKksw%253D%253D&md5=49b5af97c9d197c561b59f663b893dbf</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdp506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdp506%26sid%3Dliteratum%253Aachs%26aulast%3Ddu%2BBois%26aufirst%3DA.%26aulast%3DHuober%26aufirst%3DJ.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3DPfisterer%26aufirst%3DJ.%26aulast%3DWimberger%26aufirst%3DP.%26aulast%3DLoibl%26aufirst%3DS.%26aulast%3DReichardt%26aufirst%3DV.%2BL.%26aulast%3DHarter%26aufirst%3DP.%26atitle%3DA%2520phase%2520I%2520open-label%2520dose-escalation%2520study%2520of%2520oral%2520BIBF%25201120%2520combined%2520with%2520standard%2520paclitaxel%2520and%2520carboplatin%2520in%2520patients%2520with%2520advanced%2520gynecological%2520malignancies%26jtitle%3DAnn.%2520Oncol.%26date%3D2010%26volume%3D21%26spage%3D370%26epage%3D375" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eschbach, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Love, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gatzemeier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stopfer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span> </span><span class="NLM_article-title">A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1374</span><span class="NLM_x">â</span> <span class="NLM_lpage">1381</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1093%2Fannonc%2Fmdq618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21212157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A280%3ADC%252BC3MrkvFyhtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2011&pages=1374-1381&author=M.+Reckauthor=R.+Kaiserauthor=C.+Eschbachauthor=M.+Stefanicauthor=J.+Loveauthor=U.+Gatzemeierauthor=P.+Stopferauthor=J.+von+Pawel&title=A+phase+II+double-blind+study+to+investigate+efficacy+and+safety+of+two+doses+of+the+triple+angiokinase+inhibitor+BIBF+1120+in+patients+with+relapsed+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer</span></div><div class="casAuthors">Reck M; Kaiser R; Eschbach C; Stefanic M; Love J; Gatzemeier U; Stopfer P; von Pawel J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1374-81</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  To assess the efficacy, safety, tolerability and pharmacokinetics of BIBF 1120 in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).  METHODS:  Patients with locally advanced or metastatic relapsed NSCLC in whom first- or second-line platinum-based chemotherapy failed were randomly allocated to daily 250 mg BIBF 1120 b.i.d. or 150 mg BIBF 1120 b.i.d.  Primary end points were progression-free survival (PFS) and objective tumour response (RECIST).  Incidence and severity of adverse events (AEs) were reported.  RESULTS:  Seventy-three patients received BIBF 1120.  Median PFS was 6.9 weeks, with no significant difference between treatment arms.  Median overall survival (OS) was 21.9 weeks.  Eastern Cooperative Oncology Group (ECOG) 0-1 patients (n = 56) had a median PFS of 11.6 weeks and a median OS of 37.7 weeks.  Tumour stabilisation was achieved in 46% of patients (ECOG 0-1 patients: 59%), with one confirmed partial response (250 mg b.i.d.).  Most commonly reported drug-related AEs were nausea (57.5%), diarrhoea (47.9%), vomiting (42.5%), anorexia (28.8%), abdominal pain (13.7%) and reversible alanine transaminase (13.7%) and aspartate aminotransferase elevations (9.6%).  BIBF 1120 displayed dose-linear pharmacokinetic characteristics.  CONCLUSION:  Continuous treatment with BIBF 1120 was well tolerated, with no difference in efficacy between treatment arms.  PFS and objective response with single-agent treatment in advanced disease warrants further exploration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwkcPypD6aCAaK-_ZudimnfW6udTcc2ebAswziJIfKn7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MrkvFyhtw%253D%253D&md5=4bb9f15176ce2e68bc2d5d83d8f6deb0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdq618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdq618%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DEschbach%26aufirst%3DC.%26aulast%3DStefanic%26aufirst%3DM.%26aulast%3DLove%26aufirst%3DJ.%26aulast%3DGatzemeier%26aufirst%3DU.%26aulast%3DStopfer%26aufirst%3DP.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26atitle%3DA%2520phase%2520II%2520double-blind%2520study%2520to%2520investigate%2520efficacy%2520and%2520safety%2520of%2520two%2520doses%2520of%2520the%2520triple%2520angiokinase%2520inhibitor%2520BIBF%25201120%2520in%2520patients%2520with%2520relapsed%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DAnn.%2520Oncol.%26date%3D2011%26volume%3D22%26spage%3D1374%26epage%3D1381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Van Cutsem, E.; Prenen, H.; Guillen-Ponce, C.</span><span> </span><span class="NLM_article-title">A phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus FOLFOX6 in patients with metastatic colorectal cancer</span>.  <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span>, Abstract 14LBA.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&author=E.+Van+Cutsem&author=H.+Prenen&author=C.+Guillen-Ponce&title=A+phase+I%2FII%2C+open-label%2C+randomised+study+of+BIBF+1120+plus+mFOLFOX6+compared+to+bevacizumab+plus+FOLFOX6+in+patients+with+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26atitle%3DA%2520phase%2520I%252FII%252C%2520open-label%252C%2520randomised%2520study%2520of%2520BIBF%25201120%2520plus%2520mFOLFOX6%2520compared%2520to%2520bevacizumab%2520plus%2520FOLFOX6%2520in%2520patients%2520with%2520metastatic%2520colorectal%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shparyk, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macleod, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallenstein, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khder, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallinger, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studeny, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loembe, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span> </span><span class="NLM_article-title">Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1283</span><span class="NLM_x">â</span> <span class="NLM_lpage">1293</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1283-1293&author=T.+Eisenauthor=Y.+Shparykauthor=N.+Macleodauthor=R.+Jonesauthor=G.+Wallensteinauthor=G.+Templeauthor=Y.+Khderauthor=C.+Dallingerauthor=M.+Studenyauthor=A.+B.+Loembeauthor=I.+Bondarenko&title=Effect+of+small+angiokinase+inhibitor+nintedanib+%28BIBF+1120%29+on+QT+interval+in+patients+with+previously+untreated%2C+advanced+renal+cell+cancer+in+an+open-label%2C+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DShparyk%26aufirst%3DY.%26aulast%3DMacleod%26aufirst%3DN.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DWallenstein%26aufirst%3DG.%26aulast%3DTemple%26aufirst%3DG.%26aulast%3DKhder%26aufirst%3DY.%26aulast%3DDallinger%26aufirst%3DC.%26aulast%3DStudeny%26aufirst%3DM.%26aulast%3DLoembe%26aufirst%3DA.%2BB.%26aulast%3DBondarenko%26aufirst%3DI.%26atitle%3DEffect%2520of%2520small%2520angiokinase%2520inhibitor%2520nintedanib%2520%2528BIBF%25201120%2529%2520on%2520QT%2520interval%2520in%2520patients%2520with%2520previously%2520untreated%252C%2520advanced%2520renal%2520cell%2520cancer%2520in%2520an%2520open-label%252C%2520phase%2520II%2520study%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D1283%26epage%3D1293" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Prenen, H.; DâHaens, G.; Capdevila, J.; Carrato, A.; Sobrero, A.; Ducreux, M.; FranÃ§ois, E.; Staines, H.; Amellal, N.; Van Cutsem, E.</span><span> </span><span class="NLM_article-title">A phase I dose escalation study of BIBF 1120 combined with FOLFOX in metastatic colorectal cancer (mCRC) patients</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span>, Abstract e14054.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&author=H.+Prenen&author=G.+D%E2%80%99Haens&author=J.+Capdevila&author=A.+Carrato&author=A.+Sobrero&author=M.+Ducreux&author=E.+Fran%C3%A7ois&author=H.+Staines&author=N.+Amellal&author=E.+Van+Cutsem&title=A+phase+I+dose+escalation+study+of+BIBF+1120+combined+with+FOLFOX+in+metastatic+colorectal+cancer+%28mCRC%29+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPrenen%26aufirst%3DH.%26atitle%3DA%2520phase%2520I%2520dose%2520escalation%2520study%2520of%2520BIBF%25201120%2520combined%2520with%2520FOLFOX%2520in%2520metastatic%2520colorectal%2520cancer%2520%2528mCRC%2529%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellemgaard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douillard, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orlov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gottfried, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bondarenko, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gann, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrueco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novello, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LUME-Lung 1 Study Group</span><span> </span><span class="NLM_article-title">Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">143</span><span class="NLM_x">â</span> <span class="NLM_lpage">155</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1016%2FS1470-2045%2813%2970586-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24411639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXns1Sjtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=143-155&author=M.+Reckauthor=R.+Kaiserauthor=A.+Mellemgaardauthor=J.+Y.+Douillardauthor=S.+Orlovauthor=M.+Krzakowskiauthor=J.+von+Pawelauthor=M.+Gottfriedauthor=I.+Bondarenkoauthor=M.+Liaoauthor=C.+N.+Gannauthor=J.+Barruecoauthor=B.+Gaschler-Markefskiauthor=S.+Novelloauthor=+LUME-Lung+1+Study+Group&title=Docetaxel+plus+nintedanib+versus+docetaxel+plus+placebo+in+patients+with+previously+treated+non-small-cell+lung+cancer+%28LUME-Lung+1%29%3A+a+phase+3%2C+double-blind%2C+randomised+controlled+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial</span></div><div class="casAuthors">Reck, Martin; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Sergey; Krzakowski, Maciej; von Pawel, Joachim; Gottfried, Maya; Bondarenko, Igor; Liao, Meilin; Gann, Claudia-Nanette; Barrueco, Jose; Gaschler-Markefski, Birgit; Novello, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">143-155</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC).  Patients from 211 centers in 27 countries with stage IIIB/IV recurrent NSCLC progressing after first-line chemotherapy, stratified by ECOG performance status, previous bevacizumab treatment, histol., and presence of brain metastases, were allocated (by computer-generated sequence through an interactive third-party system, in 1:1 ratio), to receive docetaxel 75 mg/m2 by i.v. infusion on day 1 plus either nintedanib 200 mg orally twice daily or matching placebo on days 2-21, every 3 wk until unacceptable adverse events or disease progression.  Investigators and patients were masked to assignment.  The primary endpoint was progression-free survival (PFS) by independent central review, analyzed by intention to treat after 714 events in all patients.  The key secondary endpoint was overall survival, analyzed by intention to treat after 1121 events had occurred, in a prespecified stepwise order: first in patients with adenocarcinoma who progressed within 9 mo after start of first-line therapy, then in all patients with adenocarcinoma, then in all patients.  This trial is registered with ClinicalTrials.gov, no. NCT00805194.  Between Dec 23, 2008, and Feb 9, 2011, 655 patients were randomly assigned to receive docetaxel plus nintedanib and 659 to receive docetaxel plus placebo.  The primary anal. was done after a median follow-up of 7Â·1 mo (IQR 3Â·8-11Â·0).  PFS was significantly improved in the docetaxel plus nintedanib group compared with the docetaxel plus placebo group (median 3Â·4 mo [95% CI 2Â·9-3Â·9] vs 2Â·7 mo [2Â·6-2Â·8]; hazard ratio [HR] 0Â·79 [95% CI 0Â·68-0Â·92], p=0Â·0019).  After a median follow-up of 31Â·7 mo (IQR 27Â·8-36Â·1), overall survival was significantly improved for patients with adenocarcinoma histol. who progressed within 9 mo after start of first-line treatment in the docetaxel plus nintedanib group (206 patients) compared with those in the docetaxel plus placebo group (199 patients; median 10Â·9 mo [95% CI 8Â·5-12Â·6] vs 7Â·9 mo [6Â·7-9Â·1]; HR 0Â·75 [95% CI 0Â·60-0Â·92], p=0Â·0073).  Similar results were noted for all patients with adenocarcinoma histol. (322 patients in the docetaxel plus nintedanib group and 336 in the docetaxel plus placebo group; median overall survival 12Â·6 mo [95% CI 10Â·6-15Â·1] vs 10Â·3 mo [95% CI 8Â·6-12Â·2]; HR 0Â·83 [95% CI 0Â·70-0Â·99], p=0Â·0359), but not in the total study population (median 10Â·1 mo [95% CI 8Â·8-11Â·2] vs 9Â·1 mo [8Â·4-10Â·4]; HR 0Â·94, 95% CI 0Â·83-1Â·05, p=0Â·2720).  Grade 3 or worse adverse events that were more common in the docetaxel plus nintedanib group than in the docetaxel plus placebo group were diarrhoea (43 [6Â·6%] of 652 vs 17 [2Â·6%] of 655), reversible increases in alanine aminotransferase (51 [7Â·8%] vs six [0Â·9%]), and reversible increases in aspartate aminotransferase (22 [3Â·4%] vs three [0Â·5%]).  35 Patients in the docetaxel plus nintedanib group and 25 in the docetaxel plus placebo group died of adverse events possibly unrelated to disease progression; the most common of these events were sepsis (five with docetaxel plus nintedanib vs one with docetaxel plus placebo), pneumonia (two vs seven), respiratory failure (four vs none), and pulmonary embolism (none vs three).  Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced NSCLC previously treated with one line of platinum-based therapy, esp. for patients with adenocarcinoma.Boehringer Ingelheim.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-E4GE6PlVPrVg90H21EOLACvtfcHk0lilYa7M6Yistw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXns1Sjtg%253D%253D&md5=6a774d4be37ac998e7635ba155507424</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970586-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970586-2%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DM.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DMellemgaard%26aufirst%3DA.%26aulast%3DDouillard%26aufirst%3DJ.%2BY.%26aulast%3DOrlov%26aufirst%3DS.%26aulast%3DKrzakowski%26aufirst%3DM.%26aulast%3Dvon%2BPawel%26aufirst%3DJ.%26aulast%3DGottfried%26aufirst%3DM.%26aulast%3DBondarenko%26aufirst%3DI.%26aulast%3DLiao%26aufirst%3DM.%26aulast%3DGann%26aufirst%3DC.%2BN.%26aulast%3DBarrueco%26aufirst%3DJ.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DNovello%26aufirst%3DS.%26aulast%3DLUME-Lung%2B1%2BStudy%2BGroup%26atitle%3DDocetaxel%2520plus%2520nintedanib%2520versus%2520docetaxel%2520plus%2520placebo%2520in%2520patients%2520with%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%2520%2528LUME-Lung%25201%2529%253A%2520a%2520phase%25203%252C%2520double-blind%252C%2520randomised%2520controlled%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D143%26epage%3D155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Hanna, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aren, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiangco, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voccia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrueco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glomb, P.</span><span> </span><span class="NLM_article-title">Retrospective evaluation of the futility analysis in LUME Lung 2, a randomized, double-blind, placebo-controlled phase 3 trial of nintedanib (BIBF 1120) in combination with pemetrexed in NSCLC patients progressing after one prior first line chemotherapy</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">S802</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S802&author=N.+Hannaauthor=R.+Kaiserauthor=J.+H.+Kimauthor=R.+Sullivanauthor=O.+Arenauthor=M.+J.+Ahnauthor=B.+J.+Tiangcoauthor=I.+Vocciaauthor=J.+Barruecoauthor=P.+Glomb&title=Retrospective+evaluation+of+the+futility+analysis+in+LUME+Lung+2%2C+a+randomized%2C+double-blind%2C+placebo-controlled+phase+3+trial+of+nintedanib+%28BIBF+1120%29+in+combination+with+pemetrexed+in+NSCLC+patients+progressing+after+one+prior+first+line+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DSullivan%26aufirst%3DR.%26aulast%3DAren%26aufirst%3DO.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DTiangco%26aufirst%3DB.%2BJ.%26aulast%3DVoccia%26aufirst%3DI.%26aulast%3DBarrueco%26aufirst%3DJ.%26aulast%3DGlomb%26aufirst%3DP.%26atitle%3DRetrospective%2520evaluation%2520of%2520the%2520futility%2520analysis%2520in%2520LUME%2520Lung%25202%252C%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520phase%25203%2520trial%2520of%2520nintedanib%2520%2528BIBF%25201120%2529%2520in%2520combination%2520with%2520pemetrexed%2520in%2520NSCLC%2520patients%2520progressing%2520after%2520one%2520prior%2520first%2520line%2520chemotherapy%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D49%26spage%3DS802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Hanna, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aren, O. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiangco, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zvirbule, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demirkazik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voccia, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrueco, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. H.</span><span> </span><span class="NLM_article-title">Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">8034</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1200%2FJCO.2013.48.8932" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=8034&author=N.+H.+Hannaauthor=R.+Kaiserauthor=R.+N.+Sullivanauthor=O.+R.+Arenauthor=M.+J.+Ahnauthor=B.+J.+Tiangcoauthor=Z.+Zvirbuleauthor=C.+H.+Barriosauthor=A.+Demirkazikauthor=B.+Gaschler-Markefskiauthor=I.+Vocciaauthor=J.+Barruecoauthor=J.+H.+Kim&title=Lume-lung+2%3A+A+multicenter%2C+randomized%2C+double-blind%2C+phase+III+study+of+nintedanib+plus+pemetrexed+versus+placebo+plus+pemetrexed+in+patients+with+advanced+nonsquamous+non-small+cell+lung+cancer+%28NSCLC%29+after+failure+of+first-line+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.48.8932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.48.8932%26sid%3Dliteratum%253Aachs%26aulast%3DHanna%26aufirst%3DN.%2BH.%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DSullivan%26aufirst%3DR.%2BN.%26aulast%3DAren%26aufirst%3DO.%2BR.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DTiangco%26aufirst%3DB.%2BJ.%26aulast%3DZvirbule%26aufirst%3DZ.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DDemirkazik%26aufirst%3DA.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26aulast%3DVoccia%26aufirst%3DI.%26aulast%3DBarrueco%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26atitle%3DLume-lung%25202%253A%2520A%2520multicenter%252C%2520randomized%252C%2520double-blind%252C%2520phase%2520III%2520study%2520of%2520nintedanib%2520plus%2520pemetrexed%2520versus%2520placebo%2520plus%2520pemetrexed%2520in%2520patients%2520with%2520advanced%2520nonsquamous%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520after%2520failure%2520of%2520first-line%2520chemotherapy%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D8034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">du Bois, A.; Kristensen, G.; Ray-Coquard, I.; ReuÃ, A.; Pignata, S.; Colombo, N.; Denison, U.; Vergote, I.; del Campo, J. M.; Ottevanger, P.; Merger, M.; Harter, P.</span><span> </span><span class="NLM_article-title">AGO-Ovar 12: A randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy Â± nintedanib for advanced ovarian cancer</span>.  <span class="citation_source-journal">Int. J. Gynecol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span>, Abstract.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&author=A.+du+Bois&author=G.+Kristensen&author=I.+Ray-Coquard&author=A.+Reu%C3%9F&author=S.+Pignata&author=N.+Colombo&author=U.+Denison&author=I.+Vergote&author=J.+M.+del+Campo&author=P.+Ottevanger&author=M.+Merger&author=P.+Harter&title=AGO-Ovar+12%3A+A+randomized+placebo-controlled+GCIG%2FENGOT-intergroup+phase+III+trial+of+standard+frontline+chemotherapy+%C2%B1+nintedanib+for+advanced+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Ddu%2BBois%26aufirst%3DA.%26atitle%3DAGO-Ovar%252012%253A%2520A%2520randomized%2520placebo-controlled%2520GCIG%252FENGOT-intergroup%2520phase%2520III%2520trial%2520of%2520standard%2520frontline%2520chemotherapy%2520%25C2%25B1%2520nintedanib%2520for%2520advanced%2520ovarian%2520cancer%26jtitle%3DInt.%2520J.%2520Gynecol.%2520Cancer%26date%3D2013%26volume%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Ledermann, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackshaw, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabra, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNeish, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earl, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perren, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Persic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustin, G.</span><span> </span><span class="NLM_article-title">Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3798</span><span class="NLM_x">â</span> <span class="NLM_lpage">3804</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1200%2FJCO.2010.33.5208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21859991" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVWrsb%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=3798-3804&author=J.+A.+Ledermannauthor=A.+Hackshawauthor=S.+Kayeauthor=G.+Jaysonauthor=H.+Gabraauthor=I.+McNeishauthor=H.+Earlauthor=T.+Perrenauthor=M.+Goreauthor=M.+Persicauthor=M.+Adamsauthor=L.+Jamesauthor=G.+Templeauthor=M.+Mergerauthor=G.+Rustin&title=Randomized+phase+II+placebo-controlled+trial+of+maintenance+therapy+using+the+oral+triple+angiokinase+inhibitor+BIBF+1120+after+chemotherapy+for+relapsed+ovarian+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer</span></div><div class="casAuthors">Ledermann, Jonathan A.; Hackshaw, Allan; Kaye, Stan; Jayson, Gordon; Gabra, Hani; McNeish, Iain; Earl, Helena; Perren, Tim; Gore, Martin; Persic, Mojca; Adams, Malcolm; James, Lindsay; Temple, Graham; Merger, Michael; Rustin, Gordon</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3798-3804</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer.  We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease.  Patients and Methods: We conducted a randomized, double-blind, controlled phase II trial in 83 patients who had just completed chemotherapy for relapsed ovarian cancer, with evidence of response, but at high risk of further early recurrence.  The patients were randomly assigned to receive maintenance therapy using BIBF 1120 250 mg or placebo, twice per day, continuously for 36 wk.  End points were progression-free survival (PFS), toxicity, and overall survival.  Results: Thirty-six-week PFS rates were 16.3% and 5.0% in the BIBF 1120 and placebo groups, resp. (hazard ratio, 0.65; 95% CI, 0.42 to 1.02; P = .06).  Four patients continued on BIBF 1120, including two patients for another year or more.  The proportion of patients with any grade 3 or 4 adverse events was similar between the groups (34.9% for BIBF 1120 v 27.5% for placebo; P = .49; mostly grade 3).  However, more patients on BIBF 1120 experienced diarrhea, nausea, or vomiting (mainly grade 1 or 2 and no grade 4).  There was a higher rate of grade 3 or 4 hepatotoxicity in patients on BIBF 1120 (51.2%) compared with patients on placebo (7.5%; P < .001), but this was rarely of clin. significance, and patients continued with the trial treatment.  A single-level dose redn. to 150 mg was made in 15 patients, all on active drug.  Conclusion: BIBF 1120 is well tolerated and assocd. with a potential improvement in PFS.  The obsd. treatment effect is sufficient to justify further study within a large phase III trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGZqwdS23hObVg90H21EOLACvtfcHk0liyUM3HA5ZsmA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVWrsb%252FE&md5=98a6a8e9c2a8c4cbcfa2fbb4f9c21c01</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1200%2FJCO.2010.33.5208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2010.33.5208%26sid%3Dliteratum%253Aachs%26aulast%3DLedermann%26aufirst%3DJ.%2BA.%26aulast%3DHackshaw%26aufirst%3DA.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DJayson%26aufirst%3DG.%26aulast%3DGabra%26aufirst%3DH.%26aulast%3DMcNeish%26aufirst%3DI.%26aulast%3DEarl%26aufirst%3DH.%26aulast%3DPerren%26aufirst%3DT.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DPersic%26aufirst%3DM.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DL.%26aulast%3DTemple%26aufirst%3DG.%26aulast%3DMerger%26aufirst%3DM.%26aulast%3DRustin%26aufirst%3DG.%26atitle%3DRandomized%2520phase%2520II%2520placebo-controlled%2520trial%2520of%2520maintenance%2520therapy%2520using%2520the%2520oral%2520triple%2520angiokinase%2520inhibitor%2520BIBF%25201120%2520after%2520chemotherapy%2520for%2520relapsed%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D3798%26epage%3D3804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Van Cutsem, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillen-Ponce, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Benedetto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouche, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Staines, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OumâHamed, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studeny, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdevila, J.</span><span> </span><span class="NLM_article-title">A phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancer</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">8</span><span class="NLM_x">â</span> <span class="NLM_lpage">9</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2011&pages=8-9&author=E.+Van+Cutsemauthor=H.+Prenenauthor=C.+Guillen-Ponceauthor=J.+Bennounaauthor=M.+Di+Benedettoauthor=O.+Boucheauthor=H.+Stainesauthor=Z.+Oum%E2%80%99Hamedauthor=M.+Studenyauthor=J.+Capdevila&title=A+phase+I%2FII%2C+open-label%2C+randomised+study+of+BIBF+1120+plus+mFOLFOX6+compared+to+bevacizumab+plus+mFOLFOX6+in+patients+with+metastatic+colorectal+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BCutsem%26aufirst%3DE.%26aulast%3DPrenen%26aufirst%3DH.%26aulast%3DGuillen-Ponce%26aufirst%3DC.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DDi%2BBenedetto%26aufirst%3DM.%26aulast%3DBouche%26aufirst%3DO.%26aulast%3DStaines%26aufirst%3DH.%26aulast%3DOum%25E2%2580%2599Hamed%26aufirst%3DZ.%26aulast%3DStudeny%26aufirst%3DM.%26aulast%3DCapdevila%26aufirst%3DJ.%26atitle%3DA%2520phase%2520I%252FII%252C%2520open-label%252C%2520randomised%2520study%2520of%2520BIBF%25201120%2520plus%2520mFOLFOX6%2520compared%2520to%2520bevacizumab%2520plus%2520mFOLFOX6%2520in%2520patients%2520with%2520metastatic%2520colorectal%2520cancer%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2011%26volume%3D47%26spage%3D8%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Eisen, T.; Shparyk, Y.; Jones, R.; Macleod, N. J.; Temple, G.; Finnigan, H.; Kaiser, R.; Studeny, M.; Loembe, A. B.; Bondarenko, I.</span><span> </span><span class="NLM_article-title">Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span>, Abstract 4506.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24019545" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&author=T.+Eisen&author=Y.+Shparyk&author=R.+Jones&author=N.+J.+Macleod&author=G.+Temple&author=H.+Finnigan&author=R.+Kaiser&author=M.+Studeny&author=A.+B.+Loembe&author=I.+Bondarenko&title=Phase+II+efficacy+and+safety+study+of+nintedanib+versus+sunitinib+in+previously+untreated+renal+cell+carcinoma+%28RCC%29+patients"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DT.%26atitle%3DPhase%2520II%2520efficacy%2520and%2520safety%2520study%2520of%2520nintedanib%2520versus%2520sunitinib%2520in%2520previously%2520untreated%2520renal%2520cell%2520carcinoma%2520%2528RCC%2529%2520patients%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Yen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Studeny, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocke, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, D. C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryoo, B. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. L.</span><span> </span><span class="NLM_article-title">Efficacy and safety of nintedanib vs sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): a randomised Phase II trial</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">S612</span><div class="note"><p class="first last">(Abstract 2580)</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S612&author=C.+Yenauthor=T.+Y.+Kimauthor=Y.+H.+Fengauthor=Y.+Chaoauthor=D.+Y.+Linauthor=M.+Studenyauthor=J.+Hockeauthor=D.+C.+L.+Huangauthor=B.+Y.+Ryooauthor=A.+L.+Cheng&title=Efficacy+and+safety+of+nintedanib+vs+sorafenib+in+Asian+patients+with+advanced+hepatocellular+carcinoma+%28HCC%29%3A+a+randomised+Phase+II+trial"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYen%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DT.%2BY.%26aulast%3DFeng%26aufirst%3DY.%2BH.%26aulast%3DChao%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DD.%2BY.%26aulast%3DStudeny%26aufirst%3DM.%26aulast%3DHocke%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BL.%26aulast%3DRyoo%26aufirst%3DB.%2BY.%26aulast%3DCheng%26aufirst%3DA.%2BL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520nintedanib%2520vs%2520sorafenib%2520in%2520Asian%2520patients%2520with%2520advanced%2520hepatocellular%2520carcinoma%2520%2528HCC%2529%253A%2520a%2520randomised%2520Phase%2520II%2520trial%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3DS612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juhel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kluglich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span> </span><span class="NLM_article-title">Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">365</span><span class="NLM_x">, </span> <span class="NLM_fpage">1079</span><span class="NLM_x">â</span> <span class="NLM_lpage">1087</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1056%2FNEJMoa1103690" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21992121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1WqsbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=2011&pages=1079-1087&author=L.+Richeldiauthor=U.+Costabelauthor=M.+Selmanauthor=D.+S.+Kimauthor=D.+M.+Hansellauthor=A.+G.+Nicholsonauthor=K.+K.+Brownauthor=K.+R.+Flahertyauthor=P.+W.+Nobleauthor=G.+Raghuauthor=M.+Brunauthor=A.+Guptaauthor=N.+Juhelauthor=M.+Kluglichauthor=R.+M.+du+Bois&title=Efficacy+of+a+tyrosine+kinase+inhibitor+in+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; Costabel, Ulrich; Selman, Moises; Kim, Dong Soon; Hansell, David M.; Nicholson, Andrew G.; Brown, Kevin K.; Flaherty, Kevin R.; Noble, Paul W.; Raghu, Ganesh; Brun, Michele; Gupta, Abhya; Juhel, Nolwenn; Kluglich, Matthias; du Bois, Roland M.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1079-1087</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate.  Because the signaling pathways activated by several tyrosine kinase receptors were shown to be involved in lung fibrosis, it was suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis.  In a 12-mo, phase 2 trial, we assessed the efficacy and safety of 4 different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity.  A total of 432 patients underwent randomization to receive one of 4 doses of B1BF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo.  In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 L per yr, as compared with 0.19 L per yr in the placebo group, a 68.4% redn. in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure).  This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007).  Gastrointestinal symptoms (which led to more discontinuations in the. group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group.  In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was assocd. with a trend toward a redn. in the decline in lung function, with fewer acute exacerbations and preserved quality of life.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4JXOIjFKCRbVg90H21EOLACvtfcHk0liI4ciL4yPKOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1WqsbrN&md5=6c076ac8d837944b4638ee7c444bb775</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103690%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DJuhel%26aufirst%3DN.%26aulast%3DKluglich%26aufirst%3DM.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26atitle%3DEfficacy%2520of%2520a%2520tyrosine%2520kinase%2520inhibitor%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D365%26spage%3D1079%26epage%3D1087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Richeldi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">du Bois, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raghu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cottin, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansell, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolb, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Maulf, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stowasser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlenker-Herceg, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Disse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, H. R.</span><span> </span><span class="NLM_article-title">INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">370</span><span class="NLM_x">, </span> <span class="NLM_fpage">2071</span><span class="NLM_x">â</span> <span class="NLM_lpage">2082</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1056%2FNEJMoa1402584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24836310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2014&pages=2071-2082&author=L.+Richeldiauthor=R.+M.+du+Boisauthor=G.+Raghuauthor=A.+Azumaauthor=K.+K.+Brownauthor=U.+Costabelauthor=V.+Cottinauthor=K.+R.+Flahertyauthor=D.+M.+Hansellauthor=Y.+Inoueauthor=D.+S.+Kimauthor=M.+Kolbauthor=A.+G.+Nicholsonauthor=P.+W.+Nobleauthor=M.+Selmanauthor=H.+Taniguchiauthor=M.+Brunauthor=F.+Le+Maulfauthor=M.+Girardauthor=S.+Stowasserauthor=R.+Schlenker-Hercegauthor=B.+Disseauthor=H.+R.+Collard&title=INPULSIS+Trial+Investigators.+Efficacy+and+safety+of+nintedanib+in+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Richeldi, Luca; du Bois, Roland M.; Raghu, Ganesh; Azuma, Arata; Brown, Kevin K.; Costabel, Ulrich; Cottin, Vincent; Flaherty, Kevin R.; Hansell, David M.; Inoue, Yoshikazu; Kim, Dong Soon; Kolb, Martin; Nicholson, Andrew G.; Noble, Paul W.; Selman, Moises; Taniguchi, Hiroyuki; Brun, Michele; Le Maulf, Florence; Girard, Mannaig; Stowasser, Susanne; Schlenker-Herceg, Rozsa; Disse, Bernd; Collard, Harold R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2071-2082, 12 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases.  A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis.  Methods: We conducted two replicate 52-wk, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis.  The primary end point was the annual rate of decline in forced vital capacity (FVC).  Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St.  George's Respiratory Questionnaire, both assessed over a 52-wk period.  Results: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo.  The adjusted annual rate of change in FVC was -114.7 mL with nintedanib vs. -239.9 mL with placebo (difference, 125.3 mL; 95% confidence interval [CI], 77.7 to 172.8; P < 0.001) in INPULSIS-1 and -113.6 mL with nintedanib vs. -207.3 mL with placebo (difference, 93.7 mL; 95% CI, 44.8 to 142.7; P < 0.001) in INPULSIS-2.  In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P = 0.67); in INPULSIS-2, there was a significant benefit with nintedanib vs. placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).  The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, resp., in INPULSIS-1 and 63.2% and 18.3% in the two groups, resp., in INPULSIS-2.  Conclusions: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently assocd. with diarrhea, which led to discontinuation of the study medication in less than 5% of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGuOhVKeZaSrVg90H21EOLACvtfcHk0liI4ciL4yPKOQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGksbfK&md5=be977cd3b402c7c401f4a3dfaa0f484f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1402584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1402584%26sid%3Dliteratum%253Aachs%26aulast%3DRicheldi%26aufirst%3DL.%26aulast%3Ddu%2BBois%26aufirst%3DR.%2BM.%26aulast%3DRaghu%26aufirst%3DG.%26aulast%3DAzuma%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DK.%2BK.%26aulast%3DCostabel%26aufirst%3DU.%26aulast%3DCottin%26aufirst%3DV.%26aulast%3DFlaherty%26aufirst%3DK.%2BR.%26aulast%3DHansell%26aufirst%3DD.%2BM.%26aulast%3DInoue%26aufirst%3DY.%26aulast%3DKim%26aufirst%3DD.%2BS.%26aulast%3DKolb%26aufirst%3DM.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DNoble%26aufirst%3DP.%2BW.%26aulast%3DSelman%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DBrun%26aufirst%3DM.%26aulast%3DLe%2BMaulf%26aufirst%3DF.%26aulast%3DGirard%26aufirst%3DM.%26aulast%3DStowasser%26aufirst%3DS.%26aulast%3DSchlenker-Herceg%26aufirst%3DR.%26aulast%3DDisse%26aufirst%3DB.%26aulast%3DCollard%26aufirst%3DH.%2BR.%26atitle%3DINPULSIS%2520Trial%2520Investigators.%2520Efficacy%2520and%2520safety%2520of%2520nintedanib%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D370%26spage%3D2071%26epage%3D2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Jubb, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, A. L.</span><span> </span><span class="NLM_article-title">Biomarkers to predict the clinical efficacy of bevacizumab in cancer</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1172</span><span class="NLM_x">â</span> <span class="NLM_lpage">1183</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1016%2FS1470-2045%2810%2970232-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=21126687" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVyhsLbP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1172-1183&author=A.+M.+Jubbauthor=A.+L.+Harris&title=Biomarkers+to+predict+the+clinical+efficacy+of+bevacizumab+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers to predict the clinical efficacy of bevacizumab in cancer</span></div><div class="casAuthors">Jubb, Adrian M.; Harris, Adrian L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1172-1183</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that has antiangiogenic activity and improves progression-free survival in many solid malignancies when combined with cytotoxic chemotherapy, but has little effect on overall survival.  Despite the effects of this drug in unselected patients, the Response Evaluation Criteria in Solid Tumors are suboptimum to predict benefit.  Addnl., tumors show inherent and emerging resistance to regimens that include bevacizumab.  The ability to target therapy towards well selected subgroups of patients would increase the likelihood of benefits and would improve cost-effectiveness and therapeutic outcomes.  In this review we discuss putative clin., radiol., and mol. markers of bevacizumab efficacy, derived from data obtained in clin. trials.  Current evidence indicates some predictive value for hypertension, vascular imaging, and polymorphisms affecting components of the vascular endothelial growth factor pathway in patients receiving bevacizumab.  Many questions relating to these and other surrogate biomarkers, however, remain unanswered and their clin. usefulness has yet to be proven.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0K3HztmENnbVg90H21EOLACvtfcHk0lh1EQTbRRYdrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVyhsLbP&md5=9a58aada56298f4d7feaf5c49ba86ddf</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970232-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970232-1%26sid%3Dliteratum%253Aachs%26aulast%3DJubb%26aufirst%3DA.%2BM.%26aulast%3DHarris%26aufirst%3DA.%2BL.%26atitle%3DBiomarkers%2520to%2520predict%2520the%2520clinical%2520efficacy%2520of%2520bevacizumab%2520in%2520cancer%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26spage%3D1172%26epage%3D1183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Kaiser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrueco, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reck, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glomb, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaschler-Markefski, B.</span><span> </span><span class="NLM_article-title">Identification of a clinical biomarker for 2nd line combination with nintedanib in adenocarcinoma non-small cell lung cancer (NSCLC) patients in two phase III trials</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">S822</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2013&pages=S822&author=R.+Kaiserauthor=J.+R.+Barruecoauthor=M.+Reckauthor=N.+Hannaauthor=C.+Gannauthor=P.+Glombauthor=B.+Gaschler-Markefski&title=Identification+of+a+clinical+biomarker+for+2nd+line+combination+with+nintedanib+in+adenocarcinoma+non-small+cell+lung+cancer+%28NSCLC%29+patients+in+two+phase+III+trials"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKaiser%26aufirst%3DR.%26aulast%3DBarrueco%26aufirst%3DJ.%2BR.%26aulast%3DReck%26aufirst%3DM.%26aulast%3DHanna%26aufirst%3DN.%26aulast%3DGann%26aufirst%3DC.%26aulast%3DGlomb%26aufirst%3DP.%26aulast%3DGaschler-Markefski%26aufirst%3DB.%26atitle%3DIdentification%2520of%2520a%2520clinical%2520biomarker%2520for%25202nd%2520line%2520combination%2520with%2520nintedanib%2520in%2520adenocarcinoma%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520patients%2520in%2520two%2520phase%2520III%2520trials%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2013%26volume%3D49%26spage%3DS822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Reck, M.; Novello, S.; Mellemgaard, A.; Orlov, S.; Kaiser, R.; Barrueco, J.; Gaschler-Markefski, B.; Douillard, J. Y.</span><span> </span><span class="NLM_article-title">Impact of tumor burden on the overall survival analysis of the LUME-Lung 1 study: A randomized, double-blind phase 3 trial of nintedanib (BIBF 1120) + docetaxel in NSCLC patients progressing after first-line chemotherapy</span>.  <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span>, Presented at WCLC 2013, Abstract O16.01.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=24389434" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=M.+Reck&author=S.+Novello&author=A.+Mellemgaard&author=S.+Orlov&author=R.+Kaiser&author=J.+Barrueco&author=B.+Gaschler-Markefski&author=J.+Y.+Douillard&title=Impact+of+tumor+burden+on+the+overall+survival+analysis+of+the+LUME-Lung+1+study%3A+A+randomized%2C+double-blind+phase+3+trial+of+nintedanib+%28BIBF+1120%29+%2B+docetaxel+in+NSCLC+patients+progressing+after+first-line+chemotherapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReck%26aufirst%3DM.%26atitle%3DImpact%2520of%2520tumor%2520burden%2520on%2520the%2520overall%2520survival%2520analysis%2520of%2520the%2520LUME-Lung%25201%2520study%253A%2520A%2520randomized%252C%2520double-blind%2520phase%25203%2520trial%2520of%2520nintedanib%2520%2528BIBF%25201120%2529%2520%252B%2520docetaxel%2520in%2520NSCLC%2520patients%2520progressing%2520after%2520first-line%2520chemotherapy%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2013%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Hilberg, F.; Haslinger, C.; Garin-Chesa, P.; Adolf, G. R.</span><span> </span><span class="NLM_article-title">Molecular correlates of clinical benefit from anti-angiogenic therapy of lung adenocarcinoma: a hypothesis</span>.  <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span>Presented at ASCO 2014, Abstract e22080.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=F.+Hilberg&author=C.+Haslinger&author=P.+Garin-Chesa&author=G.+R.+Adolf&title=Molecular+correlates+of+clinical+benefit+from+anti-angiogenic+therapy+of+lung+adenocarcinoma%3A+a+hypothesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHilberg%26aufirst%3DF.%26atitle%3DMolecular%2520correlates%2520of%2520clinical%2520benefit%2520from%2520anti-angiogenic%2520therapy%2520of%2520lung%2520adenocarcinoma%253A%2520a%2520hypothesis%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Demedts, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costabel, U.</span><span> </span><span class="NLM_article-title">ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias</span> <span class="citation_source-journal">Eur. Respir. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">794</span><span class="NLM_x">â</span> <span class="NLM_lpage">796</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1183%2F09031936.02.00492002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=12030715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVCqsbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=794-796&author=M.+Demedtsauthor=U.+Costabel&title=ATS%2FERS+international+multidisciplinary+consensus+classification+of+the+idiopathic+interstitial+pneumonias"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias</span></div><div class="casAuthors">Demedts, M.; Costabel, U.</div><div class="citationInfo"><span class="NLM_cas:title">European Respiratory Journal</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">794-796</span>CODEN:
                <span class="NLM_cas:coden">ERJOEI</span>;
        ISSN:<span class="NLM_cas:issn">0903-1936</span>.
    
            (<span class="NLM_cas:orgname">European Respiratory Society</span>)
        </div><div class="casAbstract">A review.  The article discusses the publication of the "ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias".  Previously, several classifications had been proposed, of which the most influential were the landmark histol. classification of chronic interstitial pneumonias.  The importance of the present ATS/ERS consensus classification is based on several issues.  First, it provides an integrated clin., radiol., and pathol. definition and classification of the whole group of IIP.  Secondly, it proposes multidisciplinary consensus guidelines to establish uniform criteria for the diagnosis of the different IIP, aimed at pulmonologists as well as radiologists and pathologists.  Third, while previous classifications have largely been conceived by individual authoritative pathologists or clinicians or by small collaborative groups of experts, the present consensus classification has been worked out by an international multidisciplinary core panel of some 20 pulmonologists, pulmonary pathologists, and thoracic radiologists, and was then approved by an extended review panel of some 65 experts from over 20 countries.  Also discussed are major new innovations in the ATS/ERS document as well as points raised that still require some discussion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsi9ZMmw7g1LVg90H21EOLACvtfcHk0lh1EQTbRRYdrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVCqsbw%253D&md5=5403e07ec7d6349c1c8d1cc91885ae39</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1183%2F09031936.02.00492002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1183%252F09031936.02.00492002%26sid%3Dliteratum%253Aachs%26aulast%3DDemedts%26aufirst%3DM.%26aulast%3DCostabel%26aufirst%3DU.%26atitle%3DATS%252FERS%2520international%2520multidisciplinary%2520consensus%2520classification%2520of%2520the%2520idiopathic%2520interstitial%2520pneumonias%26jtitle%3DEur.%2520Respir.%2520J.%26date%3D2002%26volume%3D19%26spage%3D794%26epage%3D796" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaminski, N.</span><span> </span><span class="NLM_article-title">Biomarkers in idiopathic pulmonary fibrosis</span> <span class="citation_source-journal">Curr. Opin. Pulm. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">â</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Fjm501562a&amp;key=10.1097%2FMCP.0b013e328356d03c" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Fjm501562a&amp;key=22847105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm501562a&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCmsb7P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=441-446&author=Y.+Zhangauthor=N.+Kaminski&title=Biomarkers+in+idiopathic+pulmonary+fibrosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Biomarkers in idiopathic pulmonary fibrosis</span></div><div class="casAuthors">Zhang, Yingze; Kaminski, Naftali</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pulmonary Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">441-446</span>CODEN:
                <span class="NLM_cas:coden">COPMFY</span>;
        ISSN:<span class="NLM_cas:issn">1070-5287</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Purpose of review: This review examines the recent literature on mol. biomarkers of idiopathic pulmonary fibrosis (IPF).  Specific attention is dedicated to the recent studies that identified the genes assocd. with IPF and the peripheral blood biomarkers that predict outcome in IPF.  Recent findings: Multiple studies attempted to identify diagnostic and predictive biomarkers in IPF.  Until recently, these studies were limited in size and lacked replication, but still when taken together provided convincing evidence that changes in blood proteins (KL-6, SP-A, MMP-7, CCL-18, among others) or cells (fibrocytes and T-cell subpopulations) are indicative of the disease presence and outcome.  More recently, larger studies have identified gene polymorphisms assocd. with IPF, as well as protein markers and integrated clin. and mol. prediction rules that accurately predict outcome in patients with IPF.  Summary: The peripheral blood contains disease presence and outcome relevant information, and suggests distinct biol. defined outcome trajectories in patients with IPF.  Although recently identified biomarkers should still be validated in multiple clin. contexts, there is sufficient evidence to suggest that collection of peripheral blood biomarkers needs to be incorporated in the design of drug studies and that some of these markers be clin. evaluated in lung transplant prioritization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMcTz1Tn-157Vg90H21EOLACvtfcHk0lgAsESs3mD9Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCmsb7P&md5=921e8b6cd0ada474dc1021859e154f2e</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1097%2FMCP.0b013e328356d03c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FMCP.0b013e328356d03c%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKaminski%26aufirst%3DN.%26atitle%3DBiomarkers%2520in%2520idiopathic%2520pulmonary%2520fibrosis%26jtitle%3DCurr.%2520Opin.%2520Pulm.%2520Med.%26date%3D2012%26volume%3D18%26spage%3D441%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span> </span><span class="NLM_article-title">CHMP summary of positive opinion for Vargatef</span>. September 25,<span class="NLM_x"> </span><span class="NLM_year">2014</span>. <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002569/WC500173607.pdf" class="extLink">http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002569/WC500173607.pdf</a> (accessed November 2014).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CHMP+summary+of+positive+opinion+for+Vargatef.+September+25%2C+2014.+http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FSummary_of_opinion_-_Initial_authorisation%2Fhuman%2F002569%2FWC500173607.pdf+%28accessed+November+2014%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DCHMP%2520summary%2520of%2520positive%2520opinion%2520for%2520Vargatef%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span> </span><span class="NLM_article-title">FDA approves Ofev to treat idiopathic pulmonary fibrosis</span>. October 15, 2014. <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418994.htm</a> (accessed November<span class="NLM_x"> </span><span class="NLM_year">2014</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=FDA+approves+Ofev+to+treat+idiopathic+pulmonary+fibrosis.+October+15%2C+2014.+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm418994.htm+%28accessed+November+2014%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26atitle%3DFDA%2520approves%2520Ofev%2520to%2520treat%2520idiopathic%2520pulmonary%2520fibrosis%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm501562a&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Fjm501562a%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-3" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm501562a" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                385KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b1ae6fae8d18b","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
